Prediction,Label,Document,Sentence,Text
0,background,10070506,1,"BACKGROUND"
0,intervention,10070506,1,"BACKGROUND"
0,population,10070506,1,"BACKGROUND"
0,outcome,10070506,1,"BACKGROUND"
1,other,10070506,1,"BACKGROUND"
0,"study design",10070506,1,"BACKGROUND"
1,background,10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
0,intervention,10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
0,population,10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
0,outcome,10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
0,other,10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
0,"study design",10070506,2,"Subfoveal choroidal neovascular membranes (CNV) are a cause of significant visual impairment."
1,background,10070506,3,"Laser treatment of such lesions results in visual loss."
0,intervention,10070506,3,"Laser treatment of such lesions results in visual loss."
0,population,10070506,3,"Laser treatment of such lesions results in visual loss."
0,outcome,10070506,3,"Laser treatment of such lesions results in visual loss."
0,other,10070506,3,"Laser treatment of such lesions results in visual loss."
0,"study design",10070506,3,"Laser treatment of such lesions results in visual loss."
1,background,10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
0,intervention,10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
0,population,10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
0,outcome,10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
0,other,10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
0,"study design",10070506,4,"Surgical excision of CNV may allow stabilisation or improvement of vision."
1,background,10070506,5,"A series of results of surgical excision are presented."
0,intervention,10070506,5,"A series of results of surgical excision are presented."
0,population,10070506,5,"A series of results of surgical excision are presented."
0,outcome,10070506,5,"A series of results of surgical excision are presented."
0,other,10070506,5,"A series of results of surgical excision are presented."
0,"study design",10070506,5,"A series of results of surgical excision are presented."
0,background,10070506,6,"METHODS"
0,intervention,10070506,6,"METHODS"
0,population,10070506,6,"METHODS"
0,outcome,10070506,6,"METHODS"
1,other,10070506,6,"METHODS"
0,"study design",10070506,6,"METHODS"
0,background,10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
1,intervention,10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
1,population,10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
0,outcome,10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
0,other,10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
0,"study design",10070506,7,"The records for 43 eyes of 40 consecutive patients undergoing surgical excision of CNV not associated with age-related macular degeneration (AMD) were reviewed retrospectively."
0,background,10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
0,intervention,10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
0,population,10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
0,outcome,10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
1,other,10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
0,"study design",10070506,8,"Statistical analyses of the relationship between pre-operative factors and post-operative visual results were made."
0,background,10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
0,intervention,10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
0,population,10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
0,outcome,10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
1,other,10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
0,"study design",10070506,9,"Improvement or worsening of visual acuity was defined as a change of more than 2 lines of Snellen acuity."
0,background,10070506,10,"RESULTS"
0,intervention,10070506,10,"RESULTS"
0,population,10070506,10,"RESULTS"
0,outcome,10070506,10,"RESULTS"
1,other,10070506,10,"RESULTS"
0,"study design",10070506,10,"RESULTS"
0,background,10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
0,intervention,10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
0,population,10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
1,outcome,10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
0,other,10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
0,"study design",10070506,11,"In 79.1% of patients visual acuity was improved or unchanged following surgery, and in 20.9% there was a reduction of Snellen acuity."
0,background,10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
0,intervention,10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
0,population,10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
1,outcome,10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
0,other,10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
0,"study design",10070506,12,"There was no statistically significant association between visual outcome and age, gender, duration of visual symptoms, cause of CNV, presence of subretinal haemorrhage, elevation of retina by subretinal fluid, prior laser surgery, or the presence of pre-"
0,background,10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
0,intervention,10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
0,population,10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
1,outcome,10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
0,other,10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
0,"study design",10070506,13,"There was a possible association between the non-use of gas tamponade and an increased chance of reduced vision."
0,background,10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
0,intervention,10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
0,population,10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
1,outcome,10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
0,other,10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
0,"study design",10070506,14,"Visual loss was more likely in those eyes with good pre-operative visual acuity."
0,background,10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
0,intervention,10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
0,population,10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
1,outcome,10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
0,other,10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
0,"study design",10070506,15,"Recurrence of CNV was noted in 10 (23%) eyes; repeat surgery was not associated with a worse visual outcome."
0,background,10070506,16,"CONCLUSIONS"
0,intervention,10070506,16,"CONCLUSIONS"
0,population,10070506,16,"CONCLUSIONS"
0,outcome,10070506,16,"CONCLUSIONS"
1,other,10070506,16,"CONCLUSIONS"
0,"study design",10070506,16,"CONCLUSIONS"
0,background,10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
0,intervention,10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
0,population,10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
1,outcome,10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
0,other,10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
0,"study design",10070506,17,"Surgical excision of CNV not related to AMD is a promising technique."
0,background,10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
0,intervention,10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
0,population,10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
1,outcome,10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
0,other,10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
0,"study design",10070506,18,"More meaningful assessment of visual function in these patients will allow refinement of case selection."
1,background,10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
0,intervention,10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
0,population,10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
0,outcome,10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
0,other,10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
0,"study design",10159577,1,"One aspect of the Clinton Healthcare Reform programme is to assist health maintenance organizations (HMOs) in collecting and analysing data for the purpose of continuous quality improvement."
1,background,10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
0,intervention,10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
0,population,10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
0,outcome,10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
0,other,10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
0,"study design",10159577,2,"The HEDIS 2.0 quality performance measurement model is currently in use and endorsed by the National Committee for Quality Assurance (NCQA)."
1,background,10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
0,intervention,10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
0,population,10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
0,outcome,10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
0,other,10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
0,"study design",10159577,3,"Outlines a process using HEDIS 2.0 by which an HMO can identify crucial problem areas and track the success of the solution process."
1,background,10159577,4,"Discusses the use of other relevant statistical tools."
0,intervention,10159577,4,"Discusses the use of other relevant statistical tools."
0,population,10159577,4,"Discusses the use of other relevant statistical tools."
0,outcome,10159577,4,"Discusses the use of other relevant statistical tools."
0,other,10159577,4,"Discusses the use of other relevant statistical tools."
0,"study design",10159577,4,"Discusses the use of other relevant statistical tools."
0,background,10414734,1,"OBJECTIVES"
0,intervention,10414734,1,"OBJECTIVES"
0,population,10414734,1,"OBJECTIVES"
0,outcome,10414734,1,"OBJECTIVES"
1,other,10414734,1,"OBJECTIVES"
0,"study design",10414734,1,"OBJECTIVES"
1,background,10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,intervention,10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,population,10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,outcome,10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,other,10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,"study design",10414734,2,"To determine the feasibility of contrast-enhanced three-dimensional (3D) imaging of the prostatic vasculature using power Doppler imaging and to analyze whether semiquantitative judgments of 3D images with respect to symmetry and distribution of vascular "
0,background,10414734,3,"METHODS"
0,intervention,10414734,3,"METHODS"
0,population,10414734,3,"METHODS"
0,outcome,10414734,3,"METHODS"
1,other,10414734,3,"METHODS"
0,"study design",10414734,3,"METHODS"
0,background,10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
1,intervention,10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
0,population,10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
0,outcome,10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
0,other,10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
0,"study design",10414734,4,"3D power Doppler images were obtained before and after intravenous administration of 2.5 g Levovist."
0,background,10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
1,intervention,10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
0,population,10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
0,outcome,10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
0,other,10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
0,"study design",10414734,5,"Subsequently, random and/or directed transrectal ultrasound (TRUS)-guided biopsies were performed."
0,background,10414734,6,"Vascular images were analyzed by two experts."
0,intervention,10414734,6,"Vascular images were analyzed by two experts."
0,population,10414734,6,"Vascular images were analyzed by two experts."
0,outcome,10414734,6,"Vascular images were analyzed by two experts."
1,other,10414734,6,"Vascular images were analyzed by two experts."
0,"study design",10414734,6,"Vascular images were analyzed by two experts."
0,background,10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
0,intervention,10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
0,population,10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
0,outcome,10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
1,other,10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
0,"study design",10414734,7,"Prostate vasculature was judged with respect to symmetry and vessel distribution using a (scale) grading system."
0,background,10414734,8,"RESULTS"
0,intervention,10414734,8,"RESULTS"
0,population,10414734,8,"RESULTS"
0,outcome,10414734,8,"RESULTS"
1,other,10414734,8,"RESULTS"
0,"study design",10414734,8,"RESULTS"
0,background,10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
0,intervention,10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
1,population,10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
0,outcome,10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
0,other,10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
0,"study design",10414734,9,"Eighteen patients with a suspicion of prostate cancer either because of an elevated prostate-specific antigen (greater than 4.0 ng/mL; Tandem-R-assay) or an abnormal digital rectal examination were included in the study."
0,background,10414734,10,"Prostate cancer was detected in 13 patients."
0,intervention,10414734,10,"Prostate cancer was detected in 13 patients."
0,population,10414734,10,"Prostate cancer was detected in 13 patients."
1,outcome,10414734,10,"Prostate cancer was detected in 13 patients."
0,other,10414734,10,"Prostate cancer was detected in 13 patients."
0,"study design",10414734,10,"Prostate cancer was detected in 13 patients."
0,background,10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
0,intervention,10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
0,population,10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
1,outcome,10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
0,other,10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
0,"study design",10414734,11,"Vascular anatomy was judged abnormal in unenhanced images in 6 cases, of which 5 proved malignant."
0,background,10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
0,intervention,10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
0,population,10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
1,outcome,10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
0,other,10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
0,"study design",10414734,12,"Enhanced images were considered suspicious for malignancy in 12 cases, including 1 benign and 11 malignant biopsy results."
0,background,10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
0,intervention,10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
0,population,10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
1,outcome,10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
0,other,10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
0,"study design",10414734,13,"Sensitivity of enhanced images was 85% (specificity 80%) compared with 38% for unenhanced images (specificity 80%) and 77% for conventional gray-scale TRUS (specificity 60%)."
0,background,10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
0,intervention,10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
0,population,10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
1,outcome,10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
0,other,10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
0,"study design",10414734,14,"Of 6 patients who showed no B-mode abnormalities, vascular patterns were judged abnormal in 4 cases, of which 3 were malignant."
0,background,10414734,15,"CONCLUSIONS"
0,intervention,10414734,15,"CONCLUSIONS"
0,population,10414734,15,"CONCLUSIONS"
0,outcome,10414734,15,"CONCLUSIONS"
1,other,10414734,15,"CONCLUSIONS"
0,"study design",10414734,15,"CONCLUSIONS"
0,background,10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
0,intervention,10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
0,population,10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
1,outcome,10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
0,other,10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
0,"study design",10414734,16,"Contrast-enhanced 3D power Doppler angiography is feasible in patients with suspicion of prostate cancer who are scheduled for prostate biopsies."
0,background,10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
0,intervention,10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
0,population,10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
1,outcome,10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
0,other,10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
0,"study design",10414734,17,"The sensitivity of power Doppler 3D imaging for the detection of prostate malignancy increased from 38% (5 of 13) to 85% (11 of 13) after administration of intravascular microbubble contrast (Levovist), and specificity was found to be 80% (4 of 5) for bot"
0,background,10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
0,intervention,10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
0,population,10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
1,outcome,10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
0,other,10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
0,"study design",10414734,18,"Thus, the use of Levovist when combined with the power Doppler display mode and 3D image reconstruction offers a promising new research area that might prove useful in prostate cancer detection in the future."
1,background,10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
0,intervention,10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
1,population,10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
0,outcome,10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
0,other,10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
0,"study design",10465500,1,"In order to clarify whether or not marked changes in the social environment during the past 50 years in Japan may have altered the clinical phenotypes of multiple sclerosis (MS), we retrospectively analyzed 143 consecutive patients with clinically definit"
0,background,10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
0,intervention,10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
0,population,10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
1,outcome,10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
0,other,10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
0,"study design",10465500,2,"Fifty-two patients were classified as Asian type MS showing a selective involvement of the optic nerves and the spinal cord, while 91 patients were considered to have Western type MS which demonstrated the involvement of multiple sites in the central nerv"
0,background,10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
0,intervention,10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
0,population,10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
1,outcome,10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
0,other,10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
0,"study design",10465500,3,"The ratio of Asian type versus Western type MS was 1:0.5 in the patients born in the 1920s and 1:1.27, 1:1.64 and 1:1.7 in those born in the 1930s, 1940s and 1950s, respectively, and thereafter it increased to 1:4.67 in those born in the 1960s and 1:4 in "
0,background,10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
0,intervention,10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
0,population,10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
1,outcome,10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
0,other,10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
0,"study design",10465500,4,"As a result, the proportion of Asian type MS significantly decreased in the patients born after 1960 as compared with those born from 1930 to 1959 (P=0.0121)."
0,background,10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
0,intervention,10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
0,population,10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
1,outcome,10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
0,other,10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
0,"study design",10465500,5,"In the Asian type MS, the age of onset was significantly higher in the patients who developed the disease from 1985 to 1997 (42.4+/-13.5 years) than in those who developed the disease from 1950 to 1984 (32.3+/-12.4 years) (P=0.0149), while in the Western "
0,background,10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
0,intervention,10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
0,population,10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
1,outcome,10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
0,other,10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
0,"study design",10465500,6,"These findings suggest that the frequency of Asian type MS has apparently decreased in younger Japanese born after 1960 when Japan's rapid economic growth had just started, and environmental factors are therefore considered to contribute to determine the "
1,background,10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
0,intervention,10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
0,population,10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
0,outcome,10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
0,other,10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
0,"study design",10582786,1,"Low-dose follicle stimulating hormone (FSH) regimens for induction of ovulation for women with polycystic ovaries have succeeded in reducing the rate of ovarian hyperstimulation syndrome (OHSS) almost to nil and the rate of multiple pregnancies to a minim"
1,background,10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
1,intervention,10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
0,population,10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
0,outcome,10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
0,other,10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
0,"study design",10582786,2,"This has been achieved by reaching, but not exceeding, the threshold level of FSH, starting with a daily dose of 75 IU for 14 days, using small incremental dose rises where necessary, and inducing uniovulation in 70% of cycles."
0,background,10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
0,intervention,10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
0,population,10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
1,outcome,10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
0,other,10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
0,"study design",10582786,3,"Conception rates are as good, if not better, than those achieved with conventional therapy."
0,background,10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
0,intervention,10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
0,population,10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
1,outcome,10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
0,other,10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
0,"study design",10582786,4,"The miscarriage rate is still relatively high (20-25%) and obese women fare worse."
0,background,10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
0,intervention,10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
0,population,10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
1,outcome,10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
0,other,10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
0,"study design",10582786,5,"Serum oestradiol concentrations and the number of large and intermediate follicles on the day of human chorionic gonadotrophin administration are much lower, in parallel with lower serum FSH concentrations."
0,background,10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
0,intervention,10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
0,population,10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
1,outcome,10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
0,other,10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
0,"study design",10582786,6,"Inhibin values increase with the rise in serum FSH concentrations but those of luteinizing hormone decrease steadily throughout the follicular phase."
0,background,10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
0,intervention,10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
0,population,10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
1,outcome,10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
0,other,10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
0,"study design",10582786,7,"New data using recombinant hFSH (rhFSH), rather than urinary gonadotrophin as the ovarian stimulant, demonstrate that treatment time is shortened."
0,background,10582786,8,"However, the ideal regimen has still to be formulated."
0,intervention,10582786,8,"However, the ideal regimen has still to be formulated."
0,population,10582786,8,"However, the ideal regimen has still to be formulated."
1,outcome,10582786,8,"However, the ideal regimen has still to be formulated."
0,other,10582786,8,"However, the ideal regimen has still to be formulated."
0,"study design",10582786,8,"However, the ideal regimen has still to be formulated."
0,background,10629371,1,"OBJECTIVE"
0,intervention,10629371,1,"OBJECTIVE"
0,population,10629371,1,"OBJECTIVE"
0,outcome,10629371,1,"OBJECTIVE"
1,other,10629371,1,"OBJECTIVE"
0,"study design",10629371,1,"OBJECTIVE"
1,background,10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,intervention,10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,population,10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,outcome,10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,other,10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,"study design",10629371,2,"To determine the therapeutic value of selective salpingography (SSG) for infertile women with patent fallopian tubes."
0,background,10629371,3,"DESIGN"
0,intervention,10629371,3,"DESIGN"
0,population,10629371,3,"DESIGN"
0,outcome,10629371,3,"DESIGN"
1,other,10629371,3,"DESIGN"
0,"study design",10629371,3,"DESIGN"
0,background,10629371,4,"Retrospective, case-control analysis."
0,intervention,10629371,4,"Retrospective, case-control analysis."
0,population,10629371,4,"Retrospective, case-control analysis."
0,outcome,10629371,4,"Retrospective, case-control analysis."
0,other,10629371,4,"Retrospective, case-control analysis."
1,"study design",10629371,4,"Retrospective, case-control analysis."
0,background,10629371,5,"Setting"
0,intervention,10629371,5,"Setting"
0,population,10629371,5,"Setting"
0,outcome,10629371,5,"Setting"
1,other,10629371,5,"Setting"
0,"study design",10629371,5,"Setting"
0,background,10629371,6,"University Hospital, infertility clinic."
0,intervention,10629371,6,"University Hospital, infertility clinic."
0,population,10629371,6,"University Hospital, infertility clinic."
0,outcome,10629371,6,"University Hospital, infertility clinic."
1,other,10629371,6,"University Hospital, infertility clinic."
0,"study design",10629371,6,"University Hospital, infertility clinic."
0,background,10629371,7,"PATIENTS"
0,intervention,10629371,7,"PATIENTS"
0,population,10629371,7,"PATIENTS"
0,outcome,10629371,7,"PATIENTS"
1,other,10629371,7,"PATIENTS"
0,"study design",10629371,7,"PATIENTS"
0,background,10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
0,intervention,10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
1,population,10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
0,outcome,10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
0,other,10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
0,"study design",10629371,8,"Infertile cases with patent tubes documented by hysterosalpingography (HSG) or by HSG followed by laparoscopic examination (n = 80)."
0,background,10629371,9,"INTERVENTION(S)"
0,intervention,10629371,9,"INTERVENTION(S)"
0,population,10629371,9,"INTERVENTION(S)"
0,outcome,10629371,9,"INTERVENTION(S)"
1,other,10629371,9,"INTERVENTION(S)"
0,"study design",10629371,9,"INTERVENTION(S)"
0,background,10629371,10,"Hysteroscopic SSG."
1,intervention,10629371,10,"Hysteroscopic SSG."
0,population,10629371,10,"Hysteroscopic SSG."
0,outcome,10629371,10,"Hysteroscopic SSG."
0,other,10629371,10,"Hysteroscopic SSG."
0,"study design",10629371,10,"Hysteroscopic SSG."
0,background,10629371,11,"MAIN OUTCOME MEASURE(S)"
0,intervention,10629371,11,"MAIN OUTCOME MEASURE(S)"
0,population,10629371,11,"MAIN OUTCOME MEASURE(S)"
0,outcome,10629371,11,"MAIN OUTCOME MEASURE(S)"
1,other,10629371,11,"MAIN OUTCOME MEASURE(S)"
0,"study design",10629371,11,"MAIN OUTCOME MEASURE(S)"
0,background,10629371,12,"Patency rate of tubes by SSG."
0,intervention,10629371,12,"Patency rate of tubes by SSG."
0,population,10629371,12,"Patency rate of tubes by SSG."
0,outcome,10629371,12,"Patency rate of tubes by SSG."
1,other,10629371,12,"Patency rate of tubes by SSG."
0,"study design",10629371,12,"Patency rate of tubes by SSG."
0,background,10629371,13,"Pregnancy rate following SSG."
0,intervention,10629371,13,"Pregnancy rate following SSG."
0,population,10629371,13,"Pregnancy rate following SSG."
0,outcome,10629371,13,"Pregnancy rate following SSG."
1,other,10629371,13,"Pregnancy rate following SSG."
0,"study design",10629371,13,"Pregnancy rate following SSG."
0,background,10629371,14,"RESULT(S)"
0,intervention,10629371,14,"RESULT(S)"
0,population,10629371,14,"RESULT(S)"
0,outcome,10629371,14,"RESULT(S)"
1,other,10629371,14,"RESULT(S)"
0,"study design",10629371,14,"RESULT(S)"
0,background,10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
0,intervention,10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
0,population,10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
1,outcome,10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
0,other,10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
0,"study design",10629371,15,"Eighty cases were divided into the study group (SSG performed, 37 cases) and the case-control group (SSG not performed, 43 cases)."
0,background,10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
0,intervention,10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
0,population,10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
1,outcome,10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
0,other,10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
0,"study design",10629371,16,"Successful SSG of at least one tube was obtained in all of 37 cases (100%) in whom SSG was attempted."
0,background,10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
0,intervention,10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
0,population,10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
1,outcome,10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
0,other,10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
0,"study design",10629371,17,"A patency rate of 95.9% was documented in the 73 cannulated tubes of these cases."
0,background,10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
0,intervention,10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
0,population,10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
1,outcome,10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
0,other,10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
0,"study design",10629371,18,"The total subsequent pregnancy rate (48.6%) within 12 months of follow-up after SSG was significantly higher than that (11.6%) obtained in the control group (p &lt; 0.001)."
0,background,10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
0,intervention,10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
0,population,10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
1,outcome,10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
0,other,10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
0,"study design",10629371,19,"The cumulative pregnancy rate in the study group was also significantly higher than that in the control group (p &lt; 0.001)."
0,background,10629371,20,"CONCLUSION(S)"
0,intervention,10629371,20,"CONCLUSION(S)"
0,population,10629371,20,"CONCLUSION(S)"
0,outcome,10629371,20,"CONCLUSION(S)"
1,other,10629371,20,"CONCLUSION(S)"
0,"study design",10629371,20,"CONCLUSION(S)"
0,background,10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
0,intervention,10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
0,population,10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
1,outcome,10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
0,other,10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
0,"study design",10629371,21,"The findings of the present study encourage the application of SSG to infertile women, either as a sole therapeutic approach or in association with other methods of assisted reproductive technology, even if their fallopian tubes are shown to be patent by "
0,background,10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
0,intervention,10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
1,population,10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
0,outcome,10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
0,other,10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
0,"study design",10640920,1,"The beneficial effects of ventral intermediate nucleus (VIM) stimulation were evaluated in 20 patients with tremor refractory to medical therapy."
1,background,10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,intervention,10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,population,10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,outcome,10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,other,10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,"study design",10640920,2,"Thalamic stimulation is a non-ablative procedure which has the advantage of a reversible, non-destructive lesion."
0,background,10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
1,intervention,10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
0,population,10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
0,outcome,10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
0,other,10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
0,"study design",10640920,3,"Eleven patients [7 with Parkinson's disease (PD) and 4 with essential tremor (ET)] received unilateral VIM implantation, while 9 patients had staged bilateral VIM implantation (4 with PD, 5 with ET)."
0,background,10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
0,intervention,10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
0,population,10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
1,outcome,10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
0,other,10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
0,"study design",10640920,4,"PD patients showed a significant improvement in contralateral arm and leg rest tremor and ipsilateral leg rest tremor (p &lt; 0.02) at a mean follow-up period of 16.2 +/- 7.0 months."
0,background,10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
0,intervention,10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
0,population,10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
1,outcome,10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
0,other,10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
0,"study design",10640920,5,"Patients with PD did not demonstrate any significant decrease in medication use at follow-up."
0,background,10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
0,intervention,10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
0,population,10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
1,outcome,10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
0,other,10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
0,"study design",10640920,6,"ET patients demonstrated significant improvement in postural and action tremor in the contralateral arm (p &lt; 0.001), but no significant improvement in the contralateral leg tremor at follow-up."
0,background,10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
0,intervention,10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
0,population,10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
1,outcome,10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
0,other,10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
0,"study design",10640920,7,"Significant improvements were also seen in ET patients in the Clinical Rating Scale for Tremor (p &lt; 0.001) with respect to several activities of daily living at a mean follow-up of 14.9 +/- 8. 1 months."
0,background,10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
0,intervention,10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
0,population,10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
1,outcome,10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
0,other,10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
0,"study design",10640920,8,"Deep brain stimulation is a safe and effective treatment for severe tremor refractory to medications."
0,background,10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
0,intervention,10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
0,population,10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
1,outcome,10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
0,other,10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
0,"study design",10640920,9,"It is a highly effective, reversible, adaptable, and predictable procedure which avoids the complication of cognitive deficit seen in patients with bilateral thalamotomies."
0,background,10694717,1,"OBJECTIVE"
0,intervention,10694717,1,"OBJECTIVE"
0,population,10694717,1,"OBJECTIVE"
0,outcome,10694717,1,"OBJECTIVE"
1,other,10694717,1,"OBJECTIVE"
0,"study design",10694717,1,"OBJECTIVE"
1,background,10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
0,intervention,10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
1,population,10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
0,outcome,10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
0,other,10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
0,"study design",10694717,2,"We examined affective and cognitive components of body image related to physical appearance, weight, and health among 120 university men and women of three racial/ethnic groups: African American, European American, and Latino/a American."
0,background,10694717,3,"METHOD"
0,intervention,10694717,3,"METHOD"
0,population,10694717,3,"METHOD"
0,outcome,10694717,3,"METHOD"
1,other,10694717,3,"METHOD"
0,"study design",10694717,3,"METHOD"
0,background,10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
0,intervention,10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
0,population,10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
0,outcome,10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
1,other,10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
0,"study design",10694717,4,"Participants completed a Background Information Sheet, the Multidimensional Body-Self Relations Questionnaire (MBSRQ), the Body-Esteem Scale (BES) with additional items, and the Balanced Inventory of Desirable Responding (BIDR)."
0,background,10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
0,intervention,10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
0,population,10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
0,outcome,10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
1,other,10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
0,"study design",10694717,5,"We tested for effects of race/ethnicity and gender on the body image measures while controlling for age, body size, social desirability, and socioeconomic status (SES)."
0,background,10694717,6,"RESULTS"
0,intervention,10694717,6,"RESULTS"
0,population,10694717,6,"RESULTS"
0,outcome,10694717,6,"RESULTS"
1,other,10694717,6,"RESULTS"
0,"study design",10694717,6,"RESULTS"
0,background,10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
0,intervention,10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
0,population,10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
1,outcome,10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
0,other,10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
0,"study design",10694717,7,"African Americans reported greatest body satisfaction and least overestimation of weight."
0,background,10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
0,intervention,10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
0,population,10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
1,outcome,10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
0,other,10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
0,"study design",10694717,8,"Latino/a Americans were equal to or higher than European Americans on all indices."
0,background,10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
0,intervention,10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
0,population,10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
1,outcome,10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
0,other,10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
0,"study design",10694717,9,"Gender differences occurred on global body image, weight concerns, fitness, and health."
0,background,10694717,10,"There were no Gender x Race/Ethnicity interactions."
0,intervention,10694717,10,"There were no Gender x Race/Ethnicity interactions."
0,population,10694717,10,"There were no Gender x Race/Ethnicity interactions."
1,outcome,10694717,10,"There were no Gender x Race/Ethnicity interactions."
0,other,10694717,10,"There were no Gender x Race/Ethnicity interactions."
0,"study design",10694717,10,"There were no Gender x Race/Ethnicity interactions."
0,background,10694717,11,"DISCUSSION"
0,intervention,10694717,11,"DISCUSSION"
0,population,10694717,11,"DISCUSSION"
0,outcome,10694717,11,"DISCUSSION"
1,other,10694717,11,"DISCUSSION"
0,"study design",10694717,11,"DISCUSSION"
0,background,10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
0,intervention,10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
0,population,10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
1,outcome,10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
0,other,10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
0,"study design",10694717,12,"This pattern of racial/ethnic and gender differences shows a need for exploring a wider range of culturally relevant body image dimensions."
1,background,10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
0,intervention,10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
0,population,10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
0,outcome,10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
0,other,10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
0,"study design",10709685,1,"Considerable evidence has now accumulated that permanent pacing may provide symptomatic benefit for at least some patients with CHF."
1,background,10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
0,intervention,10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
0,population,10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
0,outcome,10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
0,other,10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
0,"study design",10709685,2,"Recently, the most promising results with left ventricular or biventricular pacing have been obtained."
1,background,10709685,3,"The data for improvement in survival with pacing is less compelling."
0,intervention,10709685,3,"The data for improvement in survival with pacing is less compelling."
0,population,10709685,3,"The data for improvement in survival with pacing is less compelling."
0,outcome,10709685,3,"The data for improvement in survival with pacing is less compelling."
0,other,10709685,3,"The data for improvement in survival with pacing is less compelling."
0,"study design",10709685,3,"The data for improvement in survival with pacing is less compelling."
1,background,10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
0,intervention,10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
0,population,10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
0,outcome,10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
0,other,10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
0,"study design",10709685,4,"The mortality of CHF associated with systolic dysfunction of the left ventricle remains high and arrhythmic deaths are frequent."
1,background,10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
0,intervention,10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
0,population,10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
0,outcome,10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
0,other,10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
0,"study design",10709685,5,"Clinical trials such as the Sudden Cardiac Death Heart Failure Trial (SCD-HeFT) are currently underway to investigate the role of the implantable defibrillator in patients with heart failure."
1,background,10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,intervention,10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,population,10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,outcome,10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,other,10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,"study design",10709685,6,"The development and general availability of ICDs with biventricular pacing capability may play an increasingly important role in the overall therapeutic plan for this group of patients to allow for optimization of functional status with pacing and protect"
0,background,10783181,1,"OBJECTIVE"
0,intervention,10783181,1,"OBJECTIVE"
0,population,10783181,1,"OBJECTIVE"
0,outcome,10783181,1,"OBJECTIVE"
1,other,10783181,1,"OBJECTIVE"
0,"study design",10783181,1,"OBJECTIVE"
1,background,10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
1,intervention,10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
0,population,10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
0,outcome,10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
0,other,10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
1,"study design",10783181,2,"The review examined the historical progression and current status of pharmacotherapy of child and adolescent major affective disorder."
0,background,10783181,3,"METHODS"
0,intervention,10783181,3,"METHODS"
0,population,10783181,3,"METHODS"
0,outcome,10783181,3,"METHODS"
1,other,10783181,3,"METHODS"
0,"study design",10783181,3,"METHODS"
0,background,10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
0,intervention,10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
1,population,10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
0,outcome,10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
0,other,10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
0,"study design",10783181,4,"A MEDLINE search was used to identify double-blind, placebo-controlled studies of child and adolescent major depression."
0,background,10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
0,intervention,10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
0,population,10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
0,outcome,10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
1,other,10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
0,"study design",10783181,5,"Only studies that used reliable diagnostic and recovery parameters were included."
0,background,10783181,6,"RESULTS"
0,intervention,10783181,6,"RESULTS"
0,population,10783181,6,"RESULTS"
0,outcome,10783181,6,"RESULTS"
1,other,10783181,6,"RESULTS"
0,"study design",10783181,6,"RESULTS"
0,background,10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
0,intervention,10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
0,population,10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
1,outcome,10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
0,other,10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
0,"study design",10783181,7,"Few well-designed studies have compared placebo and tricyclic antidepressants in the treatment of major depressive disorder in children and adolescents."
0,background,10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
0,intervention,10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
0,population,10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
1,outcome,10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
0,other,10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
0,"study design",10783181,8,"However, results consistently suggest that tricyclic antidepressants are not efficacious."
0,background,10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
0,intervention,10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
0,population,10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
1,outcome,10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
0,other,10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
0,"study design",10783181,9,"Early results of double-blind placebo-controlled trials with fluoxetine and paroxetine have shown a significant drug effect."
0,background,10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
0,intervention,10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
0,population,10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
1,outcome,10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
0,other,10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
0,"study design",10783181,10,"However, the results are inconsistent, which could reflect the ways that response to medication is defined, the ways that rating scales measure recovery, and uncertainties of dosing strategies with second-generation antidepressants."
0,background,10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
0,intervention,10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
0,population,10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
1,outcome,10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
0,other,10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
0,"study design",10783181,11,"Hypothesized reasons for the unique response pattern in youths include the changing hormonal status of children, the differential maturation of the noradrenergic versus serotonergic neurotransmitter systems, and the possibility that a large proportion of "
0,background,10783181,12,"CONCLUSIONS"
0,intervention,10783181,12,"CONCLUSIONS"
0,population,10783181,12,"CONCLUSIONS"
0,outcome,10783181,12,"CONCLUSIONS"
1,other,10783181,12,"CONCLUSIONS"
0,"study design",10783181,12,"CONCLUSIONS"
0,background,10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
0,intervention,10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
0,population,10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
1,outcome,10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
0,other,10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
0,"study design",10783181,13,"Tricyclic antidepressants are not superior to placebo for the treatment of child and adolescent major depressive disorder."
0,background,10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
0,intervention,10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
0,population,10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
1,outcome,10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
0,other,10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
0,"study design",10783181,14,"Although two of three trials of second-generation antidepressants in this age group have had negative results, data suggest that these drugs may be more promising."
0,background,10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
0,intervention,10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
0,population,10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
1,outcome,10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
0,other,10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
0,"study design",10783181,15,"It is too early in our investigation to know whether these agents will be effective in treating major depressive disorder in children and adolescents."
1,background,10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
0,intervention,10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
0,population,10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
0,outcome,10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
0,other,10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
0,"study design",10802963,1,"Overall, this study demonstrates significant deficiencies in end-of-life care content in nursing textbooks."
1,background,10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
0,intervention,10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
0,population,10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
0,outcome,10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
0,other,10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
0,"study design",10802963,2,"Defining palliative care, quality of life at the end of life, and issues of policy, ethics, and law are the foundation of end-of-life care."
1,background,10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
0,intervention,10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
0,population,10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
0,outcome,10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
0,other,10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
0,"study design",10802963,3,"Analysis of these topics revealed a need to clarify concepts and to apply them within the context of end-of-life care."
1,background,10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
0,intervention,10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
0,population,10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
0,outcome,10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
0,other,10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
0,"study design",10802963,4,"The analysis also demonstrated a need to transfer findings from palliative care research and concepts from hospice into basic education."
1,background,10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
0,intervention,10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
0,population,10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
0,outcome,10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
0,other,10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
0,"study design",10802963,5,"In March 1999 the investigators convened a conference in New York in collaboration with a group of medical investigators analyzing EOL content in medical textbooks."
1,background,10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
0,intervention,10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
0,population,10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
0,outcome,10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
0,other,10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
0,"study design",10802963,6,"The conference was also attended by publishers, editors, and authors of textbooks."
1,background,10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
0,intervention,10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
0,population,10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
0,outcome,10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
0,other,10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
0,"study design",10802963,7,"The investigators were very encouraged by their interest in and commitment to correcting any weaknesses in their books."
1,background,10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
0,intervention,10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
0,population,10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
0,outcome,10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
0,other,10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
0,"study design",10802963,8,"The investigators provided them with specific recommendations for improvement and resources for locating both appropriate content and authors with palliative care expertise."
1,background,10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
0,intervention,10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
0,population,10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
0,outcome,10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
0,other,10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
0,"study design",10802963,9,"These resources are also made available on the City of Hope Pain Resource Center Web site (http:@mayday.coh.org)."
1,background,10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
0,intervention,10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
0,population,10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
0,outcome,10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
0,other,10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
0,"study design",10802963,10,"Achieving the overall project goal of strengthened nursing education in end-of-life care will be reached through a variety of measures."
1,background,10802963,11,"Improving textbooks is but one important step."
0,intervention,10802963,11,"Improving textbooks is but one important step."
0,population,10802963,11,"Improving textbooks is but one important step."
0,outcome,10802963,11,"Improving textbooks is but one important step."
0,other,10802963,11,"Improving textbooks is but one important step."
0,"study design",10802963,11,"Improving textbooks is but one important step."
1,background,10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,intervention,10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,population,10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,outcome,10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,other,10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,"study design",10802963,12,"The various disciplines involved in palliative care can contribute to this project by working in collaboration with textbook publishers."
0,background,10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
1,intervention,10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
1,population,10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
0,outcome,10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
0,other,10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
0,"study design",10815841,1,"The self-awareness of brain injured patients in an acute inpatient rehabilitation programme was measured using the Functional Self-Appraisal Scale (FSAS), which compares patient and staff ratings of patient performance on tasks relevant for acute rehabili"
0,background,10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
0,intervention,10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
0,population,10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
1,outcome,10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
0,other,10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
0,"study design",10815841,2,"There was a significant difference between patients' and staffs ratings near admission, consistent with previous findings in post-acute settings that brain injured patients tend to overestimate their abilities relative to other raters."
0,background,10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
0,intervention,10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
0,population,10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
1,outcome,10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
0,other,10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
0,"study design",10815841,3,"Patient and staff ratings tended to converge at time of discharge, likely reflecting patients' improvements on rehabilitation tasks rather than increased self-awareness."
0,background,10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
0,intervention,10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
0,population,10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
1,outcome,10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
0,other,10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
0,"study design",10815841,4,"The average difference between patients' and staffs ratings did not correlate with neuropsychological functioning on admission, supporting evidence that self-awareness early in the recovery process is a unique construct."
0,background,10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
0,intervention,10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
0,population,10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
1,outcome,10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
0,other,10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
0,"study design",10815841,5,"Future research is outlined, including investigating the relationship of early levels of self-awareness following TBI to functional outcome."
0,background,10851110,1,"STUDY DESIGN"
0,intervention,10851110,1,"STUDY DESIGN"
0,population,10851110,1,"STUDY DESIGN"
0,outcome,10851110,1,"STUDY DESIGN"
1,other,10851110,1,"STUDY DESIGN"
0,"study design",10851110,1,"STUDY DESIGN"
0,background,10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
0,intervention,10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
0,population,10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
0,outcome,10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
0,other,10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
1,"study design",10851110,2,"A case report of ureteral injury as a complication incurred during a laparoscopy-assisted lumbar fusion."
0,background,10851110,3,"OBJECTIVE"
0,intervention,10851110,3,"OBJECTIVE"
0,population,10851110,3,"OBJECTIVE"
0,outcome,10851110,3,"OBJECTIVE"
1,other,10851110,3,"OBJECTIVE"
0,"study design",10851110,3,"OBJECTIVE"
0,background,10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
0,intervention,10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
0,population,10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
0,outcome,10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
1,other,10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
0,"study design",10851110,4,"To alert orthopedic surgeons to this injury, which may occur during such surgery."
0,background,10851110,5,"SUMMARY OF BACKGROUND DATA"
0,intervention,10851110,5,"SUMMARY OF BACKGROUND DATA"
0,population,10851110,5,"SUMMARY OF BACKGROUND DATA"
0,outcome,10851110,5,"SUMMARY OF BACKGROUND DATA"
1,other,10851110,5,"SUMMARY OF BACKGROUND DATA"
0,"study design",10851110,5,"SUMMARY OF BACKGROUND DATA"
1,background,10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,intervention,10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,population,10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,outcome,10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,other,10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,"study design",10851110,6,"Laparoscopy-assisted lumbar fusion is a minimally invasive surgical technique to accomplish lumbar fusion with excellent patient satisfaction, reduced hospital stay, and decreased rehabilitative time."
0,background,10851110,7,"METHOD AND RESULTS"
0,intervention,10851110,7,"METHOD AND RESULTS"
0,population,10851110,7,"METHOD AND RESULTS"
0,outcome,10851110,7,"METHOD AND RESULTS"
1,other,10851110,7,"METHOD AND RESULTS"
0,"study design",10851110,7,"METHOD AND RESULTS"
0,background,10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
0,intervention,10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
0,population,10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
0,outcome,10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
1,other,10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
0,"study design",10851110,8,"A case report is presented detailing ureteral injury as a complication of laparoscopy-assisted lumbar fusion and the subsequent treatment of the injury."
0,background,10851110,9,"CONCLUSION"
0,intervention,10851110,9,"CONCLUSION"
0,population,10851110,9,"CONCLUSION"
0,outcome,10851110,9,"CONCLUSION"
1,other,10851110,9,"CONCLUSION"
0,"study design",10851110,9,"CONCLUSION"
0,background,10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
0,intervention,10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
0,population,10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
1,outcome,10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
0,other,10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
0,"study design",10851110,10,"Laparoscopy-assisted lumbar fusion is a new, less invasive technique with excellent patient satisfaction; however, ureteral injury may occur, and the surgeon should keep this in mind if a postoperative fluid collection occurs in the pelvis."
0,background,10908939,1,"STUDY DESIGN"
0,intervention,10908939,1,"STUDY DESIGN"
0,population,10908939,1,"STUDY DESIGN"
0,outcome,10908939,1,"STUDY DESIGN"
1,other,10908939,1,"STUDY DESIGN"
0,"study design",10908939,1,"STUDY DESIGN"
0,background,10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
0,intervention,10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
0,population,10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
0,outcome,10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
0,other,10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
1,"study design",10908939,2,"A prospective study was developed to quantify acute low back pain recovery."
0,background,10908939,3,"OBJECTIVE"
0,intervention,10908939,3,"OBJECTIVE"
0,population,10908939,3,"OBJECTIVE"
0,outcome,10908939,3,"OBJECTIVE"
1,other,10908939,3,"OBJECTIVE"
0,"study design",10908939,3,"OBJECTIVE"
0,background,10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
0,intervention,10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
0,population,10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
0,outcome,10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
1,other,10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
0,"study design",10908939,4,"To compare traditional self-report measures of low back pain recovery with a quantitative measure of recovery."
0,background,10908939,5,"SUMMARY OF BACKGROUND DATA"
0,intervention,10908939,5,"SUMMARY OF BACKGROUND DATA"
0,population,10908939,5,"SUMMARY OF BACKGROUND DATA"
0,outcome,10908939,5,"SUMMARY OF BACKGROUND DATA"
1,other,10908939,5,"SUMMARY OF BACKGROUND DATA"
0,"study design",10908939,5,"SUMMARY OF BACKGROUND DATA"
1,background,10908939,6,"The magnitude of low back disorders in society continues to be a problem."
0,intervention,10908939,6,"The magnitude of low back disorders in society continues to be a problem."
0,population,10908939,6,"The magnitude of low back disorders in society continues to be a problem."
0,outcome,10908939,6,"The magnitude of low back disorders in society continues to be a problem."
0,other,10908939,6,"The magnitude of low back disorders in society continues to be a problem."
0,"study design",10908939,6,"The magnitude of low back disorders in society continues to be a problem."
1,background,10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,intervention,10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,population,10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,outcome,10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,other,10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,"study design",10908939,7,"To prevent secondary injuries, an understanding of recovery must be gained by comparing the natural course of recovery using several outcome measures."
0,background,10908939,8,"METHODS"
0,intervention,10908939,8,"METHODS"
0,population,10908939,8,"METHODS"
0,outcome,10908939,8,"METHODS"
1,other,10908939,8,"METHODS"
0,"study design",10908939,8,"METHODS"
0,background,10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
0,intervention,10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
1,population,10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
0,outcome,10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
0,other,10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
0,"study design",10908939,9,"For this study, 16 occupational and 16 nonoccupational patients with low back pain were recruited."
0,background,10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
0,intervention,10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
0,population,10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
0,outcome,10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
1,other,10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
0,"study design",10908939,10,"Recovery was monitored prospectively every 2 weeks for 3 to 6 months, using subjective work status, pain symptoms, activities of daily living, and objective functional performance probability (trunk kinematics)."
0,background,10908939,11,"RESULTS"
0,intervention,10908939,11,"RESULTS"
0,population,10908939,11,"RESULTS"
0,outcome,10908939,11,"RESULTS"
1,other,10908939,11,"RESULTS"
0,"study design",10908939,11,"RESULTS"
0,background,10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
0,intervention,10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
0,population,10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
1,outcome,10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
0,other,10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
0,"study design",10908939,12,"Return to work underestimated the percentage of subjects impaired, as compared with all other outcome measures."
0,background,10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
0,intervention,10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
0,population,10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
1,outcome,10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
0,other,10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
0,"study design",10908939,13,"Symptoms, activities of daily living, and functional performance probability all showed similar patterns of recovery for 0 to 12 weeks."
0,background,10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
0,intervention,10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
0,population,10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
1,outcome,10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
0,other,10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
0,"study design",10908939,14,"At 14 weeks, there was a lag in functional performance recovery."
0,background,10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
0,intervention,10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
0,population,10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
1,outcome,10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
0,other,10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
0,"study design",10908939,15,"Both symptoms and activities of daily living indicated that 80% of the population was recovered, whereas functional performance indicated the figure to be 68%."
0,background,10908939,16,"CONCLUSION"
0,intervention,10908939,16,"CONCLUSION"
0,population,10908939,16,"CONCLUSION"
0,outcome,10908939,16,"CONCLUSION"
1,other,10908939,16,"CONCLUSION"
0,"study design",10908939,16,"CONCLUSION"
0,background,10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
0,intervention,10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
0,population,10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
1,outcome,10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
0,other,10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
0,"study design",10908939,17,"This prospective study demonstrates the natural course of recovery using several outcome measures."
0,background,10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
0,intervention,10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
0,population,10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
1,outcome,10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
0,other,10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
0,"study design",10908939,18,"The objective kinematic functional performance measure of recovery quantifies a different aspect of impairment not evaluated by traditional subjective measures."
0,background,10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
0,intervention,10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
0,population,10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
1,outcome,10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
0,other,10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
0,"study design",10908939,19,"Use of several outcome measures may lead to a better understanding of low back pain recovery or residual impairment, which may minimize the risk of recurrent injury."
1,background,10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
0,intervention,10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
1,population,10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
0,outcome,10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
0,other,10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
0,"study design",10915567,1,"We have recently demonstrated that following a moderate contusion spinal cord injury (SCI) to rats, subsequent administration of basic fibroblast growth factor (bFGF) significantly enhances functional recovery and tissue sparing."
1,background,10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,intervention,10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,population,10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,outcome,10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,other,10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,"study design",10915567,2,"To further characterize the effects of bFGF, we evaluated its efficacy after a more severe contusion injury at T(10) using the NYU impactor."
0,background,10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
1,intervention,10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
0,population,10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
0,outcome,10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
0,other,10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
0,"study design",10915567,3,"Immediately after SCI, osmotic minipumps were implanted into the lateral ventricle and lumbar thecal sac to deliver bFGF at 3 or 6 microg per day versus control vehicle for 1 week."
0,background,10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
0,intervention,10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
0,population,10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
0,outcome,10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
1,other,10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
0,"study design",10915567,4,"Animals were behaviorally tested for 6 weeks before histological assessment of tissue sparing through the injured segment and glial reactivity distal to the lesion."
0,background,10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
0,intervention,10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
0,population,10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
1,outcome,10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
0,other,10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
0,"study design",10915567,5,"Compared to moderate SCI, all rats had more prolonged and sustained functional deficits 6 weeks after severe contusion."
0,background,10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
0,intervention,10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
0,population,10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
1,outcome,10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
0,other,10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
0,"study design",10915567,6,"Subjects treated with bFGF had pronounced recovery of hindlimb movements from 2 to 6 weeks compared to controls, manifested in significantly higher behavioral scores."
0,background,10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
0,intervention,10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
0,population,10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
1,outcome,10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
0,other,10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
0,"study design",10915567,7,"Only marginal tissue sparing was seen rostral to the injury in bFGF-treated spinal cords versus controls."
0,background,10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
0,intervention,10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
0,population,10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
1,outcome,10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
0,other,10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
0,"study design",10915567,8,"Optical density measurements of astrocyte and microglial cell immunoreactivity in bFGF-treated spinal cords showed that after 6 weeks they approximated controls, although astrocyte immunoreactivity remained higher in controls rostrally."
0,background,10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
0,intervention,10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
0,population,10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
1,outcome,10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
0,other,10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
0,"study design",10915567,9,"In summary, intrathecal infusion of bFGF following severe SCI significantly restores gross hindlimb motor function that is not correlated with significant tissue sparing."
0,background,10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
0,intervention,10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
0,population,10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
1,outcome,10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
0,other,10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
0,"study design",10915567,10,"In light of previous evidence that pharmacological intervention with bFGF after moderate SCI enhances tissue preservation, the current findings indicate that yet undefined mechanisms contribute to the enhanced functional recovery following bFGF treatment."
0,background,11004368,1,"OBJECTIVE"
0,intervention,11004368,1,"OBJECTIVE"
0,population,11004368,1,"OBJECTIVE"
0,outcome,11004368,1,"OBJECTIVE"
1,other,11004368,1,"OBJECTIVE"
0,"study design",11004368,1,"OBJECTIVE"
1,background,11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,intervention,11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,population,11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,outcome,11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,other,11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,"study design",11004368,2,"To examine the relation between leisure-time physical activity and ovarian cancer."
0,background,11004368,3,"METHODS"
0,intervention,11004368,3,"METHODS"
0,population,11004368,3,"METHODS"
0,outcome,11004368,3,"METHODS"
1,other,11004368,3,"METHODS"
0,"study design",11004368,3,"METHODS"
0,background,11004368,4,"We used data from a population based case-control study."
0,intervention,11004368,4,"We used data from a population based case-control study."
0,population,11004368,4,"We used data from a population based case-control study."
0,outcome,11004368,4,"We used data from a population based case-control study."
0,other,11004368,4,"We used data from a population based case-control study."
1,"study design",11004368,4,"We used data from a population based case-control study."
0,background,11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
0,intervention,11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
1,population,11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
0,outcome,11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
0,other,11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
0,"study design",11004368,5,"Cases (n = 767) were women 20-69 years of age in whom epithelial ovarian cancer was diagnosed during 1994-1998 and who resided in a defined region of Pennsylvania, New Jersey, or Delaware."
0,background,11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
0,intervention,11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
1,population,11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
0,outcome,11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
0,other,11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
0,"study design",11004368,6,"Controls (n = 1367) were ascertained by using random-digit dialing and Health Care Financing Administration files and were frequency-matched to cases for age and county of residence."
0,background,11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
0,intervention,11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
0,population,11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
0,outcome,11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
1,other,11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
0,"study design",11004368,7,"Information on lifetime leisure-time physical activity was obtained during in-person interviews."
0,background,11004368,8,"RESULTS"
0,intervention,11004368,8,"RESULTS"
0,population,11004368,8,"RESULTS"
0,outcome,11004368,8,"RESULTS"
1,other,11004368,8,"RESULTS"
0,"study design",11004368,8,"RESULTS"
0,background,11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
0,intervention,11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
0,population,11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
1,outcome,11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
0,other,11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
0,"study design",11004368,9,"Leisure-time physical activity was significantly associated with reduced occurrence of ovarian cancer (P =.01)."
0,background,11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
0,intervention,11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
0,population,11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
1,outcome,11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
0,other,11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
0,"study design",11004368,10,"After adjustment for age, parity, oral contraceptive use, tubal ligation, family history of ovarian cancer, race, and body mass index, women with the highest level of activity had an odds ratio of 0.73 (95% CI 0.56, 0.94) for ovarian cancer compared with "
0,background,11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
0,intervention,11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
0,population,11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
1,outcome,11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
0,other,11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
0,"study design",11004368,11,"When the relation was analyzed by various recalled time periods during life, the odds ratios for the highest versus the lowest category of activity at ages 14-17, 18-21, 22-29, 30-39, 40-49, and >50 years ranged from 0.64-0.78."
0,background,11004368,12,"CONCLUSION"
0,intervention,11004368,12,"CONCLUSION"
0,population,11004368,12,"CONCLUSION"
0,outcome,11004368,12,"CONCLUSION"
1,other,11004368,12,"CONCLUSION"
0,"study design",11004368,12,"CONCLUSION"
0,background,11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
0,intervention,11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
0,population,11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
1,outcome,11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
0,other,11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
0,"study design",11004368,13,"Leisure-time physical activity is associated with reduced occurrence of epithelial ovarian cancer."
0,background,11018430,1,"PURPOSE"
0,intervention,11018430,1,"PURPOSE"
0,population,11018430,1,"PURPOSE"
0,outcome,11018430,1,"PURPOSE"
1,other,11018430,1,"PURPOSE"
0,"study design",11018430,1,"PURPOSE"
1,background,11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
0,intervention,11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
0,population,11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
0,outcome,11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
0,other,11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
0,"study design",11018430,2,"Evaluating the impact of population-based rehabilitation interventions for work-related low back disorders (WR-LBD) requires job exposure factors to be considered as time-varying covariates."
1,background,11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
0,intervention,11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
0,population,11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
0,outcome,11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
0,other,11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
0,"study design",11018430,3,"The role of job factors in recovery has not been well-established as most studies are based upon clinic samples, not working populations."
1,background,11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
0,intervention,11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
1,population,11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
0,outcome,11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
0,other,11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
0,"study design",11018430,4,"This report represents the initial exploration of variables to be included in modeling job exposures as time-varying covariates of a study of work-place based rehabilitation intervention.METHODS: The study sample consisted of 162 hourly production employe"
0,background,11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
0,intervention,11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
0,population,11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
0,outcome,11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
1,other,11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
0,"study design",11018430,5,"Data reported herein were collected at baseline from an on-going large randomized clinical trial of rehabilitation for WR-LBD."
0,background,11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
0,intervention,11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
0,population,11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
1,outcome,11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
0,other,11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
0,"study design",11018430,6,"Low back pain as measured by the North American Spine Society Baseline Form was examined in relation to: self-reported job factors from the Job Content Questionnaire and job risk category for low back disorder determined by the Lumbar Motion Monitor (LMM)"
0,background,11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
0,intervention,11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
0,population,11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
1,outcome,11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
0,other,11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
0,"study design",11018430,7,"Low back pain was significantly (p &lt; 0.05) correlated with perceptions of: how hard the work was, how much physical effort was required, how hectic the job was, whether or not there was sufficient time to do the job, and how much concentration and phys"
1,background,11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
0,intervention,11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
0,population,11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
0,outcome,11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
0,other,11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
0,"study design",11033517,1,"Intrathecal immunoglobulin synthesis is observed in more than 90% of all cases of multiple sclerosis, producing a specific CSF IgG oligoclonal electrophoretic pattern."
1,background,11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
0,intervention,11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
0,population,11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
0,outcome,11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
0,other,11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
0,"study design",11033517,2,"The consensual method used as reference is isoelectric focusing (IEF)."
1,background,11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,intervention,11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,population,11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,outcome,11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,other,11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,"study design",11033517,3,"We developed a new CSF Ig analysis method by immunofixation (IF)."
0,background,11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
1,intervention,11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
0,population,11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
0,outcome,11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
0,other,11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
0,"study design",11033517,4,"The method includes an immunoenzymatic detection step performed directly on the gel allowing the use of unconcentrated CSF and avoiding the blotting step."
1,background,11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,intervention,11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,population,11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,outcome,11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,other,11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,"study design",11033517,5,"The reliability of this method was established by the analysis of 210 CSF/serum pairs including defined, probable and possible MS, other inflammatory CNS diseases and controls (noninflammatory CNS diseases and peripheral nervous system diseases)."
0,background,11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
0,intervention,11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
0,population,11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
1,outcome,11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
0,other,11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
0,"study design",11033517,6,"Intrathecal IgG synthesis was detected in 95.5% of defined MS cases."
0,background,11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
0,intervention,11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
0,population,11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
1,outcome,11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
0,other,11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
0,"study design",11033517,7,"The specificity for CNS inflammatory diseases including MS diagnosis, evaluated by comparison with controls, was 98.8%."
0,background,11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
0,intervention,11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
0,population,11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
1,outcome,11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
0,other,11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
0,"study design",11033517,8,"This new method is quicker and visual interpretation is easier than with IEF."
0,background,11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
0,intervention,11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
0,population,11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
1,outcome,11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
0,other,11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
0,"study design",11033517,9,"It is a semi-automated method that should be considered for standardization of CSF IgG analysis."
0,background,11034763,1,"OBJECTIVES"
0,intervention,11034763,1,"OBJECTIVES"
0,population,11034763,1,"OBJECTIVES"
0,outcome,11034763,1,"OBJECTIVES"
1,other,11034763,1,"OBJECTIVES"
0,"study design",11034763,1,"OBJECTIVES"
1,background,11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,intervention,11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,population,11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,outcome,11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,other,11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,"study design",11034763,2,"To determine the effect of iNO, compared with inhaled placebo, on outcome in AHRF in children and/or adults."
0,background,11034763,3,"SEARCH STRATEGY"
0,intervention,11034763,3,"SEARCH STRATEGY"
0,population,11034763,3,"SEARCH STRATEGY"
0,outcome,11034763,3,"SEARCH STRATEGY"
1,other,11034763,3,"SEARCH STRATEGY"
0,"study design",11034763,3,"SEARCH STRATEGY"
0,background,11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
0,intervention,11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
0,population,11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
0,outcome,11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
1,other,11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
0,"study design",11034763,4,"Randomised controlled trials (RCT's) were identified from electronic databases; MEDLINE, EMBASE, the Cochrane Library, and CINAHL, as well as from bibliographies of retrieved articles."
0,background,11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
0,intervention,11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
0,population,11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
0,outcome,11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
1,other,11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
0,"study design",11034763,5,"Relevant journals and conference proceedings were hand searched and authors published in this field were contacted for knowledge of unpublished ongoing trials."
0,background,11034763,6,"SELECTION CRITERIA"
0,intervention,11034763,6,"SELECTION CRITERIA"
0,population,11034763,6,"SELECTION CRITERIA"
0,outcome,11034763,6,"SELECTION CRITERIA"
1,other,11034763,6,"SELECTION CRITERIA"
0,"study design",11034763,6,"SELECTION CRITERIA"
0,background,11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
1,intervention,11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
1,population,11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
0,outcome,11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
0,other,11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
0,"study design",11034763,7,"RCT's comparing iNO with maximal conventional therapy and inhaled placebo, for AHRF in either children or adults."
0,background,11034763,8,"DATA COLLECTION AND ANALYSIS"
0,intervention,11034763,8,"DATA COLLECTION AND ANALYSIS"
0,population,11034763,8,"DATA COLLECTION AND ANALYSIS"
0,outcome,11034763,8,"DATA COLLECTION AND ANALYSIS"
1,other,11034763,8,"DATA COLLECTION AND ANALYSIS"
0,"study design",11034763,8,"DATA COLLECTION AND ANALYSIS"
0,background,11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
0,intervention,11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
0,population,11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
0,outcome,11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
1,other,11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
0,"study design",11034763,9,"Data were extracted and the analyses performed independently by two reviewers."
0,background,11034763,10,"All 5 authors were contacted for missing data."
0,intervention,11034763,10,"All 5 authors were contacted for missing data."
0,population,11034763,10,"All 5 authors were contacted for missing data."
0,outcome,11034763,10,"All 5 authors were contacted for missing data."
1,other,11034763,10,"All 5 authors were contacted for missing data."
0,"study design",11034763,10,"All 5 authors were contacted for missing data."
0,background,11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
0,intervention,11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
0,population,11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
0,outcome,11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
1,other,11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
0,"study design",11034763,11,"Qualitative assessment of each trial was made according to methodology described by Schulz (Schulz 1995), and analyses according to statistical methods in Review Manager MetaView 3.1."
0,background,11034763,12,"The fixed effect model was applied."
0,intervention,11034763,12,"The fixed effect model was applied."
0,population,11034763,12,"The fixed effect model was applied."
0,outcome,11034763,12,"The fixed effect model was applied."
1,other,11034763,12,"The fixed effect model was applied."
0,"study design",11034763,12,"The fixed effect model was applied."
0,background,11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
0,intervention,11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
0,population,11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
0,outcome,11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
1,other,11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
0,"study design",11034763,13,"Where possible, sub-group analyses were performed to assess the impact of iNO in varied doses."
0,background,11034763,14,"MAIN RESULTS"
0,intervention,11034763,14,"MAIN RESULTS"
0,population,11034763,14,"MAIN RESULTS"
0,outcome,11034763,14,"MAIN RESULTS"
1,other,11034763,14,"MAIN RESULTS"
0,"study design",11034763,14,"MAIN RESULTS"
0,background,11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
0,intervention,11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
0,population,11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
1,outcome,11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
0,other,11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
0,"study design",11034763,15,"Five RCT's were evaluated, assessing 535 patients with AHRF."
0,background,11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
0,intervention,11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
0,population,11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
1,outcome,11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
0,other,11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
0,"study design",11034763,16,"Inhaled nitric oxide made no impact on mortality in trials without cross-over (RR 0.98, 95%CI 0.66, 1.44), or with cross-over of treatment failures to open-label iNO (RR 1.22, 95%CI 0.65, 2.29)."
0,background,11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
0,intervention,11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
0,population,11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
1,outcome,11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
0,other,11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
0,"study design",11034763,17,"Published evidence from one study demonstrated that iNO resulted in a transient improvement in oxygenation in the first 24 hours of treatment: the oxygenation index (OI) showed a mean difference of -3 [95% CI -5.354, -0.646], and PaO2/FiO2 ratio, a mean d"
0,background,11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
0,intervention,11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
0,population,11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
1,outcome,11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
0,other,11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
0,"study design",11034763,18,"Limited data demonstrated no difference in ventilator-free days between treatment and placebo groups, and no specific dose of iNO was significantly advantageous over another."
0,background,11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
0,intervention,11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
0,population,11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
1,outcome,11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
0,other,11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
0,"study design",11034763,19,"Other clinical indicators of effectiveness, such as duration of hospital and intensive care stay, were inconsistently reported."
0,background,11034763,20,"There were no complications reported to be directly attributable to this treatment."
0,intervention,11034763,20,"There were no complications reported to be directly attributable to this treatment."
0,population,11034763,20,"There were no complications reported to be directly attributable to this treatment."
1,outcome,11034763,20,"There were no complications reported to be directly attributable to this treatment."
0,other,11034763,20,"There were no complications reported to be directly attributable to this treatment."
0,"study design",11034763,20,"There were no complications reported to be directly attributable to this treatment."
0,background,11034763,21,"REVIEWER'S CONCLUSIONS"
0,intervention,11034763,21,"REVIEWER'S CONCLUSIONS"
0,population,11034763,21,"REVIEWER'S CONCLUSIONS"
0,outcome,11034763,21,"REVIEWER'S CONCLUSIONS"
1,other,11034763,21,"REVIEWER'S CONCLUSIONS"
0,"study design",11034763,21,"REVIEWER'S CONCLUSIONS"
0,background,11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
0,intervention,11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
0,population,11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
1,outcome,11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
0,other,11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
0,"study design",11034763,22,"From the data provided to date, iNO had no effect on mortality and only transiently improved oxygenation in AHRF in children and/or adults."
0,background,11034763,23,"There was a lack of data to assess other end points."
0,intervention,11034763,23,"There was a lack of data to assess other end points."
0,population,11034763,23,"There was a lack of data to assess other end points."
0,outcome,11034763,23,"There was a lack of data to assess other end points."
1,other,11034763,23,"There was a lack of data to assess other end points."
0,"study design",11034763,23,"There was a lack of data to assess other end points."
0,background,11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
0,intervention,11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
0,population,11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
1,outcome,11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
0,other,11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
0,"study design",11034763,24,"The long term adverse effects of this drug are not known, as no long term follow-up of trial participants has been reported."
0,background,11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
0,intervention,11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
0,population,11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
1,outcome,11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
0,other,11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
0,"study design",11034763,25,"If further trials comparing iNO with an inhaled placebo are to proceed, they should be stratified for primary disease and must specifically evaluate clinically relevant outcomes, before any benefit of iNO in AHRF can be excluded."
0,background,11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
1,intervention,11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
1,population,11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
0,outcome,11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
0,other,11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
0,"study design",11086439,1,"Thirty-two patients with colorectal cancer, eleven with gastric cancer and two with pancreatic cancer were treated by hepatic arterial infusion chemotherapy from March 1988 to December 1999."
0,background,11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
1,intervention,11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
0,population,11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
0,outcome,11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
0,other,11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
0,"study design",11086439,2,"A single administration of 5-FU, MMC and epirubicin (FAM group), or intermittent continuous infusion of 5-FU 500 mg/2 h (5-FU continuous group) was used for each patient once a week."
0,background,11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
0,intervention,11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
0,population,11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
1,outcome,11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
0,other,11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
0,"study design",11086439,3,"Overall survival rates were not significantly different between the gastric and colorectal cancer patients."
0,background,11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
0,intervention,11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
0,population,11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
1,outcome,11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
0,other,11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
0,"study design",11086439,4,"In patients with colorectal cancer, there was a significant prolongation in overall survival for the response group."
0,background,11086439,5,"With gastric cancer, however, there was no significant difference."
0,intervention,11086439,5,"With gastric cancer, however, there was no significant difference."
0,population,11086439,5,"With gastric cancer, however, there was no significant difference."
1,outcome,11086439,5,"With gastric cancer, however, there was no significant difference."
0,other,11086439,5,"With gastric cancer, however, there was no significant difference."
0,"study design",11086439,5,"With gastric cancer, however, there was no significant difference."
0,background,11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
0,intervention,11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
0,population,11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
1,outcome,11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
0,other,11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
0,"study design",11086439,6,"For both of the two patients with pancreatic cancer, although they were responsive to the therapy, there was no prolongation of survival."
0,background,11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
0,intervention,11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
0,population,11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
1,outcome,11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
0,other,11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
0,"study design",11086439,7,"In conclusion, intermittent continuous infusion was more effective for the patients with colorectal cancer."
0,background,11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
0,intervention,11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
0,population,11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
1,outcome,11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
0,other,11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
0,"study design",11086439,8,"In patients with gastric and pancreatic cancer, hepatic intra-arterial infusion could control the progression of liver metastasis."
1,background,11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
0,intervention,11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
0,population,11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
0,outcome,11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
0,other,11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
0,"study design",11092158,1,"Health disparities among racial and ethnic groups have a long history and continue to exist in the United States."
1,background,11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
0,intervention,11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
0,population,11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
0,outcome,11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
0,other,11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
0,"study design",11092158,2,"The U.S. government has established as a goal for the year 2010 the elimination of racial/ethnic health differences in six areas."
1,background,11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
0,intervention,11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
0,population,11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
0,outcome,11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
0,other,11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
0,"study design",11092158,3,"This article examines disparities in one of those areas: access to high-quality health care."
1,background,11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,intervention,11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,population,11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,outcome,11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,other,11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,"study design",11092158,4,"Several measures of access to and use of health care services are studied both nationally and in 13 diverse states."
0,background,11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
0,intervention,11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
0,population,11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
1,outcome,11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
0,other,11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
0,"study design",11092158,5,"The authors find that both the magnitude of racial and ethnic disparity and the reasons behind it depend significantly on the state, the ethnic group, and the type of outcome measure being studied."
0,background,11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
0,intervention,11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
0,population,11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
1,outcome,11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
0,other,11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
0,"study design",11092158,6,"Such information can be valuable for state and national policy makers in targeting resources and in designing effective strategies for the elimination of racial and ethnic disparities."
1,background,11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
0,intervention,11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
1,population,11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
0,outcome,11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
0,other,11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
0,"study design",11255596,1,"Three meta-analyses have recently been reported on the relationship between choice of resuscitation fluid and risk of mortality in critically ill patients."
0,background,11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
0,intervention,11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
0,population,11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
1,outcome,11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
0,other,11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
0,"study design",11255596,2,"The relative risk of death (1.16-1.19) in two of the meta-analyses was slightly higher in colloid than crystalloid recipients; however, this observation was not statistically significant."
0,background,11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
0,intervention,11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
0,population,11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
1,outcome,11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
0,other,11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
0,"study design",11255596,3,"In the third meta-analysis, 6% (95% confidence interval [CI], 3-9%) pooled excess mortality was documented in patients receiving albumin for hypovolaemia, burns or hypoalbuminaemia."
0,background,11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
0,intervention,11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
0,population,11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
1,outcome,11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
0,other,11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
0,"study design",11255596,4,"The mortality difference in hypovolaemia patients (4%; 95% CI, 0-8%) was not statistically significant."
0,background,11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
0,intervention,11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
0,population,11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
1,outcome,11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
0,other,11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
0,"study design",11255596,5,"A variety of serious limitations apply to the three meta-analyses, suggesting that their findings be interpreted cautiously."
0,background,11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
0,intervention,11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
0,population,11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
1,outcome,11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
0,other,11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
0,"study design",11255596,6,"More than one-half of the randomized controlled trials (RCTs) included in the meta-analyses were reported prior to 1990 and hence do not reflect current practice."
0,background,11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
0,intervention,11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
0,population,11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
1,outcome,11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
0,other,11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
0,"study design",11255596,7,"Each meta-analysis included only a subset of relevant RCTs, and therefore the scope of inferences to be drawn from the meta-analytic results is limited."
0,background,11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
0,intervention,11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
0,population,11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
0,outcome,11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
1,other,11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
0,"study design",11255596,8,"The meta-analyses combined RCTs that were notably heterogeneous with respect to patient characteristics, type of illness, administered fluids and physiologic endpoints."
0,background,11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
0,intervention,11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
0,population,11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
0,outcome,11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
1,other,11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
0,"study design",11255596,9,"Differences in illness severity, concomitant therapies and fluid management approaches were not taken into account."
0,background,11255596,10,"Very few of the RCTs were blinded."
0,intervention,11255596,10,"Very few of the RCTs were blinded."
0,population,11255596,10,"Very few of the RCTs were blinded."
0,outcome,11255596,10,"Very few of the RCTs were blinded."
1,other,11255596,10,"Very few of the RCTs were blinded."
0,"study design",11255596,10,"Very few of the RCTs were blinded."
0,background,11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
0,intervention,11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
0,population,11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
1,outcome,11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
0,other,11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
0,"study design",11255596,11,"The meta-analyses do not support the conclusion that choice of resuscitation fluid is a major determinant of mortality in critically ill patients, nor do they support changes to current fluid management practice."
0,background,11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
0,intervention,11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
0,population,11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
1,outcome,11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
0,other,11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
0,"study design",11255596,12,"Changes such as exclusive reliance on crystalloids would necessitate a reassessment of the goals and methods of fluid therapy."
0,background,11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
0,intervention,11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
0,population,11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
1,outcome,11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
0,other,11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
0,"study design",11255596,13,"Since the effect on mortality may be minimal or non-existent, choice of resuscitation fluid should rest on whether the particular fluid permits the intensive care unit to provide better patient care."
1,background,11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
0,intervention,11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
1,population,11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
0,outcome,11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
0,other,11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
0,"study design",11262719,1,"The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors."
0,background,11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
0,intervention,11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
0,population,11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
1,outcome,11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
0,other,11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
0,"study design",11262719,2,"When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample."
0,background,11262719,3,"Gender did not affect level of test performance."
0,intervention,11262719,3,"Gender did not affect level of test performance."
0,population,11262719,3,"Gender did not affect level of test performance."
1,outcome,11262719,3,"Gender did not affect level of test performance."
0,other,11262719,3,"Gender did not affect level of test performance."
0,"study design",11262719,3,"Gender did not affect level of test performance."
0,background,11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
0,intervention,11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
0,population,11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
1,outcome,11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
0,other,11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
0,"study design",11262719,4,"Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI."
0,background,11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
0,intervention,11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
0,population,11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
1,outcome,11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
0,other,11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
0,"study design",11262719,5,"This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data."
0,background,11330764,1,"OBJECTIVE"
0,intervention,11330764,1,"OBJECTIVE"
0,population,11330764,1,"OBJECTIVE"
0,outcome,11330764,1,"OBJECTIVE"
1,other,11330764,1,"OBJECTIVE"
0,"study design",11330764,1,"OBJECTIVE"
1,background,11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,intervention,11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,population,11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,outcome,11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,other,11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,"study design",11330764,2,"To establish (1) whether associated reactions could contribute to contracture formation and (2) whether the presence of spasticity was essential for their expression, after stroke."
0,background,11330764,3,"SUBJECTS"
0,intervention,11330764,3,"SUBJECTS"
0,population,11330764,3,"SUBJECTS"
0,outcome,11330764,3,"SUBJECTS"
1,other,11330764,3,"SUBJECTS"
0,"study design",11330764,3,"SUBJECTS"
0,background,11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
0,intervention,11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
1,population,11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
0,outcome,11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
0,other,11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
0,"study design",11330764,4,"Subjects were 24 hemiparetics within 13 months of a stroke, unselected for contracture or spasticity."
0,background,11330764,5,"MAIN OUTCOME MEASURES"
0,intervention,11330764,5,"MAIN OUTCOME MEASURES"
0,population,11330764,5,"MAIN OUTCOME MEASURES"
0,outcome,11330764,5,"MAIN OUTCOME MEASURES"
1,other,11330764,5,"MAIN OUTCOME MEASURES"
0,"study design",11330764,5,"MAIN OUTCOME MEASURES"
0,background,11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
0,intervention,11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
0,population,11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
0,outcome,11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
1,other,11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
0,"study design",11330764,6,"Associated reactions were identified by the presence of muscle activity in the affected biceps brachii and quantified as the amount of affected elbow flexor torque produced during a moderate contraction of either the contralateral biceps brachii or the contralateral quadriceps muscles."
0,background,11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
0,intervention,11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
0,population,11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
0,outcome,11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
1,other,11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
0,"study design",11330764,7,"Contracture was measured as loss of elbow joint range of motion and spasticity as the presence of abnormal reflex activity."
0,background,11330764,8,"RESULTS"
0,intervention,11330764,8,"RESULTS"
0,population,11330764,8,"RESULTS"
0,outcome,11330764,8,"RESULTS"
1,other,11330764,8,"RESULTS"
0,"study design",11330764,8,"RESULTS"
0,background,11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
0,intervention,11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
0,population,11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
1,outcome,11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
0,other,11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
0,"study design",11330764,9,"Associated reactions were present in at least one testing condition in seven subjects."
0,background,11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
0,intervention,11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
0,population,11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
1,outcome,11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
0,other,11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
0,"study design",11330764,10,"During contractions of the contralateral biceps brachii, the median amount of elbow flexor torque produced was 0.39 (interquartile range, IQR 2.5) Nm while during contractions of the contralateral quadriceps muscle it was 0.19 (IQR 1.6) Nm."
0,background,11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
0,intervention,11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
0,population,11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
1,outcome,11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
0,other,11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
0,"study design",11330764,11,"Associated reactions were not associated with contracture (p = 0.39) which was present in over half of the subjects."
0,background,11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
0,intervention,11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
0,population,11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
1,outcome,11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
0,other,11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
0,"study design",11330764,12,"The incidence of associated reactions was about the same as that of spasticity, but the two were not related (p = 0.61)."
0,background,11330764,13,"CONCLUSIONS"
0,intervention,11330764,13,"CONCLUSIONS"
0,population,11330764,13,"CONCLUSIONS"
0,outcome,11330764,13,"CONCLUSIONS"
1,other,11330764,13,"CONCLUSIONS"
0,"study design",11330764,13,"CONCLUSIONS"
0,background,11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
0,intervention,11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
0,population,11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
1,outcome,11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
0,other,11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
0,"study design",11330764,14,"Even though associated reactions were present in 29% of the subjects during moderate contraction of the contralateral muscles, they were not large, nor were they associated with contracture or spasticity, suggesting that this phenomenon is not usually a m"
1,background,11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
0,intervention,11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
0,population,11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
0,outcome,11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
0,other,11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
0,"study design",11362752,1,"Recent studies have suggested that serotonin reuptake inhibitors (SSRI's), prescribed for the relief of depression, can cause sexual dysfunction in up to fifty percent of those taking them."
1,background,11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
0,intervention,11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
0,population,11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
0,outcome,11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
0,other,11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
0,"study design",11362752,2,"The SSRI's--including fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil)--affect mood stabilization by promoting the transmission of the neurotransmitter serotonin, although enhancing serotonergic function can decrease libido or lead to erec"
1,background,11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
0,intervention,11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
0,population,11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
0,outcome,11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
0,other,11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
0,"study design",11362752,3,"As an alternative to lowering antidepressant dosages and risking losing therapeutic gains, administering serotonin-blockers, such as cyproheptadine (Periactin) and yohimbine (Yocon), has been shown to restore sexual function."
1,background,11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
0,intervention,11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
0,population,11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
0,outcome,11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
0,other,11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
0,"study design",11362752,4,"However, the serotonin antagonist, cyproheptadine, causes sedation and can reverse the antidepressant or anti-obsessive effect of the SSRI."
1,background,11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
0,intervention,11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
0,population,11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
0,outcome,11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
0,other,11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
0,"study design",11362752,5,"Yohimbine enhances transmission of the neurotransmitter epinephrine, increasing the flow of blood to erectile tissue and stimulating sexual desire by activating the cerebral cortex."
1,background,11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
0,intervention,11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
0,population,11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
0,outcome,11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
0,other,11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
0,"study design",11362752,6,"Its drawbacks are increased levels of panic attacks and higher required dosages."
1,background,11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
0,intervention,11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
0,population,11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
0,outcome,11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
0,other,11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
0,"study design",11362752,7,"Other potential biochemical stratagems are: amantadine (Symmetrel), bromcriptine (Parlodel), and buspirone (Buspar), which enhance dopamine and serotonin transmission; and bethanecol (Urechline), which enhances choline transmission."
1,background,11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,intervention,11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,population,11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,outcome,11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,other,11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,"study design",11362752,8,"One study indicates improved sexual response when the nonserotonergic, mildly dopamine-enhancing buproprion (Welbutrin) is substituted for fluoxetine."
0,background,11405487,1,"OBJECTIVE"
0,intervention,11405487,1,"OBJECTIVE"
0,population,11405487,1,"OBJECTIVE"
0,outcome,11405487,1,"OBJECTIVE"
1,other,11405487,1,"OBJECTIVE"
0,"study design",11405487,1,"OBJECTIVE"
1,background,11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,intervention,11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,population,11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,outcome,11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,other,11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,"study design",11405487,2,"To investigate whether left atrial appendage outflow velocity alone or in relation to left atrial diameter is a superior predictor of sinus rhythm maintenance after cardioversion compared with traditional clinical or echocardiography parameters."
0,background,11405487,3,"DESIGN"
0,intervention,11405487,3,"DESIGN"
0,population,11405487,3,"DESIGN"
0,outcome,11405487,3,"DESIGN"
1,other,11405487,3,"DESIGN"
0,"study design",11405487,3,"DESIGN"
0,background,11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
1,intervention,11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
1,population,11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
0,outcome,11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
0,other,11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
0,"study design",11405487,4,"Sixty-two patients with their first episode of atrial fibrillation were examined using echocardiography before DC-cardioversion."
0,background,11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
0,intervention,11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
0,population,11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
0,outcome,11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
1,other,11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
0,"study design",11405487,5,"At one month's follow-up, 42 patients had maintained sinus rhythm (group A), and 20 had relapsed into atrial fibrillation (group B)."
0,background,11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
0,intervention,11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
0,population,11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
0,outcome,11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
1,other,11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
0,"study design",11405487,6,"There were no differences in arrhythmia duration or antiarrhythmic therapy between the groups."
0,background,11405487,7,"RESULTS"
0,intervention,11405487,7,"RESULTS"
0,population,11405487,7,"RESULTS"
0,outcome,11405487,7,"RESULTS"
1,other,11405487,7,"RESULTS"
0,"study design",11405487,7,"RESULTS"
0,background,11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
0,intervention,11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
0,population,11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
1,outcome,11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
0,other,11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
0,"study design",11405487,8,"Left atrial diameter measured by echocardiography was smaller in group A (42 mm, 95% CI 40.9-44.1 mm) compared with group B (46 mm, 95% CI 43.4-48.2, p &lt; 0.05)."
0,background,11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
0,intervention,11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
0,population,11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
1,outcome,11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
0,other,11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
0,"study design",11405487,9,"Patients in group A had a higher left atrial appendage outflow velocity at 0.44 m/s (95% CI 0.39-0.49) compared with 0.34 m/s (95% CI 0.30-0.37) in group B (p &lt; 0.01)."
0,background,11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
0,intervention,11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
0,population,11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
1,outcome,11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
0,other,11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
0,"study design",11405487,10,"The ratio of left atrial appendage flow to left atrial diameter was 0.011 (95% CI 0.009-0.012) in group A compared with 0.008 (95% CI 0.007-0.009) in group B, and 63% (95% CI 33-78) of the patients in group A had velocity ratio >0.009 compared with 20% (9"
0,background,11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
0,intervention,11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
0,population,11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
1,outcome,11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
0,other,11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
0,"study design",11405487,11,"Stepwise multiple logistic regression analysis showed that a velocity ratio >0.009 was the only predictor for maintenance of sinus rhythm one month after cardioversion with an odds ratio of 6.4 (95% CI 1.9-23.8), (p = 0.004)."
0,background,11405487,12,"CONCLUSION"
0,intervention,11405487,12,"CONCLUSION"
0,population,11405487,12,"CONCLUSION"
0,outcome,11405487,12,"CONCLUSION"
1,other,11405487,12,"CONCLUSION"
0,"study design",11405487,12,"CONCLUSION"
0,background,11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
0,intervention,11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
0,population,11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
1,outcome,11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
0,other,11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
0,"study design",11405487,13,"The ratio of left atrial appendage outflow velocity to left atrial diameter is superior to the traditionally used criteria for prediction of maintenance of sinus rhythm following DC-conversion of first-episode atrial fibrillation."
1,background,11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
0,intervention,11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
0,population,11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
0,outcome,11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
0,other,11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
0,"study design",11490970,1,"A functional capacity evaluation (FCE) is a detailed examination and evaluation that objectively measures the individual's current level of safe functional abilities, primarily within the context of the demands of competitive employment."
1,background,11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
0,intervention,11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
0,population,11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
0,outcome,11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
0,other,11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
0,"study design",11490970,2,"It measures the ability to perform functional or work-related tasks and predicts the potential to sustain these tasks over a defined time-frame."
1,background,11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
0,intervention,11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
0,population,11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
0,outcome,11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
0,other,11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
0,"study design",11490970,3,"Measurements of function from an FCE are compared to the physical demands of a job or other functional activities, and are used to make return-to-work/activity decisions, disability determinations, or to generate a rehabilitation plan."
1,background,11490970,4,"Scientific evidence on validity and reliability is limited so far."
0,intervention,11490970,4,"Scientific evidence on validity and reliability is limited so far."
0,population,11490970,4,"Scientific evidence on validity and reliability is limited so far."
0,outcome,11490970,4,"Scientific evidence on validity and reliability is limited so far."
0,other,11490970,4,"Scientific evidence on validity and reliability is limited so far."
0,"study design",11490970,4,"Scientific evidence on validity and reliability is limited so far."
1,background,11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,intervention,11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,population,11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,outcome,11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,other,11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,"study design",11490970,5,"An FCE is time-consuming and cannot be recommended as a routine evaluation."
0,background,11493843,1,"STUDY DESIGN"
0,intervention,11493843,1,"STUDY DESIGN"
0,population,11493843,1,"STUDY DESIGN"
0,outcome,11493843,1,"STUDY DESIGN"
1,other,11493843,1,"STUDY DESIGN"
0,"study design",11493843,1,"STUDY DESIGN"
0,background,11493843,2,"Randomized controlled trial (RCT)."
0,intervention,11493843,2,"Randomized controlled trial (RCT)."
0,population,11493843,2,"Randomized controlled trial (RCT)."
0,outcome,11493843,2,"Randomized controlled trial (RCT)."
0,other,11493843,2,"Randomized controlled trial (RCT)."
1,"study design",11493843,2,"Randomized controlled trial (RCT)."
0,background,11493843,3,"OBJECTIVES"
0,intervention,11493843,3,"OBJECTIVES"
0,population,11493843,3,"OBJECTIVES"
0,outcome,11493843,3,"OBJECTIVES"
1,other,11493843,3,"OBJECTIVES"
0,"study design",11493843,3,"OBJECTIVES"
0,background,11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
0,intervention,11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
0,population,11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
0,outcome,11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
1,other,11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
0,"study design",11493843,4,"To compare the effectiveness of training and equipment to reduce musculoskeletal injuries, increase comfort, and reduce physical demands on staff performing patient lifts and transfers at a large acute care hospital."
0,background,11493843,5,"SUMMARY OF BACKGROUND DATA"
0,intervention,11493843,5,"SUMMARY OF BACKGROUND DATA"
0,population,11493843,5,"SUMMARY OF BACKGROUND DATA"
0,outcome,11493843,5,"SUMMARY OF BACKGROUND DATA"
1,other,11493843,5,"SUMMARY OF BACKGROUND DATA"
0,"study design",11493843,5,"SUMMARY OF BACKGROUND DATA"
1,background,11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
0,intervention,11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
1,population,11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
0,outcome,11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
0,other,11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
0,"study design",11493843,6,"Back injury to nursing staff during patient handling tasks is a major issue in health care."
1,background,11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,intervention,11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,population,11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,outcome,11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,other,11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,"study design",11493843,7,"The value of mechanical assistive devices in reducing injuries to these workers is unclear."
0,background,11493843,8,"METHODS"
0,intervention,11493843,8,"METHODS"
0,population,11493843,8,"METHODS"
0,outcome,11493843,8,"METHODS"
1,other,11493843,8,"METHODS"
0,"study design",11493843,8,"METHODS"
0,background,11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
0,intervention,11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
0,population,11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
0,outcome,11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
1,other,11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
0,"study design",11493843,9,"This three-armed RCT consisted of a &quot;control arm,&quot; a &quot;safe lifting&quot; arm, and a &quot;no strenuous lifting&quot; arm."
0,background,11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
0,intervention,11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
0,population,11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
0,outcome,11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
1,other,11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
0,"study design",11493843,10,"A medical, surgical, and rehabilitation ward were each randomly assigned to each arm."
0,background,11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
1,intervention,11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
0,population,11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
0,outcome,11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
0,other,11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
0,"study design",11493843,11,"Both intervention arms received intensive training in back care, patient assessment, and handling techniques."
0,background,11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
0,intervention,11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
0,population,11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
0,outcome,11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
1,other,11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
0,"study design",11493843,12,"Hence, the &quot;safe lifting&quot; arm used improved patient handling techniques using manual equipment, whereas the &quot;no strenuous lifting&quot; arm aimed to eliminate manual patient handling through use of additional mechanical and other assistive equipment."
0,background,11493843,13,"RESULTS"
0,intervention,11493843,13,"RESULTS"
0,population,11493843,13,"RESULTS"
0,outcome,11493843,13,"RESULTS"
1,other,11493843,13,"RESULTS"
0,"study design",11493843,13,"RESULTS"
0,background,11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
0,intervention,11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
0,population,11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
1,outcome,11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
0,other,11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
0,"study design",11493843,14,"Frequency of manual patient handling tasks was significantly decreased on the &quot;no strenuous lifting&quot; arm."
0,background,11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
0,intervention,11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
0,population,11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
1,outcome,11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
0,other,11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
0,"study design",11493843,15,"Self-perceived work fatigue, back and shoulder pain, safety, and frequency and intensity of physical discomfort associated with patient handling tasks were improved on both intervention arms, but staff on the mechanical equipment arm showed greater improv"
0,background,11493843,16,"Musculoskeletal injury rates were not significantly altered."
0,intervention,11493843,16,"Musculoskeletal injury rates were not significantly altered."
0,population,11493843,16,"Musculoskeletal injury rates were not significantly altered."
1,outcome,11493843,16,"Musculoskeletal injury rates were not significantly altered."
0,other,11493843,16,"Musculoskeletal injury rates were not significantly altered."
0,"study design",11493843,16,"Musculoskeletal injury rates were not significantly altered."
0,background,11493843,17,"CONCLUSIONS"
0,intervention,11493843,17,"CONCLUSIONS"
0,population,11493843,17,"CONCLUSIONS"
0,outcome,11493843,17,"CONCLUSIONS"
1,other,11493843,17,"CONCLUSIONS"
0,"study design",11493843,17,"CONCLUSIONS"
0,background,11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
0,intervention,11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
0,population,11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
1,outcome,11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
0,other,11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
0,"study design",11493843,18,"The &quot;no strenuous lifting&quot; program, which combined training with assured availability of mechanical and other assistive patient handling equipment, most effectively improved comfort with patient handling, decreased staff fatigue, and decreased p"
0,background,11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
0,intervention,11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
0,population,11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
1,outcome,11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
0,other,11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
0,"study design",11493843,19,"The fact that injury rates were not statistically significantly reduced may reflect the less sensitive nature of this indicator compared with the subjective indicators."
1,background,11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
0,intervention,11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
0,population,11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
0,outcome,11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
0,other,11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
0,"study design",11521220,1,"Perineural invasion is a histologic feature usually diagnostic of invasion in malignancies."
1,background,11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,intervention,11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,population,11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,outcome,11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,other,11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,"study design",11521220,2,"In the breast, however, it has been associated with benign lesions such as sclerosing adenosis (SA), complex sclerosing lesion/radial scar (CSL/RS), and ductal carcinoma in situ (DCIS)."
0,background,11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
0,intervention,11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
0,population,11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
0,outcome,11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
1,other,11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
0,"study design",11521220,3,"This article describes perineural invasion associated with atypical ductal hyperplasia (ADH), florid hyperplasia without atypia (FH), and DCIS."
0,background,11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
0,intervention,11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
1,population,11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
0,outcome,11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
0,other,11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
0,"study design",11521220,4,"All cases with a diagnosis of perineural invasion were selected from a series of 10,000 breast consult cases."
0,background,11521220,5,"Invasive mammary carcinomas were excluded."
0,intervention,11521220,5,"Invasive mammary carcinomas were excluded."
0,population,11521220,5,"Invasive mammary carcinomas were excluded."
0,outcome,11521220,5,"Invasive mammary carcinomas were excluded."
1,other,11521220,5,"Invasive mammary carcinomas were excluded."
0,"study design",11521220,5,"Invasive mammary carcinomas were excluded."
0,background,11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
0,intervention,11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
0,population,11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
1,outcome,11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
0,other,11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
0,"study design",11521220,6,"Fourteen cases of perineural invasion were found and associated with the following diagnoses: ADH (5), DCIS (3), FH (5), and ductal adenoma (1)."
0,background,11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
0,intervention,11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
0,population,11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
1,outcome,11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
0,other,11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
0,"study design",11521220,7,"Nine cases developed in CSL/RS, 4 cases in SA, and 1 case in a previous biopsy site of ductal adenoma; lesions were all less than 3 mm."
0,background,11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
0,intervention,11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
0,population,11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
1,outcome,11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
0,other,11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
0,"study design",11521220,8,"The glands involving nerves showed cytologic and architectural features of the adjacent ADH, DCIS, and FH."
0,background,11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
0,intervention,11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
0,population,11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
1,outcome,11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
0,other,11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
0,"study design",11521220,9,"Immunostaining for protein gene product (PGP) 9.5 marked nerves, and smooth muscle actin antibody highlighted the myoepithelial cells around glands."
0,background,11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
0,intervention,11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
0,population,11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
1,outcome,11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
0,other,11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
0,"study design",11521220,10,"Perineural invasion seen in association with DCIS and ADH, in a background of CSL/RS and SA, may pose difficulty in diagnosis, especially in small biopsy specimens."
0,background,11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
0,intervention,11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
0,population,11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
1,outcome,11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
0,other,11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
0,"study design",11521220,11,"It should be assessed with care to avoid misinterpretation as invasive mammary carcinoma."
0,background,11522694,1,"OBJECTIVE"
0,intervention,11522694,1,"OBJECTIVE"
0,population,11522694,1,"OBJECTIVE"
0,outcome,11522694,1,"OBJECTIVE"
1,other,11522694,1,"OBJECTIVE"
0,"study design",11522694,1,"OBJECTIVE"
1,background,11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,intervention,11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,population,11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,outcome,11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,other,11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,"study design",11522694,2,"To examine the associations between reported intakes of dietary fat and incident type 2 diabetes."
0,background,11522694,3,"RESEARCH DESIGN AND METHODS"
0,intervention,11522694,3,"RESEARCH DESIGN AND METHODS"
0,population,11522694,3,"RESEARCH DESIGN AND METHODS"
0,outcome,11522694,3,"RESEARCH DESIGN AND METHODS"
1,other,11522694,3,"RESEARCH DESIGN AND METHODS"
0,"study design",11522694,3,"RESEARCH DESIGN AND METHODS"
0,background,11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
0,intervention,11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
1,population,11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
0,outcome,11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
0,other,11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
1,"study design",11522694,4,"We studied the relation between dietary fatty acids and diabetes in a prospective cohort study of 35,988 older women who initially did not have diabetes."
0,background,11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
0,intervention,11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
0,population,11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
0,outcome,11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
1,other,11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
0,"study design",11522694,5,"Diet was assessed with a food frequency questionnaire at baseline, and 1,890 incident cases of diabetes occurred during 11 years of follow-up."
0,background,11522694,6,"RESULTS"
0,intervention,11522694,6,"RESULTS"
0,population,11522694,6,"RESULTS"
0,outcome,11522694,6,"RESULTS"
1,other,11522694,6,"RESULTS"
0,"study design",11522694,6,"RESULTS"
0,background,11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
0,intervention,11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
0,population,11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
1,outcome,11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
0,other,11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
0,"study design",11522694,7,"After adjusting for age, smoking, alcohol consumption, BMI, waist-to-hip ratio, physical activity, demographic factors, and dietary magnesium and cereal fiber, diabetes incidence was negatively associated with dietary polyunsaturated fatty acids, vegetabl"
0,background,11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
0,intervention,11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
0,population,11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
1,outcome,11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
0,other,11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
0,"study design",11522694,8,"After simultaneous adjustment for other dietary fat, only vegetable fat remained clearly related to diabetes risk."
0,background,11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
0,intervention,11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
0,population,11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
1,outcome,11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
0,other,11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
0,"study design",11522694,9,"Relative risks across quintiles of vegetable fat intake were 1.00, 0.90, 0.87, 0.84, and 0.82 (P = 0.02)."
0,background,11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
0,intervention,11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
0,population,11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
1,outcome,11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
0,other,11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
0,"study design",11522694,10,"Diabetes risk was also inversely related to substituting polyunsaturated fatty acids for saturated fatty acids and positively correlated to the Keys dietary score."
0,background,11522694,11,"CONCLUSIONS"
0,intervention,11522694,11,"CONCLUSIONS"
0,population,11522694,11,"CONCLUSIONS"
0,outcome,11522694,11,"CONCLUSIONS"
1,other,11522694,11,"CONCLUSIONS"
0,"study design",11522694,11,"CONCLUSIONS"
0,background,11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
0,intervention,11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
0,population,11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
1,outcome,11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
0,other,11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
0,"study design",11522694,12,"These data support an inverse relation between incident type 2 diabetes and vegetable fat and substituting polyunsaturated fatty acids for saturated fatty acids and cholesterol."
0,background,11713035,1,"CONTEXT"
0,intervention,11713035,1,"CONTEXT"
0,population,11713035,1,"CONTEXT"
0,outcome,11713035,1,"CONTEXT"
1,other,11713035,1,"CONTEXT"
0,"study design",11713035,1,"CONTEXT"
1,background,11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
0,intervention,11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
0,population,11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
0,outcome,11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
0,other,11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
0,"study design",11713035,2,"The &quot;Standards, Options and Recommendations&quot; (SOR) project, started in 1993, is a collaboration between the National Federation of Comprehensive Cancer Centres (FNCLCC), the 20 French Cancer Centers and specialists from French Public Universitie"
1,background,11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,intervention,11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,population,11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,outcome,11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,other,11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,"study design",11713035,3,"The main objective is the development of clinical practice guidelines to improve the quality of health care and outcome for cancer patients."
0,background,11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
0,intervention,11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
0,population,11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
0,outcome,11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
1,other,11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
0,"study design",11713035,4,"The methodology is based on literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery."
0,background,11713035,5,"OBJECTIVES"
0,intervention,11713035,5,"OBJECTIVES"
0,population,11713035,5,"OBJECTIVES"
0,outcome,11713035,5,"OBJECTIVES"
1,other,11713035,5,"OBJECTIVES"
0,"study design",11713035,5,"OBJECTIVES"
0,background,11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
0,intervention,11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
1,population,11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
0,outcome,11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
0,other,11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
0,"study design",11713035,6,"To develop clinical practice guidelines according to the definitions of the Standards, Options and Recommendations project for nutritional support in adult patients with advanced or terminal cancer."
0,background,11713035,7,"METHODS"
0,intervention,11713035,7,"METHODS"
0,population,11713035,7,"METHODS"
0,outcome,11713035,7,"METHODS"
1,other,11713035,7,"METHODS"
0,"study design",11713035,7,"METHODS"
0,background,11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
0,intervention,11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
0,population,11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
0,outcome,11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
1,other,11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
0,"study design",11713035,8,"Data were identified by searching Medline, web sites and using the personal reference lists of members of the expert groups."
0,background,11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
0,intervention,11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
0,population,11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
0,outcome,11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
1,other,11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
0,"study design",11713035,9,"Once the guidelines were defined, the document was submitted for review to 95 independent reviewers."
0,background,11713035,10,"RESULTS"
0,intervention,11713035,10,"RESULTS"
0,population,11713035,10,"RESULTS"
0,outcome,11713035,10,"RESULTS"
1,other,11713035,10,"RESULTS"
0,"study design",11713035,10,"RESULTS"
0,background,11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
0,intervention,11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
0,population,11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
1,outcome,11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
0,other,11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
0,"study design",11713035,11,"The main recommendations for nutritional support in adult patients with advanced or terminal cancer are: 1) Palliative care has been defined in a consensual way and is governed by the law (standard)."
0,background,11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
0,intervention,11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
0,population,11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
1,outcome,11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
0,other,11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
0,"study design",11713035,12,"Nutritional support is a palliative care which aim is to maintain and restore the &quot;well-being&quot; of the patient (standard)."
0,background,11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,intervention,11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,population,11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
1,outcome,11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,other,11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,"study design",11713035,13,"2) Digestive symptoms and nutritional troubles are frequently noted in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,background,11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
0,intervention,11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
0,population,11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
0,outcome,11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
1,other,11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
0,"study design",11713035,14,"Karnofsky index (KPS) and performance status (PS) are functional scores with a prognostic value and have to be used (standard, level of evidence B2)."
0,background,11713035,15,"3)"
0,intervention,11713035,15,"3)"
0,population,11713035,15,"3)"
0,outcome,11713035,15,"3)"
1,other,11713035,15,"3)"
0,"study design",11713035,15,"3)"
0,background,11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,intervention,11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,population,11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
1,outcome,11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,other,11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,"study design",11713035,16,"Anorexia has a bad predictive value in patients with advanced or terminal cancer (standard, level of evidence B2)."
0,background,11713035,17,"4)"
0,intervention,11713035,17,"4)"
0,population,11713035,17,"4)"
0,outcome,11713035,17,"4)"
1,other,11713035,17,"4)"
0,"study design",11713035,17,"4)"
0,background,11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
0,intervention,11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
0,population,11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
0,outcome,11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
1,other,11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
0,"study design",11713035,18,"In France, patients with advanced or terminal cancer are referred to medical institutions, palliative care units or remained at home (standard)."
0,background,11713035,19,"Patients need a multidisciplinary follow-up (standard)."
0,intervention,11713035,19,"Patients need a multidisciplinary follow-up (standard)."
0,population,11713035,19,"Patients need a multidisciplinary follow-up (standard)."
1,outcome,11713035,19,"Patients need a multidisciplinary follow-up (standard)."
0,other,11713035,19,"Patients need a multidisciplinary follow-up (standard)."
0,"study design",11713035,19,"Patients need a multidisciplinary follow-up (standard)."
0,background,11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
0,intervention,11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
0,population,11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
1,outcome,11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
0,other,11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
0,"study design",11713035,20,"An active participation of patients and/or their family circle is very important and physicians have to pay attention for their opinions (standard)."
0,background,11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
0,intervention,11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
0,population,11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
1,outcome,11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
0,other,11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
0,"study design",11713035,21,"5) Dietetic counseling can help patients to improve their alimentation and its drawbacks (standard)."
0,background,11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
0,intervention,11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
0,population,11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
1,outcome,11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
0,other,11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
0,"study design",11713035,22,"6) Palliative nutritional care often includes medicinal treatments (standard)."
0,background,11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
0,intervention,11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
0,population,11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
1,outcome,11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
0,other,11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
0,"study design",11713035,23,"7) Artificial nutrition can slow down nutritional degradation, avoid dehydration and improve quality of life in patients with advanced stage cancer (especially head and neck cancer for enteral nutrition and digestive occlusions for parenteral nutrition) a"
0,background,11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
0,intervention,11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
0,population,11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
1,outcome,11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
0,other,11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
0,"study design",11713035,24,"9) The assessment of nutritional care in patients with advanced or terminal cancer has to include functional scores measurement, quality of life and satisfaction degree of the patient and/or their family (standard, expert agreement)."
1,background,11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
0,intervention,11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
0,population,11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
0,outcome,11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
0,other,11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
0,"study design",11727721,1,"Spasticity and hypertonicity are common components of the upper motor neuron syndrome (UMNS), which is seen in various neurologic conditions."
1,background,11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
0,intervention,11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
0,population,11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
0,outcome,11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
0,other,11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
0,"study design",11727721,2,"Pharmacologic agents that can be administered through different routes can play an important part in treatment aimed at minimizing complications, pain, and functional deficits caused by UMNS."
1,background,11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
0,intervention,11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
0,population,11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
0,outcome,11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
0,other,11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
0,"study design",11727721,3,"They can be administered by way of an oral, transdermal, intramuscular, or intrathecal route and can play an important role in the management of UMNS."
1,background,11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
0,intervention,11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
0,population,11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
0,outcome,11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
0,other,11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
0,"study design",11727721,4,"This article reviews UMNS, the functional consequences that can result from it, individual agents, and their indications, complications, and adverse effects."
1,background,11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
0,intervention,11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
0,population,11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
0,outcome,11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
0,other,11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
0,"study design",11727721,5,"Algorithms for treatment of UMNS with pharmacologic agents, and these agents' efficacy in different neurologic populations, is reviewed."
1,background,11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
0,intervention,11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
0,population,11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
0,outcome,11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
0,other,11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
0,"study design",11728162,1,"We have previously shown that dietary (n-3) fatty acids decrease mammary tumor vascularization and PGE(2) production."
1,background,11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,intervention,11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,population,11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,outcome,11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,other,11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,"study design",11728162,2,"One possible mechanism may be the modulation of vascular endothelial growth factor (VEGF) production by PGE(2)."
0,background,11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
0,intervention,11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
0,population,11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
0,outcome,11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
1,other,11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
0,"study design",11728162,3,"Macrophages are major producers of VEGF, and thus we assessed the role of PGE(2) in vitro and in vivo on their VEGF production."
0,background,11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
1,intervention,11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
0,population,11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
1,outcome,11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
0,other,11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
0,"study design",11728162,4,"When added to macrophages, pharmacological (10(-7) M) but not physiological (10(-9) to 10(-11) M) concentrations of PGE(2) increased VEGF mRNA and protein levels."
0,background,11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
0,intervention,11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
0,population,11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
1,outcome,11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
0,other,11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
0,"study design",11728162,5,"That increased expression was relatively rapid and sustained up to 8 hrs, but declined by 24 hrs."
0,background,11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
0,intervention,11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
0,population,11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
1,outcome,11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
0,other,11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
0,"study design",11728162,6,"Similarly, dibutryl cAMP increased production of VEGF protein which was completely inhibited by H89."
0,background,11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
0,intervention,11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
0,population,11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
1,outcome,11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
0,other,11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
0,"study design",11728162,7,"Addition of cAMP-elevating agents further potentiated the production of VEGF by PGE(2)."
0,background,11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
0,intervention,11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
0,population,11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
1,outcome,11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
0,other,11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
0,"study design",11728162,8,"Next, (n-3) and (n-6) fatty acids were added to macrophages in vitro or provided in the diet."
0,background,11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
0,intervention,11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
1,population,11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
1,outcome,11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
0,other,11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
0,"study design",11728162,9,"Macrophages of mice fed safflower oil (n-6) had 2- to 4-fold greater copy number of VEGF transcripts after lipopolysaccarhide (LPS) stimulation compared to fish oil (n-3)."
0,background,11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
0,intervention,11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
0,population,11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
1,outcome,11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
0,other,11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
0,"study design",11728162,10,"A decreasing trend was seen in LPS-induced VEGF secretion from macrophages in vitro after docosahexaenoic acid or eicosapentaenoic acid incubation compared to arachidonic acid."
0,background,11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
0,intervention,11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
0,population,11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
1,outcome,11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
0,other,11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
0,"study design",11728162,11,"While pharmacological concentrations of PGE(2) modulate VEGF expression, physiological alterations did not alter VEGF protein production by macrophages."
0,background,11732562,1,"PURPOSE"
0,intervention,11732562,1,"PURPOSE"
0,population,11732562,1,"PURPOSE"
0,outcome,11732562,1,"PURPOSE"
1,other,11732562,1,"PURPOSE"
0,"study design",11732562,1,"PURPOSE"
1,background,11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,intervention,11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,population,11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,outcome,11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,other,11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,"study design",11732562,2,"To assess impairments, disabilities and handicap pattern in konzo."
0,background,11732562,3,"METHOD"
0,intervention,11732562,3,"METHOD"
0,population,11732562,3,"METHOD"
0,outcome,11732562,3,"METHOD"
1,other,11732562,3,"METHOD"
0,"study design",11732562,3,"METHOD"
0,background,11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
0,intervention,11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
1,population,11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
0,outcome,11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
0,other,11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
0,"study design",11732562,4,"The study included 17 konzo subjects, of which three were males and 14 females (mean age 21, median 18 years)."
0,background,11732562,5,"A detailed neurological examination was performed on all subjects."
1,intervention,11732562,5,"A detailed neurological examination was performed on all subjects."
0,population,11732562,5,"A detailed neurological examination was performed on all subjects."
0,outcome,11732562,5,"A detailed neurological examination was performed on all subjects."
0,other,11732562,5,"A detailed neurological examination was performed on all subjects."
0,"study design",11732562,5,"A detailed neurological examination was performed on all subjects."
0,background,11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
0,intervention,11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
0,population,11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
0,outcome,11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
1,other,11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
0,"study design",11732562,6,"Subsequently, an assessment of impairments, disabilities and handicap was done with a constructed rating scale partially based on the ICIDH-2 framework."
0,background,11732562,7,"RESULTS"
0,intervention,11732562,7,"RESULTS"
0,population,11732562,7,"RESULTS"
0,outcome,11732562,7,"RESULTS"
1,other,11732562,7,"RESULTS"
0,"study design",11732562,7,"RESULTS"
0,background,11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
0,intervention,11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
0,population,11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
1,outcome,11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
0,other,11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
0,"study design",11732562,8,"The overall disablement picture in all subjects consisted of motor dysfunction in lower limbs leading to limitations in walking and movement activities, and restrictions in mobility."
0,background,11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
0,intervention,11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
0,population,11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
1,outcome,11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
0,other,11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
0,"study design",11732562,9,"Hip mobility was severely impaired in most cases (15/17)."
0,background,11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
0,intervention,11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
0,population,11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
1,outcome,11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
0,other,11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
0,"study design",11732562,10,"Although konzo subjects showed normal muscle power in upper limbs (13/17), they had impaired fine motor function (10/17)."
0,background,11732562,11,"CONCLUSION"
0,intervention,11732562,11,"CONCLUSION"
0,population,11732562,11,"CONCLUSION"
0,outcome,11732562,11,"CONCLUSION"
1,other,11732562,11,"CONCLUSION"
0,"study design",11732562,11,"CONCLUSION"
0,background,11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
0,intervention,11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
0,population,11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
1,outcome,11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
0,other,11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
0,"study design",11732562,12,"Further studies are needed to assess the effectiveness of the WHO criteria for konzo in defining its forms."
0,background,11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
0,intervention,11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
0,population,11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
1,outcome,11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
0,other,11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
0,"study design",11732562,13,"The applicability of the ICIDH-2 framework in this study demonstrates the possibility of its use as a common language among researchers in the field of motor disorders."
0,background,11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
0,intervention,11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
0,population,11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
1,outcome,11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
0,other,11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
0,"study design",11732562,14,"However, a revision is suggested of its taxonomy, and a definition of operational criteria to clarify the content of different qualifiers provided to assess the level of functioning or disability."
1,background,11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
0,intervention,11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
1,population,11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
0,outcome,11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
0,other,11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
0,"study design",11748345,1,"An 18-yr-old boy presented with extreme back pain as the result of multiple vertebral fractures."
1,background,11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,intervention,11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,population,11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,outcome,11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,other,11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,"study design",11748345,2,"At age 16 he had developed a tumor of the mesencephalon."
0,background,11748345,3,"A ventriculoperitoneal shunt was established surgically."
0,intervention,11748345,3,"A ventriculoperitoneal shunt was established surgically."
0,population,11748345,3,"A ventriculoperitoneal shunt was established surgically."
0,outcome,11748345,3,"A ventriculoperitoneal shunt was established surgically."
1,other,11748345,3,"A ventriculoperitoneal shunt was established surgically."
0,"study design",11748345,3,"A ventriculoperitoneal shunt was established surgically."
1,background,11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
0,intervention,11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
0,population,11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
0,outcome,11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
0,other,11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
0,"study design",11748345,4,"One year later, he developed progressive neurologic deficits in his upper and lower limbs with an increase in the size of the tumor."
1,background,11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
0,intervention,11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
0,population,11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
0,outcome,11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
0,other,11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
0,"study design",11748345,5,"He was treated by irradiation and high doses of glucocorticoids."
1,background,11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
0,intervention,11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
0,population,11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
0,outcome,11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
0,other,11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
0,"study design",11748345,6,"Although the neurologic deficits progressively improved, he developed severe back pain resulting in complete immobilization for 3 mo in spite of neurologic recovery."
1,background,11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
0,intervention,11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
0,population,11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
0,outcome,11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
0,other,11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
0,"study design",11748345,7,"Multiple vertebral fractures were diagnosed by X-ray."
1,background,11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,intervention,11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,population,11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,outcome,11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,other,11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,"study design",11748345,8,"Bone density was extremely low (Z-score of -5.5 in the spine and -3.1 in the femoral neck)."
0,background,11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
1,intervention,11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
0,population,11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
0,outcome,11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
0,other,11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
0,"study design",11748345,9,"The patient was treated with calcium and vitamin D, calcitonin, bisphosphonates, physiotherapy, and progressive mobilization."
0,background,11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
1,intervention,11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
0,population,11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
0,outcome,11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
0,other,11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
0,"study design",11748345,10,"Glucocorticoids were decreased and could be stopped as the neurologic deficits fully recovered."
0,background,11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
0,intervention,11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
0,population,11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
1,outcome,11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
0,other,11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
0,"study design",11748345,11,"After 1 yr of treatment with intermittent i.v. pamidronate, bone density had increased by 40% in the spine and by 25% in the femoral neck despite growth arrest."
0,background,11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
0,intervention,11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
0,population,11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
1,outcome,11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
0,other,11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
0,"study design",11748345,12,"He progressively recovered from back pain and is now, at age 20, fully ambulant, studying mechanical engineering, without neurologic sequelaes and free of glucocorticoids."
0,background,11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
0,intervention,11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
0,population,11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
1,outcome,11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
0,other,11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
0,"study design",11748345,13,"Magnetic resonance imaging revealed that the tumor had disappeared."
0,background,11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
0,intervention,11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
0,population,11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
1,outcome,11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
0,other,11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
0,"study design",11748345,14,"This case proves that treatment of symptomatic glucocorticoid-induced osteoporosis during puberty can be rewarding, even when multiple and invalidating vertebral fractures already exist."
0,background,11840097,1,"STUDY DESIGN"
0,intervention,11840097,1,"STUDY DESIGN"
0,population,11840097,1,"STUDY DESIGN"
0,outcome,11840097,1,"STUDY DESIGN"
1,other,11840097,1,"STUDY DESIGN"
0,"study design",11840097,1,"STUDY DESIGN"
0,background,11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
0,intervention,11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
0,population,11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
0,outcome,11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
0,other,11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
1,"study design",11840097,2,"A prospective and controlled study of perioperative use of combined local anesthetic and corticosteroid in lumbar disc surgery."
0,background,11840097,3,"SUMMARY OF BACKGROUND DATA"
0,intervention,11840097,3,"SUMMARY OF BACKGROUND DATA"
0,population,11840097,3,"SUMMARY OF BACKGROUND DATA"
0,outcome,11840097,3,"SUMMARY OF BACKGROUND DATA"
1,other,11840097,3,"SUMMARY OF BACKGROUND DATA"
0,"study design",11840097,3,"SUMMARY OF BACKGROUND DATA"
1,background,11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
0,intervention,11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
0,population,11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
0,outcome,11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
0,other,11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
0,"study design",11840097,4,"The anti-inflammatory mechanism of corticosteroids is considered to be caused by the inhibition of phospholipase A2, which plays an important role in the pain mechanism of lumbar disc problems."
1,background,11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
0,intervention,11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
0,population,11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
0,outcome,11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
0,other,11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
0,"study design",11840097,5,"Although some authors have demonstrated that the use of intramuscular bupivacaine during lumbar discectomy resulted in a marked reduction of postoperative back pain, others have reported that the key intervention was probably the administration of epidura"
1,background,11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,intervention,11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,population,11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,outcome,11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,other,11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,"study design",11840097,6,"The coadministration of these two drugs in lumbar disc surgery for the relief of postoperative back pain has yet not been studied adequately."
0,background,11840097,7,"OBJECTIVES"
0,intervention,11840097,7,"OBJECTIVES"
0,population,11840097,7,"OBJECTIVES"
0,outcome,11840097,7,"OBJECTIVES"
1,other,11840097,7,"OBJECTIVES"
0,"study design",11840097,7,"OBJECTIVES"
0,background,11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
0,intervention,11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
0,population,11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
0,outcome,11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
1,other,11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
0,"study design",11840097,8,"Assessment of the combined use of perioperative corticosteroids and bupivacaine for the relief of postoperative pain after lumbar disc surgery."
0,background,11840097,9,"METHODS"
0,intervention,11840097,9,"METHODS"
0,population,11840097,9,"METHODS"
0,outcome,11840097,9,"METHODS"
1,other,11840097,9,"METHODS"
0,"study design",11840097,9,"METHODS"
0,background,11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
0,intervention,11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
1,population,11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
0,outcome,11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
0,other,11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
0,"study design",11840097,10,"Forty-four selected patients had acute-onset single-level unilateral herniated nucleus pulposus that were refractory to conservative management."
0,background,11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
1,intervention,11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
0,population,11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
0,outcome,11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
0,other,11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
0,"study design",11840097,11,"All patients underwent lumbar disc surgery under standard general anesthesia."
0,background,11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
1,intervention,11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
0,population,11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
0,outcome,11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
0,other,11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
0,"study design",11840097,12,"Before surgical incision, the skin and subcutaneous tissues were infiltrated with 10 mL of 1% lidocaine with 1:200,000 adrenaline to produce local vasoconstriction."
0,background,11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
1,intervention,11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
0,population,11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
0,outcome,11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
0,other,11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
0,"study design",11840097,13,"During wound closure, 20 mL 0.9% saline in Group 1 (n = 22) and 20 mL 0.25% bupivacaine in Group 2 (n = 22) were injected into the paravertebral muscles and subcutaneus tissues."
0,background,11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
1,intervention,11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
0,population,11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
0,outcome,11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
0,other,11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
0,"study design",11840097,14,"In addition, a piece of autologous fat taken from the wound was first soaked in 40 mg of methylprednisolone for 10 minutes, then placed over the exposed nerve root, and the remaining steroid was flushed into the wound in Group 2."
0,background,11840097,15,"The wound was closed after drug administration in both groups."
0,intervention,11840097,15,"The wound was closed after drug administration in both groups."
0,population,11840097,15,"The wound was closed after drug administration in both groups."
0,outcome,11840097,15,"The wound was closed after drug administration in both groups."
1,other,11840097,15,"The wound was closed after drug administration in both groups."
0,"study design",11840097,15,"The wound was closed after drug administration in both groups."
0,background,11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
1,intervention,11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
0,population,11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
0,outcome,11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
0,other,11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
0,"study design",11840097,16,"In the postoperative period, all patients received 100 mg of meperidine intramuscularly when needed and were allowed to receive a second dose at least 4 hours later than the first dose for postoperative analgesia."
0,background,11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
0,intervention,11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
0,population,11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
0,outcome,11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
1,other,11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
0,"study design",11840097,17,"Postoperative back pain intensity, heart rate, and mean arterial pressure were assessed 1, 3, 6, and 12 hours after the conclusion of surgery."
0,background,11840097,18,"RESULTS"
0,intervention,11840097,18,"RESULTS"
0,population,11840097,18,"RESULTS"
0,outcome,11840097,18,"RESULTS"
1,other,11840097,18,"RESULTS"
0,"study design",11840097,18,"RESULTS"
0,background,11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
0,intervention,11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
0,population,11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
1,outcome,11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
0,other,11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
0,"study design",11840097,19,"Visual analog scale pain scores for the postoperative recordings were lower in Group 2 than in Group 1, but these findings were not statistically significant."
0,background,11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
0,intervention,11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
0,population,11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
1,outcome,11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
0,other,11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
0,"study design",11840097,20,"Patients in Group 1 received 77.3 +/- 48.8 mg meperidine, and those in Group 2 received 31.8 +/- 45.5 mg meperidine, for pain medication in the first 12 hours (P &lt; 0.05)."
0,background,11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
0,intervention,11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
0,population,11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
1,outcome,11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
0,other,11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
0,"study design",11840097,21,"Heart rate and mean arterial pressure were not significantly different between the two groups in all recording periods."
0,background,11840097,22,"CONCLUSION"
0,intervention,11840097,22,"CONCLUSION"
0,population,11840097,22,"CONCLUSION"
0,outcome,11840097,22,"CONCLUSION"
1,other,11840097,22,"CONCLUSION"
0,"study design",11840097,22,"CONCLUSION"
0,background,11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
0,intervention,11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
0,population,11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
1,outcome,11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
0,other,11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
0,"study design",11840097,23,"It is concluded that the perioperative use of bupivacaine and corticosteroids during lumbar discectomy maintains effective postoperative analgesia and decreases opioid usage without complications."
0,background,11869609,1,"BACKGROUND"
0,intervention,11869609,1,"BACKGROUND"
0,population,11869609,1,"BACKGROUND"
0,outcome,11869609,1,"BACKGROUND"
1,other,11869609,1,"BACKGROUND"
0,"study design",11869609,1,"BACKGROUND"
1,background,11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
0,intervention,11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
0,population,11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
0,outcome,11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
0,other,11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
0,"study design",11869609,2,"Lateral epicondylitis (tennis elbow) is a frequently reported condition."
1,background,11869609,3,"A wide variety of treatment strategies has been described."
0,intervention,11869609,3,"A wide variety of treatment strategies has been described."
0,population,11869609,3,"A wide variety of treatment strategies has been described."
0,outcome,11869609,3,"A wide variety of treatment strategies has been described."
0,other,11869609,3,"A wide variety of treatment strategies has been described."
0,"study design",11869609,3,"A wide variety of treatment strategies has been described."
1,background,11869609,4,"As of yet, no optimal strategy has been identified."
0,intervention,11869609,4,"As of yet, no optimal strategy has been identified."
0,population,11869609,4,"As of yet, no optimal strategy has been identified."
0,outcome,11869609,4,"As of yet, no optimal strategy has been identified."
0,other,11869609,4,"As of yet, no optimal strategy has been identified."
0,"study design",11869609,4,"As of yet, no optimal strategy has been identified."
0,background,11869609,5,"OBJECTIVES"
0,intervention,11869609,5,"OBJECTIVES"
0,population,11869609,5,"OBJECTIVES"
0,outcome,11869609,5,"OBJECTIVES"
1,other,11869609,5,"OBJECTIVES"
0,"study design",11869609,5,"OBJECTIVES"
0,background,11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
0,intervention,11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
0,population,11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
0,outcome,11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
1,other,11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
0,"study design",11869609,6,"To assess the effectiveness of orthotic devices for the treatment of tennis elbow."
0,background,11869609,7,"SEARCH STRATEGY"
0,intervention,11869609,7,"SEARCH STRATEGY"
0,population,11869609,7,"SEARCH STRATEGY"
0,outcome,11869609,7,"SEARCH STRATEGY"
1,other,11869609,7,"SEARCH STRATEGY"
0,"study design",11869609,7,"SEARCH STRATEGY"
0,background,11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
0,intervention,11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
0,population,11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
0,outcome,11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
1,other,11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
0,"study design",11869609,8,"We searched Medline, Embase, CINAHL, the Cochrane Controlled Trial Register, Current Contents up to May 1999 and reference lists from all retrieved articles."
0,background,11869609,9,"Experts on the subjects were approached for additional trials."
0,intervention,11869609,9,"Experts on the subjects were approached for additional trials."
0,population,11869609,9,"Experts on the subjects were approached for additional trials."
0,outcome,11869609,9,"Experts on the subjects were approached for additional trials."
1,other,11869609,9,"Experts on the subjects were approached for additional trials."
0,"study design",11869609,9,"Experts on the subjects were approached for additional trials."
0,background,11869609,10,"SELECTION CRITERIA"
0,intervention,11869609,10,"SELECTION CRITERIA"
0,population,11869609,10,"SELECTION CRITERIA"
0,outcome,11869609,10,"SELECTION CRITERIA"
1,other,11869609,10,"SELECTION CRITERIA"
0,"study design",11869609,10,"SELECTION CRITERIA"
0,background,11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
1,intervention,11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
1,population,11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
0,outcome,11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
0,other,11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
0,"study design",11869609,11,"All randomised clinical trials (RCT) describing individuals with diagnosed lateral epicondylitis and comparing the use of an orthotic device as a treatment strategy were evaluated for inclusion."
0,background,11869609,12,"DATA COLLECTION AND ANALYSIS"
0,intervention,11869609,12,"DATA COLLECTION AND ANALYSIS"
0,population,11869609,12,"DATA COLLECTION AND ANALYSIS"
0,outcome,11869609,12,"DATA COLLECTION AND ANALYSIS"
1,other,11869609,12,"DATA COLLECTION AND ANALYSIS"
0,"study design",11869609,12,"DATA COLLECTION AND ANALYSIS"
0,background,11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
0,intervention,11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
0,population,11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
0,outcome,11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
1,other,11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
0,"study design",11869609,13,"Two reviewers independently assessed the validity of the included trials and extracted data on relevant outcome measures."
0,background,11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
0,intervention,11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
0,population,11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
0,outcome,11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
1,other,11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
0,"study design",11869609,14,"Dichotomous outcomes were expressed as Relative Risks (RRs) and continuous outcomes as Standardised Mean Differences (SMD), both with corresponding 95% confidence intervals (95% CI)."
0,background,11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
0,intervention,11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
0,population,11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
0,outcome,11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
1,other,11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
0,"study design",11869609,15,"Statistical pooling and subgroup analyses were intended MAIN RESULTS"
0,background,11869609,16,"Five RCTs (N per group 7-49) were included."
0,intervention,11869609,16,"Five RCTs (N per group 7-49) were included."
0,population,11869609,16,"Five RCTs (N per group 7-49) were included."
1,outcome,11869609,16,"Five RCTs (N per group 7-49) were included."
0,other,11869609,16,"Five RCTs (N per group 7-49) were included."
0,"study design",11869609,16,"Five RCTs (N per group 7-49) were included."
0,background,11869609,17,"Validity score ranged from 3-9 positive items out of 11."
0,intervention,11869609,17,"Validity score ranged from 3-9 positive items out of 11."
0,population,11869609,17,"Validity score ranged from 3-9 positive items out of 11."
1,outcome,11869609,17,"Validity score ranged from 3-9 positive items out of 11."
0,other,11869609,17,"Validity score ranged from 3-9 positive items out of 11."
0,"study design",11869609,17,"Validity score ranged from 3-9 positive items out of 11."
0,background,11869609,18,"Subgroup analyses were not performed due to the small number of trials."
0,intervention,11869609,18,"Subgroup analyses were not performed due to the small number of trials."
0,population,11869609,18,"Subgroup analyses were not performed due to the small number of trials."
1,outcome,11869609,18,"Subgroup analyses were not performed due to the small number of trials."
0,other,11869609,18,"Subgroup analyses were not performed due to the small number of trials."
0,"study design",11869609,18,"Subgroup analyses were not performed due to the small number of trials."
0,background,11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
0,intervention,11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
0,population,11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
1,outcome,11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
0,other,11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
0,"study design",11869609,19,"The limited number of included trials present few outcome measures and limited long-term results."
0,background,11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
0,intervention,11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
0,population,11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
1,outcome,11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
0,other,11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
0,"study design",11869609,20,"Pooling was not possible due to large heterogeneity amongst trials."
0,background,11869609,21,"REVIEWER'S CONCLUSIONS"
0,intervention,11869609,21,"REVIEWER'S CONCLUSIONS"
0,population,11869609,21,"REVIEWER'S CONCLUSIONS"
0,outcome,11869609,21,"REVIEWER'S CONCLUSIONS"
1,other,11869609,21,"REVIEWER'S CONCLUSIONS"
0,"study design",11869609,21,"REVIEWER'S CONCLUSIONS"
0,background,11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
0,intervention,11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
0,population,11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
1,outcome,11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
0,other,11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
0,"study design",11869609,22,"No definitive conclusions can be drawn concerning effectiveness of orthotic devices for lateral epicondylitis."
0,background,11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
0,intervention,11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
0,population,11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
1,outcome,11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
0,other,11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
0,"study design",11869609,23,"More well-designed and well-conducted RCTs of sufficient power are warranted."
1,background,11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,intervention,11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,population,11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,outcome,11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,other,11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,"study design",11916368,1,"There are few published studies assessing the efficacy of pharmacologic treatments for attention-deficit hyperactivity disorder (ADHD) among substance abusers seeking treatment."
0,background,11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
1,intervention,11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
1,population,11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
0,outcome,11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
0,other,11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
1,"study design",11916368,2,"Eleven patients who met DSM-IV diagnostic criteria for cocaine dependence and adult ADHD were entered into a 12-week single-blind trial of divided daily doses of bupropion (BPR)."
0,background,11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
1,intervention,11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
0,population,11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
0,outcome,11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
0,other,11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
0,"study design",11916368,3,"All patients received weekly individual standardized relapse prevention therapy."
0,background,11916368,4,"Treatment compliance and retention were good."
0,intervention,11916368,4,"Treatment compliance and retention were good."
0,population,11916368,4,"Treatment compliance and retention were good."
1,outcome,11916368,4,"Treatment compliance and retention were good."
0,other,11916368,4,"Treatment compliance and retention were good."
0,"study design",11916368,4,"Treatment compliance and retention were good."
0,background,11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
0,intervention,11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
0,population,11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
1,outcome,11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
0,other,11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
0,"study design",11916368,5,"Patients reported significant reductions in attention difficulties, hyperactivity and impulsivity."
0,background,11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
0,intervention,11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
0,population,11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
1,outcome,11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
0,other,11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
0,"study design",11916368,6,"Self-reported cocaine use, cocaine craving, and cocaine positive toxicologies, also decreased significantly."
0,background,11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
0,intervention,11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
0,population,11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
1,outcome,11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
0,other,11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
0,"study design",11916368,7,"In a previously published trial, 12 patients who met similar diagnostic criteria for adult ADHD and cocaine dependence were entered into a 12-week trial of divided daily doses of sustained-release methylphenidate (MPH)."
0,background,11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
0,intervention,11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
0,population,11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
1,outcome,11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
0,other,11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
0,"study design",11916368,8,"Improvements observed on BPR were similar to, and did not differ from those previously observed with MPH."
0,background,11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
0,intervention,11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
0,population,11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
1,outcome,11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
0,other,11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
0,"study design",11916368,9,"These preliminary data suggest that BPR may be as effective as sustained-release MPH, when combined with relapse prevention therapy, for cocaine abusers with adult ADHD."
0,background,11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
0,intervention,11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
0,population,11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
1,outcome,11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
0,other,11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
0,"study design",11916368,10,"However, a future study directly comparing BPR to MPH in a double-blind placebo-controlled trial is needed."
1,background,11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
0,intervention,11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
0,population,11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
0,outcome,11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
0,other,11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
0,"study design",11973698,1,"This is a self-directed learning module that reviews medical complications associated with spinal cord injury (SCI)."
1,background,11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
0,intervention,11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
0,population,11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
0,outcome,11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
0,other,11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
0,"study design",11973698,2,"It is part of a chapter on SCI medicine in the Self-Directed Physiatric Educational Program for practitioners and trainees in physical medicine and rehabilitation."
1,background,11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
0,intervention,11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
0,population,11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
0,outcome,11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
0,other,11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
0,"study design",11973698,3,"This article includes discussion of common medical complications that impact rehabilitation and long-term follow-up for individuals with SCI."
1,background,11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,intervention,11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,population,11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,outcome,11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,other,11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,"study design",11973698,4,"Issues addressed include the rehabilitation approach to SCI individuals with pressure ulcers, unilateral lower-extremity swelling (deep venous thrombosis, heterotopic ossification, fractures), along with the pathophysiology, assessment, and treatment of s"
0,background,11973698,5,"OVERALL ARTICLE OBJECTIVE"
0,intervention,11973698,5,"OVERALL ARTICLE OBJECTIVE"
0,population,11973698,5,"OVERALL ARTICLE OBJECTIVE"
0,outcome,11973698,5,"OVERALL ARTICLE OBJECTIVE"
1,other,11973698,5,"OVERALL ARTICLE OBJECTIVE"
0,"study design",11973698,5,"OVERALL ARTICLE OBJECTIVE"
1,background,11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,intervention,11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,population,11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,outcome,11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,other,11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,"study design",11973698,6,"To describe diagnostic and treatment approaches for medical complications common to individuals with SCI."
0,background,12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
0,intervention,12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
0,population,12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
0,outcome,12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
1,other,12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
0,"study design",12018607,1,"In this study, telemedicine and the use of advanced telemedicine technologies are explained."
1,background,12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
0,intervention,12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
0,population,12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
0,outcome,12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
0,other,12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
0,"study design",12018607,2,"Telemedicine is the use of modern telecommunications and information technologies for the provision of clinical care to individuals at a distance, and transmission of information to provide that care."
1,background,12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
0,intervention,12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
0,population,12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
0,outcome,12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
0,other,12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
0,"study design",12018607,3,"Telemedicine can be used for decision making, remote sensing, and collaborative arrangements for the real-time management of patients at a distance."
1,background,12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
0,intervention,12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
0,population,12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
0,outcome,12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
0,other,12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
0,"study design",12018607,4,"The use of telecommunications and information technologies in providing health services is determined."
1,background,12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
0,intervention,12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
0,population,12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
0,outcome,12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
0,other,12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
0,"study design",12018607,5,"Telemedicine is described as combination of topics from the fields of telecommunication, medicine, and informatics."
1,background,12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,intervention,12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,population,12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,outcome,12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,other,12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,"study design",12018607,6,"The medical systems infrastructure consisting of the equipment and processes used to acquire and present clinical information and to store and retrieve data are explained in details."
0,background,12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
1,intervention,12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
1,population,12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
0,outcome,12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
0,other,12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
0,"study design",12019958,1,"Twenty-four tenorrhaphies were performed at the mid-metatarsal region in 12 crossbred calves under xylazine-ketamine spinal analgesia."
0,background,12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
1,intervention,12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
0,population,12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
0,outcome,12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
0,other,12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
0,"study design",12019958,2,"A 2.5-cm long gap was created in the superficial digital flexor (SDF) tendon and immediately repaired with carbon fibres in the animals of group I and with plasma-preserved tendon allografts in group II."
0,background,12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
0,intervention,12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
0,population,12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
1,outcome,12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
0,other,12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
0,"study design",12019958,3,"Clinical examination revealed a slight increase (P &gt; 0.05) in rectal temperature, heart and respiratory rate for 2-4 days postoperation in both groups."
0,background,12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
0,intervention,12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
0,population,12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
1,outcome,12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
0,other,12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
0,"study design",12019958,4,"Milder pain and exudation as well as earlier restoration of tendon gliding movements and weight bearing were observed in group I as compared to group II."
0,background,12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
0,intervention,12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
0,population,12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
1,outcome,12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
0,other,12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
0,"study design",12019958,5,"Air-tendogram in the carbon fibre group on day 30 revealed restoration of continuity across the defect of the tendon."
0,background,12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
0,intervention,12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
0,population,12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
1,outcome,12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
0,other,12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
0,"study design",12019958,6,"whereas, in the allograft group, a dense homogeneous swelling was seen along the flexors."
0,background,12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
0,intervention,12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
0,population,12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
1,outcome,12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
0,other,12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
0,"study design",12019958,7,"Regression of peritendinous adhesions and swelling at the reconstructed site at later stages was seen in both groups."
0,background,12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
0,intervention,12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
0,population,12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
1,outcome,12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
0,other,12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
0,"study design",12019958,8,"Angiography showed hypervascularization at the reconstructed site on day 14 in the carbon fibre group, however, in the allograft group the site appeared to be relatively avascular."
0,background,12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
0,intervention,12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
0,population,12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
1,outcome,12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
0,other,12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
0,"study design",12019958,9,"On days 30 and 90, blood vessels were normally organized in both groups."
1,background,12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
0,intervention,12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
0,population,12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
0,outcome,12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
0,other,12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
0,"study design",12066560,1,"Patients with myocardial hibernation have reversible left ventricular dysfunction after revascularization."
1,background,12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,intervention,12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,population,12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,outcome,12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,other,12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,"study design",12066560,2,"Viability testing can identify those patients whose left ventricular dysfunction is primarily due to hibernation rather than scar."
0,background,12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
0,intervention,12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
0,population,12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
1,outcome,12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
0,other,12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
0,"study design",12066560,3,"Patients with a substantial amount of hibernating myocardium seem to have a better outcome with revascularization than medical therapy."
0,background,12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
0,intervention,12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
0,population,12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
1,outcome,12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
0,other,12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
0,"study design",12066560,4,"Patients with poor viability do worse after revascularization than patients with good viability."
1,background,12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
0,intervention,12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
0,population,12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
0,outcome,12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
0,other,12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
0,"study design",12079865,1,"A chronic minor imbalance between energy intake and energy expenditure may lead to obesity."
1,background,12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
0,intervention,12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
0,population,12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
0,outcome,12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
0,other,12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
0,"study design",12079865,2,"Both lean and obese subjects eventually reach energy balance and their body weight regulation implies that the adipose tissue mass is &quot;sensed&quot;, leading to appropriate responses of energy intake and energy expenditure."
1,background,12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
0,intervention,12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
0,population,12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
0,outcome,12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
0,other,12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
0,"study design",12079865,3,"The cloning of the ob gene and the identification of its encoded protein, leptin, have provided a system signaling the amount of adipose energy stores to the brain."
1,background,12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
0,intervention,12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
0,population,12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
0,outcome,12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
0,other,12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
0,"study design",12079865,4,"Leptin, a hormone secreted by fat cells, acts in rodents via hypothalamic receptors to inhibit feeding and increase thermogenesis."
1,background,12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
0,intervention,12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
0,population,12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
0,outcome,12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
0,other,12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
0,"study design",12079865,5,"A feedback regulatory loop with three distinct steps has been identified: (1) a sensor (leptin production by adipose cells) monitors the size of the adipose tissue mass; (2) hypothalamic centers receive and integrate the intensity of the leptin signal thr"
1,background,12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
0,intervention,12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
0,population,12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
0,outcome,12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
0,other,12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
0,"study design",12079865,6,"While this feedback regulatory loop is well established in rodents, there are many unsolved questions about its applicability to body weight regulation in humans."
1,background,12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
0,intervention,12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
0,population,12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
0,outcome,12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
0,other,12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
0,"study design",12079865,7,"The rate of leptin production is related to adiposity, but a large portion of the interindividual variability in plasma leptin concentration is independent of body fatness."
1,background,12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
0,intervention,12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
0,population,12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
0,outcome,12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
0,other,12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
0,"study design",12079865,8,"Gender is an important factor determining plasma leptin, with women having markedly higher leptin concentrations than men for any given degree of fat mass."
1,background,12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
0,intervention,12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
0,population,12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
0,outcome,12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
0,other,12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
0,"study design",12079865,9,"The ob mRNA expression is also upregulated by glucocorticoids, whereas stimulation of the sympathetic nervous system results in its inhibition."
1,background,12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
0,intervention,12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
0,population,12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
0,outcome,12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
0,other,12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
0,"study design",12079865,10,"Furthermore, leptin is not a satiety factor in humans because changes in food intake do not induce short-term increases in plasma leptin levels."
1,background,12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
0,intervention,12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
0,population,12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
0,outcome,12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
0,other,12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
0,"study design",12079865,11,"After its binding to LRb in the hypothalamus, leptin stimulates a specific signaling cascade that results in the inhibition of several orexigenic neuropeptides, while stimulating several anorexigenic peptides."
1,background,12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
0,intervention,12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
0,population,12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
0,outcome,12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
0,other,12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
0,"study design",12079865,12,"The orexigenic neuropeptides that are downregulated by leptin are NPY (neuropeptide Y), MCH (melanin-concentrating hormone), orexins, and AGRP (agouti-related peptide)."
1,background,12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
0,intervention,12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
0,population,12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
0,outcome,12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
0,other,12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
0,"study design",12079865,13,"The anorexigenic neuropeptides that are upregulated by leptin are alpha-MSH (alpha-melanocyte-stimulating hormone), which acts on MC4R (melanocortin-4 receptor); CART (cocaine and amphetamine-regulated transcript); and CRH (corticotropin-releasing-hormone"
1,background,12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
0,intervention,12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
0,population,12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
0,outcome,12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
0,other,12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
0,"study design",12079865,14,"Obese humans have high plasma leptin concentrations related to the size of adipose tissue, but this elevated leptin signal does not induce the expected responses (i.e., a reduction in food intake and an increase in energy expenditure)."
1,background,12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
0,intervention,12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
0,population,12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
0,outcome,12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
0,other,12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
0,"study design",12079865,15,"This suggests that obese humans are resistant to the effects of endogenous leptin."
1,background,12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
0,intervention,12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
0,population,12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
0,outcome,12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
0,other,12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
0,"study design",12079865,16,"This resistance is also shown by the lack of effect of exogenous leptin administration to induce weight loss in obese patients."
1,background,12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
0,intervention,12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
0,population,12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
0,outcome,12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
0,other,12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
0,"study design",12079865,17,"The mechanisms that may account for leptin resistance in human obesity include a limitation of the blood-brain-barrier transport system for leptin and an inhibition of the leptin signaling pathways in leptin-responsive hypothalamic neurons."
1,background,12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
0,intervention,12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
0,population,12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
0,outcome,12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
0,other,12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
0,"study design",12079865,18,"During periods of energy deficit, the fall in leptin plasma levels exceeds the rate at which fat stores are decreased."
1,background,12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
0,intervention,12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
0,population,12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
0,outcome,12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
0,other,12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
0,"study design",12079865,19,"Reduction of the leptin signal induces several neuroendocrine responses that tend to limit weight loss, such as hunger, food-seeking behavior, and suppression of plasma thyroid hormone levels."
1,background,12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,intervention,12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,population,12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,outcome,12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,other,12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,"study design",12079865,20,"Conversely, it is unlikely that leptin has evolved to prevent obesity when plenty of palatable foods are available because the elevated plasma leptin levels resulting from the increased adipose tissue mass do not prevent the development of obesity."
0,background,12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
0,intervention,12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
0,population,12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
1,outcome,12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
0,other,12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
0,"study design",12079865,21,"In conclusion, in humans, the leptin signaling system appears to be mainly involved in maintenance of adequate energy stores for survival during periods of energy deficit."
0,background,12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
0,intervention,12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
0,population,12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
1,outcome,12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
0,other,12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
0,"study design",12079865,22,"Its role in the etiology of human obesity is only demonstrated in the very rare situations of absence of the leptin signal (mutations of the leptin gene or of the leptin receptor gene), which produces an internal perception of starvation and results in a "
0,background,12135810,1,"BACKGROUND"
0,intervention,12135810,1,"BACKGROUND"
0,population,12135810,1,"BACKGROUND"
0,outcome,12135810,1,"BACKGROUND"
1,other,12135810,1,"BACKGROUND"
0,"study design",12135810,1,"BACKGROUND"
1,background,12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,intervention,12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,population,12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,outcome,12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,other,12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,"study design",12135810,2,"CYP I A1 polymorphisms, which have been reported to be associated with an elevated risk of lung cancer, are usually detected through conventional methods such as PCR-restriction fragment length polymorphism, allele-specific PCR and single-strand conformat"
0,background,12135810,3,"METHODS"
0,intervention,12135810,3,"METHODS"
0,population,12135810,3,"METHODS"
0,outcome,12135810,3,"METHODS"
1,other,12135810,3,"METHODS"
0,"study design",12135810,3,"METHODS"
0,background,12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
1,intervention,12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
0,population,12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
0,outcome,12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
0,other,12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
0,"study design",12135810,4,"An assay that makes use of differences in thermal stability between perfect match and non-perfect match hybrids has been developed."
0,background,12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
1,intervention,12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
0,population,12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
0,outcome,12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
0,other,12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
0,"study design",12135810,5,"Two oligonucleotides probes for each CYP1A1 polymorphic site were designed and labeled with digoxigenin."
0,background,12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
1,intervention,12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
0,population,12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
0,outcome,12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
0,other,12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
0,"study design",12135810,6,"After hybridization with amplified DNA fragment, the hybrids were detected with a colorimetric method and the genotype were identified by calculating the ratio of signals obtained with two probes."
0,background,12135810,7,"RESULTS"
0,intervention,12135810,7,"RESULTS"
0,population,12135810,7,"RESULTS"
0,outcome,12135810,7,"RESULTS"
1,other,12135810,7,"RESULTS"
0,"study design",12135810,7,"RESULTS"
0,background,12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
0,intervention,12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
0,population,12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
1,outcome,12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
0,other,12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
0,"study design",12135810,8,"The ratios for three genotypes obtained from 50 samples can be divided into three distinctive nonoverlapped groups when applying to m(1) and m(2) sites of CYP1A1 locus, which demonstrated the feasibility of this assay to detect CYP I A1 polymorphisms."
0,background,12135810,9,"CONCLUSION"
0,intervention,12135810,9,"CONCLUSION"
0,population,12135810,9,"CONCLUSION"
0,outcome,12135810,9,"CONCLUSION"
1,other,12135810,9,"CONCLUSION"
0,"study design",12135810,9,"CONCLUSION"
0,background,12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
0,intervention,12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
0,population,12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
1,outcome,12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
0,other,12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
0,"study design",12135810,10,"Compared with other methods, this assay has lower cost, is fast, simple and is suitable for a screening test in routine laboratory."
1,background,12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
0,intervention,12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
0,population,12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
0,outcome,12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
0,other,12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
0,"study design",12193095,1,"Congestive heart failure (CHF) is characterized by increased peripheral vascular resistance."
1,background,12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
0,intervention,12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
0,population,12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
0,outcome,12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
0,other,12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
0,"study design",12193095,2,"Endothelin-1 (ET-1), a potent endothelium-derived vasoconstrictor, is present at increased concentrations in the plasma and contributes to the regulation of vascular tone in CHF."
1,background,12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
0,intervention,12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
0,population,12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
0,outcome,12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
0,other,12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
0,"study design",12193095,3,"An endothelium-derived relaxing factor, nitric oxide (NO), also regulates vascular tone, but endothelium-dependent NO-mediated vasodilation is blunted in CHF."
1,background,12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
0,intervention,12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
0,population,12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
0,outcome,12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
0,other,12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
0,"study design",12193095,4,"An endogenous NO synthase inhibitor, asymmetric dimethylarginine (ADMA), which inhibits NO production and endothelium-dependent relaxation, is present at increased levels in the plasma and plays a role in impaired endothelial function in CHF."
1,background,12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,intervention,12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,population,12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,outcome,12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,other,12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,"study design",12193095,5,"However, at present, the relationship between ET-1 and impaired vascular relaxation in CHF is not well known."
0,background,12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
0,intervention,12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
0,population,12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
0,outcome,12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
1,other,12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
0,"study design",12193095,6,"We hypothesized that ET-1 inhibits NO-mediated vasodilation via increased ADMA production in CHF, and that an endothelin receptor antagonist can prevent this increase in plasma ADMA levels."
0,background,12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
1,intervention,12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
1,population,12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
0,outcome,12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
0,other,12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
0,"study design",12193095,7,"In the present study, we first examined whether circulating ADMA levels were increased in a dog model of CHF induced by 3 weeks of rapid ventricular pacing (n=5; 270 beats/min) compared with normal dogs (n=5)."
0,background,12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
0,intervention,12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
0,population,12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
1,outcome,12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
0,other,12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
0,"study design",12193095,8,"After 3 weeks of pacing, cardiac output had decreased significantly (1.56+/-0.16 compared with 2.93+/-0.25 litres/min; P&lt;0.01) and systemic vascular resistance had increased (4653+/-374 compared with 3227+/-396 dyn.s.cm(-5); P&lt;0.01) in dogs with CHF"
0,background,12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
0,intervention,12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
0,population,12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
1,outcome,12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
0,other,12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
0,"study design",12193095,9,"Plasma levels of both ET-1 (4.95+/-0.83 compared with 2.12+/-0.39 pg/ml; P&lt;0.05) and ADMA (3.27+/-0.49 compared with 1.91+/-0.25 nmol/ml; P&lt;0.05) were significantly increased in CHF dogs."
0,background,12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
0,intervention,12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
0,population,12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
1,outcome,12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
0,other,12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
0,"study design",12193095,10,"A significant positive correlation was observed between plasma ET-1 and ADMA levels (r=0.72, P&lt;0.05)."
0,background,12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
1,intervention,12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
0,population,12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
0,outcome,12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
0,other,12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
0,"study design",12193095,11,"Secondly, we chronically administered an ET(A) receptor antagonist, TA-0201 (0.3 mg/kg; n=5), to paced CHF dogs."
0,background,12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
0,intervention,12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
0,population,12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
0,outcome,12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
1,other,12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
0,"study design",12193095,12,"Drug administration started on day 8 of pacing and continued throughout the experiment."
0,background,12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
0,intervention,12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
0,population,12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
1,outcome,12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
0,other,12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
0,"study design",12193095,13,"TA-0201 significantly increased cardiac output (2.58+/-0.24 litres/min; P&lt;0.01) and suppressed the increases in plasma ADMA levels and systemic vascular resistance (2.36+/-0.30 nmol/ml and 2423+/-188 dyn.s.cm(-5) respectively; P&lt;0.05 for each) compa"
0,background,12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
0,intervention,12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
0,population,12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
1,outcome,12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
0,other,12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
0,"study design",12193095,14,"In conclusion, ET-1 contributes to the regulation of vascular tone due, in part, to increased levels of an endogenous NO synthase inhibitor in CHF, and an ET(A) receptor antagonist can prevent the inhibition of NO production and the increased peripheral v"
1,background,12261791,1,"This is the editorial note on a report dealing with birth planning in China."
0,intervention,12261791,1,"This is the editorial note on a report dealing with birth planning in China."
0,population,12261791,1,"This is the editorial note on a report dealing with birth planning in China."
0,outcome,12261791,1,"This is the editorial note on a report dealing with birth planning in China."
0,other,12261791,1,"This is the editorial note on a report dealing with birth planning in China."
0,"study design",12261791,1,"This is the editorial note on a report dealing with birth planning in China."
1,background,12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
0,intervention,12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
0,population,12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
0,outcome,12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
0,other,12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
0,"study design",12261791,2,"The report is a compilation of trip report excerpts and journal notes written by visitors to China in the 1977-79 period."
1,background,12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,intervention,12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,population,12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,outcome,12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,other,12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,"study design",12261791,3,"For those in the population field, China is extremely interesting because it has managed to reduce its population growth rate significantly in recent years."
0,background,12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
0,intervention,12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
0,population,12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
1,outcome,12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
0,other,12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
0,"study design",12261791,4,"The following aspects seem to account for this success on the population front: 1) use of paramedics and barefoot doctors to provide family planning service to all communities; 2) availability of a wide range of contraceptive methods, including abortion a"
1,background,12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
0,intervention,12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
0,population,12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
0,outcome,12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
0,other,12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
0,"study design",12292288,1,"In Bolivia, 50% of pregnant women experience pregnancy and childbirth without any medical attention."
1,background,12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
0,intervention,12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
0,population,12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
0,outcome,12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
0,other,12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
0,"study design",12292288,2,"Bolivia has the highest rate of maternal mortality in South America."
1,background,12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,intervention,12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,population,12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,outcome,12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,other,12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,"study design",12292288,3,"Family planning programs not only teach women about the benefits of spacing children several years apart, breast feeding, good nutrition, prenatal and postpartum visits, and safe deliveries, they also reduce the incidence of abortion, help to alleviate po"
0,background,12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
0,intervention,12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
0,population,12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
0,outcome,12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
1,other,12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
0,"study design",12292288,4,"The government, nongovernmental organizations, and the medical community therefore joined forces to launch a nationwide family planning campaign in Bolivia."
0,background,12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
0,intervention,12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
0,population,12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
0,outcome,12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
1,other,12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
0,"study design",12292288,5,"The US Agency for International Development has provided Bolivia with financial and technical assistance to establish a network of primary health care clinics."
1,background,12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
0,intervention,12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
0,population,12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
0,outcome,12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
0,other,12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
0,"study design",12292288,6,"The author, US First Lady, visited one of the clinics during her trip to participate in the Sixth Conference of Wives of Heads of State and Government of the Americas."
1,background,12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
0,intervention,12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
0,population,12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
0,outcome,12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
0,other,12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
0,"study design",12292288,7,"The US Congress recently slashed funds for international family planning program assistance by 35% and added restrictions on the delivery schedule of aid for the first 9 months of the fiscal year."
1,background,12292288,8,"Similarly harsh cuts and delays are included in the current budget."
0,intervention,12292288,8,"Similarly harsh cuts and delays are included in the current budget."
0,population,12292288,8,"Similarly harsh cuts and delays are included in the current budget."
0,outcome,12292288,8,"Similarly harsh cuts and delays are included in the current budget."
0,other,12292288,8,"Similarly harsh cuts and delays are included in the current budget."
0,"study design",12292288,8,"Similarly harsh cuts and delays are included in the current budget."
1,background,12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
0,intervention,12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
0,population,12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
0,outcome,12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
0,other,12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
0,"study design",12292288,9,"A recent analysis by five population organizations found that these funding cuts will result in 1.6 million more abortions, more than 8000 maternal deaths, and 134,000 infant deaths in developing countries."
1,background,12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
0,intervention,12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
0,population,12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
0,outcome,12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
0,other,12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
0,"study design",12292288,10,"Policymakers must be made to understand that family planning campaigns in operation in Bolivia and elsewhere are sensible, cost-effective, and long-term strategies for improving women's health, strengthening families, and lowering abortion rates.americasb"
1,background,12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,intervention,12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,population,12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,outcome,12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,other,12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,"study design",12316426,1,"Although adolescents in Reunion have a pregnancy rate of 77/1000, twice that of France, there are no published studies on the themes of adolescent pregnancy and parenthood."
0,background,12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
0,intervention,12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
1,population,12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
0,outcome,12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
0,other,12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
0,"study design",12316426,2,"105 women under 18 including 20 aged 14 who gave birth in 1 maternity center were analyzed for sociofamilial characteristics and perinatal complications."
0,background,12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
0,intervention,12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
0,population,12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
1,outcome,12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
0,other,12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
0,"study design",12316426,3,"The educational level of the adolescent mothers was low and 47% had stopped school before the pregnancy."
0,background,12316426,4,"1/3 expected to find employment or return to work after delivery."
0,intervention,12316426,4,"1/3 expected to find employment or return to work after delivery."
0,population,12316426,4,"1/3 expected to find employment or return to work after delivery."
1,outcome,12316426,4,"1/3 expected to find employment or return to work after delivery."
0,other,12316426,4,"1/3 expected to find employment or return to work after delivery."
0,"study design",12316426,4,"1/3 expected to find employment or return to work after delivery."
0,background,12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
0,intervention,12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
0,population,12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
1,outcome,12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
0,other,12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
0,"study design",12316426,5,"19% were already in consensual unions at the time of pregnancy and 34% had entered such unions after delivery."
0,background,12316426,6,"It was the 2nd pregnancy for 11.5%."
0,intervention,12316426,6,"It was the 2nd pregnancy for 11.5%."
0,population,12316426,6,"It was the 2nd pregnancy for 11.5%."
1,outcome,12316426,6,"It was the 2nd pregnancy for 11.5%."
0,other,12316426,6,"It was the 2nd pregnancy for 11.5%."
0,"study design",12316426,6,"It was the 2nd pregnancy for 11.5%."
0,background,12316426,7,"Only 8.5% used contraception."
0,intervention,12316426,7,"Only 8.5% used contraception."
0,population,12316426,7,"Only 8.5% used contraception."
1,outcome,12316426,7,"Only 8.5% used contraception."
0,other,12316426,7,"Only 8.5% used contraception."
0,"study design",12316426,7,"Only 8.5% used contraception."
0,background,12316426,8,"The age difference with the partner was over 5 years for more than half."
0,intervention,12316426,8,"The age difference with the partner was over 5 years for more than half."
0,population,12316426,8,"The age difference with the partner was over 5 years for more than half."
1,outcome,12316426,8,"The age difference with the partner was over 5 years for more than half."
0,other,12316426,8,"The age difference with the partner was over 5 years for more than half."
0,"study design",12316426,8,"The age difference with the partner was over 5 years for more than half."
0,background,12316426,9,"68% had known the father for more than 1 year."
0,intervention,12316426,9,"68% had known the father for more than 1 year."
0,population,12316426,9,"68% had known the father for more than 1 year."
1,outcome,12316426,9,"68% had known the father for more than 1 year."
0,other,12316426,9,"68% had known the father for more than 1 year."
0,"study design",12316426,9,"68% had known the father for more than 1 year."
0,background,12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
0,intervention,12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
0,population,12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
1,outcome,12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
0,other,12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
0,"study design",12316426,10,"At the time of pregnancy, 35% lived in families with 2 parents and 36% in households headed by their mothers."
0,background,12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
0,intervention,12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
0,population,12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
1,outcome,12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
0,other,12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
0,"study design",12316426,11,"Heads of 50% of all their households and 80% of those headed by the mothers were unemployed."
0,background,12316426,12,"44% had more than 6 siblings."
0,intervention,12316426,12,"44% had more than 6 siblings."
0,population,12316426,12,"44% had more than 6 siblings."
1,outcome,12316426,12,"44% had more than 6 siblings."
0,other,12316426,12,"44% had more than 6 siblings."
0,"study design",12316426,12,"44% had more than 6 siblings."
0,background,12316426,13,"20% had 1 or more sisters who were adolescent mothers."
0,intervention,12316426,13,"20% had 1 or more sisters who were adolescent mothers."
0,population,12316426,13,"20% had 1 or more sisters who were adolescent mothers."
1,outcome,12316426,13,"20% had 1 or more sisters who were adolescent mothers."
0,other,12316426,13,"20% had 1 or more sisters who were adolescent mothers."
0,"study design",12316426,13,"20% had 1 or more sisters who were adolescent mothers."
0,background,12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
0,intervention,12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
0,population,12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
1,outcome,12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
0,other,12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
0,"study design",12316426,14,"Comparison with a group of 62 adolescents seeking abortions at the same center indicated several factors that appeared to encourage continuation of the pregnancy; including being below age level in school, absence of plans for education or employment, lim"
0,background,12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
0,intervention,12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
0,population,12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
1,outcome,12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
0,other,12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
0,"study design",12316426,15,"Risk factors at the level of the family included absence of the father, maternal tolerance, poverty, and sisters who were single mothers."
0,background,12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
0,intervention,12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
0,population,12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
1,outcome,12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
0,other,12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
0,"study design",12316426,16,"27% states retrospectively that they would have preferred to terminate the pregnancy, but all stated they were satisfied after the delivery."
0,background,12316426,17,"41% had problems in pregnancy or delivery."
0,intervention,12316426,17,"41% had problems in pregnancy or delivery."
0,population,12316426,17,"41% had problems in pregnancy or delivery."
1,outcome,12316426,17,"41% had problems in pregnancy or delivery."
0,other,12316426,17,"41% had problems in pregnancy or delivery."
0,"study design",12316426,17,"41% had problems in pregnancy or delivery."
0,background,12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
0,intervention,12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
0,population,12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
1,outcome,12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
0,other,12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
0,"study design",12316426,18,"10.5% had toxemia and 23% had low birth weight babies."
0,background,12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
0,intervention,12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
0,population,12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
1,outcome,12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
0,other,12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
0,"study design",12316426,19,"5.7% had caesareans, mainly for eclampsia and acute fetal distress."
0,background,12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
0,intervention,12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
0,population,12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
1,outcome,12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
0,other,12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
0,"study design",12316426,20,"There was 1 stillbirth and 2 cases of cogenital malformations."
0,background,12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
0,intervention,12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
0,population,12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
1,outcome,12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
0,other,12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
0,"study design",12316426,21,"14 newborns were transferred were transferred to the neonatology unit for various problems, including 6 weighing under 2000 g."
0,background,12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
0,intervention,12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
0,population,12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
1,outcome,12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
0,other,12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
0,"study design",12316426,22,"Compared to the general population, the rate of fetal growth retardation was 3 times higher and that of neonatal pathology requiring transfer to the neonatology unit was 2 times higher among adolescent mothers."
0,background,12316426,23,"Prenatal care was inadequate in many cases."
0,intervention,12316426,23,"Prenatal care was inadequate in many cases."
0,population,12316426,23,"Prenatal care was inadequate in many cases."
1,outcome,12316426,23,"Prenatal care was inadequate in many cases."
0,other,12316426,23,"Prenatal care was inadequate in many cases."
0,"study design",12316426,23,"Prenatal care was inadequate in many cases."
0,background,12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
0,intervention,12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
0,population,12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
1,outcome,12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
0,other,12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
0,"study design",12316426,24,"35% of 14-year-old mothers had 3 or fewer prenatal visits.adolescent pregnancy--complicationsadolescentsadolescents femaleafricaafrica south of the saharaage factorscontraceptioncontraceptive usagedelivery of health caredemographic factorsdeveloping count"
1,background,12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,intervention,12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,population,12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,outcome,12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,other,12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,"study design",12360547,1,"We evaluated the efficacy of physiotherapy, occupational therapy, and speech and language therapy in Parkinson's disease by synthesizing six Cochrane systematic reviews."
0,background,12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
1,intervention,12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
0,population,12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
0,outcome,12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
0,other,12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
0,"study design",12360547,2,"All randomised, controlled trials examining the efficacy of a paramedical therapy versus control intervention and all those comparing the efficacy of two forms of active therapy in Parkinson's disease were included."
0,background,12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
0,intervention,12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
0,population,12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
0,outcome,12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
1,other,12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
0,"study design",12360547,3,"Trials were identified by searching biomedical databases, reference lists, hand searching, and contacting investigators."
0,background,12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
0,intervention,12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
0,population,12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
0,outcome,12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
1,other,12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
0,"study design",12360547,4,"The main outcome measures were quality of life, speech intelligibility, activities of daily living, and individual measures of motor and speech impairment."
0,background,12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
0,intervention,12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
0,population,12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
1,outcome,12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
0,other,12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
0,"study design",12360547,5,"We identified 16 physiotherapy randomised controlled trials (399 patients), two occupational therapy trials (84 patients), and five speech and language therapy for dysarthria trials (154 patients)."
0,background,12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
0,intervention,12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
0,population,12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
1,outcome,12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
0,other,12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
0,"study design",12360547,6,"None of these studies examined nonpharmacological swallowing therapy for dysphagia."
0,background,12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
0,intervention,12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
0,population,12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
1,outcome,12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
0,other,12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
0,"study design",12360547,7,"We were unable to perform meta-analysis of the results because the trials used heterogeneous therapy methods and outcome measures."
0,background,12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
0,intervention,12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
0,population,12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
1,outcome,12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
0,other,12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
0,"study design",12360547,8,"The trials also had marked methodological flaws that could have introduced bias."
0,background,12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
0,intervention,12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
0,population,12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
1,outcome,12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
0,other,12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
0,"study design",12360547,9,"In summary, we failed to find conclusive evidence of benefit for any form of paramedical therapy sufficient to recommend them in routine clinical practice."
0,background,12360547,10,"However, this lack of evidence is not proof of a lack of effect."
0,intervention,12360547,10,"However, this lack of evidence is not proof of a lack of effect."
0,population,12360547,10,"However, this lack of evidence is not proof of a lack of effect."
1,outcome,12360547,10,"However, this lack of evidence is not proof of a lack of effect."
0,other,12360547,10,"However, this lack of evidence is not proof of a lack of effect."
0,"study design",12360547,10,"However, this lack of evidence is not proof of a lack of effect."
0,background,12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
0,intervention,12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
0,population,12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
1,outcome,12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
0,other,12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
0,"study design",12360547,11,"Further large pragmatic randomised controlled trials are required to determine the effectiveness of paramedical therapies in Parkinson's disease."
1,background,12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
0,intervention,12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
0,population,12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
0,outcome,12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
0,other,12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
0,"study design",12373547,1,"Dynorphin is a neuropeptide that is present in high quantities in the dorsal horn of the spinal cord."
1,background,12373547,2,"The peptide is actively involved in pain processing pathways."
0,intervention,12373547,2,"The peptide is actively involved in pain processing pathways."
0,population,12373547,2,"The peptide is actively involved in pain processing pathways."
0,outcome,12373547,2,"The peptide is actively involved in pain processing pathways."
0,other,12373547,2,"The peptide is actively involved in pain processing pathways."
0,"study design",12373547,2,"The peptide is actively involved in pain processing pathways."
1,background,12373547,3,"However, its involvement in spinal cord injury is not well known."
0,intervention,12373547,3,"However, its involvement in spinal cord injury is not well known."
0,population,12373547,3,"However, its involvement in spinal cord injury is not well known."
0,outcome,12373547,3,"However, its involvement in spinal cord injury is not well known."
0,other,12373547,3,"However, its involvement in spinal cord injury is not well known."
0,"study design",12373547,3,"However, its involvement in spinal cord injury is not well known."
0,background,12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
0,intervention,12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
1,population,12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
0,outcome,12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
0,other,12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
0,"study design",12373547,4,"Alteration in dynorphin immunoreactivity occurs following a focal trauma to the rat spinal cord."
0,background,12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
1,intervention,12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
0,population,12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
0,outcome,12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
0,other,12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
0,"study design",12373547,5,"Infusion of dynorphin into the intrathecal space of the cord results in ischemia, cell damage and abnormal motor function."
0,background,12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
1,intervention,12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
0,population,12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
0,outcome,12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
0,other,12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
0,"study design",12373547,6,"Antibodies to dynorphin when injected into the intrathecal space of the spinal cord following trauma improve motor recovery, reduce edema and cell changes."
1,background,12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
0,intervention,12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
0,population,12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
0,outcome,12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
0,other,12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
0,"study design",12373547,7,"However, influence of dynorphin on trauma induced alteration in spinal cord bioelectrical activity is still not known."
1,background,12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
0,intervention,12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
0,population,12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
0,outcome,12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
0,other,12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
0,"study design",12373547,8,"Spinal cord evoked potentials (SCEP) are good indicator of spinal cord pathology following trauma."
1,background,12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
0,intervention,12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
0,population,12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
0,outcome,12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
0,other,12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
0,"study design",12373547,9,"Therefore, in present investigation, influence of dynorphin antibodies on trauma induced changes in SCEP were examined in our rat model."
1,background,12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,intervention,12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,population,12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,outcome,12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,other,12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,"study design",12373547,10,"In addition, spinal cord edema formation, microvascular permeability disturbances and cell injury were also investigated."
0,background,12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
0,intervention,12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
0,population,12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
1,outcome,12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
0,other,12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
0,"study design",12373547,11,"Our results show that topical application of dynorphin antiserum (1 : 200) two min before injury markedly attenuated the SCEP changes immediately after injury."
0,background,12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
0,intervention,12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
0,population,12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
1,outcome,12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
0,other,12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
0,"study design",12373547,12,"In the antiserum treated animals, a significant reduction in the microvascular permeability, edema formation and cell injury was observed in the traumatised spinal cord."
0,background,12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
0,intervention,12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
0,population,12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
1,outcome,12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
0,other,12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
0,"study design",12373547,13,"These observations suggest that (i). dynorphin is involved in the altered bioelectrical activity of the spinal cord following trauma, (ii). the peptide actively participates in the pathophysiological processes of cell injury in the spinal cord trauma, and"
1,background,12400247,1,"Central pain is a particular form of neuropathic pain."
0,intervention,12400247,1,"Central pain is a particular form of neuropathic pain."
0,population,12400247,1,"Central pain is a particular form of neuropathic pain."
0,outcome,12400247,1,"Central pain is a particular form of neuropathic pain."
0,other,12400247,1,"Central pain is a particular form of neuropathic pain."
0,"study design",12400247,1,"Central pain is a particular form of neuropathic pain."
1,background,12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
0,intervention,12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
0,population,12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
0,outcome,12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
0,other,12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
0,"study design",12400247,2,"Due to lesions in the spinothalamocortical pathways, ectopic neuronal discharges can occur into different neurons of the spinal cord and brain."
1,background,12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
0,intervention,12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
0,population,12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
0,outcome,12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
0,other,12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
0,"study design",12400247,3,"Functional MRI, and positron emission tomography might be able to visualize ongoing pain activity which is, sometimes the consequence of spinothalamocortical lesions."
1,background,12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
0,intervention,12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
1,population,12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
0,outcome,12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
0,other,12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
0,"study design",12400247,4,"Sometimes the patient experiences a burning ice-like sensation."
1,background,12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
0,intervention,12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
0,population,12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
0,outcome,12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
0,other,12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
0,"study design",12400247,5,"This is more frequent in spinal cord lesions than in brain injuries."
1,background,12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
0,intervention,12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
0,population,12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
0,outcome,12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
0,other,12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
0,"study design",12400247,6,"Some adrenergic, gabergic neurotransmitters, glycine, prostanoids and glutamate may play a role in pain transmission."
1,background,12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
0,intervention,12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
0,population,12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
0,outcome,12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
0,other,12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
0,"study design",12400247,7,"These transmitters can induce changes in the neuronal membrane potential."
1,background,12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,intervention,12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,population,12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,outcome,12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,other,12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,"study design",12400247,8,"Consequently, amitriptyline as an adrenergic reuptake inhibitor and the sodium channel blockers are the drugs of first-choice."
0,background,12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
1,intervention,12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
0,population,12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
0,outcome,12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
0,other,12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
0,"study design",12400247,9,"A test procedure with placebo, opioids, lignocaine, propofol and ketamine might give some insight into advanced drug treatment."
1,background,12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
0,intervention,12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
0,population,12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
0,outcome,12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
0,other,12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
0,"study design",12400247,10,"If oral or transdermal drug delivery is not indicated or ineffective, the intrathecal administration route can be attempted with baclofen, clonidine, opioids and midazolam."
1,background,12400247,11,"Invasive electrostimulation is the last treatment option."
0,intervention,12400247,11,"Invasive electrostimulation is the last treatment option."
0,population,12400247,11,"Invasive electrostimulation is the last treatment option."
0,outcome,12400247,11,"Invasive electrostimulation is the last treatment option."
0,other,12400247,11,"Invasive electrostimulation is the last treatment option."
0,"study design",12400247,11,"Invasive electrostimulation is the last treatment option."
1,background,12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,intervention,12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,population,12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,outcome,12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,other,12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,"study design",12400247,12,"Thalamic stimulation can be tried in spinal cord injuries, and sensory motor cortex stimulation is sometimes the last resort for brain lesions associated with pain."
0,background,12402129,1,"QUESTION"
0,intervention,12402129,1,"QUESTION"
0,population,12402129,1,"QUESTION"
0,outcome,12402129,1,"QUESTION"
1,other,12402129,1,"QUESTION"
0,"study design",12402129,1,"QUESTION"
1,background,12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,intervention,12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,population,12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,outcome,12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,other,12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,"study design",12402129,2,"To what extent does the scientific literature have an impact on current clinical practice guidelines (CPGs) in trauma surgery?"
0,background,12402129,3,"METHODS"
0,intervention,12402129,3,"METHODS"
0,population,12402129,3,"METHODS"
0,outcome,12402129,3,"METHODS"
1,other,12402129,3,"METHODS"
0,"study design",12402129,3,"METHODS"
0,background,12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
0,intervention,12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
1,population,12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
0,outcome,12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
0,other,12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
0,"study design",12402129,4,"We searched for CPGs on the initial management of multiply injured patients and assessed the quality of literature search and appraisal within these CPGs."
0,background,12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
0,intervention,12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
0,population,12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
0,outcome,12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
1,other,12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
0,"study design",12402129,5,"Secondly, we compiled a list of all medical journal with relevance to prehospital trauma care."
0,background,12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
0,intervention,12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
0,population,12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
0,outcome,12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
1,other,12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
0,"study design",12402129,6,"Lastly, we performed a hand search for randomised controlled trials (RCTs) in some of the German not in Medline indexed traumatological journals."
0,background,12402129,7,"RESULTS"
0,intervention,12402129,7,"RESULTS"
0,population,12402129,7,"RESULTS"
0,outcome,12402129,7,"RESULTS"
1,other,12402129,7,"RESULTS"
0,"study design",12402129,7,"RESULTS"
0,background,12402129,8,"We identified 22 CPGs of varying methodological quality."
0,intervention,12402129,8,"We identified 22 CPGs of varying methodological quality."
0,population,12402129,8,"We identified 22 CPGs of varying methodological quality."
1,outcome,12402129,8,"We identified 22 CPGs of varying methodological quality."
0,other,12402129,8,"We identified 22 CPGs of varying methodological quality."
0,"study design",12402129,8,"We identified 22 CPGs of varying methodological quality."
0,background,12402129,9,"The American guidelines scored highest."
0,intervention,12402129,9,"The American guidelines scored highest."
0,population,12402129,9,"The American guidelines scored highest."
1,outcome,12402129,9,"The American guidelines scored highest."
0,other,12402129,9,"The American guidelines scored highest."
0,"study design",12402129,9,"The American guidelines scored highest."
0,background,12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
0,intervention,12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
0,population,12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
1,outcome,12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
0,other,12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
0,"study design",12402129,10,"Only 21 of the 38 journals (55%) in the field of prehospital trauma surgery were indexed in Medline, while 6 were covered only by Embase and 11 were indexed in neither of both databases."
0,background,12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
0,intervention,12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
0,population,12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
1,outcome,12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
0,other,12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
0,"study design",12402129,11,"Hand searching four non-indexed German journals identified nearly 200 RCTs."
0,background,12402129,12,"CONCLUSION"
0,intervention,12402129,12,"CONCLUSION"
0,population,12402129,12,"CONCLUSION"
0,outcome,12402129,12,"CONCLUSION"
1,other,12402129,12,"CONCLUSION"
0,"study design",12402129,12,"CONCLUSION"
0,background,12402129,13,"Information flow between clinical research and CPG development remains difficult."
0,intervention,12402129,13,"Information flow between clinical research and CPG development remains difficult."
0,population,12402129,13,"Information flow between clinical research and CPG development remains difficult."
1,outcome,12402129,13,"Information flow between clinical research and CPG development remains difficult."
0,other,12402129,13,"Information flow between clinical research and CPG development remains difficult."
0,"study design",12402129,13,"Information flow between clinical research and CPG development remains difficult."
0,background,12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
0,intervention,12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
0,population,12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
1,outcome,12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
0,other,12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
0,"study design",12402129,14,"Thoroughly performed literature searches have an important role in CPG development."
0,background,12514454,1,"OBJECTIVE"
0,intervention,12514454,1,"OBJECTIVE"
0,population,12514454,1,"OBJECTIVE"
0,outcome,12514454,1,"OBJECTIVE"
1,other,12514454,1,"OBJECTIVE"
0,"study design",12514454,1,"OBJECTIVE"
1,background,12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,intervention,12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,population,12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,outcome,12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,other,12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,"study design",12514454,2,"To develop and establish the psychometric properties of a pain treatment willingness scale and identify factors associated with willingness to try specific pain treatments for spinal cord injury (SCI)-related pain."
0,background,12514454,3,"DESIGN"
0,intervention,12514454,3,"DESIGN"
0,population,12514454,3,"DESIGN"
0,outcome,12514454,3,"DESIGN"
1,other,12514454,3,"DESIGN"
0,"study design",12514454,3,"DESIGN"
0,background,12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
0,intervention,12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
0,population,12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
0,outcome,12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
1,other,12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
0,"study design",12514454,4,"As part of a larger study, a questionnaire was designed to assess willingness to use various pain medications and other types of pain treatments."
0,background,12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
0,intervention,12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
1,population,12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
0,outcome,12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
0,other,12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
0,"study design",12514454,5,"This questionnaire, which included measures of pain severity, pain interference, mood, hope, and current use of pain treatments, was completed by persons with SCI recruited through the mail or in person."
0,background,12514454,6,"SUBJECTS"
0,intervention,12514454,6,"SUBJECTS"
0,population,12514454,6,"SUBJECTS"
0,outcome,12514454,6,"SUBJECTS"
1,other,12514454,6,"SUBJECTS"
0,"study design",12514454,6,"SUBJECTS"
0,background,12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
0,intervention,12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
0,population,12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
0,outcome,12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
1,other,12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
0,"study design",12514454,7,"One hundred fifteen persons completed the questionnaire (35% response rate)."
0,background,12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
0,intervention,12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
0,population,12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
0,outcome,12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
1,other,12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
0,"study design",12514454,8,"Seventy-two percent of the participants were men, mean age was 49.1 years, and average time elapsed since injury was 8 years."
0,background,12514454,9,"RESULTS"
0,intervention,12514454,9,"RESULTS"
0,population,12514454,9,"RESULTS"
0,outcome,12514454,9,"RESULTS"
1,other,12514454,9,"RESULTS"
0,"study design",12514454,9,"RESULTS"
0,background,12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
0,intervention,12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
0,population,12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
1,outcome,12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
0,other,12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
0,"study design",12514454,10,"Factor analysis indicated two factors-willingness to use opioids and willingness to use nonpharmacological treatment (i.e., physical therapy, relaxation methods and stress management, and alternative medicine)."
0,background,12514454,11,"Internal consistency and convergent and divergent validity were established."
0,intervention,12514454,11,"Internal consistency and convergent and divergent validity were established."
0,population,12514454,11,"Internal consistency and convergent and divergent validity were established."
1,outcome,12514454,11,"Internal consistency and convergent and divergent validity were established."
0,other,12514454,11,"Internal consistency and convergent and divergent validity were established."
0,"study design",12514454,11,"Internal consistency and convergent and divergent validity were established."
0,background,12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
0,intervention,12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
0,population,12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
1,outcome,12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
0,other,12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
0,"study design",12514454,12,"Persons experiencing SCI-related pain were more willing to use pain treatments than those without current pain, and those who were currently using opioids reported greater willingness to use that treatment."
0,background,12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
0,intervention,12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
0,population,12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
1,outcome,12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
0,other,12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
0,"study design",12514454,13,"Persons who reported SCI-related pain were more willing to use nonpharmacological treatments than opioid medications."
0,background,12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
0,intervention,12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
0,population,12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
1,outcome,12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
0,other,12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
0,"study design",12514454,14,"Finally, participants demonstrated different degrees of willingness to use an opioid medication based on its name (i.e., &quot;narcotic,&quot; &quot;codeine,&quot; &quot;morphine,&quot; &quot;methadone&quot;)."
0,background,12514454,15,"CONCLUSIONS"
0,intervention,12514454,15,"CONCLUSIONS"
0,population,12514454,15,"CONCLUSIONS"
0,outcome,12514454,15,"CONCLUSIONS"
1,other,12514454,15,"CONCLUSIONS"
0,"study design",12514454,15,"CONCLUSIONS"
0,background,12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
0,intervention,12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
0,population,12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
1,outcome,12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
0,other,12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
0,"study design",12514454,16,"Willingness to use a specific pain treatment may be a key factor mediating the behavior of using that specific treatment."
0,background,12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
0,intervention,12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
0,population,12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
1,outcome,12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
0,other,12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
0,"study design",12514454,17,"Assessment of patient attitudes toward various treatments options, particularly regarding opioid medications, is warranted to optimize treatment adherence."
0,background,12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
0,intervention,12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
0,population,12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
1,outcome,12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
0,other,12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
0,"study design",12514454,18,"Once the factors that determine these attitudes are identified, interventions to increase willingness to use nonpharmacological or opioid treatments can be designed and evaluated."
0,background,12544928,1,"STUDY DESIGN"
0,intervention,12544928,1,"STUDY DESIGN"
0,population,12544928,1,"STUDY DESIGN"
0,outcome,12544928,1,"STUDY DESIGN"
1,other,12544928,1,"STUDY DESIGN"
0,"study design",12544928,1,"STUDY DESIGN"
0,background,12544928,2,"A prospective cross-sectional study was conducted."
0,intervention,12544928,2,"A prospective cross-sectional study was conducted."
0,population,12544928,2,"A prospective cross-sectional study was conducted."
0,outcome,12544928,2,"A prospective cross-sectional study was conducted."
0,other,12544928,2,"A prospective cross-sectional study was conducted."
1,"study design",12544928,2,"A prospective cross-sectional study was conducted."
0,background,12544928,3,"OBJECTIVE"
0,intervention,12544928,3,"OBJECTIVE"
0,population,12544928,3,"OBJECTIVE"
0,outcome,12544928,3,"OBJECTIVE"
1,other,12544928,3,"OBJECTIVE"
0,"study design",12544928,3,"OBJECTIVE"
0,background,12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
0,intervention,12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
0,population,12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
0,outcome,12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
1,other,12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
0,"study design",12544928,4,"To determine the relation between degeneration of all the joints in the cervical spine, and to identify the effects of litigation on pain and disability levels in trauma and nontrauma patients."
0,background,12544928,5,"SUMMARY OF BACKGROUND DATA"
0,intervention,12544928,5,"SUMMARY OF BACKGROUND DATA"
0,population,12544928,5,"SUMMARY OF BACKGROUND DATA"
0,outcome,12544928,5,"SUMMARY OF BACKGROUND DATA"
1,other,12544928,5,"SUMMARY OF BACKGROUND DATA"
0,"study design",12544928,5,"SUMMARY OF BACKGROUND DATA"
1,background,12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
0,intervention,12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
0,population,12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
0,outcome,12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
0,other,12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
0,"study design",12544928,6,"The link between spinal degeneration and patient symptoms remains controversial."
1,background,12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
0,intervention,12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
0,population,12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
0,outcome,12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
0,other,12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
0,"study design",12544928,7,"Two recent similar studies present conflicting results concerning the association between spinal degeneration and symptomatology."
1,background,12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
0,intervention,12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
0,population,12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
0,outcome,12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
0,other,12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
0,"study design",12544928,8,"These two studies, performed in different countries, did not consider the impact of impending litigation on self-reported pain and disability levels."
1,background,12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,intervention,12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,population,12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,outcome,12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,other,12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,"study design",12544928,9,"The role of the uncovertebral and facet articulations has hitherto not been investigated."
0,background,12544928,10,"METHODS"
0,intervention,12544928,10,"METHODS"
0,population,12544928,10,"METHODS"
0,outcome,12544928,10,"METHODS"
1,other,12544928,10,"METHODS"
0,"study design",12544928,10,"METHODS"
0,background,12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
0,intervention,12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
1,population,12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
0,outcome,12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
0,other,12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
0,"study design",12544928,11,"Radiographic and questionnaire data from 180 consecutive patients with neck pain were collected."
0,background,12544928,12,"Neck pain severity was measured using two time-dependent scales."
0,intervention,12544928,12,"Neck pain severity was measured using two time-dependent scales."
0,population,12544928,12,"Neck pain severity was measured using two time-dependent scales."
0,outcome,12544928,12,"Neck pain severity was measured using two time-dependent scales."
1,other,12544928,12,"Neck pain severity was measured using two time-dependent scales."
0,"study design",12544928,12,"Neck pain severity was measured using two time-dependent scales."
0,background,12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
0,intervention,12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
0,population,12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
0,outcome,12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
1,other,12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
0,"study design",12544928,13,"All patients completed the Neck Disability Index (NDI) and questions about chronicity, etiology, and associated litigation."
0,background,12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
0,intervention,12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
0,population,12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
0,outcome,12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
1,other,12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
0,"study design",12544928,14,"The radiographs were evaluated for the number of levels of degeneration and the severity of degeneration in the discs as well as the uncovertebral and facet articulations."
0,background,12544928,15,"RESULTS"
0,intervention,12544928,15,"RESULTS"
0,population,12544928,15,"RESULTS"
0,outcome,12544928,15,"RESULTS"
1,other,12544928,15,"RESULTS"
0,"study design",12544928,15,"RESULTS"
0,background,12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
0,intervention,12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
0,population,12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
1,outcome,12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
0,other,12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
0,"study design",12544928,16,"In this study, 71 patients (40.57%) reported neck pain as a result of injury."
0,background,12544928,17,"However, only 5.1% had associated litigation."
0,intervention,12544928,17,"However, only 5.1% had associated litigation."
0,population,12544928,17,"However, only 5.1% had associated litigation."
1,outcome,12544928,17,"However, only 5.1% had associated litigation."
0,other,12544928,17,"However, only 5.1% had associated litigation."
0,"study design",12544928,17,"However, only 5.1% had associated litigation."
0,background,12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
0,intervention,12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
0,population,12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
1,outcome,12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
0,other,12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
0,"study design",12544928,18,"There was no statistically significant difference in pain severity or disability levels between the patients with and those without cervical degeneration."
0,background,12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
0,intervention,12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
0,population,12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
1,outcome,12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
0,other,12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
0,"study design",12544928,19,"According to the findings, the number of levels of cervical degeneration and the severity of degeneration in the discs, facets, and uncovertebral joints are not related to the levels of pain and disability."
0,background,12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
0,intervention,12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
0,population,12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
1,outcome,12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
0,other,12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
0,"study design",12544928,20,"Patients reporting neck pain caused by injury had a tendency (P = 0.055) to more pain during the preceding week and significantly more disability (P &lt; 0.001)."
0,background,12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
0,intervention,12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
0,population,12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
1,outcome,12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
0,other,12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
0,"study design",12544928,21,"Significant differences included pain intensity (P &lt; 0.025), reading (P &lt; 0.001), headaches (P &lt; 0.025), ability to drive (P &lt; 0.01), and concentration (P &lt; 0.01)."
0,background,12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
0,intervention,12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
0,population,12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
1,outcome,12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
0,other,12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
0,"study design",12544928,22,"Women reported significantly more pain (P &lt; 0.01) and disability (P &lt; 0.001) than men, but did not have more degeneration in any of the joints."
0,background,12544928,23,"CONCLUSIONS"
0,intervention,12544928,23,"CONCLUSIONS"
0,population,12544928,23,"CONCLUSIONS"
0,outcome,12544928,23,"CONCLUSIONS"
1,other,12544928,23,"CONCLUSIONS"
0,"study design",12544928,23,"CONCLUSIONS"
0,background,12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
0,intervention,12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
0,population,12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
1,outcome,12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
0,other,12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
0,"study design",12544928,24,"In patients with neck pain, there is no difference in reported pain and disability levels between those with and those without evidence of cervical spine degeneration."
0,background,12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
0,intervention,12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
0,population,12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
1,outcome,12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
0,other,12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
0,"study design",12544928,25,"Patients whose neck pain is the result of trauma report significantly more pain and disability than nontrauma patients."
0,background,12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
0,intervention,12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
0,population,12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
1,outcome,12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
0,other,12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
0,"study design",12544928,26,"This is not because of more spinal degeneration or overriding litigation issues."
1,background,12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
0,intervention,12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
1,population,12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
0,outcome,12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
0,other,12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
0,"study design",12548347,1,"Five patients (4 women) with Parkinson's disease (PD) and primary major psychiatric disorder (PMPD) meeting DSM-IV criteria for the diagnosis of bipolar affective disorder (BAD) were studied."
0,background,12548347,2,"Four patients had early onset PD."
0,intervention,12548347,2,"Four patients had early onset PD."
0,population,12548347,2,"Four patients had early onset PD."
0,outcome,12548347,2,"Four patients had early onset PD."
1,other,12548347,2,"Four patients had early onset PD."
0,"study design",12548347,2,"Four patients had early onset PD."
0,background,12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
0,intervention,12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
0,population,12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
1,outcome,12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
0,other,12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
0,"study design",12548347,3,"Four developed a severe psychiatric disorder a few years after starting dopaminergic therapy in presence of a mild motor disability and a mild cognitive impairment, with no evidence of cerebral atrophy at CT or MRI."
0,background,12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
0,intervention,12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
0,population,12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
1,outcome,12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
0,other,12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
0,"study design",12548347,4,"Two patients developed a clear manic episode; the other three presented a severe depressive episode (in one case featuring a Cotard syndrome)."
0,background,12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
0,intervention,12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
0,population,12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
1,outcome,12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
0,other,12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
0,"study design",12548347,5,"None showed previous signs of long term L-dopa treatment syndrome (LTS), hallucinosis or other minor psychiatric disorders."
0,background,12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
0,intervention,12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
0,population,12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
1,outcome,12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
0,other,12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
0,"study design",12548347,6,"The two manic episodes occurred shortly after an increase of dopaminergic therapy and in one case rapid cyclic mood fluctuations were observed."
0,background,12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
0,intervention,12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
0,population,12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
1,outcome,12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
0,other,12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
0,"study design",12548347,7,"At the onset of psychiatric symptoms, all patients had an unspecific diagnosis of chronic delusional hallucinatory psychosis (CDHP)."
1,background,12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
0,intervention,12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
0,population,12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
0,outcome,12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
0,other,12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
0,"study design",12831648,1,"Pediatric and adolescent athletes presenting with back pain are much more likely to have a pathologic cause for their symptoms than are adult patients."
1,background,12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
0,intervention,12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
0,population,12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
0,outcome,12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
0,other,12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
0,"study design",12831648,2,"For this reason, it is important for those caring for younger athletes to maintain a high index of suspicion for some of the more common pathologic causes of back pain in this population."
1,background,12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
0,intervention,12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
0,population,12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
0,outcome,12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
0,other,12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
0,"study design",12831648,3,"Diagnostic evaluation should be undertaken more quickly in pediatric and adolescent athletes."
1,background,12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
0,intervention,12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
0,population,12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
0,outcome,12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
0,other,12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
0,"study design",12831648,4,"Sports-related diagnoses that must be considered include disc-related back pain, atypical Scheuermann's kyphosis, spondylolysis, and spondylolisthesis."
1,background,12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
0,intervention,12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
0,population,12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
0,outcome,12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
0,other,12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
0,"study design",12831648,5,"Patients of this age may also present with conditions not associated with activity, including discitis, classic Scheuermann's disease, rheumatologic disease, and spinal tumors."
1,background,12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
0,intervention,12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
0,population,12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
0,outcome,12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
0,other,12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
0,"study design",12831648,6,"History and physical exam provide valuable information to help guide further diagnostic studies which, in turn, will determine necessary treatment."
1,background,12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
0,intervention,12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
0,population,12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
0,outcome,12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
0,other,12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
0,"study design",12831648,7,"No definitive studies are available regarding the diagnosis and treatment of spondylolysis and spondylolisthesis."
1,background,12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
0,intervention,12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
0,population,12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
0,outcome,12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
0,other,12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
0,"study design",12831648,8,"Health professionals need to consider the expertise of a local radiologist when deciding upon diagnostic imaging procedures."
1,background,12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,intervention,12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,population,12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,outcome,12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,other,12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,"study design",12831648,9,"The athlete's age and sport played can contribute to the appropriate treatment plan."
0,background,12957556,1,"OBJECTIVE"
0,intervention,12957556,1,"OBJECTIVE"
0,population,12957556,1,"OBJECTIVE"
0,outcome,12957556,1,"OBJECTIVE"
1,other,12957556,1,"OBJECTIVE"
0,"study design",12957556,1,"OBJECTIVE"
0,background,12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
0,intervention,12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
0,population,12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
0,outcome,12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
1,other,12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
0,"study design",12957556,2,"The purpose of this study was to investigate changes in lumbar flexion together with the pattern and level of muscle activity of selected erector spinae during a rowing trial.Design."
0,background,12957556,3,"Cross-sectional repeated measures design."
0,intervention,12957556,3,"Cross-sectional repeated measures design."
0,population,12957556,3,"Cross-sectional repeated measures design."
0,outcome,12957556,3,"Cross-sectional repeated measures design."
0,other,12957556,3,"Cross-sectional repeated measures design."
1,"study design",12957556,3,"Cross-sectional repeated measures design."
0,background,12957556,4,"BACKGROUND"
0,intervention,12957556,4,"BACKGROUND"
0,population,12957556,4,"BACKGROUND"
0,outcome,12957556,4,"BACKGROUND"
1,other,12957556,4,"BACKGROUND"
0,"study design",12957556,4,"BACKGROUND"
1,background,12957556,5,"Low back pain is a common problem in rowers."
0,intervention,12957556,5,"Low back pain is a common problem in rowers."
0,population,12957556,5,"Low back pain is a common problem in rowers."
0,outcome,12957556,5,"Low back pain is a common problem in rowers."
0,other,12957556,5,"Low back pain is a common problem in rowers."
0,"study design",12957556,5,"Low back pain is a common problem in rowers."
1,background,12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,intervention,12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,population,12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,outcome,12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,other,12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,"study design",12957556,6,"The amount of lumbar flexion occurring during rowing might influence the possibility of injury."
0,background,12957556,7,"METHODS"
0,intervention,12957556,7,"METHODS"
0,population,12957556,7,"METHODS"
0,outcome,12957556,7,"METHODS"
1,other,12957556,7,"METHODS"
0,"study design",12957556,7,"METHODS"
0,background,12957556,8,"Sixteen young adult school rowers participated in the study."
0,intervention,12957556,8,"Sixteen young adult school rowers participated in the study."
1,population,12957556,8,"Sixteen young adult school rowers participated in the study."
0,outcome,12957556,8,"Sixteen young adult school rowers participated in the study."
0,other,12957556,8,"Sixteen young adult school rowers participated in the study."
0,"study design",12957556,8,"Sixteen young adult school rowers participated in the study."
0,background,12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
0,intervention,12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
0,population,12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
0,outcome,12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
1,other,12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
0,"study design",12957556,9,"Changes in lumbar flexion and muscle activity were recorded across the drive phase, at three stages of an ergometer based rowing trial."
0,background,12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
1,intervention,12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
0,population,12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
0,outcome,12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
0,other,12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
0,"study design",12957556,10,"Lumbar flexion was calculated by computerised motion analysis of surface markers attached to the spinous processes of L1 and S1."
0,background,12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
0,intervention,12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
0,population,12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
0,outcome,12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
1,other,12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
0,"study design",12957556,11,"Surface electromyography techniques were used to examine the magnitude of activity from three erector spinae muscles."
0,background,12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
0,intervention,12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
0,population,12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
0,outcome,12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
1,other,12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
0,"study design",12957556,12,"The median frequency of the electromyographic signal was examined to quantify fatigue in the erector spinae muscles during isometric maximal effort muscle activation prior to and after the rowing trial."
0,background,12957556,13,"RESULTS"
0,intervention,12957556,13,"RESULTS"
0,population,12957556,13,"RESULTS"
0,outcome,12957556,13,"RESULTS"
1,other,12957556,13,"RESULTS"
0,"study design",12957556,13,"RESULTS"
0,background,12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
0,intervention,12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
0,population,12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
1,outcome,12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
0,other,12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
0,"study design",12957556,14,"Lumbar flexion increased significantly (P&lt;0.05) during the rowing trial, as did the magnitude of electromyographic activity from sites over the lumbar multifidus, iliocostalis lumborum and longissimus thoracis muscles."
0,background,12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
0,intervention,12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
0,population,12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
1,outcome,12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
0,other,12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
0,"study design",12957556,15,"The median frequency decreased significantly (P&lt;0.05) in each muscle examined."
0,background,12957556,16,"CONCLUSIONS"
0,intervention,12957556,16,"CONCLUSIONS"
0,population,12957556,16,"CONCLUSIONS"
0,outcome,12957556,16,"CONCLUSIONS"
1,other,12957556,16,"CONCLUSIONS"
0,"study design",12957556,16,"CONCLUSIONS"
0,background,12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
0,intervention,12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
0,population,12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
1,outcome,12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
0,other,12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
0,"study design",12957556,17,"The findings showed that rowers attain relatively high levels of lumbar flexion during the rowing stroke, and these levels are increased during the course of the rowing trial."
0,background,12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
0,intervention,12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
0,population,12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
1,outcome,12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
0,other,12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
0,"study design",12957556,18,"Indirect evidence of muscle fatigue in erector spinae muscles was also apparent, and this observation may in part be responsible for the increased levels of lumbar flexion observed."
0,background,12957556,19,"RELEVANCE"
0,intervention,12957556,19,"RELEVANCE"
0,population,12957556,19,"RELEVANCE"
0,outcome,12957556,19,"RELEVANCE"
1,other,12957556,19,"RELEVANCE"
0,"study design",12957556,19,"RELEVANCE"
0,background,12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
0,intervention,12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
0,population,12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
1,outcome,12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
0,other,12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
0,"study design",12957556,20,"Excessive lumbar flexion may influence the potential for injury to spinal structures."
0,background,12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
0,intervention,12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
0,population,12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
1,outcome,12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
0,other,12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
0,"study design",12957556,21,"An awareness of increased lumbar flexion and muscle fatigue in the erector spinae muscles may be important for injury prevention programs for rowers."
0,background,12969780,1,"OBJECTIVE"
0,intervention,12969780,1,"OBJECTIVE"
0,population,12969780,1,"OBJECTIVE"
0,outcome,12969780,1,"OBJECTIVE"
1,other,12969780,1,"OBJECTIVE"
0,"study design",12969780,1,"OBJECTIVE"
1,background,12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,intervention,12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,population,12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,outcome,12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,other,12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,"study design",12969780,2,"This study determined whether maternal glucose tolerance has a progressive effect on the length of gestation in singleton pregnancies and whether there is an increasing tendency towards spontaneous preterm birth with increasing glucose intolerance."
0,background,12969780,3,"METHODS"
0,intervention,12969780,3,"METHODS"
0,population,12969780,3,"METHODS"
0,outcome,12969780,3,"METHODS"
1,other,12969780,3,"METHODS"
0,"study design",12969780,3,"METHODS"
0,background,12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
1,intervention,12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
1,population,12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
0,outcome,12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
0,other,12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
0,"study design",12969780,4,"A total of 2,168 consecutive Chinese women with singleton pregnancies who underwent the 75-g oral glucose tolerance test (OGTT) over a 24-month period were categorized by their OGTT 2-hour value (mmol/L) into the following six groups: 5.9 or less, 6.0-6.9"
0,background,12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
0,intervention,12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
0,population,12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
0,outcome,12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
1,other,12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
0,"study design",12969780,5,"Women with a 2-hour glucose value of 8.0 or more mmol/L were considered to have gestational diabetes mellitus (GDM) and received diet treatment."
0,background,12969780,6,"Women who eventually required insulin were excluded from the final analysis."
0,intervention,12969780,6,"Women who eventually required insulin were excluded from the final analysis."
0,population,12969780,6,"Women who eventually required insulin were excluded from the final analysis."
0,outcome,12969780,6,"Women who eventually required insulin were excluded from the final analysis."
1,other,12969780,6,"Women who eventually required insulin were excluded from the final analysis."
0,"study design",12969780,6,"Women who eventually required insulin were excluded from the final analysis."
0,background,12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
0,intervention,12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
0,population,12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
0,outcome,12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
1,other,12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
0,"study design",12969780,7,"The mean gestational age, birth weight, incidence of preterm birth, large for gestational age (LGA, birth weight > 90th percentile), and macrosomic (birth weight > or = 4.0 kg) infants were compared among the six groups."
0,background,12969780,8,"RESULTS"
0,intervention,12969780,8,"RESULTS"
0,population,12969780,8,"RESULTS"
0,outcome,12969780,8,"RESULTS"
1,other,12969780,8,"RESULTS"
0,"study design",12969780,8,"RESULTS"
0,background,12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
0,intervention,12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
0,population,12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
1,outcome,12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
0,other,12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
0,"study design",12969780,9,"The incidence of preterm birth correlated significantly with increasing glucose intolerance."
0,background,12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
0,intervention,12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
0,population,12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
1,outcome,12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
0,other,12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
0,"study design",12969780,10,"On further analysis, incidence of spontaneous birth before 37 weeks in the lowest to the highest 2-hour value groups was as follows: 5.5%, 2.6%, 3.7%, 4.9%, 8.5%, and 10.3% (P =.015) and that before 32 weeks went from 0.4%, 0.3%, 0.8%, 0.4%, 2.2%, to 3.4%"
0,background,12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
0,intervention,12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
0,population,12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
1,outcome,12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
0,other,12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
0,"study design",12969780,11,"There was no significant difference in the incidence of LGA or macrosomic infants."
0,background,12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
0,intervention,12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
0,population,12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
1,outcome,12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
0,other,12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
0,"study design",12969780,12,"Regression analysis confirmed that the OGTT 2-hour glucose value was an independent determinant of gestational length."
0,background,12969780,13,"CONCLUSION"
0,intervention,12969780,13,"CONCLUSION"
0,population,12969780,13,"CONCLUSION"
0,outcome,12969780,13,"CONCLUSION"
1,other,12969780,13,"CONCLUSION"
0,"study design",12969780,13,"CONCLUSION"
0,background,12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
0,intervention,12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
0,population,12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
1,outcome,12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
0,other,12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
0,"study design",12969780,14,"Gestational glucose intolerance affects gestation length and incidence of preterm birth, which should be considered a confounding factor in the analysis of the neonatal outcome of GDM pregnancies."
1,background,13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
0,intervention,13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
0,population,13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
0,outcome,13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
0,other,13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
0,"study design",13680311,1,"Osteoporotic vertebral compression fractures (VCFs) are associated with a series of clinical consequences leading to increased morbidity and even mortality."
1,background,13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
0,intervention,13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
0,population,13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
0,outcome,13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
0,other,13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
0,"study design",13680311,2,"Early diagnosis and therapeutic intervention is desirable in order to remobilise patients and prevent further bone loss."
1,background,13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
0,intervention,13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
0,population,13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
0,outcome,13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
0,other,13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
0,"study design",13680311,3,"Not all fractures are, however, sufficiently treatable by conservative measures."
1,background,13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,intervention,13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,population,13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,outcome,13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,other,13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,"study design",13680311,4,"Here, vertebroplasty and kyphoplasty may provide immediate pain relief by minimally invasive fracture stabilisation."
0,background,13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
0,intervention,13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
0,population,13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
1,outcome,13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
0,other,13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
0,"study design",13680311,5,"In cases of acute fractures, kyphoplasty has the potential to reduce kyphosis and restore the normal sagittal alignment of the spine."
0,background,13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
0,intervention,13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
0,population,13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
1,outcome,13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
0,other,13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
0,"study design",13680311,6,"The complex nature of systemic osteoporosis, coupled with the intricate biomechanics of vertebral fractures, leads to a clinical setting which is ideally treated interdisciplinarily by the rheumatologist and spine surgeon."
0,background,1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
1,intervention,1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
1,population,1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
0,outcome,1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
0,other,1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
0,"study design",1430128,1,"Serum concentrations of testosterone, 4-androstene-3,17-dione (androstenedione), dehydroepiandrosterone (DHA) and its sulphate and sex hormone-binding globulin (SHBG) were measured in 30 ovulatory women before and after down-regulation with gonadotrophin "
0,background,1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
0,intervention,1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
0,population,1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
1,outcome,1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
0,other,1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
0,"study design",1430128,2,"Nine of the women developed ovarian hyperstimulation syndrome (OHSS) while the others did not."
0,background,1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
0,intervention,1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
0,population,1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
1,outcome,1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
0,other,1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
0,"study design",1430128,3,"Pretreatment values of androstenedione and the androstenedione:DHA ratios were higher and the testosterone:androstenedione ratios lower in the OHSS women."
0,background,1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
0,intervention,1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
0,population,1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
1,outcome,1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
0,other,1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
0,"study design",1430128,4,"The decrease in androstenedione levels during down-regulation was greater and the absolute levels following down-regulation were lower in the OHSS group."
0,background,1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
0,intervention,1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
0,population,1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
1,outcome,1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
0,other,1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
0,"study design",1430128,5,"Higher levels of SHBG and lower testosterone:SHBG ratios, an index of biologically active testosterone, were observed in the OHSS group."
0,background,1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
0,intervention,1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
0,population,1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
1,outcome,1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
0,other,1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
0,"study design",1430128,6,"The isolated elevation in pretreatment androstenedione levels and the high SHBG levels make the OHSS group different from patients with polycystic ovarian disease."
0,background,1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
0,intervention,1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
0,population,1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
1,outcome,1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
0,other,1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
0,"study design",1430128,7,"Pretreatment values of testosterone:androstenedione or testosterone/SHBG:androstenedione ratios and/or the decrease in androstenedione during down-regulation may be used as markers, prior to stimulation, for identifying women at risk of developing OHSS."
1,background,14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
0,intervention,14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
0,population,14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
0,outcome,14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
0,other,14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
0,"study design",14499516,1,"Public health officials and the communities they serve need to: identify priority health problems; formulate effective health policies; respond to public health emergencies; select, implement, and evaluate cost-effective interventions to prevent and contr"
1,background,14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
0,intervention,14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
0,population,14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
0,outcome,14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
0,other,14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
0,"study design",14499516,2,"Despite agreement that rational, data-based decisions will lead to improved health outcomes, many public health decisions appear to be made intuitively or politically."
1,background,14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
0,intervention,14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
0,population,14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
0,outcome,14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
0,other,14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
0,"study design",14499516,3,"During 1991-1996, the US Centers for Disease Control and Prevention implemented the US Agency for International Development funded Data for Decision-Making (DDM) Project."
1,background,14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
0,intervention,14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
0,population,14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
0,outcome,14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
0,other,14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
0,"study design",14499516,4,"DDM goals were to: (a) strengthen the capacity of decision makers to identify data needs for solving problems and to interpret and use data appropriately for public health decisions; (b) enhance the capacity of technical advisors to provide valid, essenti"
1,background,14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,intervention,14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,population,14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,outcome,14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,other,14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,"study design",14499516,5,"Assessments were conducted to identify important health problems, problem-driven implementation plans with data-based solutions as objectives were developed, interdisciplinary, in-service training programs for mid-level policy makers, program managers, an"
0,background,14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
0,intervention,14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
1,population,14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
0,outcome,14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
0,other,14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
0,"study design",14499516,6,"This strategy was tested in Bolivia, Cameroon, Mexico, and the Philippines, where decentralization of health services led to a need to strengthen the capacity of policy makers and health officers at sub-national levels to use information more effectively."
0,background,14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
0,intervention,14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
0,population,14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
1,outcome,14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
0,other,14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
0,"study design",14499516,7,"Results showed that the DDM strategy improved evidence-based public health."
0,background,14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
0,intervention,14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
0,population,14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
1,outcome,14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
0,other,14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
0,"study design",14499516,8,"Subsequently, DDM concepts and practices have been institutionalized in participating countries and at CDC."
1,background,14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
0,intervention,14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
0,population,14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
0,outcome,14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
0,other,14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
0,"study design",14529539,1,"Calcitonin has been approved for the treatment of osteoporosis and other diseases involving accelerated bone turnover for approximately 25 years."
1,background,14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,intervention,14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,population,14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,outcome,14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,other,14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,"study design",14529539,2,"The most commonly studied and prescribed form is salmon calcitonin, which has a greater efficacy in clinical use."
0,background,14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
0,intervention,14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
0,population,14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
0,outcome,14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
1,other,14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
0,"study design",14529539,3,"A wealth of well-controlled clinical studies have demonstrated that calcitonin preserves or increases bone mineral density (BMD) and reduces the risk of vertebral fractures in osteoporosis."
1,background,14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
0,intervention,14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
0,population,14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
0,outcome,14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
0,other,14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
0,"study design",14529539,4,"Recent studies have indicated that while a low BMD is correlated with an increase in fracture risk, increases in BMD alone do not explain the antifracture efficacy of antiresorptive therapies such as calcitonin."
1,background,14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
0,intervention,14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
0,population,14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
0,outcome,14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
0,other,14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
0,"study design",14529539,5,"Therapies that moderately increase BMD may reduce fracture risk by reducing the rate of bone turnover and maintaining the integrity of the trabecular architecture, resulting in the preservation of bone strength and quality in osteoporotic patients."
1,background,14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
0,intervention,14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
0,population,14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
0,outcome,14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
0,other,14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
0,"study design",14529539,6,"An advantage of calcitonin that is not shared by other antiresorptive therapies is its direct analgesic effect on bone pain."
1,background,14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
0,intervention,14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
0,population,14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
0,outcome,14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
0,other,14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
0,"study design",14529539,7,"Calcitonin has been demonstrated to be clinically useful in improving pain, not only from the acute vertebral fractures of osteoporosis, but also in Paget's disease, bone malignancies, and other sources of musculoskeletal pain."
1,background,14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,intervention,14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,population,14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,outcome,14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,other,14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,"study design",14529539,8,"Drugs containing calcitonin may be approved for additional indications in the near future, and as more convenient routes of administration such as the oral route become available, the demand for the calcitonin peptide is expected to increase."
0,background,14592299,1,"OBJECTIVE"
0,intervention,14592299,1,"OBJECTIVE"
0,population,14592299,1,"OBJECTIVE"
0,outcome,14592299,1,"OBJECTIVE"
1,other,14592299,1,"OBJECTIVE"
0,"study design",14592299,1,"OBJECTIVE"
1,background,14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,intervention,14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,population,14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,outcome,14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,other,14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,"study design",14592299,2,"We sought to determine if patients with Parkinson's disease (PD), taking dopamine agonists (DAs) and reporting unintended sleep episodes (SEs), exhibit physiologically defined daytime sleepiness and can thus be differentiated from those taking DAs but not"
0,background,14592299,3,"METHODS"
0,intervention,14592299,3,"METHODS"
0,population,14592299,3,"METHODS"
0,outcome,14592299,3,"METHODS"
1,other,14592299,3,"METHODS"
0,"study design",14592299,3,"METHODS"
0,background,14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
0,intervention,14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
1,population,14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
0,outcome,14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
0,other,14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
0,"study design",14592299,4,"Twenty-four patients with abnormal Epworth Sleepiness Scale scores of >10 who were taking DAs were enrolled into one of two groups: those with SEs (SE+, n=16) and those without (SE-, n=8)."
0,background,14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
1,intervention,14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
0,population,14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
0,outcome,14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
0,other,14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
0,"study design",14592299,5,"Three consecutive days of testing included two nights of polysomnography followed by the Multiple Sleep Latency Test (MSLT)."
0,background,14592299,6,"RESULTS"
0,intervention,14592299,6,"RESULTS"
0,population,14592299,6,"RESULTS"
0,outcome,14592299,6,"RESULTS"
1,other,14592299,6,"RESULTS"
0,"study design",14592299,6,"RESULTS"
0,background,14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
0,intervention,14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
0,population,14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
1,outcome,14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
0,other,14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
0,"study design",14592299,7,"Overall frequency of pathological sleepiness (MSLT &lt;5 min) was 42% (10/24)."
0,background,14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
0,intervention,14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
0,population,14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
1,outcome,14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
0,other,14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
0,"study design",14592299,8,"Mean levels of sleepiness, frequencies of pathological sleepiness, and naps with stage 2 or REM-sleep were similar between SE+ and SE- groups."
0,background,14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
0,intervention,14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
0,population,14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
1,outcome,14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
0,other,14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
0,"study design",14592299,9,"Sleep tendency was similar in patients prescribed pergolide, ropinirole, and pramipexole combined with levodopa."
0,background,14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
0,intervention,14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
0,population,14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
1,outcome,14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
0,other,14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
0,"study design",14592299,10,"Polysomnography testing revealed no significant differences between the groups in total sleep time, sleep efficiency, sleep architecture, or presence of restless legs syndrome or periodic leg movements."
0,background,14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
0,intervention,14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
0,population,14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
1,outcome,14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
0,other,14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
0,"study design",14592299,11,"There was no relation between degree of nocturnal sleep disturbance and level of daytime sleepiness."
0,background,14592299,12,"CONCLUSIONS"
0,intervention,14592299,12,"CONCLUSIONS"
0,population,14592299,12,"CONCLUSIONS"
0,outcome,14592299,12,"CONCLUSIONS"
1,other,14592299,12,"CONCLUSIONS"
0,"study design",14592299,12,"CONCLUSIONS"
0,background,14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
0,intervention,14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
0,population,14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
1,outcome,14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
0,other,14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
0,"study design",14592299,13,"The results of this study suggest SEs in PD patients occur upon a background of excessive daytime sleepiness and are unrelated to nocturnal sleep or use of a specific DA."
0,background,14660226,1,"PRIMARY OBJECTIVE"
0,intervention,14660226,1,"PRIMARY OBJECTIVE"
0,population,14660226,1,"PRIMARY OBJECTIVE"
0,outcome,14660226,1,"PRIMARY OBJECTIVE"
1,other,14660226,1,"PRIMARY OBJECTIVE"
0,"study design",14660226,1,"PRIMARY OBJECTIVE"
1,background,14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,intervention,14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,population,14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,outcome,14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,other,14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,"study design",14660226,2,"To determine the incidence, duration and symptoms associated with acute confusion/delirium among traumatic brain injury (TBI) neuro-rehabilitation admissions."
0,background,14660226,3,"RESEARCH DESIGN"
0,intervention,14660226,3,"RESEARCH DESIGN"
0,population,14660226,3,"RESEARCH DESIGN"
0,outcome,14660226,3,"RESEARCH DESIGN"
1,other,14660226,3,"RESEARCH DESIGN"
0,"study design",14660226,3,"RESEARCH DESIGN"
0,background,14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
0,intervention,14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
0,population,14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
0,outcome,14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
0,other,14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
1,"study design",14660226,4,"Prospective evaluation of neurobehavioural impairments following TBI among inpatient neurorehabilitation admissions."
0,background,14660226,5,"METHODS AND PROCEDURES"
0,intervention,14660226,5,"METHODS AND PROCEDURES"
0,population,14660226,5,"METHODS AND PROCEDURES"
0,outcome,14660226,5,"METHODS AND PROCEDURES"
1,other,14660226,5,"METHODS AND PROCEDURES"
0,"study design",14660226,5,"METHODS AND PROCEDURES"
0,background,14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
0,intervention,14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
1,population,14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
0,outcome,14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
0,other,14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
0,"study design",14660226,6,"Eighty-five consecutive TBI model system patients were evaluated using measures of orientation, cognition, motor restlessness and delirium."
0,background,14660226,7,"MAIN OUTCOMES AND RESULTS"
0,intervention,14660226,7,"MAIN OUTCOMES AND RESULTS"
0,population,14660226,7,"MAIN OUTCOMES AND RESULTS"
0,outcome,14660226,7,"MAIN OUTCOMES AND RESULTS"
1,other,14660226,7,"MAIN OUTCOMES AND RESULTS"
0,"study design",14660226,7,"MAIN OUTCOMES AND RESULTS"
0,background,14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
0,intervention,14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
0,population,14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
0,outcome,14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
1,other,14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
0,"study design",14660226,8,"Fifty-nine individuals met Diagnostic and Statistical Manual of Mental Disorders--Fourth Edition Delirium Diagnostic Criteria (DDC) on initial evaluation and 42 of these resolved delirium during inpatient rehabilitation."
0,background,14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
0,intervention,14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
0,population,14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
0,outcome,14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
1,other,14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
0,"study design",14660226,9,"Multivariable logistic regression analyses revealed significant unique associations of the Galveston Orientation and Amnesia Test (GOAT), Delirium Rating Scale, Cognitive Test for Delirium and time elapsed since injury with DDC status."
0,background,14660226,10,"CONCLUSIONS"
0,intervention,14660226,10,"CONCLUSIONS"
0,population,14660226,10,"CONCLUSIONS"
0,outcome,14660226,10,"CONCLUSIONS"
1,other,14660226,10,"CONCLUSIONS"
0,"study design",14660226,10,"CONCLUSIONS"
0,background,14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
0,intervention,14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
0,population,14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
1,outcome,14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
0,other,14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
0,"study design",14660226,11,"Findings indicate that delirium is common among neuro-rehabilitation admissions with TBI."
0,background,14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
0,intervention,14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
0,population,14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
1,outcome,14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
0,other,14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
0,"study design",14660226,12,"Use of a single measure (e.g. GOAT) will result in poor characterization of the multi-faceted symptom complex shown by patients with post-traumatic confusion."
0,background,14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
1,intervention,14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
1,population,14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
0,outcome,14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
0,other,14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
1,"study design",14714242,1,"In a prospective randomised study with a 2-year follow-up, 103 patients were randomised to anterior cervical decompression and fusion (ACDF) with a cervical carbon-fibre intervertebral fusion cage (CIFC) or the Cloward procedure (CP)."
1,background,14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,intervention,14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,population,14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,outcome,14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,other,14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,"study design",14714242,2,"The purpose of the present study was to report predictors for fusion and also to investigate the importance of radiological variables for the clinical outcome."
0,background,14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
0,intervention,14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
0,population,14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
0,outcome,14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
1,other,14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
0,"study design",14714242,3,"Gender, age, smoking habits, disc height, segmental kyphosis and type of surgical procedure were used as independent (before surgery) variables in a multiple regression model."
0,background,14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
0,intervention,14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
0,population,14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
0,outcome,14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
1,other,14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
0,"study design",14714242,4,"Male gender, one-level surgery and CP treatment were significant predictors of fusion and explained 14% of the variability of fusion status at follow-up."
0,background,14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
0,intervention,14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
0,population,14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
0,outcome,14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
1,other,14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
0,"study design",14714242,5,"Number of levels operated on, however, did not influence the clinical outcome."
0,background,14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
0,intervention,14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
0,population,14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
1,outcome,14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
0,other,14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
0,"study design",14714242,6,"Fifty-two per cent of the women and 17% of the men in the CIFC group, and 25% of the women and 8% of the men in the CP group, had pseudarthrosis."
0,background,14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
0,intervention,14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
0,population,14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
1,outcome,14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
0,other,14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
0,"study design",14714242,7,"Although patients with a healed fusion had significantly less pain intensity than patients with pseudarthrosis, radiological variables explained only 4% of the variability of pain at follow-up."
0,background,14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
0,intervention,14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
0,population,14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
1,outcome,14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
0,other,14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
0,"study design",14714242,8,"Apart from a significant correlation between preoperative kyphosis and neck disability index at follow-up, no significant correlation between either postoperative kyphosis or preoperative or postoperative disc height and clinical outcome was found."
0,background,14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
0,intervention,14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
0,population,14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
1,outcome,14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
0,other,14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
0,"study design",14714242,9,"Neither degree of segmental kyphosis nor disc height was different between patients with healed fusion and pseudarthrosis."
0,background,14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
0,intervention,14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
0,population,14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
1,outcome,14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
0,other,14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
0,"study design",14714242,10,"One can conclude that male gender and type of surgery were significant predictors for a healed fusion and that pseudarthrosis affected outcome."
0,background,14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
0,intervention,14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
0,population,14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
1,outcome,14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
0,other,14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
0,"study design",14714242,11,"In contrast to the commonly held view based mainly on theoretical considerations, no effect on clinical outcome could be demonstrated for segmental kyphosis and disc height at follow-up."
0,background,14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
0,intervention,14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
0,population,14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
1,outcome,14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
0,other,14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
0,"study design",14714242,12,"Overall, the study shows that the importance of radiological factors as predictors for fusion as well as clinical outcome is limited."
0,background,1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
0,intervention,1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
1,population,1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
0,outcome,1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
0,other,1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
0,"study design",1471862,1,"In a large population-based multiple sclerosis (MS) sample (n = 7,951), 116 twins were identified (1.4%), of which it was possible to contact 97."
0,background,1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
0,intervention,1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
0,population,1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
0,outcome,1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
1,other,1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
0,"study design",1471862,2,"In 27 pairs, the twin of the patient with MS was dead."
0,background,1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
0,intervention,1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
0,population,1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
0,outcome,1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
1,other,1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
0,"study design",1471862,3,"Among the 70 remaining pairs, 16 were excluded because either the index patient or their twin did not accept protocol requirements."
0,background,1471862,4,"The final sample included 54 pairs."
0,intervention,1471862,4,"The final sample included 54 pairs."
0,population,1471862,4,"The final sample included 54 pairs."
0,outcome,1471862,4,"The final sample included 54 pairs."
1,other,1471862,4,"The final sample included 54 pairs."
0,"study design",1471862,4,"The final sample included 54 pairs."
0,background,1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
0,intervention,1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
0,population,1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
0,outcome,1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
1,other,1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
0,"study design",1471862,5,"Twin zygosity was determined by DNA fingerprint analysis."
0,background,1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
0,intervention,1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
0,population,1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
0,outcome,1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
1,other,1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
0,"study design",1471862,6,"We found 17 monozygotic pairs and 37 dizygotic pairs."
0,background,1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
0,intervention,1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
0,population,1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
1,outcome,1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
0,other,1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
0,"study design",1471862,7,"One of the 17 monozygotic pairs (5.9%) and 1 of the 37 dizygotic pairs (2.7%) were concordant for MS."
0,background,1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
0,intervention,1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
0,population,1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
1,outcome,1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
0,other,1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
0,"study design",1471862,8,"In 42 of the clinically unaffected twins, magnetic resonance imaging (MRI) of the brain was performed, and 9 scans were classified as indicative of MS."
0,background,1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
0,intervention,1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
0,population,1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
1,outcome,1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
0,other,1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
0,"study design",1471862,9,"Three of these 42 patients had abnormal visual-evoked potentials, but all 3 had normal MRI scans."
0,background,1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
0,intervention,1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
0,population,1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
1,outcome,1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
0,other,1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
0,"study design",1471862,10,"The overall proportion of pairs in which the co-twin had some form of clinical, radiological, or electrophysiological abnormality was approximately 30%; this proportion was independent of zygosity."
0,background,1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
0,intervention,1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
1,population,1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
0,outcome,1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
0,other,1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
0,"study design",1480810,1,"The relation between physical activity and health among retired people aged 65 and over was studied in a sample of 993 subjects, men and women, living at home in the Paris area and randomly selected from a pension fund roll."
0,background,1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
0,intervention,1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
0,population,1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
0,outcome,1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
1,other,1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
0,"study design",1480810,2,"In 1982-1983 (T1), 627 subjects were interviewed."
0,background,1480810,3,"Five years later (T2), 464 subjects participated in the survey."
0,intervention,1480810,3,"Five years later (T2), 464 subjects participated in the survey."
0,population,1480810,3,"Five years later (T2), 464 subjects participated in the survey."
0,outcome,1480810,3,"Five years later (T2), 464 subjects participated in the survey."
1,other,1480810,3,"Five years later (T2), 464 subjects participated in the survey."
0,"study design",1480810,3,"Five years later (T2), 464 subjects participated in the survey."
0,background,1480810,4,"Health was measured by the number and types of impairments and disability."
0,intervention,1480810,4,"Health was measured by the number and types of impairments and disability."
0,population,1480810,4,"Health was measured by the number and types of impairments and disability."
0,outcome,1480810,4,"Health was measured by the number and types of impairments and disability."
1,other,1480810,4,"Health was measured by the number and types of impairments and disability."
0,"study design",1480810,4,"Health was measured by the number and types of impairments and disability."
0,background,1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
0,intervention,1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
0,population,1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
1,outcome,1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
0,other,1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
0,"study design",1480810,5,"The incidence of cardiorespiratory impairment and the incidence of disability were weaker among subjects with physical activity in T1 than among subjects without physical activity."
0,background,1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
0,intervention,1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
0,population,1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
1,outcome,1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
0,other,1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
0,"study design",1480810,6,"These findings were unchanged after adjustment for age, sex, socioeconomic status, cigarette smoking, body mass index, uncomfortable housing, living alone and hard physical conditions during working life."
0,background,1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
0,intervention,1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
0,population,1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
1,outcome,1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
0,other,1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
0,"study design",1480810,7,"This result suggests the beneficial effect of physical activity in promoting health among retired people aged 65 and over."
0,background,14966719,1,"OBJECTIVE"
0,intervention,14966719,1,"OBJECTIVE"
0,population,14966719,1,"OBJECTIVE"
0,outcome,14966719,1,"OBJECTIVE"
1,other,14966719,1,"OBJECTIVE"
0,"study design",14966719,1,"OBJECTIVE"
1,background,14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
1,intervention,14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
0,population,14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
0,outcome,14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
0,other,14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
0,"study design",14966719,2,"To identify key factors associated with outcomes of patients who underwent 8 weeks of physical therapy (PT) for lateral epicondylitis."
0,background,14966719,3,"DESIGN"
0,intervention,14966719,3,"DESIGN"
0,population,14966719,3,"DESIGN"
0,outcome,14966719,3,"DESIGN"
1,other,14966719,3,"DESIGN"
0,"study design",14966719,3,"DESIGN"
0,background,14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
0,intervention,14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
0,population,14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
0,outcome,14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
0,other,14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
1,"study design",14966719,4,"Multicenter prospective design with inception cohort of lateral epicondylitis patients commencing PT."
0,background,14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
0,intervention,14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
0,population,14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
0,outcome,14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
1,other,14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
0,"study design",14966719,5,"Baseline clinical examinations were conducted by 1 physical therapist; self-report outcome measures were completed at baseline and 8 weeks later."
0,background,14966719,6,"SETTING"
0,intervention,14966719,6,"SETTING"
0,population,14966719,6,"SETTING"
0,outcome,14966719,6,"SETTING"
1,other,14966719,6,"SETTING"
0,"study design",14966719,6,"SETTING"
0,background,14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
0,intervention,14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
0,population,14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
0,outcome,14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
1,other,14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
0,"study design",14966719,7,"Nine private sports medicine clinics and 2 hospital outpatient departments in Ontario, Canada."
0,background,14966719,8,"PARTICIPANTS"
0,intervention,14966719,8,"PARTICIPANTS"
0,population,14966719,8,"PARTICIPANTS"
0,outcome,14966719,8,"PARTICIPANTS"
1,other,14966719,8,"PARTICIPANTS"
0,"study design",14966719,8,"PARTICIPANTS"
0,background,14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
0,intervention,14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
1,population,14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
0,outcome,14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
0,other,14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
0,"study design",14966719,9,"Eighty-three patients with unilateral lateral epicondylitis identified by the treating physical therapists."
0,background,14966719,10,"INTERVENTIONS"
0,intervention,14966719,10,"INTERVENTIONS"
0,population,14966719,10,"INTERVENTIONS"
0,outcome,14966719,10,"INTERVENTIONS"
1,other,14966719,10,"INTERVENTIONS"
0,"study design",14966719,10,"INTERVENTIONS"
0,background,14966719,11,"Not applicable."
0,intervention,14966719,11,"Not applicable."
0,population,14966719,11,"Not applicable."
0,outcome,14966719,11,"Not applicable."
1,other,14966719,11,"Not applicable."
0,"study design",14966719,11,"Not applicable."
0,background,14966719,12,"MAIN OUTCOME MEASURES"
0,intervention,14966719,12,"MAIN OUTCOME MEASURES"
0,population,14966719,12,"MAIN OUTCOME MEASURES"
0,outcome,14966719,12,"MAIN OUTCOME MEASURES"
1,other,14966719,12,"MAIN OUTCOME MEASURES"
0,"study design",14966719,12,"MAIN OUTCOME MEASURES"
0,background,14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
0,intervention,14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
0,population,14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
0,outcome,14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
1,other,14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
0,"study design",14966719,13,"The final scores of the Disability of the Arm, Shoulder and Hand (DASH) questionnaire and a vertical pain visual analog scale (VAS) were used as the dependent variables."
0,background,14966719,14,"RESULTS"
0,intervention,14966719,14,"RESULTS"
0,population,14966719,14,"RESULTS"
0,outcome,14966719,14,"RESULTS"
1,other,14966719,14,"RESULTS"
0,"study design",14966719,14,"RESULTS"
0,background,14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
0,intervention,14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
0,population,14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
1,outcome,14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
0,other,14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
0,"study design",14966719,15,"The final prognostic model for the 8-week DASH scores included the baseline score (95% confidence interval [CI], 0.34-0.66), sex (female) (95% CI, 3.3-14.5), and self-reported nerve symptoms (95% CI, 0.8-13.8)."
0,background,14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
0,intervention,14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
0,population,14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
1,outcome,14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
0,other,14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
0,"study design",14966719,16,"The model for the 8-week VAS scores included the baseline score (95% CI, 0.01-0.37), sex (female) (95% CI, 0.4-18.2), and self-reported nerve symptoms (95% CI, 4.7-25.5)."
0,background,14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
0,intervention,14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
0,population,14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
1,outcome,14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
0,other,14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
0,"study design",14966719,17,"A subanalysis indicated that women were more likely than men to have work-related onsets, repetitive keyboarding jobs, and cervical joint signs."
0,background,14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
0,intervention,14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
0,population,14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
1,outcome,14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
0,other,14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
0,"study design",14966719,18,"Among women, these factors were associated with higher final DASH and VAS scores."
0,background,14966719,19,"CONCLUSIONS"
0,intervention,14966719,19,"CONCLUSIONS"
0,population,14966719,19,"CONCLUSIONS"
0,outcome,14966719,19,"CONCLUSIONS"
1,other,14966719,19,"CONCLUSIONS"
0,"study design",14966719,19,"CONCLUSIONS"
0,background,14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
0,intervention,14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
0,population,14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
1,outcome,14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
0,other,14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
0,"study design",14966719,20,"Women and patients who report nerve symptoms are more likely to experience a poorer short-term outcome after PT management of lateral epicondylitis."
0,background,14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
0,intervention,14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
0,population,14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
1,outcome,14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
0,other,14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
0,"study design",14966719,21,"Work-related onsets, repetitive keyboarding jobs, and cervical joint signs have a prognostic influence on women."
0,background,15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
1,intervention,15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
1,population,15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
0,outcome,15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
0,other,15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
0,"study design",15144087,1,"Fifty Suffolk-crossbred wether lambs, with an initial live weight of 29 +/- 2.1 kg, were allocated to one of five concentrate-based diets formulated to have a similar fatty acid content (60 g/kg DM), but containing either linseed oil (high in 18:3n-3); fi"
0,background,15144087,2,"Lambs were slaughtered when they reached 40 kg."
0,intervention,15144087,2,"Lambs were slaughtered when they reached 40 kg."
0,population,15144087,2,"Lambs were slaughtered when they reached 40 kg."
0,outcome,15144087,2,"Lambs were slaughtered when they reached 40 kg."
1,other,15144087,2,"Lambs were slaughtered when they reached 40 kg."
0,"study design",15144087,2,"Lambs were slaughtered when they reached 40 kg."
0,background,15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
0,intervention,15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
0,population,15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
0,outcome,15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
1,other,15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
0,"study design",15144087,3,"Growth performance and intake were similar (P > 0.35) among treatments."
0,background,15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
0,intervention,15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
0,population,15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
1,outcome,15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
0,other,15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
0,"study design",15144087,4,"By contrast, gain:feed was higher (P &lt; 0.05) in lambs fed the fish oil compared with the linseed oil or PLS/algae diets."
0,background,15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
0,intervention,15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
0,population,15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
1,outcome,15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
0,other,15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
0,"study design",15144087,5,"Total fatty acid concentration (mg/100 g) in the neutral lipid of the longissimus muscle was not affected by treatment (P > 0.87) but was least (P &lt; 0.05) in the phospholipid fraction in lambs fed the linseed oil diet."
0,background,15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
0,intervention,15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
0,population,15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
1,outcome,15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
0,other,15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
0,"study design",15144087,6,"Lambs fed either diet containing marine algae contained the highest (P &lt; 0.05) percentage of 22:6n-3 in the phospholipid (mean of 5.2%), 2.8-fold higher than in sheep fed the fish oil diet."
0,background,15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,intervention,15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,population,15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
1,outcome,15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,other,15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,"study design",15144087,7,"In lambs fed the fish/algae diet, the percentage of 20:5n-3 was highest (P &lt; 0.05), contributing some 8.7, 0.8, and 0.5% of the total fatty acids in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,background,15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
0,intervention,15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
0,population,15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
1,outcome,15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
0,other,15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
0,"study design",15144087,8,"The percentage of 18:3n-3 in the phospholipid fraction of the LM was highest (P &lt; 0.05) in lambs fed the linseed oil diet (6.9%), a value double that of sheep fed the PLS diet."
0,background,15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
0,intervention,15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
0,population,15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
1,outcome,15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
0,other,15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
0,"study design",15144087,9,"By contrast, lambs fed the PLS diet had twice the percentage of 18:3n-3 in the muscle neutral lipids (3.8%) than those offered the linseed oil diet, and 5.5-fold greater than lambs fed the fish/algae treatment (P &lt; 0.05), an effect that was similar in "
0,background,15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,intervention,15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,population,15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
1,outcome,15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,other,15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,"study design",15144087,10,"The percentage of 18:2n-6 was highest (P &lt; 0.05) in lambs fed the PLS diet, where it contributed 33.7, 10.1, and 11.2% in the muscle phospholipid, neutral lipids, and adipose tissue, respectively."
0,background,15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
0,intervention,15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
0,population,15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
1,outcome,15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
0,other,15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
0,"study design",15144087,11,"The highest (P &lt; 0.05) muscle PUFA-to-saturated fatty acid (P:S) ratio was obtained in lambs fed the PLS diet (0.57), followed by the PLS/algae diet (0.46), and those fed the fish oil or linseed oil diets had the lowest ratios (0.19 and 0.26, respectiv"
0,background,15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
0,intervention,15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
0,population,15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
1,outcome,15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
0,other,15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
0,"study design",15144087,12,"The favorable P:S ratio of lambs fed the PLS/algae diet, in conjunction with the increased levels of 20:5n-3 and 22:6n-3, enhanced the nutritional qualities of lamb to more closely resemble what is recommended for the human diet."
0,background,15164772,1,"PURPOSE"
0,intervention,15164772,1,"PURPOSE"
0,population,15164772,1,"PURPOSE"
0,outcome,15164772,1,"PURPOSE"
1,other,15164772,1,"PURPOSE"
0,"study design",15164772,1,"PURPOSE"
1,background,15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,intervention,15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,population,15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,outcome,15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,other,15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,"study design",15164772,2,"To evaluate the radiological spectrum of sequelae of corrosive acid and alkali injury to the upper gastrointestinal (GI) tract using barium contrast examination."
0,background,15164772,3,"MATERIAL AND METHODS"
0,intervention,15164772,3,"MATERIAL AND METHODS"
0,population,15164772,3,"MATERIAL AND METHODS"
0,outcome,15164772,3,"MATERIAL AND METHODS"
1,other,15164772,3,"MATERIAL AND METHODS"
0,"study design",15164772,3,"MATERIAL AND METHODS"
0,background,15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
0,intervention,15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
1,population,15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
0,outcome,15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
0,other,15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
0,"study design",15164772,4,"Barium contrast radiographic films of 155 patients with a history of corrosive ingestion, acid in 120 and alkali in 35 patients with grade 2b and 3 injury on initial endoscopy, were retrospectively evaluated."
0,background,15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
1,intervention,15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
0,population,15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
0,outcome,15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
0,other,15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
0,"study design",15164772,5,"Barium contrast examination of the upper GI tract was performed in the course of follow-up, beyond 3 weeks of corrosive ingestion."
0,background,15164772,6,"RESULTS"
0,intervention,15164772,6,"RESULTS"
0,population,15164772,6,"RESULTS"
0,outcome,15164772,6,"RESULTS"
1,other,15164772,6,"RESULTS"
0,"study design",15164772,6,"RESULTS"
0,background,15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
0,intervention,15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
0,population,15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
1,outcome,15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
0,other,15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
0,"study design",15164772,7,"The esophagus was involved in 131 patients and the stomach in 74."
0,background,15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
0,intervention,15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
0,population,15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
1,outcome,15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
0,other,15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
0,"study design",15164772,8,"Fifty patients had simultaneous involvement of esophagus and stomach."
0,background,15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
0,intervention,15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
0,population,15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
1,outcome,15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
0,other,15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
0,"study design",15164772,9,"Radiological findings in the esophagus were solitary or multiple strictures of varying length, intramural pseudodiverticula, and carcinoma in long-standing corrosive injury."
0,background,15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
0,intervention,15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
0,population,15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
1,outcome,15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
0,other,15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
0,"study design",15164772,10,"The stomach showed cicatrization, predominantly involving the antrum, linitis plastica type deformity with multiple pseudodiverticula."
0,background,15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,intervention,15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,population,15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
1,outcome,15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,other,15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,"study design",15164772,11,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,background,15164772,12,"CONCLUSION"
0,intervention,15164772,12,"CONCLUSION"
0,population,15164772,12,"CONCLUSION"
0,outcome,15164772,12,"CONCLUSION"
1,other,15164772,12,"CONCLUSION"
0,"study design",15164772,12,"CONCLUSION"
0,background,15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
0,intervention,15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
0,population,15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
1,outcome,15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
0,other,15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
0,"study design",15164772,13,"Barium examination of the upper GI tract is useful in the evaluation of late sequelae of corrosive injury (acid/alkali)."
0,background,15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,intervention,15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,population,15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
1,outcome,15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,other,15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,"study design",15164772,14,"There was no difference in the radiological findings as to the type of corrosive ingested."
0,background,15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
0,intervention,15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
0,population,15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
1,outcome,15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
0,other,15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
0,"study design",15164772,15,"Thus, contrary to general belief, we found that acid and alkali damage both the esophagus and the stomach with equal degree of severity."
1,background,15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
0,intervention,15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
0,population,15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
0,outcome,15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
0,other,15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
0,"study design",15198633,1,"Impaired recall is a common consequence of traumatic brain injury (TBI)."
1,background,15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,intervention,15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,population,15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,outcome,15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,other,15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,"study design",15198633,2,"Predicting recall during learning is a critical part of self-monitoring."
0,background,15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
1,intervention,15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
1,population,15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
0,outcome,15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
0,other,15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
0,"study design",15198633,3,"Adults with TBI and noninjured controls made recall predictions of noun pairs that varied in prediction timing (immediate, delayed), and predictions of narrative information that varied in salience (main idea and details) and explicitness (stated and impl"
0,background,15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
0,intervention,15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
0,population,15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
1,outcome,15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
0,other,15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
0,"study design",15198633,4,"For both groups, delayed recall predictions for noun pairs and stated (narrative) information were relatively accurate, whereas immediate recall predictions of noun pairs and delayed predictions of implied information were relatively inaccurate."
0,background,15198633,5,"Both groups were more confident making predictions of stated information than implied information."
0,intervention,15198633,5,"Both groups were more confident making predictions of stated information than implied information."
0,population,15198633,5,"Both groups were more confident making predictions of stated information than implied information."
1,outcome,15198633,5,"Both groups were more confident making predictions of stated information than implied information."
0,other,15198633,5,"Both groups were more confident making predictions of stated information than implied information."
0,"study design",15198633,5,"Both groups were more confident making predictions of stated information than implied information."
0,background,15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
0,intervention,15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
0,population,15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
1,outcome,15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
0,other,15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
0,"study design",15198633,6,"Neither predictive accuracy nor confidence generalized across tasks."
0,background,15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
0,intervention,15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
0,population,15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
1,outcome,15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
0,other,15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
0,"study design",15198633,7,"Working memory load across tasks and individual differences are proposed explanations."
0,background,15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
0,intervention,15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
0,population,15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
1,outcome,15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
0,other,15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
0,"study design",15198633,8,"The lack of generalization highlights the need to train domain or task-specific self-monitoring."
0,background,15288857,1,"OBJECTIVES"
0,intervention,15288857,1,"OBJECTIVES"
0,population,15288857,1,"OBJECTIVES"
0,outcome,15288857,1,"OBJECTIVES"
1,other,15288857,1,"OBJECTIVES"
0,"study design",15288857,1,"OBJECTIVES"
0,background,15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
0,intervention,15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
0,population,15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
0,outcome,15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
1,other,15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
0,"study design",15288857,2,"To evaluate the result of rehabilitation on motor and functional improvement in spinal tuberculosis."
0,background,15288857,3,"METHOD"
0,intervention,15288857,3,"METHOD"
0,population,15288857,3,"METHOD"
0,outcome,15288857,3,"METHOD"
1,other,15288857,3,"METHOD"
0,"study design",15288857,3,"METHOD"
0,background,15288857,4,"Prospective case study."
0,intervention,15288857,4,"Prospective case study."
0,population,15288857,4,"Prospective case study."
0,outcome,15288857,4,"Prospective case study."
0,other,15288857,4,"Prospective case study."
1,"study design",15288857,4,"Prospective case study."
0,background,15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
1,intervention,15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
1,population,15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
0,outcome,15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
0,other,15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
0,"study design",15288857,5,"Data were collected from 47 patients with spinal tuberculosis medically and/or surgically treated, and rehabilitated over 6 months of period, after spinal decompression and fusion."
0,background,15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
0,intervention,15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
0,population,15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
0,outcome,15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
1,other,15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
0,"study design",15288857,6,"The main outcome measures were motor development of the patients who were evaluated at the beginning, in the 1st week, in the 3rd month, and in the 6th month."
0,background,15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
0,intervention,15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
0,population,15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
0,outcome,15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
1,other,15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
0,"study design",15288857,7,"Functional development of the patients was evaluated at the beginning and in the 6th month."
0,background,15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
0,intervention,15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
0,population,15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
0,outcome,15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
1,other,15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
0,"study design",15288857,8,"Functional assessment was made according to Modified Barthel Index (MBI), and motor examination was made according to American Spinal Injury Association (ASIA)."
0,background,15288857,9,"RESULTS"
0,intervention,15288857,9,"RESULTS"
0,population,15288857,9,"RESULTS"
0,outcome,15288857,9,"RESULTS"
1,other,15288857,9,"RESULTS"
0,"study design",15288857,9,"RESULTS"
0,background,15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
0,intervention,15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
0,population,15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
1,outcome,15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
0,other,15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
0,"study design",15288857,10,"The study population consisted of 47 patients (22 males and 25 females) mean aged 37.9 +/- 18.3 years (range 5-76 years)."
0,background,15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
0,intervention,15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
0,population,15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
1,outcome,15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
0,other,15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
0,"study design",15288857,11,"The most common site of spinal tuberculosis was the thoracic region."
0,background,15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
0,intervention,15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
0,population,15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
1,outcome,15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
0,other,15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
0,"study design",15288857,12,"Localized back pain, paraparesis, sensory dysfunction and fever were typical clinical manifestations."
0,background,15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
0,intervention,15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
0,population,15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
1,outcome,15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
0,other,15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
0,"study design",15288857,13,"Surgical management was performed as anterior or posterior drainage of abscess and/or stabilization of the spine."
0,background,15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
0,intervention,15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
0,population,15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
1,outcome,15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
0,other,15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
0,"study design",15288857,14,"The rehabilitation program was performed in all patients during the preoperative, early postoperative and late postoperative 6 month periods."
0,background,15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
0,intervention,15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
0,population,15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
1,outcome,15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
0,other,15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
0,"study design",15288857,15,"Muscle-strengthening exercises on necessary localization such as pectoral, abdominal, lower extremities; truncal and sacrospinal extensors were started for the rehabilitation."
0,background,15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
0,intervention,15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
0,population,15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
1,outcome,15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
0,other,15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
0,"study design",15288857,16,"The motor score for the lower limbs and the MBI scores for activities of daily living (ADL) and mobility improved significantly (P &lt; 0.001)."
0,background,15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
0,intervention,15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
0,population,15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
1,outcome,15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
0,other,15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
0,"study design",15288857,17,"The self-care and mobility categories of the MBI on admission; were 14.8% severely dependent and 10.6% independent."
0,background,15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
0,intervention,15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
0,population,15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
1,outcome,15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
0,other,15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
0,"study design",15288857,18,"However, at the end of the rehabilitation program, 4.2% were severely dependent and 70.2% independent."
0,background,15288857,19,"IN CONCLUSION"
0,intervention,15288857,19,"IN CONCLUSION"
0,population,15288857,19,"IN CONCLUSION"
0,outcome,15288857,19,"IN CONCLUSION"
1,other,15288857,19,"IN CONCLUSION"
0,"study design",15288857,19,"IN CONCLUSION"
0,background,15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
0,intervention,15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
0,population,15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
1,outcome,15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
0,other,15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
0,"study design",15288857,20,"Early diagnosis and appropriate medical and/or surgical treatment together with a rehabilitation program will improve the life quality of patients with spinal tuberculosis."
1,background,15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
0,intervention,15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
0,population,15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
0,outcome,15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
0,other,15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
0,"study design",15325746,1,"Epidemiological studies have identified high prevalence rates of anxiety and depression in North America [e.g., J. of Nerv. Ment. Dis. 182 (1994) 290]."
1,background,15325746,2,"However, only a small percentage of these individuals access effective treatment."
0,intervention,15325746,2,"However, only a small percentage of these individuals access effective treatment."
0,population,15325746,2,"However, only a small percentage of these individuals access effective treatment."
0,outcome,15325746,2,"However, only a small percentage of these individuals access effective treatment."
0,other,15325746,2,"However, only a small percentage of these individuals access effective treatment."
0,"study design",15325746,2,"However, only a small percentage of these individuals access effective treatment."
1,background,15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
0,intervention,15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
0,population,15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
0,outcome,15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
0,other,15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
0,"study design",15325746,3,"The undertreatment of anxiety and depression is a major public health issue and is associated with significant personal, social, and economic burden."
1,background,15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
0,intervention,15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
0,population,15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
0,outcome,15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
0,other,15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
0,"study design",15325746,4,"This article describes the existing discrepancy between prevalence of anxiety and depression and access to effective treatment for adults and children, the contributors to this discrepancy, and suggests various means through which access to effective trea"
1,background,15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
0,intervention,15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
0,population,15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
0,outcome,15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
0,other,15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
0,"study design",15325746,5,"We begin with a brief overview of the prevalence and associated personal, societal, and systemic burdens of anxiety and depression."
1,background,15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
0,intervention,15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
0,population,15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
0,outcome,15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
0,other,15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
0,"study design",15325746,6,"This is followed by a review of current rates of access to treatment and possible individual, provider, and systemic barriers to accessing treatment."
1,background,15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,intervention,15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,population,15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,outcome,15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,other,15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,"study design",15325746,7,"Recommendations for bridging the gap between the high rates of these disorders and limited accessibility of effective care are then presented."
0,background,15338064,1,"BACKGROUND AND AIMS"
0,intervention,15338064,1,"BACKGROUND AND AIMS"
0,population,15338064,1,"BACKGROUND AND AIMS"
0,outcome,15338064,1,"BACKGROUND AND AIMS"
1,other,15338064,1,"BACKGROUND AND AIMS"
0,"study design",15338064,1,"BACKGROUND AND AIMS"
1,background,15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
0,intervention,15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
0,population,15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
0,outcome,15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
0,other,15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
0,"study design",15338064,2,"Quality of life (QoL) is an important outcome measure in clinical studies."
1,background,15338064,3,"However, there is little experience with the interpretation of QoL results."
0,intervention,15338064,3,"However, there is little experience with the interpretation of QoL results."
0,population,15338064,3,"However, there is little experience with the interpretation of QoL results."
0,outcome,15338064,3,"However, there is little experience with the interpretation of QoL results."
0,other,15338064,3,"However, there is little experience with the interpretation of QoL results."
0,"study design",15338064,3,"However, there is little experience with the interpretation of QoL results."
0,background,15338064,4,"METHODS"
0,intervention,15338064,4,"METHODS"
0,population,15338064,4,"METHODS"
0,outcome,15338064,4,"METHODS"
1,other,15338064,4,"METHODS"
0,"study design",15338064,4,"METHODS"
0,background,15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
1,intervention,15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
0,population,15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
0,outcome,15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
0,other,15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
0,"study design",15338064,5,"To guide interpretation of QoL results from a randomised controlled trial (RCT) targeting the effectiveness of the immune modulator G-CSF on postoperative recovery in high risk (ASA III/IV) colorectal cancer patients, we compared RCT data with data from a"
0,background,15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
0,intervention,15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
0,population,15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
0,outcome,15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
1,other,15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
0,"study design",15338064,6,"QoL was assessed using the European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 and CR38 questionnaires."
0,background,15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
0,intervention,15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
0,population,15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
0,outcome,15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
1,other,15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
0,"study design",15338064,7,"QoL results were analysed on discharge from hospital and six months postoperatively."
0,background,15338064,8,"RESULTS"
0,intervention,15338064,8,"RESULTS"
0,population,15338064,8,"RESULTS"
0,outcome,15338064,8,"RESULTS"
1,other,15338064,8,"RESULTS"
0,"study design",15338064,8,"RESULTS"
0,background,15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
0,intervention,15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
1,population,15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
1,outcome,15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
0,other,15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
0,"study design",15338064,9,"Colorectal cancer patients (both from the RCT and the cohort study) showed the greatest differences in QoL scores compared to norm reference data at discharge from hospital."
0,background,15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
0,intervention,15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
0,population,15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
1,outcome,15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
0,other,15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
0,"study design",15338064,10,"Six months postoperatively, global quality of life and pain approximated norm reference values indicating optimal recovery."
0,background,15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
0,intervention,15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
0,population,15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
1,outcome,15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
0,other,15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
0,"study design",15338064,11,"However, deficits still appeared in scores for role functioning, physical functioning, social functioning and fatigue."
0,background,15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
0,intervention,15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
0,population,15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
1,outcome,15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
0,other,15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
0,"study design",15338064,12,"The best improvements (discharge from hospital to six months postoperatively) were seen with respect to physical functioning, fatigue and pain."
0,background,15338064,13,"CONCLUSIONS"
0,intervention,15338064,13,"CONCLUSIONS"
0,population,15338064,13,"CONCLUSIONS"
0,outcome,15338064,13,"CONCLUSIONS"
1,other,15338064,13,"CONCLUSIONS"
0,"study design",15338064,13,"CONCLUSIONS"
0,background,15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
0,intervention,15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
0,population,15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
1,outcome,15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
0,other,15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
0,"study design",15338064,14,"For further analysis of RCT data, physical functioning and fatigue scores may be more sensitive than global quality of life to detect differences in treatment effects."
1,background,15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,intervention,15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,population,15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,outcome,15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,other,15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,"study design",15366543,1,"Research has demonstrated that women with multiple sclerosis (MS) do not make maximum use of information about osteoporosis prevention and management, even when they are well-informed."
0,background,15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
0,intervention,15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
0,population,15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
0,outcome,15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
1,other,15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
0,"study design",15366543,2,"Focus-group methodology and telephone interviews were used to study how women with MS use or could use information about osteoporosis prevention and management to influence their healthcare providers to attend to osteoporosis-related needs."
0,background,15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
0,intervention,15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
1,population,15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
0,outcome,15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
0,other,15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
0,"study design",15366543,3,"Twenty-two participants were asked to discuss their own and their peers' experience of sharing osteoporosis screening results with healthcare providers, as well as factors they think might influence healthcare providers to attend to osteoporosis risk redu"
0,background,15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
0,intervention,15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
0,population,15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
1,outcome,15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
0,other,15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
0,"study design",15366543,4,"Using comparative content analysis, the transcribed data were clustered into seven thematic areas: women's need to educate themselves about osteoporosis; women's need to educate their healthcare providers about osteoporosis as well as other women's health"
0,background,15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
0,intervention,15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
0,population,15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
1,outcome,15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
0,other,15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
0,"study design",15366543,5,"These themes suggest directions for the development of strategies to enable women with MS to influence their healthcare providers in osteoporosis prevention and management."
1,background,15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
0,intervention,15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
1,population,15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
0,outcome,15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
0,other,15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
0,"study design",15484665,1,"Progress in the care of people with spinal cord injury (SCI) spans every aspect, from research in neuroregeneration to pharmacologic interventions."
0,background,15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
1,intervention,15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
0,population,15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
0,outcome,15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
0,other,15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
0,"study design",15484665,2,"This article focuses on advances in rehabilitation interventions, which have employed bioengineering, computerization, and advanced therapeutic techniques."
1,background,15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
0,intervention,15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
0,population,15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
0,outcome,15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
0,other,15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
0,"study design",15484665,3,"These interventions are being applied to functional deficits of the bladder, bowel, upper extremities, and respiratory system, as well as to improvements in ambulation and mobility."
1,background,15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
1,intervention,15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
0,population,15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
0,outcome,15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
0,other,15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
0,"study design",15484665,4,"Functional electrical stimulation (FES) is being used to augment the function of the lower extremities, the upper extremities (Freehand System), and the bowel and bladder (Vocare System)."
1,background,15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
1,intervention,15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
0,population,15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
0,outcome,15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
0,other,15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
0,"study design",15484665,5,"Tendon transfer is a reconstructive technique used to improve upper extremity function; it is sometimes combined with FES."
1,background,15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
1,intervention,15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
0,population,15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
0,outcome,15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
0,other,15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
0,"study design",15484665,6,"Body weight-supported treadmill training is being used to improve ambulation in people with incomplete SCI, and advances in wheelchair technology are expanding options for mobility."
1,background,15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
1,intervention,15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
0,population,15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
0,outcome,15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
0,other,15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
0,"study design",15484665,7,"Cushion design and pressure mapping are modalities being used to reduce the high risk for pressure ulcers in the SCI population."
1,background,15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
1,intervention,15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
0,population,15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
0,outcome,15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
0,other,15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
0,"study design",15484665,8,"Research on shoulder stressors is being applied to transfer techniques, exercise regimens, adaptive equipment and wheelchair mechanics to minimize shoulder pain, another common complication."
0,background,15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
0,intervention,15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
0,population,15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
1,outcome,15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
0,other,15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
0,"study design",15484665,9,"The effectiveness of rehabilitation interventions needs to be documented by evidence-based research."
0,background,15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
0,intervention,15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
0,population,15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
1,outcome,15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
0,other,15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
0,"study design",15484665,10,"Researchers are focusing on the identification of outcomes measures that will form the basis for established standards of care for individuals with SCI."
0,background,15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
0,intervention,15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
0,population,15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
1,outcome,15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
0,other,15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
0,"study design",15484665,11,"Perhaps the combination of conventional and newer therapies may enhance neurological recovery."
0,background,15484665,12,"Well-designed studies are needed before we can make this determination."
0,intervention,15484665,12,"Well-designed studies are needed before we can make this determination."
0,population,15484665,12,"Well-designed studies are needed before we can make this determination."
1,outcome,15484665,12,"Well-designed studies are needed before we can make this determination."
0,other,15484665,12,"Well-designed studies are needed before we can make this determination."
0,"study design",15484665,12,"Well-designed studies are needed before we can make this determination."
0,background,15490026,1,"BACKGROUND AND PURPOSE"
0,intervention,15490026,1,"BACKGROUND AND PURPOSE"
0,population,15490026,1,"BACKGROUND AND PURPOSE"
0,outcome,15490026,1,"BACKGROUND AND PURPOSE"
1,other,15490026,1,"BACKGROUND AND PURPOSE"
0,"study design",15490026,1,"BACKGROUND AND PURPOSE"
1,background,15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
0,intervention,15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
0,population,15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
0,outcome,15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
0,other,15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
0,"study design",15490026,2,"Necrotizing enterocolitis (NEC) is a gastrointestinal emergency in neonates."
1,background,15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,intervention,15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,population,15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,outcome,15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,other,15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,"study design",15490026,3,"Whether NEC affects infants' growth and development is controversial."
0,background,15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
0,intervention,15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
0,population,15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
0,outcome,15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
1,other,15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
0,"study design",15490026,4,"The purpose of this study was to explore the clinical characteristics and outcome and to assess the effect of NEC on growth and neurodevelopment in infants."
0,background,15490026,5,"METHODS"
0,intervention,15490026,5,"METHODS"
0,population,15490026,5,"METHODS"
0,outcome,15490026,5,"METHODS"
1,other,15490026,5,"METHODS"
0,"study design",15490026,5,"METHODS"
0,background,15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
0,intervention,15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
1,population,15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
0,outcome,15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
0,other,15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
0,"study design",15490026,6,"A total of 80 neonates admitted to the neonatal intensive care unit from January 1991 to April 2002 with definite, advanced NEC, including 48 with modified Bell's stage II and 32 with stage III."
0,background,15490026,7,"Sixty six of the patients were premature."
0,intervention,15490026,7,"Sixty six of the patients were premature."
0,population,15490026,7,"Sixty six of the patients were premature."
0,outcome,15490026,7,"Sixty six of the patients were premature."
1,other,15490026,7,"Sixty six of the patients were premature."
0,"study design",15490026,7,"Sixty six of the patients were premature."
0,background,15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
0,intervention,15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
0,population,15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
0,outcome,15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
1,other,15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
0,"study design",15490026,8,"Very low birth weight (VLBW) preterm infants without NEC were used as matching controls for the 15 infants with VLBW."
0,background,15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
0,intervention,15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
0,population,15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
0,outcome,15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
1,other,15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
0,"study design",15490026,9,"The growth and neurodevelopment of patients and controls were assessed using the Bayley Scales of Infant Development-II and compared at 6 and 18 months of corrected age."
0,background,15490026,10,"RESULTS"
0,intervention,15490026,10,"RESULTS"
0,population,15490026,10,"RESULTS"
0,outcome,15490026,10,"RESULTS"
1,other,15490026,10,"RESULTS"
0,"study design",15490026,10,"RESULTS"
0,background,15490026,11,"NEC developed an average of 27.7 days after feeding began."
0,intervention,15490026,11,"NEC developed an average of 27.7 days after feeding began."
0,population,15490026,11,"NEC developed an average of 27.7 days after feeding began."
1,outcome,15490026,11,"NEC developed an average of 27.7 days after feeding began."
0,other,15490026,11,"NEC developed an average of 27.7 days after feeding began."
0,"study design",15490026,11,"NEC developed an average of 27.7 days after feeding began."
0,background,15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
0,intervention,15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
0,population,15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
1,outcome,15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
0,other,15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
0,"study design",15490026,12,"The most common initial signs were abdominal distension, decreased activity, hematochezia, and abdominal tenderness."
0,background,15490026,13,"Thirty four patients (43%) required surgical intervention."
0,intervention,15490026,13,"Thirty four patients (43%) required surgical intervention."
0,population,15490026,13,"Thirty four patients (43%) required surgical intervention."
1,outcome,15490026,13,"Thirty four patients (43%) required surgical intervention."
0,other,15490026,13,"Thirty four patients (43%) required surgical intervention."
0,"study design",15490026,13,"Thirty four patients (43%) required surgical intervention."
0,background,15490026,14,"Three infants developed short bowel syndrome after surgical resection."
0,intervention,15490026,14,"Three infants developed short bowel syndrome after surgical resection."
0,population,15490026,14,"Three infants developed short bowel syndrome after surgical resection."
1,outcome,15490026,14,"Three infants developed short bowel syndrome after surgical resection."
0,other,15490026,14,"Three infants developed short bowel syndrome after surgical resection."
0,"study design",15490026,14,"Three infants developed short bowel syndrome after surgical resection."
0,background,15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
0,intervention,15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
0,population,15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
1,outcome,15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
0,other,15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
0,"study design",15490026,15,"The overall mortality was 24% (19/80) and was mostly associated with extensive bowel involvement and NEC-related sepsis or multiple organ failure."
0,background,15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
0,intervention,15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
0,population,15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
1,outcome,15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
0,other,15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
0,"study design",15490026,16,"Of the surviving 61 infants, 12 (20%) developed intestinal strictures, 2 in the ileum, 6 in the colon, and 4 in both ileum and colon."
0,background,15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
0,intervention,15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
0,population,15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
1,outcome,15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
0,other,15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
0,"study design",15490026,17,"Compared with controls, the VLBW infants with NEC were shorter and had delayed psychomotor development at 18 months of corrected age."
0,background,15490026,18,"Mental development, however, did not differ significantly."
0,intervention,15490026,18,"Mental development, however, did not differ significantly."
0,population,15490026,18,"Mental development, however, did not differ significantly."
1,outcome,15490026,18,"Mental development, however, did not differ significantly."
0,other,15490026,18,"Mental development, however, did not differ significantly."
0,"study design",15490026,18,"Mental development, however, did not differ significantly."
0,background,15490026,19,"CONCLUSIONS"
0,intervention,15490026,19,"CONCLUSIONS"
0,population,15490026,19,"CONCLUSIONS"
0,outcome,15490026,19,"CONCLUSIONS"
1,other,15490026,19,"CONCLUSIONS"
0,"study design",15490026,19,"CONCLUSIONS"
0,background,15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
0,intervention,15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
0,population,15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
1,outcome,15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
0,other,15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
0,"study design",15490026,20,"Intestinal stricture was the most common gastrointestinal complication in this series of infants with NEC."
0,background,15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
0,intervention,15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
0,population,15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
1,outcome,15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
0,other,15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
0,"study design",15490026,21,"Besides the bowel sequelae, VLBW infants who survive NEC are at risk for impairment of growth and neurodevelopment."
0,background,15495040,1,"BACKGROUND"
0,intervention,15495040,1,"BACKGROUND"
0,population,15495040,1,"BACKGROUND"
0,outcome,15495040,1,"BACKGROUND"
1,other,15495040,1,"BACKGROUND"
0,"study design",15495040,1,"BACKGROUND"
1,background,15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
0,intervention,15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
0,population,15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
0,outcome,15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
0,other,15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
0,"study design",15495040,2,"Cardiac tamponade may occur following cardiac surgery as a result of blood or fluid collecting in the pericardial space compressing the heart and reducing cardiac output."
1,background,15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
0,intervention,15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
0,population,15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
0,outcome,15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
0,other,15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
0,"study design",15495040,3,"Mediastinal chest drains (including pericardial drains) are inserted as standard post-operative practice following cardiac surgery to assist the clearance of blood from the pericardial space and to prevent cardiac tamponade."
1,background,15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
0,intervention,15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
0,population,15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
0,outcome,15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
0,other,15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
0,"study design",15495040,4,"To prevent chest tubes from blocking and so causing tamponade nurses manipulate them to prevent or remove clots."
1,background,15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
0,intervention,15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
0,population,15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
0,outcome,15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
0,other,15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
0,"study design",15495040,5,"Manipulation methods including milking, stripping, fanfolding and tapping may be applied to the tubes to keep them from blocking."
1,background,15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,intervention,15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,population,15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,outcome,15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,other,15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,"study design",15495040,6,"Evidence is required as to the safest and most effective means of preventing chest tube blockage and preventing cardiac tamponade."
0,background,15495040,7,"OBJECTIVES"
0,intervention,15495040,7,"OBJECTIVES"
0,population,15495040,7,"OBJECTIVES"
0,outcome,15495040,7,"OBJECTIVES"
1,other,15495040,7,"OBJECTIVES"
0,"study design",15495040,7,"OBJECTIVES"
0,background,15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
1,intervention,15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
1,population,15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
0,outcome,15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
0,other,15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
0,"study design",15495040,8,"To compare different methods of chest drain clearance (i.e. varying levels of suction or suction in combination with milking, stripping, fanfolding and tapping of chest drains) in preventing cardiac tamponade in patients following cardiac surgery."
0,background,15495040,9,"SEARCH STRATEGY"
0,intervention,15495040,9,"SEARCH STRATEGY"
0,population,15495040,9,"SEARCH STRATEGY"
0,outcome,15495040,9,"SEARCH STRATEGY"
1,other,15495040,9,"SEARCH STRATEGY"
0,"study design",15495040,9,"SEARCH STRATEGY"
0,background,15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
0,intervention,15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
0,population,15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
0,outcome,15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
1,other,15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
0,"study design",15495040,10,"Over both the initial review and the 2004 revision, we searched the Cochrane Heart Group trials register, the Cochrane Controlled Trials Register (CCTR) (Issue 4, 2003) The Cochrane Database of Systematic Reviews (CDSR), the Database of Abstracts of Reviews of Effectiveness (DARE), Issue 4, 2003, MEDLINE (1966 to Nov Week 2, 2003), EMBASE (1980 to 2003 Week 47), CINAHL (1982 to Nov 2003), the Clinical Trials site of the NIH, (USA) (24.11.03) and reference lists of articles."
0,background,15495040,11,"SELECTION CRITERIA"
0,intervention,15495040,11,"SELECTION CRITERIA"
0,population,15495040,11,"SELECTION CRITERIA"
0,outcome,15495040,11,"SELECTION CRITERIA"
1,other,15495040,11,"SELECTION CRITERIA"
0,"study design",15495040,11,"SELECTION CRITERIA"
0,background,15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
0,intervention,15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
0,population,15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
0,outcome,15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
1,other,15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
0,"study design",15495040,12,"Randomised, quasi-randomised or systematically allocated clinical trials of chest tube manipulation methods in adults and children with mediastinal chest drains following cardiac surgery were included."
0,background,15495040,13,"DATA COLLECTION AND ANALYSIS"
0,intervention,15495040,13,"DATA COLLECTION AND ANALYSIS"
0,population,15495040,13,"DATA COLLECTION AND ANALYSIS"
0,outcome,15495040,13,"DATA COLLECTION AND ANALYSIS"
1,other,15495040,13,"DATA COLLECTION AND ANALYSIS"
0,"study design",15495040,13,"DATA COLLECTION AND ANALYSIS"
0,background,15495040,14,"Two reviewers independently assessed trial quality and extracted data."
0,intervention,15495040,14,"Two reviewers independently assessed trial quality and extracted data."
0,population,15495040,14,"Two reviewers independently assessed trial quality and extracted data."
0,outcome,15495040,14,"Two reviewers independently assessed trial quality and extracted data."
1,other,15495040,14,"Two reviewers independently assessed trial quality and extracted data."
0,"study design",15495040,14,"Two reviewers independently assessed trial quality and extracted data."
0,background,15495040,15,"Study authors were contacted for additional information where required."
0,intervention,15495040,15,"Study authors were contacted for additional information where required."
0,population,15495040,15,"Study authors were contacted for additional information where required."
0,outcome,15495040,15,"Study authors were contacted for additional information where required."
1,other,15495040,15,"Study authors were contacted for additional information where required."
0,"study design",15495040,15,"Study authors were contacted for additional information where required."
0,background,15495040,16,"Adverse effects information was collected from the trials."
0,intervention,15495040,16,"Adverse effects information was collected from the trials."
0,population,15495040,16,"Adverse effects information was collected from the trials."
0,outcome,15495040,16,"Adverse effects information was collected from the trials."
1,other,15495040,16,"Adverse effects information was collected from the trials."
0,"study design",15495040,16,"Adverse effects information was collected from the trials."
0,background,15495040,17,"MAIN RESULTS"
0,intervention,15495040,17,"MAIN RESULTS"
0,population,15495040,17,"MAIN RESULTS"
0,outcome,15495040,17,"MAIN RESULTS"
1,other,15495040,17,"MAIN RESULTS"
0,"study design",15495040,17,"MAIN RESULTS"
0,background,15495040,18,"Three studies with a total of 471 participants were included."
0,intervention,15495040,18,"Three studies with a total of 471 participants were included."
0,population,15495040,18,"Three studies with a total of 471 participants were included."
0,outcome,15495040,18,"Three studies with a total of 471 participants were included."
1,other,15495040,18,"Three studies with a total of 471 participants were included."
0,"study design",15495040,18,"Three studies with a total of 471 participants were included."
0,background,15495040,19,"There was no data, however, which could be included in a meta-analysis."
0,intervention,15495040,19,"There was no data, however, which could be included in a meta-analysis."
0,population,15495040,19,"There was no data, however, which could be included in a meta-analysis."
1,outcome,15495040,19,"There was no data, however, which could be included in a meta-analysis."
0,other,15495040,19,"There was no data, however, which could be included in a meta-analysis."
0,"study design",15495040,19,"There was no data, however, which could be included in a meta-analysis."
0,background,15495040,20,"This was due to inadequate data provision by two of the studies."
0,intervention,15495040,20,"This was due to inadequate data provision by two of the studies."
0,population,15495040,20,"This was due to inadequate data provision by two of the studies."
1,outcome,15495040,20,"This was due to inadequate data provision by two of the studies."
0,other,15495040,20,"This was due to inadequate data provision by two of the studies."
0,"study design",15495040,20,"This was due to inadequate data provision by two of the studies."
0,background,15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
0,intervention,15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
0,population,15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
1,outcome,15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
0,other,15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
0,"study design",15495040,21,"Where adequate data were provided there were no common interventions or outcomes to pool."
0,background,15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
0,intervention,15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
0,population,15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
1,outcome,15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
0,other,15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
0,"study design",15495040,22,"On the basis of single studies there was no evidence of a difference between groups on incidence of chest tube blockage, heart rate, cardiac tamponade or incidence of surgical re-entry."
0,background,15495040,23,"REVIEWERS' CONCLUSIONS"
0,intervention,15495040,23,"REVIEWERS' CONCLUSIONS"
0,population,15495040,23,"REVIEWERS' CONCLUSIONS"
0,outcome,15495040,23,"REVIEWERS' CONCLUSIONS"
1,other,15495040,23,"REVIEWERS' CONCLUSIONS"
0,"study design",15495040,23,"REVIEWERS' CONCLUSIONS"
0,background,15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
0,intervention,15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
0,population,15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
1,outcome,15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
0,other,15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
0,"study design",15495040,24,"There are insufficient studies which compare differing methods of chest drain clearance to support or refute the relative efficacy of the various methods in preventing cardiac tamponade."
0,background,15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
0,intervention,15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
0,population,15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
1,outcome,15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
0,other,15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
0,"study design",15495040,25,"Nor can the need to manipulate chest drains be supported or refuted by results from RCT's."
0,background,15502735,1,"OBJECTIVE"
0,intervention,15502735,1,"OBJECTIVE"
0,population,15502735,1,"OBJECTIVE"
0,outcome,15502735,1,"OBJECTIVE"
1,other,15502735,1,"OBJECTIVE"
0,"study design",15502735,1,"OBJECTIVE"
1,background,15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,intervention,15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,population,15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,outcome,15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,other,15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,"study design",15502735,2,"The purpose of this study was to examine pain experience among patients with chronic wounds, assess the utility of pain assessment scales for chronic wound-related pain, and determine the relation of wound-related pain to wound stage, affective distress, "
0,background,15502735,3,"DESIGN"
0,intervention,15502735,3,"DESIGN"
0,population,15502735,3,"DESIGN"
0,outcome,15502735,3,"DESIGN"
1,other,15502735,3,"DESIGN"
0,"study design",15502735,3,"DESIGN"
0,background,15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
1,intervention,15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
1,population,15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
0,outcome,15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
0,other,15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
1,"study design",15502735,4,"In this cross-sectional study of patients with a mix of chronic wounds (n = 69) recruited for a study evaluating a telemedicine system for assessing chronic wounds, 19 men (12 with spinal cord injury) with wound-related pain were identified."
0,background,15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
1,intervention,15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
0,population,15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
0,outcome,15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
0,other,15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
0,"study design",15502735,5,"Questionnaires included the Numerical Pain Rating Scale, McGill Pain Questionnaire, Brief Symptom Inventory, Center for Epidemiologic Studies Depression Scale, and the catastrophizing scale of the Coping Strategies Questionnaire."
0,background,15502735,6,"RESULTS"
0,intervention,15502735,6,"RESULTS"
0,population,15502735,6,"RESULTS"
0,outcome,15502735,6,"RESULTS"
1,other,15502735,6,"RESULTS"
0,"study design",15502735,6,"RESULTS"
0,background,15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
0,intervention,15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
0,population,15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
1,outcome,15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
0,other,15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
0,"study design",15502735,7,"The McGill Pain Questionnaire was more sensitive to pain experience than a single rating of pain intensity."
0,background,15502735,8,"Wound stage was positively related to severity of pain."
0,intervention,15502735,8,"Wound stage was positively related to severity of pain."
0,population,15502735,8,"Wound stage was positively related to severity of pain."
1,outcome,15502735,8,"Wound stage was positively related to severity of pain."
0,other,15502735,8,"Wound stage was positively related to severity of pain."
0,"study design",15502735,8,"Wound stage was positively related to severity of pain."
0,background,15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
0,intervention,15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
0,population,15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
1,outcome,15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
0,other,15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
0,"study design",15502735,9,"Pain catastrophizing was positively related to pain intensity and higher levels of affective distress and depressive symptoms."
0,background,15502735,10,"CONCLUSIONS"
0,intervention,15502735,10,"CONCLUSIONS"
0,population,15502735,10,"CONCLUSIONS"
0,outcome,15502735,10,"CONCLUSIONS"
1,other,15502735,10,"CONCLUSIONS"
0,"study design",15502735,10,"CONCLUSIONS"
0,background,15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
0,intervention,15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
0,population,15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
1,outcome,15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
0,other,15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
0,"study design",15502735,11,"Pain associated with chronic wounds is a significant clinical challenge for both patients and health practitioners."
1,background,15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
0,intervention,15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
0,population,15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
0,outcome,15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
0,other,15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
0,"study design",15561549,1,"Older individuals with TBI differ from younger adults with TBI in several ways, including their incidence rates, etiology of injury, nature of complications, lengths of hospitalization, functional outcomes, and mortality."
1,background,15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,intervention,15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,population,15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,outcome,15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,other,15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,"study design",15561549,2,"Despite the greater likelihood of poorer functional outcomes, older adults with TBI often achieve good functional outcomes and can live in community settings after receiving appropriate rehabilitation services, although at higher costs and longer hospital"
0,background,15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
0,intervention,15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
0,population,15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
1,outcome,15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
0,other,15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
0,"study design",15561549,3,"The future of rehabilitation care for elderly patients after TBI is uncertain due to financial limitations associated with the implementation of the PPS payment system by CMS."
0,background,15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
0,intervention,15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
0,population,15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
1,outcome,15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
0,other,15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
0,"study design",15561549,4,"Little is known regarding the long-term impact of TBI on individuals as they age, but this is an important issue as the population ages."
0,background,15566835,1,"BACKGROUND"
0,intervention,15566835,1,"BACKGROUND"
0,population,15566835,1,"BACKGROUND"
0,outcome,15566835,1,"BACKGROUND"
1,other,15566835,1,"BACKGROUND"
0,"study design",15566835,1,"BACKGROUND"
1,background,15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
0,intervention,15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
0,population,15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
0,outcome,15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
0,other,15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
0,"study design",15566835,2,"Chronic progressive disorders of the central nervous system (CNS) impose diagnostic problems, particularly in younger patients."
1,background,15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,intervention,15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,population,15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,outcome,15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,other,15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,"study design",15566835,3,"The demonstration of antibodies against measles virus (MV) in the cerebrospinal fluid (CSF) plays a major role in the laboratory diagnosis of subacute sclerosing panencephalitis (SSPE) as well as multiple sclerosis (MS)."
0,background,15566835,4,"OBJECTIVES"
0,intervention,15566835,4,"OBJECTIVES"
0,population,15566835,4,"OBJECTIVES"
0,outcome,15566835,4,"OBJECTIVES"
1,other,15566835,4,"OBJECTIVES"
0,"study design",15566835,4,"OBJECTIVES"
0,background,15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
0,intervention,15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
0,population,15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
0,outcome,15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
1,other,15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
0,"study design",15566835,5,"Because intrathecally synthesized antibodies against MV can be found in both diseases, it is necessary to establish easy and reliable methods to improve the differential diagnosis."
0,background,15566835,6,"STUDY DESIGN"
0,intervention,15566835,6,"STUDY DESIGN"
0,population,15566835,6,"STUDY DESIGN"
0,outcome,15566835,6,"STUDY DESIGN"
1,other,15566835,6,"STUDY DESIGN"
0,"study design",15566835,6,"STUDY DESIGN"
0,background,15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
0,intervention,15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
1,population,15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
0,outcome,15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
0,other,15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
0,"study design",15566835,7,"Seventy-one paired serum/CSF samples obtained from patients with the diagnosis of SSPE (n = 23), MS (n = 14), or acute postinfectious measles encephalitis (APME, n = 8) have been examined."
0,background,15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
0,intervention,15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
0,population,15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
0,outcome,15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
1,other,15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
0,"study design",15566835,8,"The reactivity of intrathecally synthesized immunoglobulin to individual recombinant MV structural proteins was assessed using Western blot analysis, ELISA as well as isoelectric focusing (IEF)."
0,background,15566835,9,"RESULTS"
0,intervention,15566835,9,"RESULTS"
0,population,15566835,9,"RESULTS"
0,outcome,15566835,9,"RESULTS"
1,other,15566835,9,"RESULTS"
0,"study design",15566835,9,"RESULTS"
0,background,15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
0,intervention,15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
0,population,15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
1,outcome,15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
0,other,15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
0,"study design",15566835,10,"All CSF samples obtained from patients suffering from SSPE showed a strong antibody response to MV-nucleocapsid (N) and phosphoprotein (P)."
0,background,15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
0,intervention,15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
0,population,15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
1,outcome,15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
0,other,15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
0,"study design",15566835,11,"Sera from 15 of the 23 SSPE patients were reactive to MV-fusion protein (F)."
0,background,15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
0,intervention,15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
0,population,15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
1,outcome,15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
0,other,15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
0,"study design",15566835,12,"Faint reactivity was obtained against MV-matrix (M) or hemagglutinin protein (H) in the minority of samples (40 and 20%, respectively)."
0,background,15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
0,intervention,15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
0,population,15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
1,outcome,15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
0,other,15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
0,"study design",15566835,13,"CSF samples of MS patients only revealed a clear response to N, and in two cases to F."
0,background,15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
0,intervention,15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
0,population,15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
1,outcome,15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
0,other,15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
0,"study design",15566835,14,"The other proteins were not recognized in the CSF samples of MS patients."
0,background,15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
0,intervention,15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
0,population,15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
1,outcome,15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
0,other,15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
0,"study design",15566835,15,"In contrast to SSPE, the IEF of CSF from MS patients revealed only few MV-specific oligoclonal bands."
0,background,15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
0,intervention,15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
0,population,15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
1,outcome,15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
0,other,15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
0,"study design",15566835,16,"In the CSF samples from APME patients, intrathecal MV antibodies were not detected."
0,background,15566835,17,"CONCLUSIONS"
0,intervention,15566835,17,"CONCLUSIONS"
0,population,15566835,17,"CONCLUSIONS"
0,outcome,15566835,17,"CONCLUSIONS"
1,other,15566835,17,"CONCLUSIONS"
0,"study design",15566835,17,"CONCLUSIONS"
0,background,15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
0,intervention,15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
0,population,15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
1,outcome,15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
0,other,15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
0,"study design",15566835,18,"This study shows that discrimination between SSPE and MS can be achieved in doubtful cases by IEF using MV-N, P and F proteins."
1,background,15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
0,intervention,15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
0,population,15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
0,outcome,15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
0,other,15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
0,"study design",15620075,1,"This study assessed the validity of standardized assessment data collected with the Minimum Data Set (MDS) in postacute care settings and used to create performance indicators."
1,background,15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
0,intervention,15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
0,population,15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
1,outcome,15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
0,other,15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
0,"study design",15620075,2,"Our results show that performance indicators derived from information collected with the MDS demonstrate convergent validity with data collected with other research or standardized assessment instruments."
0,background,15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
0,intervention,15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
0,population,15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
0,outcome,15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
1,other,15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
0,"study design",15620075,3,"Results were most favorable for areas of physical functioning, cognitive and communicative functioning, and clinical complexity."
0,background,15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
0,intervention,15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
0,population,15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
1,outcome,15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
0,other,15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
0,"study design",15620075,4,"Results were encouraging for affective functioning, but further research and development in this area is clearly needed."
0,background,15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
0,intervention,15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
0,population,15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
1,outcome,15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
0,other,15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
0,"study design",15620075,5,"There is a pressing need for better quality data on performance measurement in the postacute environment, given the rapid growth in the volume of services and expenditures for such care and the associated need to ensure that patients receive the most appr"
0,background,15634429,1,"OBJECTIVE"
0,intervention,15634429,1,"OBJECTIVE"
0,population,15634429,1,"OBJECTIVE"
0,outcome,15634429,1,"OBJECTIVE"
1,other,15634429,1,"OBJECTIVE"
0,"study design",15634429,1,"OBJECTIVE"
1,background,15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
1,intervention,15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
0,population,15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
0,outcome,15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
0,other,15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
0,"study design",15634429,2,"To contrast single and double balloon-inflated kyphoplasty for vertebral compression fractures (VCFs) and evaluate its clinical efficacy."
0,background,15634429,3,"METHODS"
0,intervention,15634429,3,"METHODS"
0,population,15634429,3,"METHODS"
0,outcome,15634429,3,"METHODS"
1,other,15634429,3,"METHODS"
0,"study design",15634429,3,"METHODS"
0,background,15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
0,intervention,15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
1,population,15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
0,outcome,15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
0,other,15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
0,"study design",15634429,4,"From May 2000 to May 2004, 90 consecutive procedures were performed in 58 patients who suffered from painful vertebral compression fractures, transferring tumour and angioma."
0,background,15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
0,intervention,15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
0,population,15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
0,outcome,15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
1,other,15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
0,"study design",15634429,5,"Ninety vertebrae were inflated while 62 as A group were double balloon and 28 as B group were single balloon, fracture reduction and bone cement augmentation."
0,background,15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
0,intervention,15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
0,population,15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
0,outcome,15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
1,other,15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
0,"study design",15634429,6,"Preoperative and postoperative symptom levels, variables, complications were recorded and the vertebral height and Cobb angle were measured and analyzed."
0,background,15634429,7,"RESULTS"
0,intervention,15634429,7,"RESULTS"
0,population,15634429,7,"RESULTS"
0,outcome,15634429,7,"RESULTS"
1,other,15634429,7,"RESULTS"
0,"study design",15634429,7,"RESULTS"
0,background,15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
0,intervention,15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
0,population,15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
1,outcome,15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
0,other,15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
0,"study design",15634429,8,"All patients' pain was alleviated or disappeared without syndrome, and the vertebral height and Cobb angle of both groups were improved."
0,background,15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
0,intervention,15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
0,population,15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
1,outcome,15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
0,other,15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
0,"study design",15634429,9,"The average recovery rate was 72.6% (22.9% approximately 100%), Cobb angle from 17.9 degrees (3.1 degrees approximately 31.6 degrees ) were corrected to 9.6 degrees (0.6 degrees approximately 28.2 degrees ), the average angle was 8.7 degrees (0.3 degrees "
0,background,15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
0,intervention,15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
0,population,15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
1,outcome,15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
0,other,15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
0,"study design",15634429,10,"The average recovery rate of A group was 77.6% (55.3% approximately 100%), B group was 64.3% (22.9% approximately 100%)."
0,background,15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
0,intervention,15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
0,population,15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
1,outcome,15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
0,other,15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
0,"study design",15634429,11,"The average postoperative Cobb angle of A group was 9.9 degrees (0.3 degrees approximately 27.2 degrees ), B group was 8.6 degrees (0.6 degrees approximately 19.8 degrees ) (P &gt;0.05)."
0,background,15634429,12,"CONCLUSIONS"
0,intervention,15634429,12,"CONCLUSIONS"
0,population,15634429,12,"CONCLUSIONS"
0,outcome,15634429,12,"CONCLUSIONS"
1,other,15634429,12,"CONCLUSIONS"
0,"study design",15634429,12,"CONCLUSIONS"
0,background,15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
0,intervention,15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
0,population,15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
1,outcome,15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
0,other,15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
0,"study design",15634429,13,"As a promising minimally invasive surgery, balloon kyphoplasty can provide early relief of pain and improve the function as well as spinal alignment in treatment of painful compression fracture owing to recovering the vertebral height and Cobb angle of th"
0,background,15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
0,intervention,15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
0,population,15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
1,outcome,15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
0,other,15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
0,"study design",15634429,14,"Single balloon-inflated kyphoplasty can improve VCFs as double balloon."
1,background,15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
0,intervention,15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
0,population,15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
0,outcome,15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
0,other,15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
0,"study design",15712978,1,"Percutaneous vertebral body injection procedures currently are used to stabilize and reinforce weakened or fractured bone resulting from metastatic disease and severe osteoporosis."
1,background,15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
0,intervention,15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
0,population,15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
0,outcome,15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
0,other,15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
0,"study design",15712978,2,"Both vertebroplasty and kyphoplasty can reinforce the structure of a vertebral body and provide pain relief, but the procedures have technical differences."
1,background,15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
0,intervention,15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
0,population,15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
0,outcome,15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
0,other,15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
0,"study design",15712978,3,"Kyphoplasty improves vertebral height to varying degrees in nearly three quarters of patients."
1,background,15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
0,intervention,15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
0,population,15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
0,outcome,15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
0,other,15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
0,"study design",15712978,4,"Kyphosis is improved more effectively when the procedure is performed within 3 months from the onset of fracture pain."
1,background,15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,intervention,15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,population,15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,outcome,15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,other,15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,"study design",15712978,5,"To date, it is unknown whether vertebroplasty with preprocedure postural reduction can provide similar improvement of deformity."
0,background,15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
0,intervention,15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
0,population,15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
1,outcome,15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
0,other,15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
0,"study design",15712978,6,"Complications are relatively infrequent with both vertebroplasty and kyphoplasty."
0,background,15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
0,intervention,15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
0,population,15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
1,outcome,15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
0,other,15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
0,"study design",15712978,7,"Cement leakage from the vertebral body is more likely with vertebroplasty than with kyphoplasty."
0,background,15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
0,intervention,15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
0,population,15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
1,outcome,15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
0,other,15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
0,"study design",15712978,8,"Leakage is more common in the treatment of pathologic fractures resulting from metastatic disease."
0,background,15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
0,intervention,15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
0,population,15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
1,outcome,15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
0,other,15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
0,"study design",15712978,9,"Clinical complications caused by cement leakage and neural compression are infrequent."
0,background,15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
0,intervention,15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
0,population,15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
1,outcome,15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
0,other,15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
0,"study design",15712978,10,"Specific indications for these injection procedures need to be more clearly refined."
0,background,15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
0,intervention,15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
0,population,15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
1,outcome,15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
0,other,15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
0,"study design",15712978,11,"Long-term outcomes, including the fate of the injected material and the effect on adjacent vertebrae, have yet to be determined."
1,background,15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,intervention,15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,population,15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,outcome,15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,other,15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,"study design",15725222,1,"The aims of the present study were to investigate whether temporal summation of the nociceptive withdrawal reflex depends on the stimulation site on the sole of the human foot, and to characterize the reflex receptive fields (RRF) of lower limb muscles to"
0,background,15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
1,intervention,15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
1,population,15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
0,outcome,15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
0,other,15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
0,"study design",15725222,2,"The cutaneous RRFs were assessed in 15 subjects in sitting position by recording the EMG from five lower leg muscles and the kinematic responses (ankle, knee, and hip joints) to repetitive painful electrical stimulation."
0,background,15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
1,intervention,15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
0,population,15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
0,outcome,15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
0,other,15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
0,"study design",15725222,3,"The stimulus consisted of a series of five stimuli (frequency: 3 Hz) delivered randomly at 10 different sites on the sole of the foot."
0,background,15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
0,intervention,15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
0,population,15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
1,outcome,15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
0,other,15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
0,"study design",15725222,4,"The size of the reflexes increased generally between the first and the second stimulus, however, the increment depended on the stimulation site."
0,background,15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
0,intervention,15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
0,population,15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
1,outcome,15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
0,other,15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
0,"study design",15725222,5,"In tibialis anterior, the RRF covered the distal sole of the foot and gradually expanded during the stimulus train."
0,background,15725222,6,"No expansion toward the heel area was detected."
0,intervention,15725222,6,"No expansion toward the heel area was detected."
0,population,15725222,6,"No expansion toward the heel area was detected."
1,outcome,15725222,6,"No expansion toward the heel area was detected."
0,other,15725222,6,"No expansion toward the heel area was detected."
0,"study design",15725222,6,"No expansion toward the heel area was detected."
0,background,15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
0,intervention,15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
0,population,15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
1,outcome,15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
0,other,15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
0,"study design",15725222,7,"In soleus, the reflexes were facilitated after the second stimulus at all sites and remained in this state until the last stimulus."
0,background,15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
0,intervention,15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
0,population,15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
1,outcome,15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
0,other,15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
0,"study design",15725222,8,"In vastus lateralis, biceps femoris, and iliopsoas a gradual expansion of the RRF was seen, resulting in RRFs covering the lateral, distal foot, and part of the proximal foot (iliopsoas)."
0,background,15725222,9,"Knee and hip flexion were evoked at all sites."
0,intervention,15725222,9,"Knee and hip flexion were evoked at all sites."
0,population,15725222,9,"Knee and hip flexion were evoked at all sites."
1,outcome,15725222,9,"Knee and hip flexion were evoked at all sites."
0,other,15725222,9,"Knee and hip flexion were evoked at all sites."
0,"study design",15725222,9,"Knee and hip flexion were evoked at all sites."
0,background,15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
0,intervention,15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
0,population,15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
1,outcome,15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
0,other,15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
0,"study design",15725222,10,"Ankle dorsiflexion was evoked at the distal foot, while ankle plantarflexion was evoked at the heel."
0,background,15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
0,intervention,15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
0,population,15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
1,outcome,15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
0,other,15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
0,"study design",15725222,11,"The enlargement of the RRF reflects spinal temporal summation leading to gradually stronger reflex responses."
0,background,15725222,12,"The degree of temporal summation was dependent on stimulation site."
0,intervention,15725222,12,"The degree of temporal summation was dependent on stimulation site."
0,population,15725222,12,"The degree of temporal summation was dependent on stimulation site."
1,outcome,15725222,12,"The degree of temporal summation was dependent on stimulation site."
0,other,15725222,12,"The degree of temporal summation was dependent on stimulation site."
0,"study design",15725222,12,"The degree of temporal summation was dependent on stimulation site."
0,background,15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
0,intervention,15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
0,population,15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
1,outcome,15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
0,other,15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
0,"study design",15725222,13,"The facilitation of the withdrawal reflex responses due to repetitive stimulation might have potential applications in the rehabilitation engineering field, where these reflexes could be used to assist gait of patients with central nervous system injuries"
1,background,1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
0,intervention,1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
0,population,1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
0,outcome,1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
0,other,1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
0,"study design",1588072,1,"The prognosis for survival has improved dramatically for cancer patients over the past three decades."
1,background,1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
0,intervention,1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
0,population,1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
0,outcome,1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
0,other,1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
0,"study design",1588072,2,"Advances in systemic therapy have prolonged survival even in those who cannot be cured."
1,background,1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
0,intervention,1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
0,population,1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
0,outcome,1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
0,other,1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
0,"study design",1588072,3,"The importance of managing spinal column disease and protecting the spinal cord has subsequently been amplified."
1,background,1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
0,intervention,1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
0,population,1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
0,outcome,1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
0,other,1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
0,"study design",1588072,4,"Almost any patient presenting with detectable neurologic function and enough physical reserve to withstand an operation will benefit from a spinal stabilization, pain relief, and neural decompression; there are few exceptions."
1,background,1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
0,intervention,1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
0,population,1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
0,outcome,1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
0,other,1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
0,"study design",1588072,5,"Advances in surgical technique and biomaterials have not only improved survival and functional outcome, they have diminished many of the postoperative complications that plagued earlier treatment techniques."
1,background,1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
0,intervention,1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
0,population,1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
0,outcome,1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
0,other,1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
0,"study design",1588072,6,"Methods of preventing or correcting iatrogenic deformity have improved outcome."
1,background,1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
0,intervention,1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
0,population,1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
0,outcome,1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
0,other,1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
0,"study design",1588072,7,"Newer fixation techniques promise to eliminate many of the causes of hardware and fixation failure previously seen."
1,background,1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
0,intervention,1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
0,population,1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
0,outcome,1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
0,other,1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
0,"study design",1588072,8,"Improved medical management, antibiotics, and preoperative planning, along with techniques of preoperative embolization and early postoperative mobilization have made surgical management much less risky."
1,background,1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
0,intervention,1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
0,population,1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
0,outcome,1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
0,other,1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
0,"study design",1588072,9,"Vertebrectomy, considered a last alternative in the past, is now coming to be seen as the conservative approach to tumor management in many situations."
1,background,1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
0,intervention,1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
0,population,1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
0,outcome,1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
0,other,1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
0,"study design",1588072,10,"Appropriate surgical treatment can have a dramatic impact on function and outcome in patients with tumors of the spinal column, and should never be dismissed as an option without serious consideration."
1,background,1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,intervention,1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,population,1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,outcome,1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,other,1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,"study design",1588072,11,"Advances in fixation systems, local and systemic therapy, and in our understanding of the biology of cancer promise even greater improvements for the future."
0,background,15881697,1,"OBJECTIVE"
0,intervention,15881697,1,"OBJECTIVE"
0,population,15881697,1,"OBJECTIVE"
0,outcome,15881697,1,"OBJECTIVE"
1,other,15881697,1,"OBJECTIVE"
0,"study design",15881697,1,"OBJECTIVE"
1,background,15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,intervention,15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,population,15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,outcome,15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,other,15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,"study design",15881697,2,"Our aim was to find out which factors favor the occurrence of pain in adult patients with Scheuermann's disease--a juvenile manifestation of osteochondrosis of the spine, to study the clinical and radiological signs, the role of rehabilitation and the mea"
0,background,15881697,3,"PATIENTS AND METHODS"
0,intervention,15881697,3,"PATIENTS AND METHODS"
0,population,15881697,3,"PATIENTS AND METHODS"
0,outcome,15881697,3,"PATIENTS AND METHODS"
1,other,15881697,3,"PATIENTS AND METHODS"
0,"study design",15881697,3,"PATIENTS AND METHODS"
0,background,15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
1,intervention,15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
1,population,15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
0,outcome,15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
0,other,15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
1,"study design",15881697,4,"Descriptive and retrospective study about 45 adults treated by rehabilitation."
0,background,15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
0,intervention,15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
0,population,15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
0,outcome,15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
1,other,15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
0,"study design",15881697,5,"A data sheet listed the patient's occupation, current practice of sport, antecedents (violent sport, traumatism, pain), presence of a family form, motive of consultation, clinical and paraclinical examinations and immediate and long-term results of rehabilitation."
0,background,15881697,6,"RESULTS"
0,intervention,15881697,6,"RESULTS"
0,population,15881697,6,"RESULTS"
0,outcome,15881697,6,"RESULTS"
1,other,15881697,6,"RESULTS"
0,"study design",15881697,6,"RESULTS"
0,background,15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
0,intervention,15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
0,population,15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
1,outcome,15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
0,other,15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
0,"study design",15881697,7,"Average age 35 years (18 to 65), male predominance (1.8:1), occupational risk factors: 16%; only 24% practiced sports currently."
0,background,15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
0,intervention,15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
0,population,15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
1,outcome,15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
0,other,15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
0,"study design",15881697,8,"Antecedents: sports 49%, spinal column traumatism 13%, dorsal and lumbar pain during adolescence 16%."
0,background,15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
0,intervention,15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
0,population,15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
1,outcome,15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
0,other,15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
0,"study design",15881697,9,"Consultation motive: abnormal posture 4% and pain 96%."
0,background,15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
0,intervention,15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
0,population,15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
1,outcome,15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
0,other,15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
0,"study design",15881697,10,"According to the examination: abnormal spinal column in 80% of cases."
0,background,15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
0,intervention,15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
0,population,15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
1,outcome,15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
0,other,15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
0,"study design",15881697,11,"According to radiography, our patients were divided into 49% who were carriers of growth vertebral dystrophy and 51% who were carriers of the real Scheuermann's disease."
0,background,15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
0,intervention,15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
0,population,15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
1,outcome,15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
0,other,15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
0,"study design",15881697,12,"The immediate results of rehabilitation were satisfactory, 75% of the results were very good and good."
0,background,15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
0,intervention,15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
0,population,15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
1,outcome,15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
0,other,15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
0,"study design",15881697,13,"Between six months and four years, 70% of the results were very satisfactory."
0,background,15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
0,intervention,15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
0,population,15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
1,outcome,15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
0,other,15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
0,"study design",15881697,14,"Exercises were observed in only 11% of the cases, and stopped after two months on average."
0,background,15881697,15,"CONCLUSION"
0,intervention,15881697,15,"CONCLUSION"
0,population,15881697,15,"CONCLUSION"
0,outcome,15881697,15,"CONCLUSION"
1,other,15881697,15,"CONCLUSION"
0,"study design",15881697,15,"CONCLUSION"
0,background,15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
0,intervention,15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
0,population,15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
1,outcome,15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
0,other,15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
0,"study design",15881697,16,"Scheuermann's disease in adults is a different entity from that of the teenager for the major manifestation is pain and not aesthetic quality."
0,background,15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
0,intervention,15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
0,population,15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
1,outcome,15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
0,other,15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
0,"study design",15881697,17,"The patient's occupation is rather sedentary; sport is beneficial."
0,background,15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
0,intervention,15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
0,population,15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
1,outcome,15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
0,other,15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
0,"study design",15881697,18,"The functional rehabilitation is the basic treatment and recourse to surgery or dorso-lumbar braces is rare."
0,background,15889700,1,"BACKGROUND"
0,intervention,15889700,1,"BACKGROUND"
0,population,15889700,1,"BACKGROUND"
0,outcome,15889700,1,"BACKGROUND"
1,other,15889700,1,"BACKGROUND"
0,"study design",15889700,1,"BACKGROUND"
1,background,15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
0,intervention,15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
0,population,15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
0,outcome,15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
0,other,15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
0,"study design",15889700,2,"Fournier gangrene is a necrotizing fasciitis of the perineal and genital region resulting from polymicrobial infection in which infection spreads along fascial planes, causing soft-tissue necrosis."
1,background,15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
0,intervention,15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
0,population,15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
0,outcome,15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
0,other,15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
0,"study design",15889700,3,"If surgical debridement and control of infection are delayed, the disease can progress and result in septic shock, multiorgan failure, and death."
1,background,15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
0,intervention,15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
0,population,15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
0,outcome,15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
0,other,15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
0,"study design",15889700,4,"Initial symptoms are severe pain in the genital region followed by swelling and erythema."
1,background,15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
0,intervention,15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
0,population,15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
0,outcome,15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
0,other,15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
0,"study design",15889700,5,"In patients with spinal cord injury (SCI), lack of pain sensation could cause delay in seeking medical attention."
1,background,15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,intervention,15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,population,15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,outcome,15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,other,15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,"study design",15889700,6,"SCI patients are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,background,15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
0,intervention,15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
0,population,15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
0,outcome,15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
1,other,15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
0,"study design",15889700,7,"A literature search resulted in only 1 report of Fournier gangrene with localized necrosis of the scrotum in a patient with SCI."
0,background,15889700,8,"METHODS"
0,intervention,15889700,8,"METHODS"
0,population,15889700,8,"METHODS"
0,outcome,15889700,8,"METHODS"
1,other,15889700,8,"METHODS"
0,"study design",15889700,8,"METHODS"
0,background,15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
0,intervention,15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
1,population,15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
0,outcome,15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
0,other,15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
1,"study design",15889700,9,"Case report of a 47-year-old man with C4 tetraplegia."
0,background,15889700,10,"RESULTS"
0,intervention,15889700,10,"RESULTS"
0,population,15889700,10,"RESULTS"
0,outcome,15889700,10,"RESULTS"
1,other,15889700,10,"RESULTS"
0,"study design",15889700,10,"RESULTS"
0,background,15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
0,intervention,15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
0,population,15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
1,outcome,15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
0,other,15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
0,"study design",15889700,11,"Patient presented with a necrotic ulceration on the ventral aspect of the penis and scrotum of 2 days duration and was diagnosed with fulminant Fournier gangrene."
0,background,15889700,12,"CONCLUSIONS"
0,intervention,15889700,12,"CONCLUSIONS"
0,population,15889700,12,"CONCLUSIONS"
0,outcome,15889700,12,"CONCLUSIONS"
1,other,15889700,12,"CONCLUSIONS"
0,"study design",15889700,12,"CONCLUSIONS"
0,background,15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,intervention,15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,population,15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
1,outcome,15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,other,15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,"study design",15889700,13,"Patients with SCI are at higher risk for Fournier gangrene secondary to neurogenic bladder, neurogenic bowel, and impaired sensation."
0,background,15889700,14,"Mortality is high."
0,intervention,15889700,14,"Mortality is high."
0,population,15889700,14,"Mortality is high."
1,outcome,15889700,14,"Mortality is high."
0,other,15889700,14,"Mortality is high."
0,"study design",15889700,14,"Mortality is high."
0,background,15889700,15,"Prevention and early diagnosis are essential."
0,intervention,15889700,15,"Prevention and early diagnosis are essential."
0,population,15889700,15,"Prevention and early diagnosis are essential."
1,outcome,15889700,15,"Prevention and early diagnosis are essential."
0,other,15889700,15,"Prevention and early diagnosis are essential."
0,"study design",15889700,15,"Prevention and early diagnosis are essential."
0,background,15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
0,intervention,15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
0,population,15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
1,outcome,15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
0,other,15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
0,"study design",15889700,16,"Prompt aggressive intervention is warranted to maximize outcomes."
1,background,15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
1,intervention,15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
1,population,15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
0,outcome,15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
0,other,15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
1,"study design",15991104,1,"A primary care group diabetes care program using telemedicine was developed and its feasibility and acceptability were tested in 22 subjects with Type 2 diabetes mellitus using a one-group, pretest-posttest quasi-experimental design."
0,background,15991104,2,"Compliance with the program was 100%."
0,intervention,15991104,2,"Compliance with the program was 100%."
0,population,15991104,2,"Compliance with the program was 100%."
0,outcome,15991104,2,"Compliance with the program was 100%."
1,other,15991104,2,"Compliance with the program was 100%."
0,"study design",15991104,2,"Compliance with the program was 100%."
0,background,15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
0,intervention,15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
0,population,15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
1,outcome,15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
0,other,15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
0,"study design",15991104,3,"Significant reductions in total calorie intake as well as body mass index were achieved, with an increase in the percentage of subjects achieving better diabetes control as measured by the 2-hr hemastix."
0,background,15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
0,intervention,15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
0,population,15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
1,outcome,15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
0,other,15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
0,"study design",15991104,4,"Improvements in diabetes knowledge and disease-specific and generic measures of quality of life were also observed."
0,background,15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
0,intervention,15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
0,population,15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
0,outcome,15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
1,other,15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
0,"study design",15991104,5,"Most subjects evaluated this mode of service delivery favorably in the questionnaire and focus group discussions."
0,background,15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
0,intervention,15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
0,population,15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
1,outcome,15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
0,other,15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
0,"study design",15991104,6,"There is potential for the integration of this mode of service delivery into current health services."
0,background,16009872,1,"BACKGROUND"
0,intervention,16009872,1,"BACKGROUND"
0,population,16009872,1,"BACKGROUND"
0,outcome,16009872,1,"BACKGROUND"
1,other,16009872,1,"BACKGROUND"
0,"study design",16009872,1,"BACKGROUND"
1,background,16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
0,intervention,16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
0,population,16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
0,outcome,16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
0,other,16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
0,"study design",16009872,2,"Acute urinary retention (AUR) is characterized by the sudden inability to urinate, which is usually extremely painful and requires catheterization."
1,background,16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
0,intervention,16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
0,population,16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
0,outcome,16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
0,other,16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
0,"study design",16009872,3,"Prostaglandins play an important role in the genitourinary function as they provoke contractions of the detrusor muscle."
1,background,16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,intervention,16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,population,16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,outcome,16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,other,16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,"study design",16009872,4,"Relaxation of the detrusor muscle, via the inhibition of the prostaglandin synthesis, could result in AUR."
0,background,16009872,5,"METHODS"
0,intervention,16009872,5,"METHODS"
0,population,16009872,5,"METHODS"
0,outcome,16009872,5,"METHODS"
1,other,16009872,5,"METHODS"
0,"study design",16009872,5,"METHODS"
0,background,16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
1,intervention,16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
0,population,16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
0,outcome,16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
0,other,16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
1,"study design",16009872,6,"We conducted a population-based case-control study within the Integrated Primary Care Information project in the Netherlands to investigate whether the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with an increased risk of AUR."
0,background,16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
0,intervention,16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
1,population,16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
0,outcome,16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
0,other,16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
0,"study design",16009872,7,"All men 45 years or older registered in the database between 1995 and 2002 and with at least 6 months of valid history were included."
0,background,16009872,8,"Cases were all men with a validated diagnosis of AUR."
0,intervention,16009872,8,"Cases were all men with a validated diagnosis of AUR."
0,population,16009872,8,"Cases were all men with a validated diagnosis of AUR."
0,outcome,16009872,8,"Cases were all men with a validated diagnosis of AUR."
1,other,16009872,8,"Cases were all men with a validated diagnosis of AUR."
0,"study design",16009872,8,"Cases were all men with a validated diagnosis of AUR."
0,background,16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
0,intervention,16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
0,population,16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
0,outcome,16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
1,other,16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
0,"study design",16009872,9,"To each case, up to 10 controls were matched on age and calendar time."
0,background,16009872,10,"RESULTS"
0,intervention,16009872,10,"RESULTS"
0,population,16009872,10,"RESULTS"
0,outcome,16009872,10,"RESULTS"
1,other,16009872,10,"RESULTS"
0,"study design",16009872,10,"RESULTS"
0,background,16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
0,intervention,16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
0,population,16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
1,outcome,16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
0,other,16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
0,"study design",16009872,11,"Within the source population of 72 114 men, we identified 536 cases of AUR and 5348 matched controls."
0,background,16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
0,intervention,16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
0,population,16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
1,outcome,16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
0,other,16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
0,"study design",16009872,12,"Risk of AUR was 2.02-fold higher in current users of NSAIDs than in nonusers (95% confidence interval, 1.23-3.31)."
0,background,16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
0,intervention,16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
0,population,16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
1,outcome,16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
0,other,16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
0,"study design",16009872,13,"The highest risk for AUR (adjusted odds ratio, 3.3; 95% confidence interval, 1.2-9.2) was observed in patients who recently started using NSAIDs and in those using a dose equal to or higher than the recommended daily dose."
0,background,16009872,14,"CONCLUSION"
0,intervention,16009872,14,"CONCLUSION"
0,population,16009872,14,"CONCLUSION"
0,outcome,16009872,14,"CONCLUSION"
1,other,16009872,14,"CONCLUSION"
0,"study design",16009872,14,"CONCLUSION"
0,background,16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
0,intervention,16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
0,population,16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
1,outcome,16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
0,other,16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
0,"study design",16009872,15,"This study shows that the risk of AUR is about 2-fold higher in men who use NSAIDs."
1,background,16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,intervention,16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,population,16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,outcome,16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,other,16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,"study design",16010446,1,"The aim of this study was to determine whether the probability of osteoporosis and osteopenia was affected by the risk factors, physical examination findings, or radiological investigations such as spinal X-rays in postmenopausal women."
0,background,16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
0,intervention,16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
0,population,16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
0,outcome,16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
1,other,16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
0,"study design",16010446,2,"We assessed risk factors such as use of hormone replacement therapy, physical activity level, calcium intake, smoking, caffeine consumption, long-term immobilization, previous history of fracture, family history of fracture, presence of certain systemic diseases (hyperthyroidism or hyperparathyroidism), or use of medications (corticosteroids or others), physical examinations, and presence of vertebral fractures on spinal X-rays."
0,background,16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
1,intervention,16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
0,population,16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
0,outcome,16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
0,other,16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
0,"study design",16010446,3,"Patients' bone mineral density (BMD) was evaluated using dual energy X-ray absorptiometry (DXA) in the lumbar spine, and we compared the risk factors between osteopenic and osteoporotic women according to DXA."
0,background,16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
0,intervention,16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
1,population,16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
0,outcome,16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
0,other,16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
0,"study design",16010446,4,"We evaluated 235 postmenopausal women who attended our osteoporosis outpatient clinic."
0,background,16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
0,intervention,16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
0,population,16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
0,outcome,16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
1,other,16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
0,"study design",16010446,5,"Those patients were divided into two groups as either osteopenic (n = 67, mean age 63.1 years) or osteoporotic (n = 168, mean age 66.2 years) according to WHO criteria."
0,background,16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
0,intervention,16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
0,population,16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
1,outcome,16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
0,other,16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
0,"study design",16010446,6,"The lumbar spinal (L1-L2) T-score values were -1.5 +/- 0.6 and -3.1 +/- 0.6 in osteopenic and osteoporotic groups, respectively."
0,background,16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
0,intervention,16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
0,population,16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
1,outcome,16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
0,other,16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
0,"study design",16010446,7,"There were significant differences between the two groups in terms of mean age and lumbar BMD (p = 0.009 and p &lt; 0.001, respectively)."
0,background,16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
0,intervention,16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
0,population,16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
1,outcome,16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
0,other,16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
0,"study design",16010446,8,"We also observed that vertebral tenderness on palpation, back pain, and existing vertebral fracture (fx) were significantly different between the osteopenic and osteoporotic groups (p &lt; 0.05)."
0,background,16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
0,intervention,16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
0,population,16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
1,outcome,16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
0,other,16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
0,"study design",16010446,9,"As a result of the statistical analysis, we found an equation to determine osteopenic and osteoporotic women by using those four factors (age, vertebral tenderness on palpation, back pain, and existing vertebral fx) in multivariate stepwise logistic regre"
0,background,16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
0,intervention,16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
0,population,16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
1,outcome,16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
0,other,16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
0,"study design",16010446,10,"The equation is as follows: Y (DXA) = -2.9024 + 0.044 (age in year) + 0.819 (vertebral fx) + 0.877 (pain) + 1.136 (vertebral tenderness)."
0,background,16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
0,intervention,16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
0,population,16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
1,outcome,16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
0,other,16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
0,"study design",16010446,11,"We can estimate whether a postmenopausal woman is osteopenic or osteoporotic based on these risk factors by using the stepwise logistic regression equation."
1,background,1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
0,intervention,1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
0,population,1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
0,outcome,1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
0,other,1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
0,"study design",1609040,1,"Serotonin basic neuroscience discoveries are evolving at a very fast pace and are leading to innovations in clinical psychiatry and in drug development."
1,background,1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
0,intervention,1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
0,population,1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
0,outcome,1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
0,other,1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
0,"study design",1609040,2,"Numerous novel pharmacological tools, each selective for a given serotonin receptor subtype, are being applied to several psychiatric disorders."
1,background,1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
0,intervention,1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
0,population,1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
0,outcome,1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
0,other,1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
0,"study design",1609040,3,"The strategy employed is theory driven and hypothesis oriented, aiming for new drug development that selectively targets receptors that are rational sites for therapeutic actions."
1,background,1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
0,intervention,1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
0,population,1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
0,outcome,1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
0,other,1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
0,"study design",1609040,4,"Thus, serotonin uptake inhibitors are targeting not only depression, but also obsessive-compulsive disorder (OCD)."
1,background,1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
0,intervention,1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
0,population,1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
0,outcome,1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
0,other,1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
0,"study design",1609040,5,"Serotonin1A agonists are targeting not only depression and anxiety, but also mixed anxiety depression."
1,background,1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
0,intervention,1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
0,population,1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
0,outcome,1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
0,other,1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
0,"study design",1609040,6,"These and other agents selective for additional receptors are being tested in impulse control disorders; eating disorders; addictive disorders; and aggressive, violent, self-destructive, and suicidal behaviors."
1,background,1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
0,intervention,1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
0,population,1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
0,outcome,1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
0,other,1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
0,"study design",1609040,7,"Serotonin research is an excellent example of how basic science discoveries in the 1990's &quot;Decade of the Brain&quot; are resulting in important advances in therapeutics for psychiatry."
1,background,1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
0,intervention,1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
0,population,1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
0,outcome,1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
0,other,1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
0,"study design",1610984,1,"Dialysis patients have an inordinate risk of cardiovascular events."
1,background,1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
0,intervention,1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
0,population,1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
0,outcome,1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
0,other,1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
0,"study design",1610984,2,"Fish oils, rich in n-3 fatty acids, are believed to be beneficial in the prevention of atherosclerosis and thrombosis."
1,background,1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
0,intervention,1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
0,population,1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
0,outcome,1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
0,other,1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
0,"study design",1610984,3,"Hence, the use of fish oils deserves consideration as a preventative or therapeutic intervention in dialysis patients."
1,background,1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
0,intervention,1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
0,population,1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
0,outcome,1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
0,other,1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
0,"study design",1610984,4,"The suggestion has been made that n-3 fatty acids could increase the risk of bleeding, and thus, the safety of the use of these agents in dialysis patients must be established before long-term studies are undertaken."
1,background,1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,intervention,1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,population,1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,outcome,1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,other,1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,"study design",1610984,5,"This study addresses the effect of n-3 fatty acids on the hemostatic profile of dialysis patients."
0,background,1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
1,intervention,1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
1,population,1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
0,outcome,1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
0,other,1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
1,"study design",1610984,6,"Sixteen patients on chronic dialysis therapy were randomized to fish oil (MaxEPA) or placebo (olive oil) in a double-blind cross-over study."
0,background,1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
1,intervention,1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
0,population,1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
0,outcome,1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
0,other,1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
0,"study design",1610984,7,"They received 3.6 g of n-3 fatty acids for 4 wk."
0,background,1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
0,intervention,1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
0,population,1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
1,outcome,1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
0,other,1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
0,"study design",1610984,8,"Bleeding times were 4.8 +/- 0.4 min on MaxEPA and 4.5 +/- 0.3 min on placebo."
0,background,1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
0,intervention,1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
0,population,1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
1,outcome,1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
0,other,1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
0,"study design",1610984,9,"Platelet aggregation to low-dose ADP or collagen also remained unchanged."
0,background,1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
0,intervention,1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
0,population,1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
1,outcome,1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
0,other,1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
0,"study design",1610984,10,"There was a trend to lower serum triglyceride levels (2.7 +/- 0.5 versus 3.4 +/- 0.6 mmol/L, fish oil versus placebo) that did not reach statistical significance."
0,background,1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
0,intervention,1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
0,population,1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
1,outcome,1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
0,other,1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
0,"study design",1610984,11,"Gastrointestinal side effects occurred in 10 of the 16 subjects and were severe in 5 patients."
0,background,1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
0,intervention,1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
0,population,1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
1,outcome,1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
0,other,1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
0,"study design",1610984,12,"These side effects occurred in both the olive oil and the fish oil groups."
0,background,1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
0,intervention,1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
0,population,1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
1,outcome,1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
0,other,1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
0,"study design",1610984,13,"The study had a 95% chance of detecting a clinically doubling significant increase in bleeding time, i.e., beta error less than 5%."
0,background,1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
0,intervention,1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
0,population,1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
1,outcome,1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
0,other,1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
0,"study design",1610984,14,"In conclusion, n-3 fatty acids do not introduce a clinically important risk of bleeding for patients with end-stage renal disease."
0,background,16133135,1,"RATIONALE"
0,intervention,16133135,1,"RATIONALE"
0,population,16133135,1,"RATIONALE"
0,outcome,16133135,1,"RATIONALE"
1,other,16133135,1,"RATIONALE"
0,"study design",16133135,1,"RATIONALE"
1,background,16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
0,intervention,16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
0,population,16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
0,outcome,16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
0,other,16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
0,"study design",16133135,2,"Neuropathic pain is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as allodynia and hyperalgesia and remains difficult to treat with standard analgesics."
1,background,16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,intervention,16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,population,16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,outcome,16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,other,16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,"study design",16133135,3,"However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of neuropathic pain."
0,background,16133135,4,"OBJECTIVES"
0,intervention,16133135,4,"OBJECTIVES"
0,population,16133135,4,"OBJECTIVES"
0,outcome,16133135,4,"OBJECTIVES"
1,other,16133135,4,"OBJECTIVES"
0,"study design",16133135,4,"OBJECTIVES"
0,background,16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
0,intervention,16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
0,population,16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
0,outcome,16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
1,other,16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
0,"study design",16133135,5,"To ascertain whether inhibition of serotonin (5-HT) and/or noradrenaline (NA) and/or dopamine (DA) re-uptake preferentially mediates superior anti-nociception in preclinical pain models."
0,background,16133135,6,"METHODS"
0,intervention,16133135,6,"METHODS"
0,population,16133135,6,"METHODS"
0,outcome,16133135,6,"METHODS"
1,other,16133135,6,"METHODS"
0,"study design",16133135,6,"METHODS"
0,background,16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
1,intervention,16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
1,population,16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
0,outcome,16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
0,other,16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
0,"study design",16133135,7,"The 5-HT re-uptake inhibitor fluoxetine (3-30 mg/kg), the NA re-uptake inhibitor reboxetine (3-30 mg/kg), the dual 5-HT and NA re-uptake inhibitor venlafaxine (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor bupropion (3-30 mg/kg) were tested afte"
0,background,16133135,8,"RESULTS"
0,intervention,16133135,8,"RESULTS"
0,population,16133135,8,"RESULTS"
0,outcome,16133135,8,"RESULTS"
1,other,16133135,8,"RESULTS"
0,"study design",16133135,8,"RESULTS"
0,background,16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
0,intervention,16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
0,population,16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
1,outcome,16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
0,other,16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
0,"study design",16133135,9,"Reboxetine and venlafaxine dose-dependently attenuated second-phase flinching in the formalin test; fluoxetine attenuated flinching only at the highest dose tested, whereas bupropion was ineffective."
0,background,16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
0,intervention,16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
0,population,16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
1,outcome,16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
0,other,16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
0,"study design",16133135,10,"In the chronic constriction injury (CCI) and spinal nerve ligation models of neuropathic pain, hindpaw mechanical allodynia was significantly attenuated by fluoxetine and particularly by bupropion."
0,background,16133135,11,"Reboxetine and venlafaxine were completely ineffective."
0,intervention,16133135,11,"Reboxetine and venlafaxine were completely ineffective."
0,population,16133135,11,"Reboxetine and venlafaxine were completely ineffective."
1,outcome,16133135,11,"Reboxetine and venlafaxine were completely ineffective."
0,other,16133135,11,"Reboxetine and venlafaxine were completely ineffective."
0,"study design",16133135,11,"Reboxetine and venlafaxine were completely ineffective."
0,background,16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
0,intervention,16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
0,population,16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
1,outcome,16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
0,other,16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
0,"study design",16133135,12,"In contrast, reboxetine and venlafaxine reversed thermal hyperalgesia in CCI rats, whereas bupropion and fluoxetine were either minimally effective or ineffective."
0,background,16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
0,intervention,16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
0,population,16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
1,outcome,16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
0,other,16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
0,"study design",16133135,13,"Fluoxetine, reboxetine and venlafaxine transiently increased the tail-flick latency in uninjured animals."
0,background,16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
0,intervention,16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
0,population,16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
1,outcome,16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
0,other,16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
0,"study design",16133135,14,"Anti-nociceptive doses of drugs had no effect on motor function."
0,background,16133135,15,"CONCLUSIONS"
0,intervention,16133135,15,"CONCLUSIONS"
0,population,16133135,15,"CONCLUSIONS"
0,outcome,16133135,15,"CONCLUSIONS"
1,other,16133135,15,"CONCLUSIONS"
0,"study design",16133135,15,"CONCLUSIONS"
0,background,16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
0,intervention,16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
0,population,16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
1,outcome,16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
0,other,16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
0,"study design",16133135,16,"Combined re-uptake inhibition of 5-HT and NA appears to confer a greater degree of anti-nociception in animal models of experimental pain than single mechanism of action inhibitors."
0,background,16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
0,intervention,16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
0,population,16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
1,outcome,16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
0,other,16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
0,"study design",16133135,17,"The selective attenuation of mechanical allodynia by bupropion suggests that the additional re-uptake of DA may further augment 5-HT/NA re-uptake mediated anti-nociception after nerve injury."
0,background,16227129,1,"PURPOSE"
0,intervention,16227129,1,"PURPOSE"
0,population,16227129,1,"PURPOSE"
0,outcome,16227129,1,"PURPOSE"
1,other,16227129,1,"PURPOSE"
0,"study design",16227129,1,"PURPOSE"
0,background,16227129,2,"(a)"
0,intervention,16227129,2,"(a)"
0,population,16227129,2,"(a)"
0,outcome,16227129,2,"(a)"
1,other,16227129,2,"(a)"
0,"study design",16227129,2,"(a)"
1,background,16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,intervention,16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,population,16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,outcome,16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,other,16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,"study design",16227129,3,"To examine how self-reported well-being, weight-related concerns, self-image, peer relationships and psychiatric disorders are associated with obesity at ages 11 and 15 years."
0,background,16227129,4,"(b)"
0,intervention,16227129,4,"(b)"
0,population,16227129,4,"(b)"
0,outcome,16227129,4,"(b)"
1,other,16227129,4,"(b)"
0,"study design",16227129,4,"(b)"
1,background,16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,intervention,16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,population,16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,outcome,16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,other,16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,"study design",16227129,5,"To identify and describe those who slim down (become nonobese) or become obese."
0,background,16227129,6,"METHODS"
0,intervention,16227129,6,"METHODS"
0,population,16227129,6,"METHODS"
0,outcome,16227129,6,"METHODS"
1,other,16227129,6,"METHODS"
0,"study design",16227129,6,"METHODS"
0,background,16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
0,intervention,16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
1,population,16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
0,outcome,16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
0,other,16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
0,"study design",16227129,7,"A cohort of 2127 school pupils was surveyed at ages 11 and 15 years."
0,background,16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
0,intervention,16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
0,population,16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
0,outcome,16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
1,other,16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
0,"study design",16227129,8,"At each age, those with body mass index above the 95th percentile for age and gender were categorized as obese."
0,background,16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
0,intervention,16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
0,population,16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
0,outcome,16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
1,other,16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
0,"study design",16227129,9,"Characteristics associated with obesity, slimming down and becoming obese were examined using ANOVA and chi-square procedures for univariate, and logistic regression for multivariate analyses."
0,background,16227129,10,"RESULTS"
0,intervention,16227129,10,"RESULTS"
0,population,16227129,10,"RESULTS"
0,outcome,16227129,10,"RESULTS"
1,other,16227129,10,"RESULTS"
0,"study design",16227129,10,"RESULTS"
0,background,16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
0,intervention,16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
0,population,16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
1,outcome,16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
0,other,16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
0,"study design",16227129,11,"At age 11, 9.6% (males) and 10.5% (females) were obese, compared with 10.5% (males) and 11.6% (females) at age 15."
0,background,16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
0,intervention,16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
0,population,16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
1,outcome,16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
0,other,16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
0,"study design",16227129,12,"Slimming down occurred for 3.5% of the total sample, whereas 4.5% became obese."
0,background,16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
0,intervention,16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
0,population,16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
1,outcome,16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
0,other,16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
0,"study design",16227129,13,"Obesity was associated with significant but small differences in low mood (males at 11) and self-esteem (males at 11, females at both ages), and reduced rates of behavior disorders (data on psychiatric disorders available only at age 15)."
0,background,16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
0,intervention,16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
0,population,16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
1,outcome,16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
0,other,16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
0,"study design",16227129,14,"Obesity was associated with weight-related worries, dieting, and poor self-rated appearance, but not most measures of peer relationships, except that obese 11-year-olds experienced greater victimization, partly accounting for their poorer well-being."
0,background,16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
0,intervention,16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
0,population,16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
1,outcome,16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
0,other,16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
0,"study design",16227129,15,"In comparison with the continuously nonobese, those who became obese had lower prior self-esteem and greater victimization, but improvements in well-being and relative reductions in victimization by age 15."
0,background,16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
0,intervention,16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
0,population,16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
0,outcome,16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
1,other,16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
0,"study design",16227129,16,"Slimming down was related to neither prior nor subsequent well-being in comparison with continual obesity, but was associated with better age 15 mood in comparison with continual nonobesity."
0,background,16227129,17,"CONCLUSIONS"
0,intervention,16227129,17,"CONCLUSIONS"
0,population,16227129,17,"CONCLUSIONS"
0,outcome,16227129,17,"CONCLUSIONS"
1,other,16227129,17,"CONCLUSIONS"
0,"study design",16227129,17,"CONCLUSIONS"
0,background,16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
0,intervention,16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
0,population,16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
1,outcome,16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
0,other,16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
0,"study design",16227129,18,"Although overweight was fairly stable, there were shifts in and out of the obese category during adolescence."
0,background,16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
0,intervention,16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
0,population,16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
1,outcome,16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
0,other,16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
0,"study design",16227129,19,"Obesity during this life-stage, though strongly related to worries about putting on weight and self-report dieting, was associated with only small differences in psychological well-being."
1,background,16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
0,intervention,16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
0,population,16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
0,outcome,16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
0,other,16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
0,"study design",16253898,1,"Neuroendocrine tumours of the colon and rectum are rare but distinct with regard to clinical symptoms, diagnostic and therapeutic management and prognosis compared to other neuroendocrine tumours of the gut as well as ordinary colorectal cancer."
1,background,16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
0,intervention,16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
0,population,16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
0,outcome,16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
0,other,16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
0,"study design",16253898,2,"Therapeutic algorithms are proposed depending mainly on analogous TNM categories and grading considering conventional and experimental surgical and non-surgical therapy."
1,background,16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
0,intervention,16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
0,population,16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
0,outcome,16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
0,other,16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
0,"study design",16253898,3,"Colonic neuroendocrine tumours are often misdiagnosed as undifferentiated adenocarcinoma and are therefore not properly treated with adjuvant and additive chemotherapy."
1,background,16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
0,intervention,16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
0,population,16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
0,outcome,16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
0,other,16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
0,"study design",16253898,4,"As most rectal neuroendocrine tumours are benign because of submucosal extension only, the size and infiltration depth correlates with lymph-node and distant metastases and therefore with the prognosis."
1,background,16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
0,intervention,16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
0,population,16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
0,outcome,16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
0,other,16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
0,"study design",16253898,5,"It is unknown whether endoscopic ultrasound can improve the diagnostic accuracy compared to size-related conclusions, and therefore whether it can change therapeutic strategies and improve survival by modern rectal surgery."
1,background,16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
0,intervention,16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
1,population,16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
0,outcome,16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
0,other,16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
0,"study design",16256102,1,"Injury to the spinal nerves of mice induces mechanical allodynia and thermal hyperalgesia."
0,background,16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
0,intervention,16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
0,population,16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
1,outcome,16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
0,other,16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
0,"study design",16256102,2,"In the injured spinal cord, the expression of glucocorticoid receptor mRNA was increased, whereas it was decreased in N-type Ca(2+)-channel-deficient mice, in which neuropathic pain is eliminated."
0,background,16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
1,intervention,16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
0,population,16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
1,outcome,16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
0,other,16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
0,"study design",16256102,3,"Intrathecal and intraperitoneal injection of the glucocorticoid receptor antagonist RU486 produced antinociceptive effects, whereas intracerebroventricular injection was without effect."
0,background,16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
0,intervention,16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
0,population,16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
1,outcome,16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
0,other,16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
0,"study design",16256102,4,"The more selective antagonist dexamethasone 21-mesylate suppressed both mechanical allodynia and thermal hyperalgesia."
0,background,16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
0,intervention,16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
0,population,16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
1,outcome,16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
0,other,16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
0,"study design",16256102,5,"These results suggest that spinal glucocorticoid receptors play an important role in neuropathic pain, and that controlling the activity of glucocorticoid receptors may be of great importance in the treatment of neuropathic pain."
0,background,16282004,1,"BACKGROUND"
0,intervention,16282004,1,"BACKGROUND"
0,population,16282004,1,"BACKGROUND"
0,outcome,16282004,1,"BACKGROUND"
1,other,16282004,1,"BACKGROUND"
0,"study design",16282004,1,"BACKGROUND"
1,background,16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,intervention,16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,population,16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,outcome,16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,other,16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,"study design",16282004,2,"Anxiety disorders are common in general practice and are associated with several problems regarding recognition and management."
0,background,16282004,3,"AIM"
0,intervention,16282004,3,"AIM"
0,population,16282004,3,"AIM"
0,outcome,16282004,3,"AIM"
1,other,16282004,3,"AIM"
0,"study design",16282004,3,"AIM"
0,background,16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
0,intervention,16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
1,population,16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
0,outcome,16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
0,other,16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
0,"study design",16282004,4,"To systematically evaluate the effectiveness of interventions aimed at improving recognition, diagnosis, and management of patients with anxiety disorders."
0,background,16282004,5,"DESIGN OF STUDY: Systematic review."
0,intervention,16282004,5,"DESIGN OF STUDY: Systematic review."
0,population,16282004,5,"DESIGN OF STUDY: Systematic review."
0,outcome,16282004,5,"DESIGN OF STUDY: Systematic review."
0,other,16282004,5,"DESIGN OF STUDY: Systematic review."
1,"study design",16282004,5,"DESIGN OF STUDY: Systematic review."
0,background,16282004,6,"METHOD"
0,intervention,16282004,6,"METHOD"
0,population,16282004,6,"METHOD"
0,outcome,16282004,6,"METHOD"
1,other,16282004,6,"METHOD"
0,"study design",16282004,6,"METHOD"
0,background,16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
0,intervention,16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
0,population,16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
0,outcome,16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
1,other,16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
0,"study design",16282004,7,"MEDLINE, EMBASE, PsychINFO, and the Cochrane Clinical Trials' Register were searched up until 2003."
0,background,16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
0,intervention,16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
0,population,16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
0,outcome,16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
1,other,16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
0,"study design",16282004,8,"Randomised controlled trials, controlled before/after trials, and interrupted time series for professional, organisational, financial, and regulatory interventions were eligible."
0,background,16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
0,intervention,16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
0,population,16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
0,outcome,16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
1,other,16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
0,"study design",16282004,9,"Primary effect measures consisted of anxiety outcomes, diagnosis, prescription, and referral."
0,background,16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
0,intervention,16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
0,population,16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
0,outcome,16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
1,other,16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
0,"study design",16282004,10,"Two reviewers independently made eligibility judgments eight out of 563 articles were found to be eligible."
0,background,16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
0,intervention,16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
0,population,16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
0,outcome,16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
1,other,16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
0,"study design",16282004,11,"Two reviewers participated independently in the quality assessment and data extraction process using a standardised form based on the Effective Practice and Organisation of Care checklist."
0,background,16282004,12,"Relative risks or standardised mean differences were calculated when possible."
0,intervention,16282004,12,"Relative risks or standardised mean differences were calculated when possible."
0,population,16282004,12,"Relative risks or standardised mean differences were calculated when possible."
0,outcome,16282004,12,"Relative risks or standardised mean differences were calculated when possible."
1,other,16282004,12,"Relative risks or standardised mean differences were calculated when possible."
0,"study design",16282004,12,"Relative risks or standardised mean differences were calculated when possible."
0,background,16282004,13,"RESULTS"
0,intervention,16282004,13,"RESULTS"
0,population,16282004,13,"RESULTS"
0,outcome,16282004,13,"RESULTS"
1,other,16282004,13,"RESULTS"
0,"study design",16282004,13,"RESULTS"
0,background,16282004,14,"Four professional interventions and three organisational interventions were examined."
1,intervention,16282004,14,"Four professional interventions and three organisational interventions were examined."
0,population,16282004,14,"Four professional interventions and three organisational interventions were examined."
0,outcome,16282004,14,"Four professional interventions and three organisational interventions were examined."
0,other,16282004,14,"Four professional interventions and three organisational interventions were examined."
0,"study design",16282004,14,"Four professional interventions and three organisational interventions were examined."
0,background,16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
0,intervention,16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
0,population,16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
1,outcome,16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
0,other,16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
0,"study design",16282004,15,"In general, the professional interventions seemed to increase recognition, referral, and prescription as well as improving anxiety outcomes."
0,background,16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
0,intervention,16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
0,population,16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
1,outcome,16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
0,other,16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
0,"study design",16282004,16,"Two out of three organisational interventions showed a positive effect on anxiety outcomes."
0,background,16282004,17,"The one study that took prescription into account showed no effect."
0,intervention,16282004,17,"The one study that took prescription into account showed no effect."
0,population,16282004,17,"The one study that took prescription into account showed no effect."
1,outcome,16282004,17,"The one study that took prescription into account showed no effect."
0,other,16282004,17,"The one study that took prescription into account showed no effect."
0,"study design",16282004,17,"The one study that took prescription into account showed no effect."
0,background,16282004,18,"CONCLUSIONS"
0,intervention,16282004,18,"CONCLUSIONS"
0,population,16282004,18,"CONCLUSIONS"
0,outcome,16282004,18,"CONCLUSIONS"
1,other,16282004,18,"CONCLUSIONS"
0,"study design",16282004,18,"CONCLUSIONS"
0,background,16282004,19,"The quality of care for patients with anxiety can be improved."
0,intervention,16282004,19,"The quality of care for patients with anxiety can be improved."
0,population,16282004,19,"The quality of care for patients with anxiety can be improved."
1,outcome,16282004,19,"The quality of care for patients with anxiety can be improved."
0,other,16282004,19,"The quality of care for patients with anxiety can be improved."
0,"study design",16282004,19,"The quality of care for patients with anxiety can be improved."
0,background,16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
0,intervention,16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
0,population,16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
1,outcome,16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
0,other,16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
0,"study design",16282004,20,"A combination of professional and organisational interventions in which an external expert is introduced seems to be most promising."
0,background,16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
0,intervention,16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
0,population,16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
1,outcome,16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
0,other,16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
0,"study design",16282004,21,"Additional research is nevertheless necessary to determine the exact effects of such interventions using patient effect measures, economic evaluations, and feasibility studies."
1,background,16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,intervention,16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,population,16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,outcome,16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,other,16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,"study design",16300868,1,"Studies assessing the clinical and economic benefits of vaccination in the elderly have used different clinical outcomes (e.g. hospitalizations for pneumonia or influenza versus hospitalizations for respiratory and cardiovascular causes) and different out"
0,background,16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
1,intervention,16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
1,population,16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
0,outcome,16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
0,other,16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
0,"study design",16300868,2,"We explored the implications of these varying approaches by comparing two health economic analysis models of influenza vaccination of community-dwelling elderly persons."
0,background,16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
0,intervention,16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
0,population,16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
0,outcome,16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
1,other,16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
0,"study design",16300868,3,"We developed computerized models using clinical data from 3 large US HMOs for the 1998-1999 and 1999-2000 influenza seasons."
0,background,16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
0,intervention,16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
0,population,16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
1,outcome,16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
0,other,16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
0,"study design",16300868,4,"The primary health economic model used a broad definition of clinical events and outcome period and included hospitalizations for all respiratory and cardiovascular events that occurred during the entire influenza season."
0,background,16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
0,intervention,16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
0,population,16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
1,outcome,16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
0,other,16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
0,"study design",16300868,5,"The alternative model used more restrictive definitions and included pneumonia or influenza hospitalizations occurring during the peak influenza season."
0,background,16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
0,intervention,16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
0,population,16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
1,outcome,16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
0,other,16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
0,"study design",16300868,6,"The results of Monte Carlo simulation showed that, with the more inclusive primary model, influenza vaccination resulted in net medical care cost savings due to fewer respiratory or cardiovascular hospitalizations of Dollars 71/person vaccinated (5th-95th"
0,background,16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
0,intervention,16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
0,population,16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
1,outcome,16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
0,other,16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
0,"study design",16300868,7,"In contrast, the alternate model found costs of Dollars 3.50/person vaccinated (5th-95th percentile Dollars -11 to 5) and net costs of Dollars 91/year of life saved (5th-95th percentile Dollars -309 to 126)."
0,background,16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
0,intervention,16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
0,population,16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
1,outcome,16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
0,other,16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
0,"study design",16300868,8,"Our findings confirm that influenza vaccination of the elderly is most likely cost saving and supports policies and programs that advocate routine immunization of all persons 65 and older."
0,background,16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
0,intervention,16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
0,population,16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
1,outcome,16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
0,other,16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
0,"study design",16300868,9,"They also highlight how different outcome definitions can influence the results of health economic analyses."
1,background,16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,intervention,16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,population,16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,outcome,16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,other,16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,"study design",16341623,1,"Health-related quality of life (HRQL) is an important consideration in the management of patients with vertebral fractures."
0,background,16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
0,intervention,16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
0,population,16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
0,outcome,16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
1,other,16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
0,"study design",16341623,2,"The purpose of this study was to examine patient-related factors that contribute to HRQL after vertebral fractures, including co-morbidities, medications, fracture history, family disease history, demographics, exercise, education and living environment."
0,background,16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
0,intervention,16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
1,population,16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
0,outcome,16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
0,other,16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
0,"study design",16341623,3,"A total of 1,129 post-menopausal women (mean age 67.2, SD 11.9 years) was studied from the Canadian Database of Osteoporosis and Osteopenia (CANDOO)."
0,background,16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
0,intervention,16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
0,population,16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
0,outcome,16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
1,other,16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
0,"study design",16341623,4,"HRQL was measured using the mini-osteoporosis quality of life questionnaire (mini-OQLQ)."
0,background,16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
0,intervention,16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
0,population,16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
0,outcome,16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
1,other,16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
0,"study design",16341623,5,"Separate multivariable linear regression analyses [parameter estimates and corresponding 95% confidence intervals (CI)] were performed for each of the five mini-OQLQ domains symptoms, physical functioning, emotional functioning, activities of daily living and leisure domains."
0,background,16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
0,intervention,16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
0,population,16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
1,outcome,16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
0,other,16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
0,"study design",16341623,6,"A strong positive association was found between HRQL and post-secondary education, a family history of osteoporosis, working and thiazide therapy."
0,background,16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
0,intervention,16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
0,population,16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
1,outcome,16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
0,other,16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
0,"study design",16341623,7,"Exercise improved HRQL; however, several hours a week were required to be meaningful."
0,background,16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
0,intervention,16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
0,population,16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
1,outcome,16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
0,other,16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
0,"study design",16341623,8,"Living in long-term care had the most marked negative effect on HRQL."
0,background,16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
0,intervention,16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
0,population,16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
1,outcome,16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
0,other,16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
0,"study design",16341623,9,"Smoking, past surgery of the hip or spine, sedatives, anticonvulsants, atherosclerotic disease and hypertension were also associated with a substantially decreased HRQL across several domains."
0,background,16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
0,intervention,16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
0,population,16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
1,outcome,16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
0,other,16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
0,"study design",16341623,10,"Calcium channel-blockers, chemotherapy, corticosteroids, diabetes, migraines, the number of non-vertebral fractures and falls had a negative impact on selected domains."
0,background,16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
0,intervention,16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
0,population,16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
1,outcome,16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
0,other,16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
0,"study design",16341623,11,"We demonstrated that several modifiable factors influence HRQL in patients with vertebral fractures, and physicians should be aware of these and other markers of reduced HRQL to enhance patient care."
0,background,16389204,1,"CONTEXT"
0,intervention,16389204,1,"CONTEXT"
0,population,16389204,1,"CONTEXT"
0,outcome,16389204,1,"CONTEXT"
1,other,16389204,1,"CONTEXT"
0,"study design",16389204,1,"CONTEXT"
1,background,16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,intervention,16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,population,16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,outcome,16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,other,16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,"study design",16389204,2,"Effective alternatives to long waiting lists for entry into methadone hydrochloride maintenance treatment are needed to reduce the complications of continuing heroin dependence and to increase methadone treatment entry."
0,background,16389204,3,"OBJECTIVE"
0,intervention,16389204,3,"OBJECTIVE"
0,population,16389204,3,"OBJECTIVE"
0,outcome,16389204,3,"OBJECTIVE"
1,other,16389204,3,"OBJECTIVE"
0,"study design",16389204,3,"OBJECTIVE"
0,background,16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
0,intervention,16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
0,population,16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
0,outcome,16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
1,other,16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
0,"study design",16389204,4,"To compare the effectiveness of interim methadone maintenance with that of the usual waiting list condition in facilitating methadone treatment entry and reducing heroin and cocaine use and criminal behavior."
0,background,16389204,5,"DESIGN"
0,intervention,16389204,5,"DESIGN"
0,population,16389204,5,"DESIGN"
0,outcome,16389204,5,"DESIGN"
1,other,16389204,5,"DESIGN"
0,"study design",16389204,5,"DESIGN"
0,background,16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
0,intervention,16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
0,population,16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
0,outcome,16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
0,other,16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
1,"study design",16389204,6,"Randomized, controlled, clinical trial using 2 conditions, with treatment assignment on a 3:2 basis to interim maintenance-waiting list control."
0,background,16389204,7,"SETTING"
0,intervention,16389204,7,"SETTING"
0,population,16389204,7,"SETTING"
0,outcome,16389204,7,"SETTING"
1,other,16389204,7,"SETTING"
0,"study design",16389204,7,"SETTING"
0,background,16389204,8,"A methadone treatment program in Baltimore."
0,intervention,16389204,8,"A methadone treatment program in Baltimore."
0,population,16389204,8,"A methadone treatment program in Baltimore."
0,outcome,16389204,8,"A methadone treatment program in Baltimore."
1,other,16389204,8,"A methadone treatment program in Baltimore."
0,"study design",16389204,8,"A methadone treatment program in Baltimore."
0,background,16389204,9,"PARTICIPANTS"
0,intervention,16389204,9,"PARTICIPANTS"
0,population,16389204,9,"PARTICIPANTS"
0,outcome,16389204,9,"PARTICIPANTS"
1,other,16389204,9,"PARTICIPANTS"
0,"study design",16389204,9,"PARTICIPANTS"
0,background,16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
0,intervention,16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
1,population,16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
0,outcome,16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
0,other,16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
0,"study design",16389204,10,"A total of 319 individuals meeting the criteria for current heroin dependence and methadone maintenance treatment."
0,background,16389204,11,"INTERVENTIONS"
0,intervention,16389204,11,"INTERVENTIONS"
0,population,16389204,11,"INTERVENTIONS"
0,outcome,16389204,11,"INTERVENTIONS"
1,other,16389204,11,"INTERVENTIONS"
0,"study design",16389204,11,"INTERVENTIONS"
0,background,16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
1,intervention,16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
0,population,16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
0,outcome,16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
0,other,16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
0,"study design",16389204,12,"Participants were randomly assigned to either interim methadone maintenance, consisting of an individually determined methadone dose and emergency counseling only for up to 120 days, or referral to community-based methadone treatment programs."
0,background,16389204,13,"MAIN OUTCOME MEASURES"
0,intervention,16389204,13,"MAIN OUTCOME MEASURES"
0,population,16389204,13,"MAIN OUTCOME MEASURES"
0,outcome,16389204,13,"MAIN OUTCOME MEASURES"
1,other,16389204,13,"MAIN OUTCOME MEASURES"
0,"study design",16389204,13,"MAIN OUTCOME MEASURES"
0,background,16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
0,intervention,16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
0,population,16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
0,outcome,16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
1,other,16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
0,"study design",16389204,14,"Entry into comprehensive methadone maintenance therapy at 4 months from baseline; self-reported days of heroin use, cocaine use, and criminal behavior; and number of urine drug test results positive for heroin and cocaine at the follow-up interview conducted at time of entry into comprehensive methadone treatment (or at 4 months from baseline for participants who did not enter regular treatment)."
0,background,16389204,15,"RESULTS"
0,intervention,16389204,15,"RESULTS"
0,population,16389204,15,"RESULTS"
0,outcome,16389204,15,"RESULTS"
1,other,16389204,15,"RESULTS"
0,"study design",16389204,15,"RESULTS"
0,background,16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
0,intervention,16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
0,population,16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
1,outcome,16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
0,other,16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
0,"study design",16389204,16,"Significantly more participants assigned to the interim methadone maintenance condition entered comprehensive methadone maintenance treatment by the 120th day from baseline (75.9%) than those assigned to the waiting list control condition (20.8%) (P&lt;.0"
0,background,16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
0,intervention,16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
0,population,16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
1,outcome,16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
0,other,16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
0,"study design",16389204,17,"Overall, in the past 30 days at follow-up, interim participants reported significantly fewer days of heroin use (P&lt;.001), had a significant reduction in heroin-positive drug test results (P&lt;.001), reported spending less money on drugs (P&lt;.001), a"
0,background,16389204,18,"CONCLUSION"
0,intervention,16389204,18,"CONCLUSION"
0,population,16389204,18,"CONCLUSION"
0,outcome,16389204,18,"CONCLUSION"
1,other,16389204,18,"CONCLUSION"
0,"study design",16389204,18,"CONCLUSION"
0,background,16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
0,intervention,16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
0,population,16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
1,outcome,16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
0,other,16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
0,"study design",16389204,19,"Interim methadone maintenance results in a substantial increase in the likelihood of entry into comprehensive treatment, and is an effective means of reducing heroin use and criminal behavior among opioid-dependent individuals awaiting entry into a compre"
0,background,16390771,1,"OBJECTIVE"
0,intervention,16390771,1,"OBJECTIVE"
0,population,16390771,1,"OBJECTIVE"
0,outcome,16390771,1,"OBJECTIVE"
1,other,16390771,1,"OBJECTIVE"
0,"study design",16390771,1,"OBJECTIVE"
1,background,16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,intervention,16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,population,16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,outcome,16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,other,16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,"study design",16390771,2,"To evaluate the association between physical activity and the morphological, functional and physiological components of physical fitness in postmenopausal women."
0,background,16390771,3,"METHODS"
0,intervention,16390771,3,"METHODS"
0,population,16390771,3,"METHODS"
0,outcome,16390771,3,"METHODS"
1,other,16390771,3,"METHODS"
0,"study design",16390771,3,"METHODS"
0,background,16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
0,intervention,16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
1,population,16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
0,outcome,16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
0,other,16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
1,"study design",16390771,4,"A cross-sectional study of 162 postmenopausal women, 40-65 years of age, who verbally responded to the International Physical Activity Questionnaire applied to evaluate their level of physical activity."
0,background,16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
0,intervention,16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
0,population,16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
0,outcome,16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
1,other,16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
0,"study design",16390771,5,"Physical fitness was evaluated by measuring body mass index, waist circumference, body fat percentage, maximum oxygen consumption, plasma levels of total and fractional cholesterol, triglycerides and fasting glucose, as well as blood pressure."
0,background,16390771,6,"RESULTS"
0,intervention,16390771,6,"RESULTS"
0,population,16390771,6,"RESULTS"
0,outcome,16390771,6,"RESULTS"
1,other,16390771,6,"RESULTS"
0,"study design",16390771,6,"RESULTS"
0,background,16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
0,intervention,16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
0,population,16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
1,outcome,16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
0,other,16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
0,"study design",16390771,7,"Approximately 83.5% of the women were active, principal physical activities being household chores and transportation walking."
0,background,16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
0,intervention,16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
0,population,16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
1,outcome,16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
0,other,16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
0,"study design",16390771,8,"Approximately 80% of the women were overweight or obese and presented a waist circumference indicative of high or very high risk for cardiovascular disease, and fat percentage above 33%."
0,background,16390771,9,"Over 50% were found to have low oxygen consumption."
0,intervention,16390771,9,"Over 50% were found to have low oxygen consumption."
0,population,16390771,9,"Over 50% were found to have low oxygen consumption."
1,outcome,16390771,9,"Over 50% were found to have low oxygen consumption."
0,other,16390771,9,"Over 50% were found to have low oxygen consumption."
0,"study design",16390771,9,"Over 50% were found to have low oxygen consumption."
0,background,16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
0,intervention,16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
0,population,16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
1,outcome,16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
0,other,16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
0,"study design",16390771,10,"There were no significant differences between the groups of active and inactive women with respect to mean body mass index (p = 0.43), percentage of body fat (p = 0.60), hip-to-waist ratio (p = 0.93), waist circumference (p = 0.44), maximum VO2 (p = 0.32)"
0,background,16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
0,intervention,16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
0,population,16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
1,outcome,16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
0,other,16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
0,"study design",16390771,11,"Adjusted prevalence ratios also showed no significant differences between the groups."
0,background,16390771,12,"CONCLUSIONS"
0,intervention,16390771,12,"CONCLUSIONS"
0,population,16390771,12,"CONCLUSIONS"
0,outcome,16390771,12,"CONCLUSIONS"
1,other,16390771,12,"CONCLUSIONS"
0,"study design",16390771,12,"CONCLUSIONS"
0,background,16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
0,intervention,16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
0,population,16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
1,outcome,16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
0,other,16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
0,"study design",16390771,13,"Habitual physical activity is not associated with variations in the components that are used to describe physical fitness."
0,background,16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
0,intervention,16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
0,population,16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
1,outcome,16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
0,other,16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
0,"study design",16390771,14,"It is important to encourage physical activity and provide guidelines to ensure that it is carried out in the quantity, duration and intensity required for improving physical fitness level and obtaining health benefits."
0,background,16393297,1,"AIM"
0,intervention,16393297,1,"AIM"
0,population,16393297,1,"AIM"
0,outcome,16393297,1,"AIM"
1,other,16393297,1,"AIM"
0,"study design",16393297,1,"AIM"
1,background,16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,intervention,16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,population,16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,outcome,16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,other,16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,"study design",16393297,2,"To determine the effect of a laxative alone and in combination with tegaserod in alleviating pain and improving stool frequency in adolescents with constipation predominant irritable bowel syndrome."
0,background,16393297,3,"PATIENTS"
0,intervention,16393297,3,"PATIENTS"
0,population,16393297,3,"PATIENTS"
0,outcome,16393297,3,"PATIENTS"
1,other,16393297,3,"PATIENTS"
0,"study design",16393297,3,"PATIENTS"
0,background,16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
1,intervention,16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
1,population,16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
0,outcome,16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
0,other,16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
0,"study design",16393297,4,"Forty-eight postpubertal adolescents of both sexes with constipation predominant irritable bowel syndrome, as defined by Rome II criteria, were randomly allocated to Group A (n = 27) for treatment with a laxative (polyethylene glycol 3350 oral solution) o"
0,background,16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
0,intervention,16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
0,population,16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
0,outcome,16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
1,other,16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
0,"study design",16393297,5,"Symptoms of abdominal pain (scale 0-10) and frequency of bowel movements were recorded daily in the pre-treatment phase and the post-treatment phase after a 7-day 'washout' period."
0,background,16393297,6,"Patients served as their own controls."
0,intervention,16393297,6,"Patients served as their own controls."
0,population,16393297,6,"Patients served as their own controls."
0,outcome,16393297,6,"Patients served as their own controls."
1,other,16393297,6,"Patients served as their own controls."
0,"study design",16393297,6,"Patients served as their own controls."
0,background,16393297,7,"RESULTS"
0,intervention,16393297,7,"RESULTS"
0,population,16393297,7,"RESULTS"
0,outcome,16393297,7,"RESULTS"
1,other,16393297,7,"RESULTS"
0,"study design",16393297,7,"RESULTS"
0,background,16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
0,intervention,16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
0,population,16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
1,outcome,16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
0,other,16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
0,"study design",16393297,8,"Treatment with the laxative alone (Group A) resulted in significant increase in frequency of bowel movements (P &lt; 0.05), but not significant improvement in pain (P > 0.05)."
0,background,16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
0,intervention,16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
0,population,16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
1,outcome,16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
0,other,16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
0,"study design",16393297,9,"Treatment with the combination of the laxative and tegaserod (Group B) led to significant increase in the frequency of bowel movements and also significant reduction in pain (P &lt; 0.05)."
0,background,16393297,10,"CONCLUSIONS"
0,intervention,16393297,10,"CONCLUSIONS"
0,population,16393297,10,"CONCLUSIONS"
0,outcome,16393297,10,"CONCLUSIONS"
1,other,16393297,10,"CONCLUSIONS"
0,"study design",16393297,10,"CONCLUSIONS"
0,background,16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
0,intervention,16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
0,population,16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
1,outcome,16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
0,other,16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
0,"study design",16393297,11,"The laxative alone improved stooling but not pain in adolescents with constipation predominant irritable bowel syndrome."
0,background,16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
0,intervention,16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
0,population,16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
1,outcome,16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
0,other,16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
0,"study design",16393297,12,"Addition of tegaserod resulted in alleviation of pain as well."
0,background,1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
0,intervention,1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
1,population,1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
0,outcome,1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
0,other,1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
0,"study design",1642528,1,"Three hundred and twenty-six persons with light, moderate, or severe diffuse traumatic brain injury (TBI) were assessed during initial hospitalization in Johannesburg."
0,background,1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
0,intervention,1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
0,population,1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
0,outcome,1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
1,other,1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
0,"study design",1642528,2,"One hundred and forty-four were followed up at approximately six months, 83 at 12 months, and 71 at 24 months posttrauma."
0,background,1642528,3,"The sample attrition rate was high."
0,intervention,1642528,3,"The sample attrition rate was high."
0,population,1642528,3,"The sample attrition rate was high."
0,outcome,1642528,3,"The sample attrition rate was high."
1,other,1642528,3,"The sample attrition rate was high."
0,"study design",1642528,3,"The sample attrition rate was high."
0,background,1642528,4,"When patients could not be found, data were obtained from their caregivers."
0,intervention,1642528,4,"When patients could not be found, data were obtained from their caregivers."
0,population,1642528,4,"When patients could not be found, data were obtained from their caregivers."
0,outcome,1642528,4,"When patients could not be found, data were obtained from their caregivers."
1,other,1642528,4,"When patients could not be found, data were obtained from their caregivers."
0,"study design",1642528,4,"When patients could not be found, data were obtained from their caregivers."
0,background,1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
0,intervention,1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
0,population,1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
0,outcome,1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
1,other,1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
0,"study design",1642528,5,"Recovery was measured in five different areas of functioning family relationships, psychologic problems, activities of daily living (ADL), employment status, and physical status."
0,background,1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
0,intervention,1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
0,population,1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
1,outcome,1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
0,other,1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
0,"study design",1642528,6,"Psychologic problems and family relationships worsened with time, but proficiency in ADL improved; physical and employment status remained relatively stable during the survey period."
0,background,1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
0,intervention,1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
0,population,1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
1,outcome,1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
0,other,1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
0,"study design",1642528,7,"Severity of injury was significantly correlated with outcome in each functional area at some point in the follow-up period."
0,background,1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
0,intervention,1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
0,population,1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
1,outcome,1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
0,other,1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
0,"study design",1642528,8,"Discrepancies between patients' and caregivers' perceptions of outcome were noted, particularly in the area of psychologic functioning."
0,background,1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
0,intervention,1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
0,population,1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
1,outcome,1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
0,other,1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
0,"study design",1642528,9,"Caregivers tended to rate the recovery made by the patient as better than the outcome patients perceived themselves to have made."
0,background,1642528,10,"These differences in perception diminished with time."
0,intervention,1642528,10,"These differences in perception diminished with time."
0,population,1642528,10,"These differences in perception diminished with time."
1,outcome,1642528,10,"These differences in perception diminished with time."
0,other,1642528,10,"These differences in perception diminished with time."
0,"study design",1642528,10,"These differences in perception diminished with time."
0,background,1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
0,intervention,1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
0,population,1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
1,outcome,1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
0,other,1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
0,"study design",1642528,11,"The multifactorial nature of recovery after TBI is indicated by the improvements seen in some functional areas and the worsening of outcome in other areas."
0,background,1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
0,intervention,1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
0,population,1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
1,outcome,1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
0,other,1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
0,"study design",1642528,12,"These findings suggest that rehabilitation programs for persons with TBI should (1) include caregivers, (2) focus on the adjustment of both parties to their new circumstances, and (3) facilitate a convergence in their perceptions."
0,background,1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
0,intervention,1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
0,population,1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
1,outcome,1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
0,other,1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
0,"study design",1642528,13,"Adequately defining recovery is a first step to estimating the prevalence of TBI, but necessitates further work."
0,background,1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
0,intervention,1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
0,population,1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
1,outcome,1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
0,other,1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
0,"study design",1642528,14,"Epidemiology awaits a better understanding of the recovery process after TBI."
1,background,16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
0,intervention,16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
0,population,16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
0,outcome,16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
0,other,16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
0,"study design",16492098,1,"One of the core propositions in most clinical and descriptive models of personality disorders (PDs) is that these conditions are stable over time."
1,background,16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,intervention,16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,population,16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,outcome,16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,other,16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,"study design",16492098,2,"However, the available empirical literature suggests that PDs are far less stable than these models imply."
0,background,16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
0,intervention,16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
1,population,16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
0,outcome,16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
0,other,16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
0,"study design",16492098,3,"The present study examines the 10-year stability of PDs in a sample of depressed outpatients who were assessed for the full range of Axis II conditions across 5 assessments."
0,background,16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
0,intervention,16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
0,population,16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
0,outcome,16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
1,other,16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
0,"study design",16492098,4,"Three primary issues are addressed (a) the stability of categorical PD diagnoses, (b) the relative stability of dimensional PD traits, and (c) the absolute stability of PD traits."
0,background,16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
0,intervention,16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
0,population,16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
1,outcome,16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
0,other,16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
0,"study design",16492098,5,"The stability of PD diagnoses was poor to fair, and the stability of dimensional PD traits was fair to moderate."
0,background,16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
0,intervention,16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
0,population,16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
1,outcome,16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
0,other,16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
0,"study design",16492098,6,"Growth curve analyses revealed complex patterns of change in absolute scores for PD traits across the 10-year interval."
0,background,16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
0,intervention,16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
0,population,16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
1,outcome,16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
0,other,16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
0,"study design",16492098,7,"Stability of PDs was generally comparable to that of anxiety disorder diagnoses and normal personality traits."
1,background,16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,intervention,16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,population,16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,outcome,16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,other,16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,"study design",16547708,1,"The aim was to compare the accuracy of magnetic resonance imaging (MRI) and intraoperative consultation (IC) for the diagnosis of adnexal masses, with reference to final histology."
0,background,16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
1,intervention,16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
1,population,16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
0,outcome,16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
0,other,16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
0,"study design",16547708,2,"MRI was performed in 136 women with sonographically indeterminate adnexal masses."
0,background,16547708,3,"IC included macroscopic and frozen-section examination."
0,intervention,16547708,3,"IC included macroscopic and frozen-section examination."
0,population,16547708,3,"IC included macroscopic and frozen-section examination."
0,outcome,16547708,3,"IC included macroscopic and frozen-section examination."
1,other,16547708,3,"IC included macroscopic and frozen-section examination."
0,"study design",16547708,3,"IC included macroscopic and frozen-section examination."
0,background,16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
0,intervention,16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
0,population,16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
1,outcome,16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
0,other,16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
0,"study design",16547708,4,"Macroscopic examination and MRI determined size, nature, and presence of vegetations or solid portions within masses."
0,background,16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
0,intervention,16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
0,population,16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
1,outcome,16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
0,other,16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
0,"study design",16547708,5,"All masses were characterized as benign or malignant according to previously published MR imaging and histopathologic criteria."
0,background,16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
0,intervention,16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
0,population,16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
1,outcome,16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
0,other,16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
0,"study design",16547708,6,"Sensitivities, specificities, and predictive values for the diagnosis of malignancy of MRI and IC were assessed."
0,background,16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
0,intervention,16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
0,population,16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
1,outcome,16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
0,other,16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
0,"study design",16547708,7,"Histology revealed 168 adnexal masses (99 benign, 23 borderline and 46 invasive)."
0,background,16547708,8,"Frozen sections were examined in 151 cases."
0,intervention,16547708,8,"Frozen sections were examined in 151 cases."
0,population,16547708,8,"Frozen sections were examined in 151 cases."
1,outcome,16547708,8,"Frozen sections were examined in 151 cases."
0,other,16547708,8,"Frozen sections were examined in 151 cases."
0,"study design",16547708,8,"Frozen sections were examined in 151 cases."
0,background,16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
0,intervention,16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
0,population,16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
1,outcome,16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
0,other,16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
0,"study design",16547708,9,"Among the 151 adnexal masses studied by both MRI and IC, respective sensitivities, specificities, positive and predictive values of both methods for the diagnosis of malignancy were 89.7% and 84.5%, 91.4% and 100%, 86.7% and 100%, and 93.4% and 91.3%."
0,background,16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
0,intervention,16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
0,population,16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
0,outcome,16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
1,other,16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
0,"study design",16547708,10,"Sensitivities of MR imaging and frozen section for the diagnosis of serous versus mucinous borderline tumors were 33.3% and 93.3%, and 62.5% and 12.5%, respectively."
0,background,16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
0,intervention,16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
0,population,16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
1,outcome,16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
0,other,16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
0,"study design",16547708,11,"MRI is less accurate than IC for characterizing adnexal masses."
0,background,16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
0,intervention,16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
0,population,16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
1,outcome,16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
0,other,16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
0,"study design",16547708,12,"However, MRI may increase the relevance of IC for borderline mucinous tumors."
0,background,16608618,1,"BACKGROUND"
0,intervention,16608618,1,"BACKGROUND"
0,population,16608618,1,"BACKGROUND"
0,outcome,16608618,1,"BACKGROUND"
1,other,16608618,1,"BACKGROUND"
0,"study design",16608618,1,"BACKGROUND"
1,background,16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
0,intervention,16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
0,population,16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
0,outcome,16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
0,other,16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
0,"study design",16608618,2,"Obesity is well known to be associated with an increased prevalence of metabolic complications."
1,background,16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,intervention,16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,population,16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,outcome,16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,other,16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,"study design",16608618,3,"Severe obesity is thus expected to have more important alterations of the metabolic profile than moderate obesity."
0,background,16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
0,intervention,16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
0,population,16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
0,outcome,16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
1,other,16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
0,"study design",16608618,4,"This study aimed to compare the metabolic profile of pre- and postmenopausal severely obese women with moderately obese women."
0,background,16608618,5,"METHODS"
0,intervention,16608618,5,"METHODS"
0,population,16608618,5,"METHODS"
0,outcome,16608618,5,"METHODS"
1,other,16608618,5,"METHODS"
0,"study design",16608618,5,"METHODS"
0,background,16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
0,intervention,16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
1,population,16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
0,outcome,16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
0,other,16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
0,"study design",16608618,6,"First, the metabolic profile of pre- (n=165) and postmenopausal (n=43) severely obese women (body mass index (BMI) > or =40 kg/m(2)) was compared to that of pre- (n=52) and postmenopausal (n=35) moderately obese women (BMI of 30-40 kg/m(2))."
0,background,16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
0,intervention,16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
0,population,16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
0,outcome,16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
1,other,16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
0,"study design",16608618,7,"Thereafter, pre- and postmenopausal severely obese women were divided into two subgroups according to the presence/absence of a dysmetabolic profile."
0,background,16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
0,intervention,16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
0,population,16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
0,outcome,16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
1,other,16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
0,"study design",16608618,8,"We used for comparison, a group of pre- and postmenopausal moderately obese women without a dysmetabolic profile."
0,background,16608618,9,"RESULTS"
0,intervention,16608618,9,"RESULTS"
0,population,16608618,9,"RESULTS"
0,outcome,16608618,9,"RESULTS"
1,other,16608618,9,"RESULTS"
0,"study design",16608618,9,"RESULTS"
0,background,16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
0,intervention,16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
0,population,16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
1,outcome,16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
0,other,16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
0,"study design",16608618,10,"The metabolic profile of pre- and postmenopausal severely obese women was less deteriorated than expected when compared to moderately obese women."
0,background,16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
0,intervention,16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
0,population,16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
1,outcome,16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
0,other,16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
0,"study design",16608618,11,"Moreover, severely obese women with or without a dysmetabolic profile displayed comparable or even lower plasma levels of cholesterol, HDL and LDL-cholesterol, and a lower cholesterol/HDL-cholesterol ratio than moderately obese women (P&lt; or =0.05)."
0,background,16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
0,intervention,16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
0,population,16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
1,outcome,16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
0,other,16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
0,"study design",16608618,12,"After menopause, the metabolic profile of severely obese women, dysmetabolic or not, was similar to that of moderately obese women."
0,background,16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
0,intervention,16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
0,population,16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
1,outcome,16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
0,other,16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
0,"study design",16608618,13,"Blood pressure was, however, higher in severely obese women compared to moderately obese women, only before menopause (P&lt; or =0.0001)."
0,background,16608618,14,"CONCLUSION"
0,intervention,16608618,14,"CONCLUSION"
0,population,16608618,14,"CONCLUSION"
0,outcome,16608618,14,"CONCLUSION"
1,other,16608618,14,"CONCLUSION"
0,"study design",16608618,14,"CONCLUSION"
0,background,16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
0,intervention,16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
0,population,16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
1,outcome,16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
0,other,16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
0,"study design",16608618,15,"These results indicate that despite their large accumulation of adipose tissue, most of the severely obese women had a metabolic profile less deteriorated than expected, when compared to moderately obese women."
0,background,16625603,1,"BACKGROUND"
0,intervention,16625603,1,"BACKGROUND"
0,population,16625603,1,"BACKGROUND"
0,outcome,16625603,1,"BACKGROUND"
1,other,16625603,1,"BACKGROUND"
0,"study design",16625603,1,"BACKGROUND"
1,background,16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
0,intervention,16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
0,population,16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
0,outcome,16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
0,other,16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
0,"study design",16625603,2,"Thrombolytic therapy is usually reserved for patients with clinically serious or massive pulmonary embolism (PE)."
1,background,16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
0,intervention,16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
0,population,16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
0,outcome,16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
0,other,16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
0,"study design",16625603,3,"Evidence suggests that thrombolytic agents may dissolve blood clot more rapidly than heparin and might reduce the death rate associated with PE."
1,background,16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,intervention,16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,population,16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,outcome,16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,other,16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,"study design",16625603,4,"However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages."
0,background,16625603,5,"OBJECTIVES"
0,intervention,16625603,5,"OBJECTIVES"
0,population,16625603,5,"OBJECTIVES"
0,outcome,16625603,5,"OBJECTIVES"
1,other,16625603,5,"OBJECTIVES"
0,"study design",16625603,5,"OBJECTIVES"
0,background,16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
0,intervention,16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
0,population,16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
0,outcome,16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
1,other,16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
0,"study design",16625603,6,"To assess the effectiveness and safety of thrombolytic therapy in patients with acute PE."
0,background,16625603,7,"SEARCH STRATEGY"
0,intervention,16625603,7,"SEARCH STRATEGY"
0,population,16625603,7,"SEARCH STRATEGY"
0,outcome,16625603,7,"SEARCH STRATEGY"
1,other,16625603,7,"SEARCH STRATEGY"
0,"study design",16625603,7,"SEARCH STRATEGY"
0,background,16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
0,intervention,16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
0,population,16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
0,outcome,16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
1,other,16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
0,"study design",16625603,8,"We sought trials through the Cochrane Peripheral Vascular Diseases Group's Specialised Register (January 18, 2006), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 1, 2006), MEDLINE (January 1966 to December 2004), EMBASE, CINAHL, LILACS and SCISEARCH (all November 2004)."
0,background,16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
0,intervention,16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
0,population,16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
0,outcome,16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
1,other,16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
0,"study design",16625603,9,"We also searched individual trial collections and private databases, along with bibliographies of relevant articles."
0,background,16625603,10,"Relevant medical journals were handsearched."
0,intervention,16625603,10,"Relevant medical journals were handsearched."
0,population,16625603,10,"Relevant medical journals were handsearched."
0,outcome,16625603,10,"Relevant medical journals were handsearched."
1,other,16625603,10,"Relevant medical journals were handsearched."
0,"study design",16625603,10,"Relevant medical journals were handsearched."
0,background,16625603,11,"The most recent search was on February 6, 2006."
0,intervention,16625603,11,"The most recent search was on February 6, 2006."
0,population,16625603,11,"The most recent search was on February 6, 2006."
0,outcome,16625603,11,"The most recent search was on February 6, 2006."
1,other,16625603,11,"The most recent search was on February 6, 2006."
0,"study design",16625603,11,"The most recent search was on February 6, 2006."
0,background,16625603,12,"SELECTION CRITERIA"
0,intervention,16625603,12,"SELECTION CRITERIA"
0,population,16625603,12,"SELECTION CRITERIA"
0,outcome,16625603,12,"SELECTION CRITERIA"
1,other,16625603,12,"SELECTION CRITERIA"
0,"study design",16625603,12,"SELECTION CRITERIA"
0,background,16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
1,intervention,16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
1,population,16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
0,outcome,16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
0,other,16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
0,"study design",16625603,13,"Randomised controlled trials that compared thrombolytic therapy with placebo or heparin or surgical intervention in patients with acute PE."
0,background,16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
0,intervention,16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
0,population,16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
0,outcome,16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
1,other,16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
0,"study design",16625603,14,"We did not include trials comparing two different thrombolytic agents or different doses of the same thrombolytic drug."
0,background,16625603,15,"DATA COLLECTION AND ANALYSIS"
0,intervention,16625603,15,"DATA COLLECTION AND ANALYSIS"
0,population,16625603,15,"DATA COLLECTION AND ANALYSIS"
0,outcome,16625603,15,"DATA COLLECTION AND ANALYSIS"
1,other,16625603,15,"DATA COLLECTION AND ANALYSIS"
0,"study design",16625603,15,"DATA COLLECTION AND ANALYSIS"
0,background,16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
0,intervention,16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
0,population,16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
0,outcome,16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
1,other,16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
0,"study design",16625603,16,"Two authors (DB and WQ) assessed the eligibility and quality of trials and extracted data."
0,background,16625603,17,"MAIN RESULTS"
0,intervention,16625603,17,"MAIN RESULTS"
0,population,16625603,17,"MAIN RESULTS"
0,outcome,16625603,17,"MAIN RESULTS"
1,other,16625603,17,"MAIN RESULTS"
0,"study design",16625603,17,"MAIN RESULTS"
0,background,16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
0,intervention,16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
0,population,16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
1,outcome,16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
0,other,16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
0,"study design",16625603,18,"Results were similar between thrombolytics compared with heparin alone or placebo and heparin in terms of:a) death rate: odds ratio (OR) 0.89; 95% confidence interval (CI) 0.45 to 1.78; b) recurrence of pulmonary embolism: OR 0.63; 95% CI 0.33 to 1.20;c) "
0,background,16625603,19,"AUTHORS' CONCLUSIONS"
0,intervention,16625603,19,"AUTHORS' CONCLUSIONS"
0,population,16625603,19,"AUTHORS' CONCLUSIONS"
0,outcome,16625603,19,"AUTHORS' CONCLUSIONS"
1,other,16625603,19,"AUTHORS' CONCLUSIONS"
0,"study design",16625603,19,"AUTHORS' CONCLUSIONS"
0,background,16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
0,intervention,16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
0,population,16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
1,outcome,16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
0,other,16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
0,"study design",16625603,20,"We cannot conclude whether thrombolytic therapy is better than heparin for pulmonary embolism based on the limited evidence found."
0,background,16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
0,intervention,16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
0,population,16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
1,outcome,16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
0,other,16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
0,"study design",16625603,21,"More double-blind RCTs, with subgroup analysis of patients presenting with haemodynamically stable acute pulmonary embolism compared to those patients with a haemodynamic unstable condition, are required."
1,background,16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
0,intervention,16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
1,population,16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
0,outcome,16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
0,other,16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
0,"study design",16630324,1,"We present a case of an 8-year-old girl with collapse of her T6 and T7 vertebrae secondary to chronic recurrent multifocal osteomyelitis."
1,background,16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
0,intervention,16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
0,population,16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
0,outcome,16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
0,other,16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
0,"study design",16630324,2,"She presented with chronic abdominal pain and was found to have multiple bony lesions involving her spine, clavicle and mandible."
1,background,16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,intervention,16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,population,16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,outcome,16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,other,16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,"study design",16630324,3,"Extensive investigations, including tissue biopsy, were unable to identify an infective cause and there was no response to a prolonged course of intravenous antibiotics."
0,background,16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
1,intervention,16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
0,population,16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
1,outcome,16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
0,other,16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
0,"study design",16630324,4,"She made a good response to regular non-steroidal anti-inflammatory medication."
0,background,16674806,1,"BACKGROUND"
0,intervention,16674806,1,"BACKGROUND"
0,population,16674806,1,"BACKGROUND"
0,outcome,16674806,1,"BACKGROUND"
1,other,16674806,1,"BACKGROUND"
0,"study design",16674806,1,"BACKGROUND"
1,background,16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
0,intervention,16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
0,population,16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
0,outcome,16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
0,other,16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
0,"study design",16674806,2,"The main aims of this paper are to describe the setting and design of a Minimal Intervention in general practice for Stress-related mental disorders in patients on Sick leave (MISS), as well as to ascertain the study complies with the requirements for a c"
1,background,16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
0,intervention,16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
0,population,16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
0,outcome,16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
0,other,16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
0,"study design",16674806,3,"The potential adverse consequences of sick leave due to Stress-related Mental Disorders (SMDs) are extensive, but often not recognised."
1,background,16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
0,intervention,16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
0,population,16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
0,outcome,16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
0,other,16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
0,"study design",16674806,4,"Since most people having SMDs with sick leave consult their general practitioner (GP) at an early stage, a tailored intervention given by GPs is justified."
1,background,16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,intervention,16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,population,16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,outcome,16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,other,16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,"study design",16674806,5,"We provide a detailed description of the MISS; that is more accurate assessment, education, advice and monitoring to treat SMDs in patients on sick leave."
0,background,16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
0,intervention,16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
0,population,16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
0,outcome,16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
1,other,16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
0,"study design",16674806,6,"Our hypothesis is that the MISS will be more effective compared to the usual care, in reducing days of sick leave of these patients."
0,background,16674806,7,"METHODS"
0,intervention,16674806,7,"METHODS"
0,population,16674806,7,"METHODS"
0,outcome,16674806,7,"METHODS"
1,other,16674806,7,"METHODS"
0,"study design",16674806,7,"METHODS"
0,background,16674806,8,"The design is a pragmatic RCT."
0,intervention,16674806,8,"The design is a pragmatic RCT."
0,population,16674806,8,"The design is a pragmatic RCT."
0,outcome,16674806,8,"The design is a pragmatic RCT."
0,other,16674806,8,"The design is a pragmatic RCT."
1,"study design",16674806,8,"The design is a pragmatic RCT."
0,background,16674806,9,"Randomisation is at the level of GPs."
0,intervention,16674806,9,"Randomisation is at the level of GPs."
1,population,16674806,9,"Randomisation is at the level of GPs."
0,outcome,16674806,9,"Randomisation is at the level of GPs."
0,other,16674806,9,"Randomisation is at the level of GPs."
0,"study design",16674806,9,"Randomisation is at the level of GPs."
0,background,16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
1,intervention,16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
0,population,16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
0,outcome,16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
0,other,16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
0,"study design",16674806,10,"They received the MISS-training versus no training, in order to compare the MISS vs. usual care at patient level."
0,background,16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
0,intervention,16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
0,population,16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
0,outcome,16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
1,other,16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
0,"study design",16674806,11,"Enrollment of patients took place after screening in the source population, that comprised 20-60 year old primary care attendees."
0,background,16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
0,intervention,16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
0,population,16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
0,outcome,16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
1,other,16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
0,"study design",16674806,12,"Inclusion criteria were moderately elevated distress levels, having a paid job and sick leave for no longer than three months."
0,background,16674806,13,"There is a one year follow up."
0,intervention,16674806,13,"There is a one year follow up."
0,population,16674806,13,"There is a one year follow up."
0,outcome,16674806,13,"There is a one year follow up."
1,other,16674806,13,"There is a one year follow up."
0,"study design",16674806,13,"There is a one year follow up."
0,background,16674806,14,"The primary outcome measure is lasting full return to work."
0,intervention,16674806,14,"The primary outcome measure is lasting full return to work."
0,population,16674806,14,"The primary outcome measure is lasting full return to work."
0,outcome,16674806,14,"The primary outcome measure is lasting full return to work."
1,other,16674806,14,"The primary outcome measure is lasting full return to work."
0,"study design",16674806,14,"The primary outcome measure is lasting full return to work."
0,background,16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
0,intervention,16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
0,population,16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
0,outcome,16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
1,other,16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
0,"study design",16674806,15,"Reduction of SMD- symptoms is one of the secondary outcome measures."
0,background,16674806,16,"Forty-six GPs and 433 patients agreed to participate."
0,intervention,16674806,16,"Forty-six GPs and 433 patients agreed to participate."
0,population,16674806,16,"Forty-six GPs and 433 patients agreed to participate."
0,outcome,16674806,16,"Forty-six GPs and 433 patients agreed to participate."
1,other,16674806,16,"Forty-six GPs and 433 patients agreed to participate."
0,"study design",16674806,16,"Forty-six GPs and 433 patients agreed to participate."
0,background,16674806,17,"DISCUSSION"
0,intervention,16674806,17,"DISCUSSION"
0,population,16674806,17,"DISCUSSION"
0,outcome,16674806,17,"DISCUSSION"
1,other,16674806,17,"DISCUSSION"
0,"study design",16674806,17,"DISCUSSION"
0,background,16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
0,intervention,16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
0,population,16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
1,outcome,16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
0,other,16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
0,"study design",16674806,18,"In our study design, attention is given to the practical application of the requirements for a pragmatic trial."
0,background,16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
0,intervention,16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
0,population,16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
1,outcome,16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
0,other,16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
0,"study design",16674806,19,"The results of this cluster RCT will add to the evidence about treatment options in general practice for SMDs in patients on sick leave, and might contribute to a new and appropriate guideline."
0,background,16674806,20,"These results will be available at the end of 2006."
0,intervention,16674806,20,"These results will be available at the end of 2006."
0,population,16674806,20,"These results will be available at the end of 2006."
1,outcome,16674806,20,"These results will be available at the end of 2006."
0,other,16674806,20,"These results will be available at the end of 2006."
0,"study design",16674806,20,"These results will be available at the end of 2006."
0,background,16753394,1,"PURPOSE"
0,intervention,16753394,1,"PURPOSE"
0,population,16753394,1,"PURPOSE"
0,outcome,16753394,1,"PURPOSE"
1,other,16753394,1,"PURPOSE"
0,"study design",16753394,1,"PURPOSE"
1,background,16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,intervention,16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,population,16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,outcome,16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,other,16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,"study design",16753394,2,"We present the long-term results of a large consecutive series of patients undergoing ileal orthotopic bladder substitution following radical cystectomy."
0,background,16753394,3,"MATERIALS AND METHODS"
0,intervention,16753394,3,"MATERIALS AND METHODS"
0,population,16753394,3,"MATERIALS AND METHODS"
0,outcome,16753394,3,"MATERIALS AND METHODS"
1,other,16753394,3,"MATERIALS AND METHODS"
0,"study design",16753394,3,"MATERIALS AND METHODS"
0,background,16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
1,intervention,16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
1,population,16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
0,outcome,16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
0,other,16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
0,"study design",16753394,4,"Between April 1985 and 2005 orthotopic bladder substitution with an ileal low pressure reservoir was performed in 482 patients (including 40 women) after radical and, if possible, nerve sparing cystectomy."
0,background,16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
1,intervention,16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
0,population,16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
0,outcome,16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
0,other,16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
0,"study design",16753394,5,"In 447 cases the procedure was combined with an afferent ileal isoperistaltic tubular segment."
0,background,16753394,6,"The patients were followed prospectively."
0,intervention,16753394,6,"The patients were followed prospectively."
0,population,16753394,6,"The patients were followed prospectively."
0,outcome,16753394,6,"The patients were followed prospectively."
1,other,16753394,6,"The patients were followed prospectively."
0,"study design",16753394,6,"The patients were followed prospectively."
0,background,16753394,7,"RESULTS"
0,intervention,16753394,7,"RESULTS"
0,population,16753394,7,"RESULTS"
0,outcome,16753394,7,"RESULTS"
1,other,16753394,7,"RESULTS"
0,"study design",16753394,7,"RESULTS"
0,background,16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
0,intervention,16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
0,population,16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
1,outcome,16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
0,other,16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
0,"study design",16753394,8,"In the 482 patients 61 early (less than 30 days) diversion related complications requiring prolonged hospital stay or readmission were noted and 115 late complications required treatment."
0,background,16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
0,intervention,16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
0,population,16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
1,outcome,16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
0,other,16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
0,"study design",16753394,9,"At 1 year continence was good in 92% of patients during the day and in 79% at night."
0,background,16753394,10,"At last followup 93% of patients could void spontaneously."
0,intervention,16753394,10,"At last followup 93% of patients could void spontaneously."
0,population,16753394,10,"At last followup 93% of patients could void spontaneously."
1,outcome,16753394,10,"At last followup 93% of patients could void spontaneously."
0,other,16753394,10,"At last followup 93% of patients could void spontaneously."
0,"study design",16753394,10,"At last followup 93% of patients could void spontaneously."
0,background,16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
0,intervention,16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
0,population,16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
1,outcome,16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
0,other,16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
0,"study design",16753394,11,"Of 442 evaluable men 99 (22.4%) reported having erections without and 68 (15.4%) with medical assistance."
0,background,16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
0,intervention,16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
0,population,16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
1,outcome,16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
0,other,16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
0,"study design",16753394,12,"Ureteroileal stenosis was observed in 12 of 447 (2.7%) patients."
0,background,16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
0,intervention,16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
0,population,16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
1,outcome,16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
0,other,16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
0,"study design",16753394,13,"Urethral recurrence was detected in 25 of 482 (5%) patients."
0,background,16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
0,intervention,16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
0,population,16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
1,outcome,16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
0,other,16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
0,"study design",16753394,14,"A total of 15 (5%) patients received vitamin B12 substitution."
0,background,16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
0,intervention,16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
0,population,16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
1,outcome,16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
0,other,16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
0,"study design",16753394,15,"Renal parenchyma decreased only in patients with preoperative or postoperative ureteral obstruction."
0,background,16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
0,intervention,16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
0,population,16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
1,outcome,16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
0,other,16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
0,"study design",16753394,16,"After 10 years patients with normal renal function had no long-term acidosis and in 20 patients the incidence of osteoporosis resembled that of the normal population."
0,background,16753394,17,"CONCLUSIONS"
0,intervention,16753394,17,"CONCLUSIONS"
0,population,16753394,17,"CONCLUSIONS"
0,outcome,16753394,17,"CONCLUSIONS"
1,other,16753394,17,"CONCLUSIONS"
0,"study design",16753394,17,"CONCLUSIONS"
0,background,16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
0,intervention,16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
0,population,16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
1,outcome,16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
0,other,16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
0,"study design",16753394,18,"Ileal orthotopic bladder substitution combined with an afferent ileal tubular segment allows for good long-term functional results provided patients are restrictively selected, postoperative instructions are followed carefully, and typical complications s"
0,background,16783255,1,"AIM"
0,intervention,16783255,1,"AIM"
0,population,16783255,1,"AIM"
0,outcome,16783255,1,"AIM"
1,other,16783255,1,"AIM"
0,"study design",16783255,1,"AIM"
1,background,16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,intervention,16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,population,16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,outcome,16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,other,16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,"study design",16783255,2,"To characterize the factors associated with the 'doctor' effect in primary care, as reported in randomized controlled trials (RCTs)."
0,background,16783255,3,"METHOD"
0,intervention,16783255,3,"METHOD"
0,population,16783255,3,"METHOD"
0,outcome,16783255,3,"METHOD"
1,other,16783255,3,"METHOD"
0,"study design",16783255,3,"METHOD"
0,background,16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
0,intervention,16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
0,population,16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
0,outcome,16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
1,other,16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
0,"study design",16783255,4,"A systematic search of Medline (1964-2004) sought to identify all original reports of RCTs, as well as those reported in reviews and metaanalyses."
0,background,16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
0,intervention,16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
0,population,16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
0,outcome,16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
1,other,16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
0,"study design",16783255,5,"We used the following key words RCT, doctor-patient relationship, doctor-patient communication, knowledge, skill, attitude, non-pharmacologic effectiveness, primary care."
0,background,16783255,6,"RESULTS"
0,intervention,16783255,6,"RESULTS"
0,population,16783255,6,"RESULTS"
0,outcome,16783255,6,"RESULTS"
1,other,16783255,6,"RESULTS"
0,"study design",16783255,6,"RESULTS"
0,background,16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
0,intervention,16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
0,population,16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
1,outcome,16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
0,other,16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
0,"study design",16783255,7,"Ten RCTs and one metaanalysis provided evidence that a combination of emotional and cognitive care has a consistently positive effect on health outcomes."
0,background,16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
0,intervention,16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
0,population,16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
1,outcome,16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
0,other,16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
0,"study design",16783255,8,"This effect relies on specific attitudes and skills: empathy, reassurance, explanation, counseling, influencing patients' 'health beliefs and expectations, promoting change in behavior, thoughts or emotions."
0,background,16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
0,intervention,16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
0,population,16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
1,outcome,16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
0,other,16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
0,"study design",16783255,9,"These can be integrated into a specific patient-centered approach to general practice."
0,background,16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
0,intervention,16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
0,population,16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
1,outcome,16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
0,other,16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
0,"study design",16783255,10,"Medical education must provide training in the relational skills needed for effective treatment."
0,background,16783255,11,"CONCLUSION"
0,intervention,16783255,11,"CONCLUSION"
0,population,16783255,11,"CONCLUSION"
0,outcome,16783255,11,"CONCLUSION"
1,other,16783255,11,"CONCLUSION"
0,"study design",16783255,11,"CONCLUSION"
0,background,16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
0,intervention,16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
0,population,16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
1,outcome,16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
0,other,16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
0,"study design",16783255,12,"Qualitative and quantitative research, including RCTs, are necessary; they should be designed to deal with the heterogenous situations and specific characteristics of general practice."
0,background,16818834,1,"OBJECTIVE"
0,intervention,16818834,1,"OBJECTIVE"
0,population,16818834,1,"OBJECTIVE"
0,outcome,16818834,1,"OBJECTIVE"
1,other,16818834,1,"OBJECTIVE"
0,"study design",16818834,1,"OBJECTIVE"
1,background,16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
0,intervention,16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
1,population,16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
0,outcome,16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
0,other,16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
0,"study design",16818834,2,"To address the following questions: (1) What evidence (ie, psychometric data collected in pediatric primary care, patient outcome data) exists for the various methods used to identify adolescent depression in primary care?"
1,background,16818834,3,"and (2) What identification practices are currently in use?"
0,intervention,16818834,3,"and (2) What identification practices are currently in use?"
0,population,16818834,3,"and (2) What identification practices are currently in use?"
0,outcome,16818834,3,"and (2) What identification practices are currently in use?"
0,other,16818834,3,"and (2) What identification practices are currently in use?"
0,"study design",16818834,3,"and (2) What identification practices are currently in use?"
0,background,16818834,4,"DATA SOURCES"
0,intervention,16818834,4,"DATA SOURCES"
0,population,16818834,4,"DATA SOURCES"
0,outcome,16818834,4,"DATA SOURCES"
1,other,16818834,4,"DATA SOURCES"
0,"study design",16818834,4,"DATA SOURCES"
0,background,16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
0,intervention,16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
0,population,16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
0,outcome,16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
1,other,16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
0,"study design",16818834,5,"We systematically searched MEDLINE for English-language articles using specific search terms and examined relevant titles, abstracts, and articles."
0,background,16818834,6,"STUDY SELECTION"
0,intervention,16818834,6,"STUDY SELECTION"
0,population,16818834,6,"STUDY SELECTION"
0,outcome,16818834,6,"STUDY SELECTION"
1,other,16818834,6,"STUDY SELECTION"
0,"study design",16818834,6,"STUDY SELECTION"
0,background,16818834,7,"We reviewed 1743 MEDLINE abstracts."
0,intervention,16818834,7,"We reviewed 1743 MEDLINE abstracts."
0,population,16818834,7,"We reviewed 1743 MEDLINE abstracts."
0,outcome,16818834,7,"We reviewed 1743 MEDLINE abstracts."
1,other,16818834,7,"We reviewed 1743 MEDLINE abstracts."
0,"study design",16818834,7,"We reviewed 1743 MEDLINE abstracts."
0,background,16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
0,intervention,16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
0,population,16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
0,outcome,16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
1,other,16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
0,"study design",16818834,8,"Seventy-four articles were pulled for examination, with 30 articles meeting full criteria."
0,background,16818834,9,"DATA EXTRACTION"
0,intervention,16818834,9,"DATA EXTRACTION"
0,population,16818834,9,"DATA EXTRACTION"
0,outcome,16818834,9,"DATA EXTRACTION"
1,other,16818834,9,"DATA EXTRACTION"
0,"study design",16818834,9,"DATA EXTRACTION"
0,background,16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
0,intervention,16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
0,population,16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
0,outcome,16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
1,other,16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
0,"study design",16818834,10,"Five studies had adequate psychometric data on various adolescent depression identification methods in primary care."
0,background,16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
0,intervention,16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
0,population,16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
0,outcome,16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
1,other,16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
0,"study design",16818834,11,"Only 1 compared the diagnostic accuracy of physicians trained to ask depression questions vs physicians trained in the use of a diagnostic aid."
0,background,16818834,12,"Six studies reported on current practice."
0,intervention,16818834,12,"Six studies reported on current practice."
0,population,16818834,12,"Six studies reported on current practice."
0,outcome,16818834,12,"Six studies reported on current practice."
1,other,16818834,12,"Six studies reported on current practice."
0,"study design",16818834,12,"Six studies reported on current practice."
0,background,16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
0,intervention,16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
0,population,16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
0,outcome,16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
1,other,16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
0,"study design",16818834,13,"Evidence regarding sensitivity, specificity, positive predictive value, and negative predictive value was sought for question 1."
0,background,16818834,14,"Frequency of screening was sought for question 2."
0,intervention,16818834,14,"Frequency of screening was sought for question 2."
0,population,16818834,14,"Frequency of screening was sought for question 2."
0,outcome,16818834,14,"Frequency of screening was sought for question 2."
1,other,16818834,14,"Frequency of screening was sought for question 2."
0,"study design",16818834,14,"Frequency of screening was sought for question 2."
0,background,16818834,15,"DATA SYNTHESIS"
0,intervention,16818834,15,"DATA SYNTHESIS"
0,population,16818834,15,"DATA SYNTHESIS"
0,outcome,16818834,15,"DATA SYNTHESIS"
1,other,16818834,15,"DATA SYNTHESIS"
0,"study design",16818834,15,"DATA SYNTHESIS"
0,background,16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
0,intervention,16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
0,population,16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
1,outcome,16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
0,other,16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
0,"study design",16818834,16,"Review of these articles found that few health care professionals use systematic depression identification methods, despite some growing evidence for their validity, feasibility, and possible efficacy."
0,background,16818834,17,"CONCLUSION"
0,intervention,16818834,17,"CONCLUSION"
0,population,16818834,17,"CONCLUSION"
0,outcome,16818834,17,"CONCLUSION"
1,other,16818834,17,"CONCLUSION"
0,"study design",16818834,17,"CONCLUSION"
0,background,16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
0,intervention,16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
0,population,16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
1,outcome,16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
0,other,16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
0,"study design",16818834,18,"Available evidence indicates that primary care professionals would improve their rates of depression diagnosis through training, but even more so by using adolescent symptom rating scales."
1,background,16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,intervention,16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,population,16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,outcome,16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,other,16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,"study design",16961565,1,"A qualitative study of parents' perceptions of local environmental health risks was conducted to assess the fit between concepts from Dixon's Integrative Environmental Health Model (DIEH model) and field-generated data."
0,background,16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
0,intervention,16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
1,population,16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
0,outcome,16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
0,other,16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
1,"study design",16961565,2,"This research was part of a prospective study addressing environmental exposures of rural low-income children."
0,background,16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
0,intervention,16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
0,population,16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
0,outcome,16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
1,other,16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
0,"study design",16961565,3,"Home visit data from 11 parents were analyzed (1) thematically and (2) according to DIEH concepts."
0,background,16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
0,intervention,16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
0,population,16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
0,outcome,16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
1,other,16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
0,"study design",16961565,4,"These complementary analyses allowed the researchers to examine perceptions that were congruent with or diverged from the DIEH model."
0,background,16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
0,intervention,16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
0,population,16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
1,outcome,16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
0,other,16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
0,"study design",16961565,5,"Findings revealed that participants were concerned about children's exposure to pathogenic molds and cigarette smoke and felt uninformed about risks and prevention strategies."
0,background,16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
0,intervention,16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
0,population,16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
1,outcome,16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
0,other,16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
0,"study design",16961565,6,"Barriers to preventive actions included families' lack of time and a disinterest in brochures."
0,background,16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
0,intervention,16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
0,population,16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
1,outcome,16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
0,other,16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
0,"study design",16961565,7,"Participants reported being &quot;stuck&quot; in substandard housing by poverty and family demands."
0,background,16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
0,intervention,16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
0,population,16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
1,outcome,16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
0,other,16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
0,"study design",16961565,8,"They expressed concern about risks, but were unsure &quot;what to worry about.&quot; Results provided the researchers with confidence that the DIEH model aligned with participants' cognitive constructions of risk."
0,background,16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
0,intervention,16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
0,population,16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
1,outcome,16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
0,other,16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
0,"study design",16961565,9,"As a result, the DIEH model was incorporated into the conceptualization for the clinical trial phase of the study."
0,background,16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
0,intervention,16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
0,population,16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
1,outcome,16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
0,other,16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
0,"study design",16961565,10,"This type of check between a theoretical approach and field data can be a helpful intermediate step for researchers involved in multiyear studies."
0,background,17030353,1,"OBJECTIVES"
0,intervention,17030353,1,"OBJECTIVES"
0,population,17030353,1,"OBJECTIVES"
0,outcome,17030353,1,"OBJECTIVES"
1,other,17030353,1,"OBJECTIVES"
0,"study design",17030353,1,"OBJECTIVES"
1,background,17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
0,intervention,17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
0,population,17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
0,outcome,17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
0,other,17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
0,"study design",17030353,2,"Cervical cancer is a disease of middle-aged and elderly but still there are young women diagnosed with advanced disease that is incurable with local treatment and is treated with platinum-based combination chemotherapy."
1,background,17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,intervention,17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,population,17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,outcome,17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,other,17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,"study design",17030353,3,"It is unknown whether these young patients have a poorer outcome compared to older patients or whether elderly patients have inferior outcome than younger patients when treated with combination chemotherapy."
0,background,17030353,4,"METHODS"
0,intervention,17030353,4,"METHODS"
0,population,17030353,4,"METHODS"
0,outcome,17030353,4,"METHODS"
1,other,17030353,4,"METHODS"
0,"study design",17030353,4,"METHODS"
0,background,17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
1,intervention,17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
1,population,17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
0,outcome,17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
0,other,17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
0,"study design",17030353,5,"We compared the outcome between young (&lt;35), elderly (>70) and middle-aged (35-70) women who were treated with platinum-based combination chemotherapy for advanced, recurrent or persistent disease."
0,background,17030353,6,"RESULTS"
0,intervention,17030353,6,"RESULTS"
0,population,17030353,6,"RESULTS"
0,outcome,17030353,6,"RESULTS"
1,other,17030353,6,"RESULTS"
0,"study design",17030353,6,"RESULTS"
0,background,17030353,7,"Two hundred and eighteen patients were included in our database."
0,intervention,17030353,7,"Two hundred and eighteen patients were included in our database."
0,population,17030353,7,"Two hundred and eighteen patients were included in our database."
0,outcome,17030353,7,"Two hundred and eighteen patients were included in our database."
1,other,17030353,7,"Two hundred and eighteen patients were included in our database."
0,"study design",17030353,7,"Two hundred and eighteen patients were included in our database."
0,background,17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
0,intervention,17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
0,population,17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
1,outcome,17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
0,other,17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
0,"study design",17030353,8,"The baseline clinical and disease characteristics were not different between age groups but anemia and thrombocytosis were more frequent in younger patients."
0,background,17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
0,intervention,17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
0,population,17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
1,outcome,17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
0,other,17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
0,"study design",17030353,9,"Median survival for all patients was 13.4 (95%CI 11-15.8) months while survival of patients&lt;35 years of age was 9 months (95% CI 5.8-12), of patients older than 70 was 10 months (95% CI 6.9-13) of patients 35 to 70 years of age was 14.5 months (95% CI "
0,background,17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
0,intervention,17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
0,population,17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
1,outcome,17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
0,other,17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
0,"study design",17030353,10,"Multiple factors were significant for survival in univariate analysis but only weight loss, pain score and relapse inside an irradiated filed were significant predictors of outcome in multivariate analysis."
0,background,17030353,11,"CONCLUSIONS"
0,intervention,17030353,11,"CONCLUSIONS"
0,population,17030353,11,"CONCLUSIONS"
0,outcome,17030353,11,"CONCLUSIONS"
1,other,17030353,11,"CONCLUSIONS"
0,"study design",17030353,11,"CONCLUSIONS"
0,background,17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
0,intervention,17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
0,population,17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
1,outcome,17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
0,other,17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
0,"study design",17030353,12,"Very young (&lt;35) and elderly (>70) patients have a worse prognosis after treatment with combination chemotherapy for advanced or recurrent cervical cancer."
0,background,17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
0,intervention,17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
0,population,17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
1,outcome,17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
0,other,17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
0,"study design",17030353,13,"Nevertheless, this difference is not significant when adjusted for other prognostic factors."
1,background,1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
0,intervention,1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
0,population,1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
0,outcome,1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
0,other,1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
0,"study design",1714897,1,"The JAR human placental choriocarcinoma cell line transports serotonin, accumulating the monoamine inside the cell against a concentration gradient."
1,background,1714897,2,"The transport is energized by an NaCl gradient."
0,intervention,1714897,2,"The transport is energized by an NaCl gradient."
0,population,1714897,2,"The transport is energized by an NaCl gradient."
0,outcome,1714897,2,"The transport is energized by an NaCl gradient."
0,other,1714897,2,"The transport is energized by an NaCl gradient."
0,"study design",1714897,2,"The transport is energized by an NaCl gradient."
0,background,1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
0,intervention,1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
0,population,1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
1,outcome,1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
0,other,1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
0,"study design",1714897,3,"Tricyclic (imipramine and desipramine) and non-tricyclic (paroxetine and fluoxetine) antidepressants inhibit the transporter markedly, but reserpine and 5-hydroxytryptophan do not."
0,background,1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
0,intervention,1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
0,population,1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
1,outcome,1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
0,other,1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
0,"study design",1714897,4,"Ouabain, gramicidin, and nigericin, which reduce or abolish the transmembrane Na+ gradient, and phloridzin, which interferes with glucose transport into the cells, inhibit the transport."
0,background,1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
0,intervention,1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
0,population,1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
1,outcome,1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
0,other,1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
0,"study design",1714897,5,"Preincubation of the cells with glucose-free medium also causes similar inhibition."
0,background,1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
0,intervention,1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
0,population,1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
1,outcome,1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
0,other,1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
0,"study design",1714897,6,"The activity of the serotonin transporter in this cell line is stimulated in response to overnight (16-h) incubation with increasing concentrations of cholera toxin (0.1-1,000 ng/ml)."
0,background,1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
0,intervention,1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
0,population,1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
1,outcome,1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
0,other,1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
0,"study design",1714897,7,"Under these conditions the stimulation is maximal at 10 ng/ml cholera toxin (3.1 +/- 0.2-fold)."
0,background,1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
0,intervention,1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
0,population,1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
1,outcome,1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
0,other,1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
0,"study design",1714897,8,"Cholera toxin increases the cAMP content of these cells by several hundredfold within 2 h."
0,background,1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
0,intervention,1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
0,population,1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
1,outcome,1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
0,other,1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
0,"study design",1714897,9,"Isobutylmethylxanthine (100 microM), dibutyryl cAMP (100 microM), and forskolin (100 microM) mimic the action of cholera toxin, eliciting a 1.6-2.5-fold stimulation of the serotonin transporter activity."
0,background,1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
0,intervention,1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
0,population,1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
1,outcome,1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
0,other,1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
0,"study design",1714897,10,"The stimulatory effect of cholera toxin is antagonized significantly by simultaneous incubation of the cells with 50 microM N-(2-aminoethyl)-5-isoquinolinesulfonamide, a protein kinase inhibitor."
0,background,1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
0,intervention,1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
0,population,1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
1,outcome,1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
0,other,1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
0,"study design",1714897,11,"The effect of cholera toxin on serotonin transport is specific because, under similar conditions, cholera toxin inhibits 3-O-methyl-D-glucose transport and does not influence taurine transport in this cell line."
0,background,1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
0,intervention,1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
0,population,1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
1,outcome,1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
0,other,1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
0,"study design",1714897,12,"There is also no significant change in the protein content of the cells after cholera toxin treatment."
0,background,1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
0,intervention,1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
0,population,1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
1,outcome,1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
0,other,1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
0,"study design",1714897,13,"Kinetic analysis reveals that cholera toxin causes an increase in the maximal velocity (7.89 +/- 0.67 to 17.55 +/- 1.06 pmol/mg of protein/5 min) and a decrease in the Michaelis-Menten constant (0.52 +/- 0.09 to 0.29 +/- 0.04 microM)."
0,background,1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
0,intervention,1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
0,population,1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
1,outcome,1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
0,other,1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
0,"study design",1714897,14,"These data show that the JAR human placental choriocarcinoma cell line expresses a high affinity serotonin transporter that is sensitive to inhibition by antidepressants and that the activity of the transporter is under cAMP-dependent regulation."
0,background,17172556,1,"BACKGROUND AND PURPOSE"
0,intervention,17172556,1,"BACKGROUND AND PURPOSE"
0,population,17172556,1,"BACKGROUND AND PURPOSE"
0,outcome,17172556,1,"BACKGROUND AND PURPOSE"
1,other,17172556,1,"BACKGROUND AND PURPOSE"
0,"study design",17172556,1,"BACKGROUND AND PURPOSE"
1,background,17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,intervention,17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,population,17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,outcome,17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,other,17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,"study design",17172556,2,"The application of motor imagery practice in the treatment of Parkinson's disease (PD) is a novel treatment approach for improving motor function."
0,background,17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
0,intervention,17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
0,population,17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
0,outcome,17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
1,other,17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
0,"study design",17172556,3,"The purpose of this study was to compare group treatment using a combination of physical and motor imagery practice with group treatment using only physical practice in subjects with PD."
0,background,17172556,4,"METHODS"
0,intervention,17172556,4,"METHODS"
0,population,17172556,4,"METHODS"
0,outcome,17172556,4,"METHODS"
1,other,17172556,4,"METHODS"
0,"study design",17172556,4,"METHODS"
0,background,17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
1,intervention,17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
1,population,17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
0,outcome,17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
0,other,17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
0,"study design",17172556,5,"Of 23 patients with idiopathic PD, 12 received combined therapy, whereas 11 received physical therapy alone."
0,background,17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
0,intervention,17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
0,population,17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
0,outcome,17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
1,other,17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
0,"study design",17172556,6,"Exercises for both groups were applied during 1-h sessions held twice a week for 12 weeks."
0,background,17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
1,intervention,17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
0,population,17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
0,outcome,17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
0,other,17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
0,"study design",17172556,7,"Comparable motor tasks provided to both groups included callisthenic exercises, functional tasks, and relaxation exercises."
0,background,17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
1,intervention,17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
0,population,17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
0,outcome,17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
0,other,17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
0,"study design",17172556,8,"However, the experimental group was treated with both imagery and real practice, whereas the control group received only physical exercises."
0,background,17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
0,intervention,17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
0,population,17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
0,outcome,17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
1,other,17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
0,"study design",17172556,9,"Outcome measures included the time required to complete sequences of movements, the performance of balance tasks, impairment and functional scores on the Unified Parkinson's Disease Rating Scale (UPDRS), and specific cognitive abilities (Stroop and clock drawing tests)."
0,background,17172556,10,"RESULTS"
0,intervention,17172556,10,"RESULTS"
0,population,17172556,10,"RESULTS"
0,outcome,17172556,10,"RESULTS"
1,other,17172556,10,"RESULTS"
0,"study design",17172556,10,"RESULTS"
0,background,17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
0,intervention,17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
0,population,17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
1,outcome,17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
0,other,17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
0,"study design",17172556,11,"Following the intervention, the combined treatment group exhibited significantly faster performance of movement sequences than the control group."
0,background,17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
0,intervention,17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
0,population,17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
1,outcome,17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
0,other,17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
0,"study design",17172556,12,"In addition, the experimental subjects demonstrated higher gains in the mental and motor subsets of the UPDRS and in the cognitive tests."
0,background,17172556,13,"Both groups improved on the activities of daily living scale."
0,intervention,17172556,13,"Both groups improved on the activities of daily living scale."
0,population,17172556,13,"Both groups improved on the activities of daily living scale."
1,outcome,17172556,13,"Both groups improved on the activities of daily living scale."
0,other,17172556,13,"Both groups improved on the activities of daily living scale."
0,"study design",17172556,13,"Both groups improved on the activities of daily living scale."
0,background,17172556,14,"CONCLUSIONS"
0,intervention,17172556,14,"CONCLUSIONS"
0,population,17172556,14,"CONCLUSIONS"
0,outcome,17172556,14,"CONCLUSIONS"
1,other,17172556,14,"CONCLUSIONS"
0,"study design",17172556,14,"CONCLUSIONS"
0,background,17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
0,intervention,17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
0,population,17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
1,outcome,17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
0,other,17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
0,"study design",17172556,15,"The combination of motor imagery and real practice may be effective in the treatment of PD, especially for reducing bradykinesia."
0,background,17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
0,intervention,17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
0,population,17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
1,outcome,17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
0,other,17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
0,"study design",17172556,16,"The implementation of this treatment regimen allows for the extension of practice time with negligible risk and low cost."
0,background,17253573,1,"BACKGROUND"
0,intervention,17253573,1,"BACKGROUND"
0,population,17253573,1,"BACKGROUND"
0,outcome,17253573,1,"BACKGROUND"
1,other,17253573,1,"BACKGROUND"
0,"study design",17253573,1,"BACKGROUND"
1,background,17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
0,intervention,17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
0,population,17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
0,outcome,17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
0,other,17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
0,"study design",17253573,2,"A number of studies exist of interventions for wandering in the institutional setting, but much less work has been done on wandering in the domestic setting."
1,background,17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
0,intervention,17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
0,population,17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
0,outcome,17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
0,other,17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
0,"study design",17253573,3,"The prevalence of wandering by people with dementia is difficult to assess; wandering is not a simple or static behaviour and the reasons why people wander remain unclear."
1,background,17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
0,intervention,17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
0,population,17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
0,outcome,17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
0,other,17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
0,"study design",17253573,4,"In the absence of a theory of wandering and an agreed definition of wandering, it is difficult to discover effective strategies for managing wandering and difficult to design appropriate intervention strategies."
1,background,17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
0,intervention,17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
0,population,17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
0,outcome,17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
0,other,17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
0,"study design",17253573,5,"Also, the same behaviour or type of wandering might occur for different reasons in different individuals; any theoretical formulation is going to have to allow for different triggers for the behaviour and so to get a 'one size fits all' kind of explanatio"
1,background,17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
0,intervention,17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
0,population,17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
0,outcome,17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
0,other,17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
0,"study design",17253573,6,"Thus what we mostly encounter in this field is a 'trial and error' approach which does not always do justice to the complex interactions of personal and environmental factors that lead people with dementia to wander."
1,background,17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,intervention,17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,population,17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,outcome,17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,other,17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,"study design",17253573,7,"While there seems to be a consensus in the literature that in the majority of cases non-pharmacological approaches may work as well as drug treatment and with fewer side effects, in practice clinicians often resort to drugs as the first line of treatment."
0,background,17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
0,intervention,17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
0,population,17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
0,outcome,17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
1,other,17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
0,"study design",17253573,8,"This review reports the lack of evidence from RCTs and discusses the range of non-pharmacological interventions that have been carried out using other study designs."
0,background,17253573,9,"OBJECTIVES"
0,intervention,17253573,9,"OBJECTIVES"
0,population,17253573,9,"OBJECTIVES"
0,outcome,17253573,9,"OBJECTIVES"
1,other,17253573,9,"OBJECTIVES"
0,"study design",17253573,9,"OBJECTIVES"
0,background,17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
1,intervention,17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
1,population,17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
0,outcome,17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
0,other,17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
0,"study design",17253573,10,"To evaluate the effectiveness and safety of non-pharmacological interventions in reducing wandering in the domestic setting by people with dementia."
0,background,17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
0,intervention,17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
0,population,17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
0,outcome,17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
1,other,17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
0,"study design",17253573,11,"The secondary objective is to highlight the quality and quantity of research evidence available and to set an agenda for future research."
0,background,17253573,12,"SEARCH STRATEGY"
0,intervention,17253573,12,"SEARCH STRATEGY"
0,population,17253573,12,"SEARCH STRATEGY"
0,outcome,17253573,12,"SEARCH STRATEGY"
1,other,17253573,12,"SEARCH STRATEGY"
0,"study design",17253573,12,"SEARCH STRATEGY"
0,background,17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
0,intervention,17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
0,population,17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
0,outcome,17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
1,other,17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
0,"study design",17253573,13,"The trials were identified from a search of the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group on 11 May 2006 using the terms exit* or wander* or elopement or ambulat* or walk*."
0,background,17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
0,intervention,17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
0,population,17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
0,outcome,17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
1,other,17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
0,"study design",17253573,14,"This Register contains records from all major healthcare databases and many ongoing trial databases and is updated regularly."
0,background,17253573,15,"SELECTION CRITERIA"
0,intervention,17253573,15,"SELECTION CRITERIA"
0,population,17253573,15,"SELECTION CRITERIA"
0,outcome,17253573,15,"SELECTION CRITERIA"
1,other,17253573,15,"SELECTION CRITERIA"
0,"study design",17253573,15,"SELECTION CRITERIA"
0,background,17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
0,intervention,17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
0,population,17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
0,outcome,17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
1,other,17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
0,"study design",17253573,16,"Randomised clinical trials comparing intervention with no intervention or usual treatment ('standard care') or another intervention."
0,background,17253573,17,"DATA COLLECTION AND ANALYSIS"
0,intervention,17253573,17,"DATA COLLECTION AND ANALYSIS"
0,population,17253573,17,"DATA COLLECTION AND ANALYSIS"
0,outcome,17253573,17,"DATA COLLECTION AND ANALYSIS"
1,other,17253573,17,"DATA COLLECTION AND ANALYSIS"
0,"study design",17253573,17,"DATA COLLECTION AND ANALYSIS"
0,background,17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
0,intervention,17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
0,population,17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
0,outcome,17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
1,other,17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
0,"study design",17253573,18,"No suitable trials of non-pharmacological interventions for the prevention and management of wandering in the domestic setting were found."
0,background,17253573,19,"MAIN RESULTS"
0,intervention,17253573,19,"MAIN RESULTS"
0,population,17253573,19,"MAIN RESULTS"
0,outcome,17253573,19,"MAIN RESULTS"
1,other,17253573,19,"MAIN RESULTS"
0,"study design",17253573,19,"MAIN RESULTS"
0,background,17253573,20,"As no randomised controlled trials were found, no results can be reported."
0,intervention,17253573,20,"As no randomised controlled trials were found, no results can be reported."
0,population,17253573,20,"As no randomised controlled trials were found, no results can be reported."
1,outcome,17253573,20,"As no randomised controlled trials were found, no results can be reported."
0,other,17253573,20,"As no randomised controlled trials were found, no results can be reported."
0,"study design",17253573,20,"As no randomised controlled trials were found, no results can be reported."
0,background,17253573,21,"AUTHORS' CONCLUSIONS"
0,intervention,17253573,21,"AUTHORS' CONCLUSIONS"
0,population,17253573,21,"AUTHORS' CONCLUSIONS"
0,outcome,17253573,21,"AUTHORS' CONCLUSIONS"
1,other,17253573,21,"AUTHORS' CONCLUSIONS"
0,"study design",17253573,21,"AUTHORS' CONCLUSIONS"
0,background,17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
0,intervention,17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
0,population,17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
1,outcome,17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
0,other,17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
0,"study design",17253573,22,"There is an urgent need for randomised controlled trials of non-pharmacological interventions for wandering in the domestic setting."
1,background,17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,intervention,17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,population,17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,outcome,17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,other,17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,"study design",17309715,1,"Cervicogenic headache is a chronic hemicranial pain, usually occurring daily."
0,background,17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
1,intervention,17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
0,population,17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
0,outcome,17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
0,other,17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
1,"study design",17309715,2,"This randomized, double-blind, placebo-controlled trial evaluated the effectiveness of nerve stimulator-guided occipital nerve blockade in the treatment of cervicogenic headache."
0,background,17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
0,intervention,17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
0,population,17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
0,outcome,17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
1,other,17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
0,"study design",17309715,3,"The reduction in analgesic consumption was the primary outcome measure."
0,background,17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
0,intervention,17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
1,population,17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
0,outcome,17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
0,other,17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
0,"study design",17309715,4,"Fifty adult patients diagnosed with cervicogenic headache were randomly divided into two equal groups of 25 patients each."
0,background,17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
0,intervention,17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
0,population,17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
1,outcome,17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
0,other,17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
0,"study design",17309715,5,"All patients in both groups received greater and lesser occipital blocks, whereas only 16 patients in each group received facial nerve blockade in association with the occipital blocks."
0,background,17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
0,intervention,17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
0,population,17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
1,outcome,17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
0,other,17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
0,"study design",17309715,6,"The control group received injections of an equivalent volume of preservative-free normal saline."
0,background,17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
0,intervention,17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
0,population,17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
1,outcome,17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
0,other,17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
0,"study design",17309715,7,"Pain was assessed using the visual analog scale (VAS) and the Total Pain Index (TPI)."
0,background,17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
0,intervention,17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
0,population,17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
1,outcome,17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
0,other,17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
0,"study design",17309715,8,"Forty-seven patients entered into the final analysis as three patients were lost to follow-up."
0,background,17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
0,intervention,17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
0,population,17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
1,outcome,17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
0,other,17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
0,"study design",17309715,9,"Anesthetic block was effective in reducing the VAS and the TPI by approximately 50% from baseline values (P = 0.0001)."
0,background,17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
0,intervention,17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
0,population,17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
0,outcome,17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
1,other,17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
0,"study design",17309715,10,"Analgesic consumption, duration of headache and its frequency, nausea, vomiting, photophobia, phonophobia, decreased appetite, and limitations in functional activities were significantly less in block group compared to control group (P &lt; 0.05)."
0,background,17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
0,intervention,17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
0,population,17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
1,outcome,17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
0,other,17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
0,"study design",17309715,11,"The nerve stimulator-guided occipital nerve blockade significantly relieved cervicogenic headache and associated symptoms at two weeks following injection."
0,background,17310258,1,"STUDY DESIGN: Case report."
0,intervention,17310258,1,"STUDY DESIGN: Case report."
0,population,17310258,1,"STUDY DESIGN: Case report."
0,outcome,17310258,1,"STUDY DESIGN: Case report."
0,other,17310258,1,"STUDY DESIGN: Case report."
1,"study design",17310258,1,"STUDY DESIGN: Case report."
0,background,17310258,2,"OBJECTIVES"
0,intervention,17310258,2,"OBJECTIVES"
0,population,17310258,2,"OBJECTIVES"
0,outcome,17310258,2,"OBJECTIVES"
1,other,17310258,2,"OBJECTIVES"
0,"study design",17310258,2,"OBJECTIVES"
1,background,17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,intervention,17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,population,17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,outcome,17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,other,17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,"study design",17310258,3,"To report a novel management strategy for neuropathic pain management after spinal cord injury."
0,background,17310258,4,"SETTING"
0,intervention,17310258,4,"SETTING"
0,population,17310258,4,"SETTING"
0,outcome,17310258,4,"SETTING"
1,other,17310258,4,"SETTING"
0,"study design",17310258,4,"SETTING"
0,background,17310258,5,"Outpatient spinal cord injury (SCI) clinic."
0,intervention,17310258,5,"Outpatient spinal cord injury (SCI) clinic."
0,population,17310258,5,"Outpatient spinal cord injury (SCI) clinic."
0,outcome,17310258,5,"Outpatient spinal cord injury (SCI) clinic."
1,other,17310258,5,"Outpatient spinal cord injury (SCI) clinic."
0,"study design",17310258,5,"Outpatient spinal cord injury (SCI) clinic."
0,background,17310258,6,"METHODS"
0,intervention,17310258,6,"METHODS"
0,population,17310258,6,"METHODS"
0,outcome,17310258,6,"METHODS"
1,other,17310258,6,"METHODS"
0,"study design",17310258,6,"METHODS"
0,background,17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
0,intervention,17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
1,population,17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
0,outcome,17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
0,other,17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
0,"study design",17310258,7,"The patient demonstrated two neuropathic pain syndromes, namely at- and below-level pain."
0,background,17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
1,intervention,17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
0,population,17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
0,outcome,17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
0,other,17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
0,"study design",17310258,8,"These syndromes were recalcitrant to conservative measures and a decision was made to proceed with intrathecal therapies."
0,background,17310258,9,"RESULTS"
0,intervention,17310258,9,"RESULTS"
0,population,17310258,9,"RESULTS"
0,outcome,17310258,9,"RESULTS"
1,other,17310258,9,"RESULTS"
0,"study design",17310258,9,"RESULTS"
0,background,17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
0,intervention,17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
0,population,17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
1,outcome,17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
0,other,17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
0,"study design",17310258,10,"The patient's at-level pain was responsive to intrathecal hydromorphone but the below-level pain was unaffected by this intervention."
0,background,17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
0,intervention,17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
0,population,17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
1,outcome,17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
0,other,17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
0,"study design",17310258,11,"Intrathecal ziconotide provided an opposite response with a positive effect observed on the below-level pain and minimal effect on the at-level pain."
0,background,17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
0,intervention,17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
0,population,17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
1,outcome,17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
0,other,17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
0,"study design",17310258,12,"The combination of intrathecal ziconotide and hydromorphone provided effective relief for both components of the patient's SCI associated neuropathic pain."
0,background,17310258,13,"CONCLUSIONS"
0,intervention,17310258,13,"CONCLUSIONS"
0,population,17310258,13,"CONCLUSIONS"
0,outcome,17310258,13,"CONCLUSIONS"
1,other,17310258,13,"CONCLUSIONS"
0,"study design",17310258,13,"CONCLUSIONS"
0,background,17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
0,intervention,17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
0,population,17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
1,outcome,17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
0,other,17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
0,"study design",17310258,14,"The combination of intrathecal ziconotide and hydromorphone has the potential to provide significant pain relief for patients with neuropathic pain associated with spinal cord injury."
1,background,17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
0,intervention,17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
0,population,17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
0,outcome,17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
0,other,17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
0,"study design",17324482,1,"Previous studies have shown that spinal cord stimulation (SCS) of upper lumbar segments decreases visceromotor responses to mechanical stimuli in a sensitized rat colon and reduces symptoms of irritable bowel syndrome in patients."
1,background,17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
0,intervention,17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
0,population,17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
0,outcome,17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
0,other,17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
0,"study design",17324482,2,"SCS applied to the upper cervical spinal dorsal column reduces pain of chronic refractory angina."
1,background,17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,intervention,17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,population,17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,outcome,17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,other,17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,"study design",17324482,3,"Further, chemical stimulation of C1-C2 propriospinal neurons in rats modulates the responses of lumbosacral spinal neurons to colorectal distension."
0,background,17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
0,intervention,17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
0,population,17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
0,outcome,17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
1,other,17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
0,"study design",17324482,4,"The present study was designed to compare the effects of upper cervical and lumbar SCS on activity of lumbosacral neurons receiving noxious colorectal input."
0,background,17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
0,intervention,17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
1,population,17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
0,outcome,17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
0,other,17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
0,"study design",17324482,5,"Extracellular potentials of L6-S2 spinal neurons were recorded in pentobarbital anesthetized, paralyzed and ventilated male rats."
0,background,17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
1,intervention,17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
0,population,17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
0,outcome,17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
0,other,17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
0,"study design",17324482,6,"SCS (50 Hz, 0.2 ms) at low intensity (90% of motor threshold) was applied to the dorsal column of upper cervical (C1-C2) or upper lumbar (L2-L3) ipsilateral spinal segments."
0,background,17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
0,intervention,17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
0,population,17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
0,outcome,17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
1,other,17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
0,"study design",17324482,7,"Colorectal distension (CRD, 20 mmHg, 40 mmHg, 60 mmHg, 20s) was produced by air inflation of a latex balloon."
0,background,17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
0,intervention,17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
0,population,17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
1,outcome,17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
0,other,17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
0,"study design",17324482,8,"Results showed that SCS applied to L2-L3 and C1-C2 segments significantly reduced the excitatory responses to noxious CRD from 417.6+/-68.0 to 296.3+/-53.6 imp (P&lt;0.05, n=24) and from 336.2+/-64.5 to 225.0+/-73.3 imp (P&lt;0.05, n=18), respectively."
0,background,17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
0,intervention,17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
0,population,17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
1,outcome,17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
0,other,17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
0,"study design",17324482,9,"Effects of L2-L3 and C1-C2 SCS lasted 10.2+/-1.9 and 8.0+/-0.9 min after offset of CRD."
0,background,17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
0,intervention,17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
0,population,17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
1,outcome,17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
0,other,17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
0,"study design",17324482,10,"Effects of SCS were observed on spinal neurons with either high or low-threshold excitatory responses to CRD."
0,background,17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
0,intervention,17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
0,population,17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
1,outcome,17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
0,other,17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
0,"study design",17324482,11,"However, L2-L3 or C1-C2 SCS did not significantly affect inhibitory neuronal responses to CRD."
0,background,17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
0,intervention,17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
0,population,17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
1,outcome,17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
0,other,17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
0,"study design",17324482,12,"C1-C2 SCS-induced effects were abolished by cutting the C7-C8 dorsal column but not by spinal transection at cervicomedullary junction."
0,background,17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
0,intervention,17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
0,population,17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
1,outcome,17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
0,other,17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
0,"study design",17324482,13,"These data demonstrated that upper cervical or lumbar SCS modulated responses of lumbosacral spinal neurons to noxious mechanical stimulation of the colon, thereby, proved two loci for a potential therapeutic effect of SCS in patients with irritable bowel"
0,background,17353337,1,"BACKGROUND AND PURPOSE"
0,intervention,17353337,1,"BACKGROUND AND PURPOSE"
0,population,17353337,1,"BACKGROUND AND PURPOSE"
0,outcome,17353337,1,"BACKGROUND AND PURPOSE"
1,other,17353337,1,"BACKGROUND AND PURPOSE"
0,"study design",17353337,1,"BACKGROUND AND PURPOSE"
1,background,17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,intervention,17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,population,17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,outcome,17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,other,17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,"study design",17353337,2,"The purpose of this study was to determine the efficacy and rate of complications in patients undergoing percutaneous vertebroplasty (PVP) for vertebral compression fractures as a result of secondary osteoporosis caused by long-term corticosteroid use com"
0,background,17353337,3,"MATERIALS AND METHODS"
0,intervention,17353337,3,"MATERIALS AND METHODS"
0,population,17353337,3,"MATERIALS AND METHODS"
0,outcome,17353337,3,"MATERIALS AND METHODS"
1,other,17353337,3,"MATERIALS AND METHODS"
0,"study design",17353337,3,"MATERIALS AND METHODS"
0,background,17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
0,intervention,17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
1,population,17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
0,outcome,17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
0,other,17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
1,"study design",17353337,4,"A retrospective review of all patients undergoing PVP was conducted to identify patients who also received long-term corticosteroid therapy."
0,background,17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
0,intervention,17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
0,population,17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
0,outcome,17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
1,other,17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
0,"study design",17353337,5,"Outcomes including pain, periprocedural complications, and frequency of new fractures in patients receiving corticosteroids were compared with control patients undergoing PVP for primary osteoporosis."
0,background,17353337,6,"RESULTS"
0,intervention,17353337,6,"RESULTS"
0,population,17353337,6,"RESULTS"
0,outcome,17353337,6,"RESULTS"
1,other,17353337,6,"RESULTS"
0,"study design",17353337,6,"RESULTS"
0,background,17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
1,intervention,17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
0,population,17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
1,outcome,17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
0,other,17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
0,"study design",17353337,7,"Sixty-eight patients receiving long-term corticosteroid therapy underwent 79 PVP procedures."
0,background,17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
0,intervention,17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
0,population,17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
1,outcome,17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
0,other,17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
0,"study design",17353337,8,"Patients treated with corticosteroids undergoing PVP were significantly younger and more likely to be male compared with control subjects."
0,background,17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
0,intervention,17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
0,population,17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
1,outcome,17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
0,other,17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
0,"study design",17353337,9,"Patients receiving long-term corticosteroid treatment experienced significant pain relief immediately postprocedure and at 1 week, 1 month, 6 months, 1 year and 2 years postprocedure (P &lt; .0001 at all time points)."
0,background,17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
0,intervention,17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
0,population,17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
1,outcome,17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
0,other,17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
0,"study design",17353337,10,"Patients receiving corticosteroids experienced similar decreases in pain from baseline compared with control subjects at all follow-up time points (P &gt; .05)."
0,background,17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
0,intervention,17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
0,population,17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
1,outcome,17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
0,other,17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
0,"study design",17353337,11,"The complication rate for patients receiving corticosteroids was 4.4% compared with 3.4% for control subjects (P = .60)."
0,background,17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
0,intervention,17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
0,population,17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
1,outcome,17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
0,other,17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
0,"study design",17353337,12,"Patients on long-term corticosteroid treatment did not have an increased risk of new fractures after PVP compared with control subjects (P = .68)."
0,background,17353337,13,"CONCLUSIONS"
0,intervention,17353337,13,"CONCLUSIONS"
0,population,17353337,13,"CONCLUSIONS"
0,outcome,17353337,13,"CONCLUSIONS"
1,other,17353337,13,"CONCLUSIONS"
0,"study design",17353337,13,"CONCLUSIONS"
0,background,17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
0,intervention,17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
0,population,17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
1,outcome,17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
0,other,17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
0,"study design",17353337,14,"Percutaneous vertebroplasty performed for vertebral compression fractures as a result of long-term corticosteroid therapy is as safe and effective in relieving pain as PVP performed in patients with vertebral compression fractures as a result of primary o"
1,background,17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,intervention,17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,population,17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,outcome,17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,other,17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,"study design",17439911,1,"The purpose of this study was to evaluate the quality of life (QoL) of multiple sclerosis (MS) caregivers, and to determine relationships that may exist between caregiver and patient QoL."
0,background,17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
0,intervention,17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
1,population,17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
0,outcome,17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
0,other,17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
0,"study design",17439911,2,"Patients with definite MS (n=445) and their caregivers (n=445) were required to complete the generic, 36-item short-form (SF-36) Health Survey."
0,background,17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
0,intervention,17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
0,population,17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
0,outcome,17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
1,other,17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
0,"study design",17439911,3,"Median SF-36 dimension scores ranged from 55 to 100 for caregivers and from 46 to 78 for patients."
0,background,17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
0,intervention,17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
0,population,17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
1,outcome,17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
0,other,17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
0,"study design",17439911,4,"Although the QoL of MS carers was not as severely affected as that of patients, caregiving was associated with lower mental health, vitality and general health scores, compared to healthy subjects."
0,background,17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
0,intervention,17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
0,population,17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
1,outcome,17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
0,other,17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
0,"study design",17439911,5,"Multivariate analyses revealed significant differences between the predictors of patient QoL and caregiver QoL."
0,background,17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
0,intervention,17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
0,population,17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
1,outcome,17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
0,other,17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
0,"study design",17439911,6,"The main predictors of patient QoL were Expanded Disability Status Scale (EDSS) score, MS course, fatigue and depression."
0,background,17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
0,intervention,17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
0,population,17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
1,outcome,17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
0,other,17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
0,"study design",17439911,7,"Female gender and advanced age were the main predictors of lower QoL in caregivers."
0,background,17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
0,intervention,17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
0,population,17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
1,outcome,17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
0,other,17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
0,"study design",17439911,8,"In addition, patient BDI score was found to be a significant predictor of almost all caregiver SF-36 dimension scores, while EDSS score, disease duration and course, and patient therapeutic characteristics were found to be predictors of some caregiver SF-"
0,background,17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
0,intervention,17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
0,population,17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
1,outcome,17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
0,other,17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
0,"study design",17439911,9,"Therefore, caregiver QoL was significantly influenced by patient characteristics, and supportive strategies for MS caregivers are warranted."
0,background,17443571,1,"BACKGROUND"
0,intervention,17443571,1,"BACKGROUND"
0,population,17443571,1,"BACKGROUND"
0,outcome,17443571,1,"BACKGROUND"
1,other,17443571,1,"BACKGROUND"
0,"study design",17443571,1,"BACKGROUND"
1,background,17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
0,intervention,17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
0,population,17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
0,outcome,17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
0,other,17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
0,"study design",17443571,2,"Adherence to oral hygiene is an important aspect of the treatment of periodontal disease."
1,background,17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,intervention,17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,population,17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,outcome,17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,other,17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,"study design",17443571,3,"Traditional educational interventions have been shown to be of little value in achieving long term behaviour change."
0,background,17443571,4,"OBJECTIVES"
0,intervention,17443571,4,"OBJECTIVES"
0,population,17443571,4,"OBJECTIVES"
0,outcome,17443571,4,"OBJECTIVES"
1,other,17443571,4,"OBJECTIVES"
0,"study design",17443571,4,"OBJECTIVES"
0,background,17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
0,intervention,17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
0,population,17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
0,outcome,17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
1,other,17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
0,"study design",17443571,5,"The aim of this review was to determine the impact of interventions aimed to increase adherence to oral hygiene instructions in adult periodontal patients based on psychological models and theoretical frameworks."
0,background,17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
0,intervention,17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
0,population,17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
0,outcome,17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
1,other,17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
0,"study design",17443571,6,"This review considered the following outcomes Observational measures of oral health related behaviour Self reported oral health related behaviours, beliefs and attitudes towards oral health related behaviour Clinical markers of periodontal disease."
0,background,17443571,7,"SEARCH STRATEGY"
0,intervention,17443571,7,"SEARCH STRATEGY"
0,population,17443571,7,"SEARCH STRATEGY"
0,outcome,17443571,7,"SEARCH STRATEGY"
1,other,17443571,7,"SEARCH STRATEGY"
0,"study design",17443571,7,"SEARCH STRATEGY"
0,background,17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
0,intervention,17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
0,population,17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
0,outcome,17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
1,other,17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
0,"study design",17443571,8,"The Cochrane Oral Health Group's Trials Register (2005), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2004, Issue 4), MEDLINE (from 1966 to December 2004), EMBASE (from 1980 to December 2004), PSYCHINFO (from 1966 to December 2004), Ingenta (from 1998 to December 2004) and CINAHL (from 1966 to December 2004)."
0,background,17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
0,intervention,17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
0,population,17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
0,outcome,17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
1,other,17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
0,"study design",17443571,9,"Reference lists from relevant articles were searched and the authors of eligible trials were contacted to identify trials and obtain additional information."
0,background,17443571,10,"No language restriction was applied."
0,intervention,17443571,10,"No language restriction was applied."
0,population,17443571,10,"No language restriction was applied."
0,outcome,17443571,10,"No language restriction was applied."
1,other,17443571,10,"No language restriction was applied."
0,"study design",17443571,10,"No language restriction was applied."
0,background,17443571,11,"SELECTION CRITERIA"
0,intervention,17443571,11,"SELECTION CRITERIA"
0,population,17443571,11,"SELECTION CRITERIA"
0,outcome,17443571,11,"SELECTION CRITERIA"
1,other,17443571,11,"SELECTION CRITERIA"
0,"study design",17443571,11,"SELECTION CRITERIA"
0,background,17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
1,intervention,17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
1,population,17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
0,outcome,17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
0,other,17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
0,"study design",17443571,12,"Randomised controlled trials testing the effectiveness of interventions based on psychological models compared with educational, attention or no active intervention controls to improve adherence to oral hygiene in adults with either gingivitis or periodon"
0,background,17443571,13,"DATA COLLECTION AND ANALYSIS"
0,intervention,17443571,13,"DATA COLLECTION AND ANALYSIS"
0,population,17443571,13,"DATA COLLECTION AND ANALYSIS"
0,outcome,17443571,13,"DATA COLLECTION AND ANALYSIS"
1,other,17443571,13,"DATA COLLECTION AND ANALYSIS"
0,"study design",17443571,13,"DATA COLLECTION AND ANALYSIS"
0,background,17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
0,intervention,17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
0,population,17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
0,outcome,17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
1,other,17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
0,"study design",17443571,14,"Titles and abstracts of studies that were potentially relevant to the review were independently screened by two review authors."
0,background,17443571,15,"Those that were clearly ineligible were rejected."
0,intervention,17443571,15,"Those that were clearly ineligible were rejected."
0,population,17443571,15,"Those that were clearly ineligible were rejected."
0,outcome,17443571,15,"Those that were clearly ineligible were rejected."
1,other,17443571,15,"Those that were clearly ineligible were rejected."
0,"study design",17443571,15,"Those that were clearly ineligible were rejected."
0,background,17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
0,intervention,17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
0,population,17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
0,outcome,17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
1,other,17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
0,"study design",17443571,16,"For the remaining studies, the full paper was reviewed by two review authors and where necessary further information was sought from the author to verify eligibility."
0,background,17443571,17,"Included studies were assessed on their quality using standard criteria."
0,intervention,17443571,17,"Included studies were assessed on their quality using standard criteria."
0,population,17443571,17,"Included studies were assessed on their quality using standard criteria."
0,outcome,17443571,17,"Included studies were assessed on their quality using standard criteria."
1,other,17443571,17,"Included studies were assessed on their quality using standard criteria."
0,"study design",17443571,17,"Included studies were assessed on their quality using standard criteria."
0,background,17443571,18,"MAIN RESULTS"
0,intervention,17443571,18,"MAIN RESULTS"
0,population,17443571,18,"MAIN RESULTS"
0,outcome,17443571,18,"MAIN RESULTS"
1,other,17443571,18,"MAIN RESULTS"
0,"study design",17443571,18,"MAIN RESULTS"
0,background,17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
0,intervention,17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
0,population,17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
1,outcome,17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
0,other,17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
0,"study design",17443571,19,"The review identified four studies (including 344 participants) in which a psychological model or theory had been explicitly used as the basis for the design of the intervention."
0,background,17443571,20,"The overall quality of trials was low."
0,intervention,17443571,20,"The overall quality of trials was low."
0,population,17443571,20,"The overall quality of trials was low."
1,outcome,17443571,20,"The overall quality of trials was low."
0,other,17443571,20,"The overall quality of trials was low."
0,"study design",17443571,20,"The overall quality of trials was low."
0,background,17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
0,intervention,17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
0,population,17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
1,outcome,17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
0,other,17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
0,"study design",17443571,21,"Due to the hetereogeneity between studies, both in terms of outcome measures and psychological models adopted, a meta-analysis was not possible."
0,background,17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
0,intervention,17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
0,population,17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
1,outcome,17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
0,other,17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
0,"study design",17443571,22,"The four studies adopted four different theoretical frameworks, though there was some overlap in that three of the studies incorporated elements of Operant and Classical Conditioning."
0,background,17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
0,intervention,17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
0,population,17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
1,outcome,17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
0,other,17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
0,"study design",17443571,23,"Psychological interventions resulted in improved plaque scores in comparison to no intervention groups, and in one study in comparison to an attention control group."
0,background,17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
0,intervention,17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
0,population,17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
1,outcome,17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
0,other,17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
0,"study design",17443571,24,"One study found decreased gingival bleeding in the active intervention group but no change in pocket depth or attachment loss after 4 months."
0,background,17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
0,intervention,17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
0,population,17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
1,outcome,17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
0,other,17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
0,"study design",17443571,25,"Psychological interventions were associated with improved self reported brushing and flossing in both studies which assessed these behaviours."
0,background,17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
0,intervention,17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
0,population,17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
1,outcome,17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
0,other,17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
0,"study design",17443571,26,"Only one study explored the impact of psychological interventions on beliefs and attitudes, the psychological intervention, in comparison to educational and no intervention controls, showed improved self efficacy beliefs in relation to flossing, but no ef"
0,background,17443571,27,"AUTHORS' CONCLUSIONS"
0,intervention,17443571,27,"AUTHORS' CONCLUSIONS"
0,population,17443571,27,"AUTHORS' CONCLUSIONS"
0,outcome,17443571,27,"AUTHORS' CONCLUSIONS"
1,other,17443571,27,"AUTHORS' CONCLUSIONS"
0,"study design",17443571,27,"AUTHORS' CONCLUSIONS"
0,background,17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
0,intervention,17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
0,population,17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
1,outcome,17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
0,other,17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
0,"study design",17443571,28,"There is tentative evidence from low quality studies that psychological approaches to behaviour management can improve oral hygiene related behaviours."
0,background,17443571,29,"However, the overall quality of the included trials was low."
0,intervention,17443571,29,"However, the overall quality of the included trials was low."
0,population,17443571,29,"However, the overall quality of the included trials was low."
1,outcome,17443571,29,"However, the overall quality of the included trials was low."
0,other,17443571,29,"However, the overall quality of the included trials was low."
0,"study design",17443571,29,"However, the overall quality of the included trials was low."
0,background,17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
0,intervention,17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
0,population,17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
1,outcome,17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
0,other,17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
0,"study design",17443571,30,"Furthermore, the design of the interventions was weak and limited, ignoring key aspects of the theories."
0,background,17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
0,intervention,17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
0,population,17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
1,outcome,17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
0,other,17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
0,"study design",17443571,31,"Thus, there is a need for greater methodological rigour in the design of trials in this area."
1,background,17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
0,intervention,17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
0,population,17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
0,outcome,17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
0,other,17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
0,"study design",17477101,1,"Acute low back pain with or without sciatica usually is self-limited and has no serious underlying pathology."
1,background,17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
0,intervention,17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
0,population,17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
0,outcome,17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
0,other,17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
0,"study design",17477101,2,"For most patients, reassurance, pain medications, and advice to stay active are sufficient."
1,background,17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,intervention,17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,population,17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,outcome,17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,other,17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,"study design",17477101,3,"A more thorough evaluation is required in selected patients with &quot;red flag&quot; findings associated with an increased risk of cauda equina syndrome, cancer, infection, or fracture."
0,background,17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
0,intervention,17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
0,population,17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
0,outcome,17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
1,other,17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
0,"study design",17477101,4,"These patients also require closer follow-up and, in some cases, urgent referral to a surgeon."
0,background,17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
0,intervention,17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
0,population,17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
0,outcome,17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
1,other,17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
0,"study design",17477101,5,"In patients with nonspecific mechanical low back pain, imaging can be delayed for at least four to six weeks, which usually allows the pain to improve."
0,background,17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
0,intervention,17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
0,population,17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
1,outcome,17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
0,other,17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
0,"study design",17477101,6,"There is good evidence for the effectiveness of acetaminophen, nonsteroidal anti-inflammatory drugs, skeletal muscle relaxants, heat therapy, physical therapy, and advice to stay active."
0,background,17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
0,intervention,17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
0,population,17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
1,outcome,17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
0,other,17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
0,"study design",17477101,7,"Spinal manipulative therapy may provide short-term benefits compared with sham therapy but not when compared with conventional treatments."
0,background,17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
0,intervention,17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
0,population,17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
1,outcome,17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
0,other,17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
0,"study design",17477101,8,"Evidence for the benefit of acupuncture is conflicting, with higher-quality trials showing no benefit."
0,background,17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
0,intervention,17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
0,population,17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
1,outcome,17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
0,other,17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
0,"study design",17477101,9,"Patient education should focus on the natural history of the back pain, its overall good prognosis, and recommendations for effective treatments."
1,background,17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
0,intervention,17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
0,population,17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
0,outcome,17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
0,other,17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
0,"study design",17478048,1,"Growing evidence supports a role for the immune system in the induction and maintenance of chronic pain."
1,background,17478048,2,"ATP is a key neurotransmitter in this process."
0,intervention,17478048,2,"ATP is a key neurotransmitter in this process."
0,population,17478048,2,"ATP is a key neurotransmitter in this process."
0,outcome,17478048,2,"ATP is a key neurotransmitter in this process."
0,other,17478048,2,"ATP is a key neurotransmitter in this process."
0,"study design",17478048,2,"ATP is a key neurotransmitter in this process."
1,background,17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,intervention,17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,population,17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,outcome,17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,other,17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,"study design",17478048,3,"Recent studies demonstrate that the glial ATP receptor, P2X7, contributes to the modulation of pathological pain."
0,background,17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
0,intervention,17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
0,population,17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
0,outcome,17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
1,other,17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
0,"study design",17478048,4,"To further delineate the endogenous mechanisms that are involved in P2X7-related antinociception, we utilized a selective P2X7 receptor antagonist, A-438079, in a series of in vivo and in vitro experiments."
0,background,17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
1,intervention,17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
1,population,17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
0,outcome,17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
0,other,17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
0,"study design",17478048,5,"Injection of A-438079 (10-300 micromol/kg, i.p.) was anti-allodynic in three different rat models of neuropathic pain and it attenuated formalin-induced nocifensive behaviors."
0,background,17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
0,intervention,17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
0,population,17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
1,outcome,17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
0,other,17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
0,"study design",17478048,6,"Using in vivo electrophysiology, A-438079 (80 micromol/kg, i.v.) reduced noxious and innocuous evoked activity of different classes of spinal neurons (low threshold, nociceptive specific, wide dynamic range) in neuropathic rats."
0,background,17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
0,intervention,17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
0,population,17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
1,outcome,17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
0,other,17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
0,"study design",17478048,7,"The effects of A-438079 on evoked firing were diminished or absent in sham rats."
0,background,17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
0,intervention,17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
0,population,17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
1,outcome,17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
0,other,17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
0,"study design",17478048,8,"Spontaneous activity of all classes of spinal neurons was also significantly reduced by A-438079 in neuropathic but not sham rats."
0,background,17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
0,intervention,17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
0,population,17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
1,outcome,17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
0,other,17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
0,"study design",17478048,9,"In vitro, A-438079 (1 microM) blocked agonist-induced (2,3-O-(4-benzoylbenzoyl)-ATP, 30 microM) current in non-neuronal cells taken from the vicinity of the dorsal root ganglia."
0,background,17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
0,intervention,17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
0,population,17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
1,outcome,17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
0,other,17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
0,"study design",17478048,10,"Furthermore, A-438079 dose-dependently (0.3-3 microM) decreased the quantity of the cytokine, interleukin-1beta, released from peripheral macrophages."
0,background,17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
0,intervention,17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
0,population,17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
1,outcome,17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
0,other,17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
0,"study design",17478048,11,"Thus, ATP, acting through the P2X7 receptor, exerts a wide-ranging influence on spinal neuronal activity following a chronic injury."
0,background,17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
0,intervention,17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
0,population,17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
1,outcome,17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
0,other,17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
0,"study design",17478048,12,"Antagonism of the P2X7 receptor can in turn modulate central sensitization and produce antinociception in animal models of pathological pain."
0,background,17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
0,intervention,17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
0,population,17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
1,outcome,17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
0,other,17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
0,"study design",17478048,13,"These effects are likely mediated through immuno-neural interactions that affect the release of endogenous cytokines."
1,background,17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
0,intervention,17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
0,population,17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
0,outcome,17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
0,other,17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
0,"study design",17553569,1,"Microgliosis is implicated in the pathophysiology of several neurological disorders, including neuropathic pain."
1,background,17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,intervention,17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,population,17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,outcome,17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,other,17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,"study design",17553569,2,"Consequently, perturbation of microgliosis is a mechanistic and drug development target in neuropathic pain, which highlights the requirement for specific, sensitive and reproducible methods of microgliosis measurement."
0,background,17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
0,intervention,17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
0,population,17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
0,outcome,17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
1,other,17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
0,"study design",17553569,3,"In this study, we used the spinal microgliosis associated with L5 spinal nerve transection and minocycline-induced attenuation thereof to (1) evaluate novel software based semi-quantitative image analysis paradigms for the assessment of immunohistochemical images."
0,background,17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
0,intervention,17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
0,population,17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
0,outcome,17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
1,other,17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
0,"study design",17553569,4,"Microgliosis was revealed by immunoreactivity to OX42."
0,background,17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
0,intervention,17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
0,population,17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
0,outcome,17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
1,other,17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
0,"study design",17553569,5,"Several image analysis paradigms were assessed and compared to a previously validated subjective categorical rating scale."
0,background,17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
0,intervention,17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
0,population,17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
1,outcome,17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
0,other,17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
0,"study design",17553569,6,"This comparison revealed that grey scale measurement of the proportion of a defined area of spinal cord occupied by OX42 immunoreactive cells is a robust image analysis paradigm."
0,background,17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
0,intervention,17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
0,population,17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
1,outcome,17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
0,other,17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
0,"study design",17553569,7,"(2) Develop and validate a flow cytometric approach for quantification of spinal microgliosis."
0,background,17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
0,intervention,17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
0,population,17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
1,outcome,17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
0,other,17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
0,"study design",17553569,8,"The flow cytometric technique reliably quantified microgliosis in spinal cord cell suspensions, using OX42 and ED9 immunoreactivity to identify microglia."
0,background,17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
0,intervention,17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
0,population,17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
1,outcome,17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
0,other,17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
0,"study design",17553569,9,"The results suggest that image analysis of immunohistochemical revelation of microgliosis reliably detects the spinal microgliosis in response to peripheral nerve injury and pharmacological attenuation thereof."
0,background,17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
0,intervention,17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
0,population,17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
1,outcome,17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
0,other,17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
0,"study design",17553569,10,"In addition, flow cytometry provides an alternative approach for quantitative analysis of spinal microgliosis elicited by nerve injury."
0,background,17572250,1,"OBJECTIVES"
0,intervention,17572250,1,"OBJECTIVES"
0,population,17572250,1,"OBJECTIVES"
0,outcome,17572250,1,"OBJECTIVES"
1,other,17572250,1,"OBJECTIVES"
0,"study design",17572250,1,"OBJECTIVES"
1,background,17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,intervention,17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,population,17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,outcome,17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,other,17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,"study design",17572250,2,"This study investigated whether reduced levels of circulating endothelial progenitors cells (EPCs) in chronic heart failure (CHF) are secondary to an exhaustion of hematopoietic stem cells (HSCs) in the bone marrow or to reduced mobilization."
0,background,17572250,3,"BACKGROUND"
0,intervention,17572250,3,"BACKGROUND"
0,population,17572250,3,"BACKGROUND"
0,outcome,17572250,3,"BACKGROUND"
1,other,17572250,3,"BACKGROUND"
0,"study design",17572250,3,"BACKGROUND"
1,background,17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
0,intervention,17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
0,population,17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
0,outcome,17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
0,other,17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
0,"study design",17572250,4,"Circulating EPCs presumably originate from bone marrow-derived HSC."
1,background,17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,intervention,17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,population,17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,outcome,17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,other,17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,"study design",17572250,5,"Persistent mobilization of EPCs was shown to be associated with favorable left ventricular infarct remodeling processes."
0,background,17572250,6,"METHODS"
0,intervention,17572250,6,"METHODS"
0,population,17572250,6,"METHODS"
0,outcome,17572250,6,"METHODS"
1,other,17572250,6,"METHODS"
0,"study design",17572250,6,"METHODS"
0,background,17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
0,intervention,17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
1,population,17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
0,outcome,17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
0,other,17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
0,"study design",17572250,7,"We assessed the number and functional capacity of EPCs in 17 healthy controls, 25 patients with ischemic cardiomyopathy (ICM), and 20 patients with dilated cardiomyopathy (DCM)."
0,background,17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
0,intervention,17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
0,population,17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
0,outcome,17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
1,other,17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
0,"study design",17572250,8,"To document an impairment of HSC function in the bone marrow, the colony-forming unit capacity of bone marrow-derived mononuclear cells and the number of CD34+ HSCs were examined in 6 healthy volunteers, 94 ICM patients, and 25 DCM patients."
0,background,17572250,9,"RESULTS"
0,intervention,17572250,9,"RESULTS"
0,population,17572250,9,"RESULTS"
0,outcome,17572250,9,"RESULTS"
1,other,17572250,9,"RESULTS"
0,"study design",17572250,9,"RESULTS"
0,background,17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
0,intervention,17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
0,population,17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
1,outcome,17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
0,other,17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
0,"study design",17572250,10,"The number of EPCs was reduced in CHF, irrespective of its etiology."
0,background,17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
0,intervention,17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
0,population,17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
1,outcome,17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
0,other,17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
0,"study design",17572250,11,"In contrast, the migratory capacity was selectively impaired in EPCs of ICM patients (4.8 +/- 4.0 migrated cells; DCM 9.7 +/- 5.8; p = 0.02)."
0,background,17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
0,intervention,17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
0,population,17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
1,outcome,17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
0,other,17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
0,"study design",17572250,12,"On multivariate analysis, ICM, advanced New York Heart Association functional class, and CHF were independent predictors of functional EPC impairment."
0,background,17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
0,intervention,17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
0,population,17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
1,outcome,17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
0,other,17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
0,"study design",17572250,13,"The number of bone marrow-derived CD34+ cells did not differ between the CHF populations."
0,background,17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
0,intervention,17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
0,population,17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
1,outcome,17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
0,other,17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
0,"study design",17572250,14,"However, colony-forming units (CFUs) were selectively reduced in ICM patients (54.4 +/- 24.6; DCM 68.1 +/- 26.9; p &lt; 0.02)."
0,background,17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
0,intervention,17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
0,population,17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
1,outcome,17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
0,other,17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
0,"study design",17572250,15,"Ischemic cardiomyopathy was the only independent predictor of impaired CFU capacity."
0,background,17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
0,intervention,17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
0,population,17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
1,outcome,17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
0,other,17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
0,"study design",17572250,16,"Impaired CFU capacity was associated with reduced matrix metalloproteinase-9 activity in the bone marrow plasma."
0,background,17572250,17,"CONCLUSIONS"
0,intervention,17572250,17,"CONCLUSIONS"
0,population,17572250,17,"CONCLUSIONS"
0,outcome,17572250,17,"CONCLUSIONS"
1,other,17572250,17,"CONCLUSIONS"
0,"study design",17572250,17,"CONCLUSIONS"
0,background,17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
0,intervention,17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
0,population,17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
1,outcome,17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
0,other,17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
0,"study design",17572250,18,"Ischemic cardiomyopathy is associated with selective impairment of progenitor cell function in the bone marrow and in the peripheral blood, which may contribute to an unfavorable left ventricular (LV) remodeling process."
1,background,17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
0,intervention,17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
0,population,17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
0,outcome,17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
0,other,17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
0,"study design",17624684,1,"In patients with low back pain (LBP) it is only possible to diagnose a small proportion, (approximately 20%), on a patho-anatomical basis."
1,background,17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
0,intervention,17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
0,population,17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
0,outcome,17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
0,other,17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
0,"study design",17624684,2,"Therefore, the identification of relevant LBP subgroups, preferably on a patho-anatomical basis, is strongly needed."
1,background,17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
0,intervention,17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
0,population,17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
0,outcome,17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
0,other,17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
0,"study design",17624684,3,"Signal changes on MRI in the vertebral body marrow adjacent to the end plates also known as Modic changes (MC) are common in patients with LBP (18-58%) and is strongly associated with LBP."
1,background,17624684,4,"In asymptomatic persons the prevalence is 12-13%."
0,intervention,17624684,4,"In asymptomatic persons the prevalence is 12-13%."
0,population,17624684,4,"In asymptomatic persons the prevalence is 12-13%."
0,outcome,17624684,4,"In asymptomatic persons the prevalence is 12-13%."
0,other,17624684,4,"In asymptomatic persons the prevalence is 12-13%."
0,"study design",17624684,4,"In asymptomatic persons the prevalence is 12-13%."
1,background,17624684,5,"MC are divided into three different types."
0,intervention,17624684,5,"MC are divided into three different types."
0,population,17624684,5,"MC are divided into three different types."
0,outcome,17624684,5,"MC are divided into three different types."
0,other,17624684,5,"MC are divided into three different types."
0,"study design",17624684,5,"MC are divided into three different types."
1,background,17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
0,intervention,17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
0,population,17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
0,outcome,17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
0,other,17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
0,"study design",17624684,6,"Type 1 consists of fibro vascular tissue, type 2 is yellow fat, and type 3 is sclerotic bone."
1,background,17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
0,intervention,17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
0,population,17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
0,outcome,17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
0,other,17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
0,"study design",17624684,7,"The temporal evolution of MC is uncertain, but the time span is years."
1,background,17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
0,intervention,17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
0,population,17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
0,outcome,17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
0,other,17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
0,"study design",17624684,8,"Subchondral bone marrow signal changes associated with pain can be observed in different specific infectious, degenerative and immunological diseases such as osseous infections, osteoarthritis, ankylosing spondylitis and spondylarthritis."
1,background,17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
0,intervention,17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
0,population,17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
0,outcome,17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
0,other,17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
0,"study design",17624684,9,"In the vertebrae, MC is seen in relation to vertebral fractures, spondylodiscitis, disc herniation, severe disc degeneration, injections with chymopapain, and acute Schmorl's impressions."
1,background,17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
0,intervention,17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
1,population,17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
0,outcome,17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
0,other,17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
0,"study design",17628936,1,"A 38-year-old man in a wheelchair for spinal cord injury from a traffic accident was referred to our hospital with complaint of dull right flank pain."
1,background,17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
0,intervention,17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
0,population,17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
0,outcome,17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
0,other,17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
0,"study design",17628936,2,"The patient had a history of skin ulcer formation on both toes due to poor circulation."
1,background,17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
0,intervention,17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
0,population,17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
0,outcome,17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
0,other,17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
0,"study design",17628936,3,"Abdominal ultrasonography and computed tomographic scan revealed a huge retroperitoneal tumor compressing the right kidney."
1,background,17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,intervention,17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,population,17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,outcome,17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,other,17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,"study design",17628936,4,"Serum levels of cortisol, adrenocorticotropic hormone, aldosterone, adrenalin, noradrenalin, urinary levels of vanillylmandelic acid, homovanillic acid, 17-ketosteroid and 17-hydroxycorticosteroid were all within normal limits."
0,background,17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
0,intervention,17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
0,population,17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
0,outcome,17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
1,other,17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
0,"study design",17628936,5,"Combining all preoperative diagnostic information, the possibility of retroperitoneal liposarcoma could not be thoroughly ruled out."
0,background,17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
1,intervention,17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
0,population,17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
0,outcome,17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
0,other,17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
0,"study design",17628936,6,"The patient consented to undergo resection of the tumor with the right kidney."
0,background,17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
0,intervention,17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
0,population,17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
0,outcome,17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
1,other,17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
0,"study design",17628936,7,"Prior to the scheduled operation simulation of the positioning on the operation table was done to evaluate the compressing pressure."
0,background,17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
1,intervention,17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
0,population,17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
0,outcome,17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
0,other,17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
0,"study design",17628936,8,"During operation decompressing pads were used to minimize the compressing pressure and intermittent pneumatic compression was also used to prevent pressure ulcer and facilitate circulation to the lower extremities."
0,background,17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
1,intervention,17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
0,population,17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
0,outcome,17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
0,other,17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
0,"study design",17628936,9,"Five thousands units of heparin (FragminR, Pfizer, USA) was used daily to prevent deep vein thrombosis until the patient could use his wheelchair."
0,background,17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
0,intervention,17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
0,population,17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
0,outcome,17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
1,other,17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
0,"study design",17628936,10,"Perioperative rehabilitation was conducted by a team of physical therapists."
0,background,17628936,11,"The excised tumor weighed 1,320 g."
0,intervention,17628936,11,"The excised tumor weighed 1,320 g."
0,population,17628936,11,"The excised tumor weighed 1,320 g."
0,outcome,17628936,11,"The excised tumor weighed 1,320 g."
1,other,17628936,11,"The excised tumor weighed 1,320 g."
0,"study design",17628936,11,"The excised tumor weighed 1,320 g."
0,background,17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
0,intervention,17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
0,population,17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
1,outcome,17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
0,other,17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
0,"study design",17628936,12,"Pathologic diagnosis was an adrenal myelolipoma."
0,background,17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
0,intervention,17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
0,population,17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
1,outcome,17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
0,other,17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
0,"study design",17628936,13,"Convalescence was uneventful and the patient was discharged on the 10th post operative day."
0,background,17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
0,intervention,17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
0,population,17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
1,outcome,17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
0,other,17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
0,"study design",17628936,14,"Between 1992 and 2006, 80 cases of adrenal myelolipoma were reported in Japan."
0,background,17628936,15,"Our case was found to be the second largest one."
0,intervention,17628936,15,"Our case was found to be the second largest one."
0,population,17628936,15,"Our case was found to be the second largest one."
1,outcome,17628936,15,"Our case was found to be the second largest one."
0,other,17628936,15,"Our case was found to be the second largest one."
0,"study design",17628936,15,"Our case was found to be the second largest one."
0,background,17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
0,intervention,17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
0,population,17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
1,outcome,17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
0,other,17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
0,"study design",17628936,16,"We reviewed these 80 cases and discussed the diagnosis and treatment strategy of the adrenal myelolipoma."
0,background,17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
0,intervention,17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
0,population,17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
1,outcome,17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
0,other,17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
0,"study design",17628936,17,"We also discussed the perioperative management for patients with spinal cord injury."
1,background,17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
0,intervention,17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
0,population,17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
0,outcome,17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
0,other,17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
0,"study design",17661865,1,"Intrathecal baclofen is an invaluable therapeutic modality in the management of severe spasticity, especially in patients with cerebral palsy, multiple sclerosis, and spinal cord and brain injuries."
1,background,17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,intervention,17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,population,17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,outcome,17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,other,17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,"study design",17661865,2,"This case report presents a rare complication of long-term intrathecal infusion with the development of a huge anterior abdominal wall hematoma with extension to the retroperitoneal space as a result of a repeated blunt trauma to the site of the intrathec"
0,background,17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
0,intervention,17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
0,population,17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
1,outcome,17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
0,other,17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
0,"study design",17661865,3,"This inferior epigastric artery erosion could be avoided by implanting the intrathecal pump laterally away from the rectus abdominus muscle sheath."
1,background,17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
0,intervention,17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
0,population,17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
0,outcome,17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
0,other,17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
0,"study design",17694420,1,"Inflammation appears to play a key role in the development of colorectal cancer (CRC)."
1,background,17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,intervention,17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,population,17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,outcome,17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,other,17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,"study design",17694420,2,"In this study we examine factors involved in the regulation of inflammation and risk of CRC."
0,background,17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
0,intervention,17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
1,population,17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
0,outcome,17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
0,other,17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
0,"study design",17694420,3,"Data from a multi-center case-control study of colon (N = 1579 cases and N = 1977 controls) and rectal (N = 794 cases and N = 1005 controls) cancer were used to evaluate the association between the rs1800795 and rs1800796 IL6 polymorphisms and CRC."
0,background,17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
0,intervention,17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
0,population,17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
0,outcome,17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
1,other,17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
0,"study design",17694420,4,"We evaluated the joint effects of IL6 single nucleotide polymorphisms and regular use of aspirin/NSAIDs and vitamin D receptor (VDR) genotype."
0,background,17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
0,intervention,17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
0,population,17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
1,outcome,17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
0,other,17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
0,"study design",17694420,5,"Having a C allele of the rs1800796 IL6 polymorphisms and the GG genotype of the rs1800795 IL6 polymorphisms was associated with a statistically significantly reduced the risk of colon (OR 0.76 95% CI 0.57, 1.00), but not rectal (OR 1.49 95% CI 1.02,2.16) "
0,background,17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
0,intervention,17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
0,population,17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
1,outcome,17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
0,other,17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
0,"study design",17694420,6,"Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer r"
0,background,17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
0,intervention,17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
0,population,17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
1,outcome,17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
0,other,17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
0,"study design",17694420,7,"CRC risk also was associated with an interaction between VDR and IL6 genotypes that was modified by current use of aspirin/NSAIDs."
0,background,17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
0,intervention,17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
0,population,17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
1,outcome,17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
0,other,17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
0,"study design",17694420,8,"This study provides further support for inflammation-related factors in the etiology of CRC."
0,background,17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
0,intervention,17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
0,population,17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
1,outcome,17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
0,other,17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
0,"study design",17694420,9,"Other studies are needed to explore other genes in this and other inflammation-related pathways."
1,background,17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,intervention,17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,population,17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,outcome,17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,other,17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,"study design",17825546,1,"Fatty acid deficiency symptoms (FADS) of dry hair and skin, frequent thirst and urination have been observed to be higher in children with attention deficit hyperactivity disorder (ADHD)."
0,background,17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
0,intervention,17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
1,population,17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
0,outcome,17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
0,other,17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
0,"study design",17825546,2,"Two studies investigated FADS in 7-12-year-old children; Study 1 in a general population (N=347) and Study 2 in children with ADHD symptoms (N=104)."
0,background,17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
0,intervention,17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
0,population,17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
1,outcome,17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
0,other,17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
0,"study design",17825546,3,"Correlations between FADS and ADHD-related symptoms were found at baseline in Study 1 but not Study 2."
0,background,17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
0,intervention,17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
0,population,17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
1,outcome,17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
0,other,17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
0,"study design",17825546,4,"FADS did not improve after supplementation with omega-3 and omega-6 polyunsaturated fatty acids (PUFA) versus placebo after 15 weeks in Study 2, and were not related to improvements in ADHD symptoms in the PUFA groups."
0,background,17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
0,intervention,17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
0,population,17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
1,outcome,17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
0,other,17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
0,"study design",17825546,5,"However, FADS did improve in all groups, possibly attributable to the linoleic acid present in both the PUFA and placebo (palm oil) supplements."
0,background,17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
0,intervention,17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
0,population,17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
1,outcome,17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
0,other,17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
0,"study design",17825546,6,"FADS are not a reliable selection criterion for children with ADHD who might benefit from omega-3 PUFA supplementation."
0,background,17873551,1,"OBJECTIVE"
0,intervention,17873551,1,"OBJECTIVE"
0,population,17873551,1,"OBJECTIVE"
0,outcome,17873551,1,"OBJECTIVE"
1,other,17873551,1,"OBJECTIVE"
0,"study design",17873551,1,"OBJECTIVE"
1,background,17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,intervention,17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,population,17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,outcome,17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,other,17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,"study design",17873551,2,"This study examines the effects of a low-intensity walking program on the quality of life in patients with Crohn's disease."
0,background,17873551,3,"DESIGN"
0,intervention,17873551,3,"DESIGN"
0,population,17873551,3,"DESIGN"
0,outcome,17873551,3,"DESIGN"
1,other,17873551,3,"DESIGN"
0,"study design",17873551,3,"DESIGN"
0,background,17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
0,intervention,17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
0,population,17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
0,outcome,17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
0,other,17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
1,"study design",17873551,4,"Patients were randomized into exercise and nonexercise groups for a prospective study."
0,background,17873551,5,"SETTING"
0,intervention,17873551,5,"SETTING"
0,population,17873551,5,"SETTING"
0,outcome,17873551,5,"SETTING"
1,other,17873551,5,"SETTING"
0,"study design",17873551,5,"SETTING"
0,background,17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
0,intervention,17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
0,population,17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
0,outcome,17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
1,other,17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
0,"study design",17873551,6,"Patients were recruited at the inflammatory bowel disease outpatient clinic at the London Health Science Center, London, Ontario."
0,background,17873551,7,"PATIENTS"
0,intervention,17873551,7,"PATIENTS"
0,population,17873551,7,"PATIENTS"
0,outcome,17873551,7,"PATIENTS"
1,other,17873551,7,"PATIENTS"
0,"study design",17873551,7,"PATIENTS"
0,background,17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
0,intervention,17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
1,population,17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
0,outcome,17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
0,other,17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
0,"study design",17873551,8,"Thirty-two adult patients met the inclusion criteria of (1) mildly active disease or disease in remission, (2) habitual physical activity of less than 2 times per week of vigorous activity, (3) not anticipating change of dose or type of medication for Cro"
0,background,17873551,9,"All 32 patients who entered the study completed the 3-month study."
0,intervention,17873551,9,"All 32 patients who entered the study completed the 3-month study."
0,population,17873551,9,"All 32 patients who entered the study completed the 3-month study."
0,outcome,17873551,9,"All 32 patients who entered the study completed the 3-month study."
1,other,17873551,9,"All 32 patients who entered the study completed the 3-month study."
0,"study design",17873551,9,"All 32 patients who entered the study completed the 3-month study."
0,background,17873551,10,"INTERVENTION"
0,intervention,17873551,10,"INTERVENTION"
0,population,17873551,10,"INTERVENTION"
0,outcome,17873551,10,"INTERVENTION"
1,other,17873551,10,"INTERVENTION"
0,"study design",17873551,10,"INTERVENTION"
0,background,17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
1,intervention,17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
0,population,17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
0,outcome,17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
0,other,17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
0,"study design",17873551,11,"Patients performed low-intensity walking at an interval of 3 times per week for a duration of 3 months."
0,background,17873551,12,"Each walking session lasted for 30 minutes."
0,intervention,17873551,12,"Each walking session lasted for 30 minutes."
0,population,17873551,12,"Each walking session lasted for 30 minutes."
0,outcome,17873551,12,"Each walking session lasted for 30 minutes."
1,other,17873551,12,"Each walking session lasted for 30 minutes."
0,"study design",17873551,12,"Each walking session lasted for 30 minutes."
0,background,17873551,13,"MAIN OUTCOME MEASUREMENTS"
0,intervention,17873551,13,"MAIN OUTCOME MEASUREMENTS"
0,population,17873551,13,"MAIN OUTCOME MEASUREMENTS"
0,outcome,17873551,13,"MAIN OUTCOME MEASUREMENTS"
1,other,17873551,13,"MAIN OUTCOME MEASUREMENTS"
0,"study design",17873551,13,"MAIN OUTCOME MEASUREMENTS"
0,background,17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
0,intervention,17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
0,population,17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
0,outcome,17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
1,other,17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
0,"study design",17873551,14,"The Inflammatory Bowel Disease Questionnaire, the Inflammatory Bowel Disease Stress Index, and the Harvey-Bradshaw Simple Index were used as outcome."
0,background,17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
0,intervention,17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
0,population,17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
0,outcome,17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
1,other,17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
0,"study design",17873551,15,"Survey measurements were recorded at 1-month intervals on commencement of the walking program."
0,background,17873551,16,"RESULTS"
0,intervention,17873551,16,"RESULTS"
0,population,17873551,16,"RESULTS"
0,outcome,17873551,16,"RESULTS"
1,other,17873551,16,"RESULTS"
0,"study design",17873551,16,"RESULTS"
0,background,17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
0,intervention,17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
0,population,17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
1,outcome,17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
0,other,17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
0,"study design",17873551,17,"Patients in the exercise group experienced a statistically significant (P &lt; 0.05) improvement in quality of life in all 3 of the outcome measurement questionnaires with no detrimental effects in terms of disease activity."
0,background,17873551,18,"CONCLUSION"
0,intervention,17873551,18,"CONCLUSION"
0,population,17873551,18,"CONCLUSION"
0,outcome,17873551,18,"CONCLUSION"
1,other,17873551,18,"CONCLUSION"
0,"study design",17873551,18,"CONCLUSION"
0,background,17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
0,intervention,17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
0,population,17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
1,outcome,17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
0,other,17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
0,"study design",17873551,19,"A low-intensity walking program may have a beneficial effect in patients with Crohn's disease and improve their quality of life with no exacerbations in disease symptoms."
1,background,17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,intervention,17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,population,17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,outcome,17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,other,17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,"study design",17884841,1,"Ovarian cancer is the fourth most common cancer in women in the Western world."
0,background,17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
0,intervention,17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
0,population,17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
0,outcome,17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
0,other,17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
1,"study design",17884841,2,"In a pilot scale study, we highlight changes in the total serum glycome of patients with advanced ovarian cancer that might shed insight into disease pathogenesis."
1,background,17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,intervention,17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,population,17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,outcome,17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,other,17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,"study design",17884841,3,"These changes include increases in levels of core fucosylated, agalactosyl biantennary glycans (FA2) and sialyl Lewis x (SLe(x))."
0,background,17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
0,intervention,17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
0,population,17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
0,outcome,17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
1,other,17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
0,"study design",17884841,4,"To investigate further which proteins contribute to these alterations, we developed technology to analyze simultaneously the glycosylation of protein glycoforms contained in single spots excised from a 2D gel (&lt;1 ng protein)."
0,background,17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
0,intervention,17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
0,population,17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
1,outcome,17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
0,other,17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
0,"study design",17884841,5,"The acute-phase proteins, haptoglobin, alpha1-acid glycoprotein, and alpha1-antichymotrypsin from patients contained elevated levels of subsets of glycoforms containing SLe(x)."
0,background,17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
0,intervention,17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
0,population,17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
1,outcome,17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
0,other,17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
0,"study design",17884841,6,"We also established that IgG heavy chains from patients contained twice the level of FA2 compared with healthy controls."
0,background,17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
0,intervention,17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
0,population,17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
1,outcome,17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
0,other,17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
0,"study design",17884841,7,"Serum CA125 is the only biomarker that is used routinely, and there is a need for complementary markers that will improve both sensitivity and specificity."
0,background,17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
0,intervention,17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
0,population,17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
1,outcome,17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
0,other,17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
0,"study design",17884841,8,"There was some preliminary indication that combinations of changes in the serum glycome might improve the separation of ovarian cancer and benign tumors; however, a larger study using data receiver operating characteristic curves will be required to draw "
1,background,17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,intervention,17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,population,17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,outcome,17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,other,17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,"study design",17906290,1,"Conclusions based on systematic reviews of randomized controlled trials are considered to provide the highest level of evidence about the effectiveness of an intervention."
0,background,17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
1,intervention,17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
0,population,17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
0,outcome,17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
0,other,17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
0,"study design",17906290,2,"This overview summarizes the available evidence from systematic reviews on the effects of nonpharmacological and nonsurgical interventions for rheumatoid arthritis (RA)."
0,background,17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
0,intervention,17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
1,population,17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
0,outcome,17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
0,other,17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
0,"study design",17906290,3,"Systematic reviews of studies of patients with RA (aged >18 years) published between 2000 and 2007 were identified by comprehensive literature searches."
0,background,17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
0,intervention,17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
0,population,17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
0,outcome,17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
1,other,17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
0,"study design",17906290,4,"Methodological quality was independently assessed by 2 authors, and the quality of evidence was summarized by explicit methods."
0,background,17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
0,intervention,17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
0,population,17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
0,outcome,17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
1,other,17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
0,"study design",17906290,5,"Pain, function, and patient global assessment were considered primary outcomes of interest."
0,background,17906290,6,"Twenty-eight systematic reviews were included in this overview."
0,intervention,17906290,6,"Twenty-eight systematic reviews were included in this overview."
0,population,17906290,6,"Twenty-eight systematic reviews were included in this overview."
0,outcome,17906290,6,"Twenty-eight systematic reviews were included in this overview."
1,other,17906290,6,"Twenty-eight systematic reviews were included in this overview."
0,"study design",17906290,6,"Twenty-eight systematic reviews were included in this overview."
0,background,17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
0,intervention,17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
0,population,17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
1,outcome,17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
0,other,17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
0,"study design",17906290,7,"High-quality evidence was found for beneficial effects of joint protection and patient education, moderate-quality evidence was found for beneficial effects of herbal therapy (gamma-linolenic acid) and low-level laser therapy, and low-quality evidence was"
0,background,17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
0,intervention,17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
0,population,17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
1,outcome,17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
0,other,17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
0,"study design",17906290,8,"The quality of evidence for the effectiveness of most nonpharmacological and nonsurgical interventions in RA is moderate to low."
0,background,17923847,1,"STUDY DESIGN: Case report."
0,intervention,17923847,1,"STUDY DESIGN: Case report."
0,population,17923847,1,"STUDY DESIGN: Case report."
0,outcome,17923847,1,"STUDY DESIGN: Case report."
0,other,17923847,1,"STUDY DESIGN: Case report."
1,"study design",17923847,1,"STUDY DESIGN: Case report."
0,background,17923847,2,"OBJECTIVE"
0,intervention,17923847,2,"OBJECTIVE"
0,population,17923847,2,"OBJECTIVE"
0,outcome,17923847,2,"OBJECTIVE"
1,other,17923847,2,"OBJECTIVE"
0,"study design",17923847,2,"OBJECTIVE"
1,background,17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,intervention,17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,population,17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,outcome,17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,other,17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,"study design",17923847,3,"To examine the unusual and unknown, severe side effect of a therapeutic dose of oral Baclofen on cardiac function."
0,background,17923847,4,"SETTING"
0,intervention,17923847,4,"SETTING"
0,population,17923847,4,"SETTING"
0,outcome,17923847,4,"SETTING"
1,other,17923847,4,"SETTING"
0,"study design",17923847,4,"SETTING"
0,background,17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
0,intervention,17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
0,population,17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
0,outcome,17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
1,other,17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
0,"study design",17923847,5,"Spinal Cord Unit, Rehabilitation Centre Amsterdam, Amsterdam, The Netherlands."
0,background,17923847,6,"METHODS"
0,intervention,17923847,6,"METHODS"
0,population,17923847,6,"METHODS"
0,outcome,17923847,6,"METHODS"
1,other,17923847,6,"METHODS"
0,"study design",17923847,6,"METHODS"
0,background,17923847,7,"Review of relevant literature."
0,intervention,17923847,7,"Review of relevant literature."
0,population,17923847,7,"Review of relevant literature."
0,outcome,17923847,7,"Review of relevant literature."
1,other,17923847,7,"Review of relevant literature."
0,"study design",17923847,7,"Review of relevant literature."
0,background,17923847,8,"RESULTS"
0,intervention,17923847,8,"RESULTS"
0,population,17923847,8,"RESULTS"
0,outcome,17923847,8,"RESULTS"
1,other,17923847,8,"RESULTS"
0,"study design",17923847,8,"RESULTS"
0,background,17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
0,intervention,17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
1,population,17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
0,outcome,17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
0,other,17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
0,"study design",17923847,9,"A 53-year-old patient with an incomplete C2 tetrapareses (ASIA B) developed severe and painful muscle spasms together with respiratory failure and autonomic dysreflexia."
0,background,17923847,10,"Spasmolytic treatment was started."
1,intervention,17923847,10,"Spasmolytic treatment was started."
0,population,17923847,10,"Spasmolytic treatment was started."
0,outcome,17923847,10,"Spasmolytic treatment was started."
0,other,17923847,10,"Spasmolytic treatment was started."
0,"study design",17923847,10,"Spasmolytic treatment was started."
0,background,17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
0,intervention,17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
0,population,17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
1,outcome,17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
0,other,17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
0,"study design",17923847,11,"After the first admission of 5 mg of oral Baclofen, he collapsed in bed with extreme bradycardia, hypotension, hyperventilation and decreased oxygen saturation."
0,background,17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
0,intervention,17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
0,population,17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
1,outcome,17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
0,other,17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
0,"study design",17923847,12,"A second dosage of 5 mg Baclofen resulted in the same complications."
0,background,17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
0,intervention,17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
0,population,17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
1,outcome,17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
0,other,17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
0,"study design",17923847,13,"After implantation of a pacemaker, restarting oral Baclofen induced a pacemaker rhythm with episode of hypotension and respiratory failure and also a delirium."
0,background,17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
0,intervention,17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
0,population,17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
0,outcome,17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
1,other,17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
0,"study design",17923847,14,"Intrathecal Baclofen also resulted in a pacemaker rhythm with hypotension and a decreased cardiac output."
0,background,17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
0,intervention,17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
0,population,17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
1,outcome,17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
0,other,17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
0,"study design",17923847,15,"To our knowledge, this is the first time a severe heart conduction problem was induced in a spinal cord injury patient after a single therapeutic dose of Baclofen."
0,background,17923847,16,"CONCLUSION"
0,intervention,17923847,16,"CONCLUSION"
0,population,17923847,16,"CONCLUSION"
0,outcome,17923847,16,"CONCLUSION"
1,other,17923847,16,"CONCLUSION"
0,"study design",17923847,16,"CONCLUSION"
0,background,17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
0,intervention,17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
0,population,17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
1,outcome,17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
0,other,17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
0,"study design",17923847,17,"In this case therapeutic oral Baclofen has caused serious cardiac conduction problems."
0,background,17963916,1,"BACKGROUND"
0,intervention,17963916,1,"BACKGROUND"
0,population,17963916,1,"BACKGROUND"
0,outcome,17963916,1,"BACKGROUND"
1,other,17963916,1,"BACKGROUND"
0,"study design",17963916,1,"BACKGROUND"
1,background,17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,intervention,17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,population,17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,outcome,17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,other,17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,"study design",17963916,2,"Adult mammal sensory axons avulsed through spinal dorsal root traction injuries, especially of the brachial plexus or cauda equina, cannot normally regenerate through axonal outgrowth from the DRG into the spinal cord, thus causing clinical conditions tha"
0,background,17963916,3,"METHODS"
0,intervention,17963916,3,"METHODS"
0,population,17963916,3,"METHODS"
0,outcome,17963916,3,"METHODS"
1,other,17963916,3,"METHODS"
0,"study design",17963916,3,"METHODS"
0,background,17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
0,intervention,17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
1,population,17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
0,outcome,17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
0,other,17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
0,"study design",17963916,4,"To evaluate the sensory recovery of the forelimb after transection of their left cervical dorsal and ventral roots (C6-C8) at their spinal cord junctions, 22 SD rats were randomly assigned to 3 groups: transection only (control 1); transection followed by"
0,background,17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
1,intervention,17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
0,population,17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
0,outcome,17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
0,other,17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
0,"study design",17963916,5,"The following tests were reperformed after retransecting the repaired nerve roots to discount collateral innervation from adjacent nerve roots: motor function (grasping power), mechanical sensitivity to pain and touch (foot-withdrawal response to mechanic"
0,background,17963916,6,"RESULTS"
0,intervention,17963916,6,"RESULTS"
0,population,17963916,6,"RESULTS"
0,outcome,17963916,6,"RESULTS"
1,other,17963916,6,"RESULTS"
0,"study design",17963916,6,"RESULTS"
0,background,17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
0,intervention,17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
0,population,17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
1,outcome,17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
0,other,17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
0,"study design",17963916,7,"After transection and repair, the experimental group rats showed recovery in both motor (grasping power) and sensory (touch, pain, and temperature sensation) nerve functions."
0,background,17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
0,intervention,17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
0,population,17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
1,outcome,17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
0,other,17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
0,"study design",17963916,8,"Neuronal regeneration was confirmed by the reappearance of cortical SEP and by its disappearance after retransection of the repaired cervical nerve roots."
0,background,17963916,9,"CONCLUSION"
0,intervention,17963916,9,"CONCLUSION"
0,population,17963916,9,"CONCLUSION"
0,outcome,17963916,9,"CONCLUSION"
1,other,17963916,9,"CONCLUSION"
0,"study design",17963916,9,"CONCLUSION"
0,background,17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
0,intervention,17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
0,population,17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
1,outcome,17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
0,other,17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
0,"study design",17963916,10,"Using our strategy for repairing transected cervical nerve roots, motor and sensory recovery was achieved in adult rats."
0,background,17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
0,intervention,17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
0,population,17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
1,outcome,17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
0,other,17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
0,"study design",17963916,11,"The success of our study highlights possible treatment options for humans with avulsion injuries of the dorsal roots from the spinal cord."
0,background,18055722,1,"OBJECTIVE"
0,intervention,18055722,1,"OBJECTIVE"
0,population,18055722,1,"OBJECTIVE"
0,outcome,18055722,1,"OBJECTIVE"
1,other,18055722,1,"OBJECTIVE"
0,"study design",18055722,1,"OBJECTIVE"
1,background,18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,intervention,18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,population,18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,outcome,18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,other,18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,"study design",18055722,2,"To assess whether losses in physical functioning are related to the natural menopause, hysterectomy, or calendar time during midlife, after adjustment for body size and smoking."
0,background,18055722,3,"METHODS"
0,intervention,18055722,3,"METHODS"
0,population,18055722,3,"METHODS"
0,outcome,18055722,3,"METHODS"
1,other,18055722,3,"METHODS"
0,"study design",18055722,3,"METHODS"
0,background,18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
0,intervention,18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
1,population,18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
0,outcome,18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
0,other,18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
1,"study design",18055722,4,"A longitudinal assessment of physical functioning was conducted from 2000/01 through 2005/06 in a population-based sample of 544 women at midlife enrolled in the Michigan Bone Health and Metabolism Study."
0,background,18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
0,intervention,18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
0,population,18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
0,outcome,18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
1,other,18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
0,"study design",18055722,5,"Longitudinal mixed models were used to relate menopausal status to measures of physical functioning."
0,background,18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
0,intervention,18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
0,population,18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
0,outcome,18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
1,other,18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
0,"study design",18055722,6,"Perception of physical functioning was assessed with the Medical Outcomes Study Short-Form 36 questionnaire."
0,background,18055722,7,"Eight performance-based measures of physical functioning were also included."
1,intervention,18055722,7,"Eight performance-based measures of physical functioning were also included."
0,population,18055722,7,"Eight performance-based measures of physical functioning were also included."
0,outcome,18055722,7,"Eight performance-based measures of physical functioning were also included."
0,other,18055722,7,"Eight performance-based measures of physical functioning were also included."
0,"study design",18055722,7,"Eight performance-based measures of physical functioning were also included."
0,background,18055722,8,"RESULTS"
0,intervention,18055722,8,"RESULTS"
0,population,18055722,8,"RESULTS"
0,outcome,18055722,8,"RESULTS"
1,other,18055722,8,"RESULTS"
0,"study design",18055722,8,"RESULTS"
0,background,18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
0,intervention,18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
0,population,18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
1,outcome,18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
0,other,18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
0,"study design",18055722,9,"Women with hysterectomy (with or without estrogen from ovarian conservation or exogenous replacement) had reduced levels of functioning and greater rates of change in the 2-lb lift (P&lt;.005), sit-to-stand (P&lt;.01), timed stair climb (P&lt;.01), timed "
0,background,18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
0,intervention,18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
0,population,18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
1,outcome,18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
0,other,18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
0,"study design",18055722,10,"Diminished functioning in postmenopausal women was observed in hand grip (P&lt;.005), 2-lb lift (P&lt;.05), sit-to-stand (P&lt;.05), velocity (P&lt;.05), and perceived physical functioning (P&lt;.05)."
0,background,18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
0,intervention,18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
0,population,18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
1,outcome,18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
0,other,18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
0,"study design",18055722,11,"Based on regression analyses, there was greater loss in women with hysterectomy compared with natural menopause."
0,background,18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
0,intervention,18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
0,population,18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
1,outcome,18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
0,other,18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
0,"study design",18055722,12,"Level of functioning among postmenopausal women with exogenous hormone replacement was similar to premenopausal women on eight of nine physical functioning measures."
0,background,18055722,13,"CONCLUSION"
0,intervention,18055722,13,"CONCLUSION"
0,population,18055722,13,"CONCLUSION"
0,outcome,18055722,13,"CONCLUSION"
1,other,18055722,13,"CONCLUSION"
0,"study design",18055722,13,"CONCLUSION"
0,background,18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
0,intervention,18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
0,population,18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
1,outcome,18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
0,other,18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
0,"study design",18055722,14,"Hysterectomy, even with availability of an estrogen source, seems to be a &quot;risk&quot; state for diminishing physical function at midlife, and this may initiate a vulnerable stage for future compromised quality of life."
1,background,18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
0,intervention,18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
0,population,18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
0,outcome,18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
0,other,18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
0,"study design",18060043,1,"Injury to the peripheral nervous system (PNS) initiates a response controlled by multiple extracellular mediators, many of which contribute to the development of neuropathic pain."
1,background,18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,intervention,18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,population,18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,outcome,18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,other,18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,"study design",18060043,2,"Schwann cells in an injured nerve demonstrate increased expression of LDL receptor-related protein-1 (LRP1), an endocytic receptor for diverse ligands and a cell survival factor."
0,background,18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
0,intervention,18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
0,population,18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
0,outcome,18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
1,other,18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
0,"study design",18060043,3,"Here we report that a fragment of LRP1, in which a soluble or shed form of LRP1 with an intact alpha-chain (sLRP-alpha), was shed by Schwann cells in vitro and in the PNS after injury."
0,background,18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
1,intervention,18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
1,population,18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
1,outcome,18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
0,other,18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
0,"study design",18060043,4,"Injection of purified sLRP-alpha into mouse sciatic nerves prior to chronic constriction injury (CCI) inhibited p38 MAPK activation (P-p38) and decreased expression of TNF-alpha and IL-1beta locally."
0,background,18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
0,intervention,18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
0,population,18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
1,outcome,18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
0,other,18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
0,"study design",18060043,5,"sLRP-alpha also inhibited CCI-induced spontaneous neuropathic pain and decreased inflammatory cytokine expression in the spinal dorsal horn, where neuropathic pain processing occurs."
0,background,18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
0,intervention,18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
0,population,18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
1,outcome,18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
0,other,18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
0,"study design",18060043,6,"In cultures of Schwann cells, astrocytes, and microglia, sLRP-alpha inhibited TNF-alpha-induced activation of p38 MAPK and ERK/MAPK."
0,background,18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
0,intervention,18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
0,population,18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
1,outcome,18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
0,other,18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
0,"study design",18060043,7,"The activity of sLRP-alpha did not involve TNF-alpha binding, but rather glial cell preconditioning, so that the subsequent response to TNF-alpha was inhibited."
0,background,18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
0,intervention,18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
0,population,18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
1,outcome,18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
0,other,18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
0,"study design",18060043,8,"Our results show that sLRP-alpha is biologically active and may attenuate neuropathic pain."
0,background,18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
0,intervention,18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
0,population,18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
1,outcome,18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
0,other,18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
0,"study design",18060043,9,"In the PNS, the function of LRP1 may reflect the integrated activities of the membrane-anchored and shed forms of LRP1."
0,background,18072382,1,"OBJECTIVE"
0,intervention,18072382,1,"OBJECTIVE"
0,population,18072382,1,"OBJECTIVE"
0,outcome,18072382,1,"OBJECTIVE"
1,other,18072382,1,"OBJECTIVE"
0,"study design",18072382,1,"OBJECTIVE"
1,background,18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
0,intervention,18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
0,population,18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
0,outcome,18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
0,other,18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
0,"study design",18072382,2,"Language barriers have been shown to negatively impact health care for immigrants."
1,background,18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,intervention,18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,population,18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,outcome,18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,other,18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,"study design",18072382,3,"We evaluated the association between language use and the diagnosis of hypertension among elderly Mexican Americans."
0,background,18072382,4,"STUDY POPULATION"
0,intervention,18072382,4,"STUDY POPULATION"
0,population,18072382,4,"STUDY POPULATION"
0,outcome,18072382,4,"STUDY POPULATION"
1,other,18072382,4,"STUDY POPULATION"
0,"study design",18072382,4,"STUDY POPULATION"
0,background,18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
0,intervention,18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
1,population,18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
0,outcome,18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
0,other,18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
0,"study design",18072382,5,"We studied subjects from the Hispanic Established Populations for Epidemiologic Studies of the Elderly, a cohort of 3050 Mexican American subjects age > or =65."
0,background,18072382,6,"PREDICTORS"
0,intervention,18072382,6,"PREDICTORS"
0,population,18072382,6,"PREDICTORS"
0,outcome,18072382,6,"PREDICTORS"
1,other,18072382,6,"PREDICTORS"
0,"study design",18072382,6,"PREDICTORS"
0,background,18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
0,intervention,18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
0,population,18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
0,outcome,18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
1,other,18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
0,"study design",18072382,7,"Measures of language included Spanish and/or English language read/spoken, language used in social situations, and language of mass media use."
0,background,18072382,8,"OUTCOME MEASURE"
0,intervention,18072382,8,"OUTCOME MEASURE"
0,population,18072382,8,"OUTCOME MEASURE"
0,outcome,18072382,8,"OUTCOME MEASURE"
1,other,18072382,8,"OUTCOME MEASURE"
0,"study design",18072382,8,"OUTCOME MEASURE"
0,background,18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
0,intervention,18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
0,population,18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
0,outcome,18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
1,other,18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
0,"study design",18072382,9,"Undiagnosed hypertension on physical exam was defined as systolic blood pressure > or =140 mm Hg and/or diastolic blood pressure > or =90 mm Hg in persons who did not report previous hypertension diagnosis or were not current users of anti-hypertensive medications."
0,background,18072382,10,"RESULTS"
0,intervention,18072382,10,"RESULTS"
0,population,18072382,10,"RESULTS"
0,outcome,18072382,10,"RESULTS"
1,other,18072382,10,"RESULTS"
0,"study design",18072382,10,"RESULTS"
0,background,18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
0,intervention,18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
0,population,18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
1,outcome,18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
0,other,18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
0,"study design",18072382,11,"The age- and sex-adjusted prevalence of diagnosed hypertension and undiagnosed hypertension were 50.5% and 19.3%, respectively."
0,background,18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
0,intervention,18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
0,population,18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
1,outcome,18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
0,other,18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
0,"study design",18072382,12,"Among 1347 older adults without previous diagnosis of hypertension that were included in the primary analysis, the mean age was 72 years and 43% were immigrants."
0,background,18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
0,intervention,18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
0,population,18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
1,outcome,18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
0,other,18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
0,"study design",18072382,13,"After adjusting for age, gender, and education, Spanish use more often than English use in mass media was significantly associated with undiagnosed hypertension (adjusted OR 2.2 [1.3-3.6])."
0,background,18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
0,intervention,18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
0,population,18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
1,outcome,18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
0,other,18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
0,"study design",18072382,14,"Other measures of acculturation were not independently associated with undiagnosed hypertension."
0,background,18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
0,intervention,18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
0,population,18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
1,outcome,18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
0,other,18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
0,"study design",18072382,15,"In analyses restricted to persons with hypertension, similar language factors distinguished those who had been diagnosed from those whose hypertension was undiagnosed."
0,background,18072382,16,"CONCLUSIONS"
0,intervention,18072382,16,"CONCLUSIONS"
0,population,18072382,16,"CONCLUSIONS"
0,outcome,18072382,16,"CONCLUSIONS"
1,other,18072382,16,"CONCLUSIONS"
0,"study design",18072382,16,"CONCLUSIONS"
0,background,18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
0,intervention,18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
0,population,18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
1,outcome,18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
0,other,18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
0,"study design",18072382,17,"Mexican American elders who reported using Spanish more often than English use in mass media were more likely to have undiagnosed hypertension compared to those using English language in mass media."
0,background,18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
0,intervention,18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
0,population,18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
1,outcome,18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
0,other,18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
0,"study design",18072382,18,"Further studies are needed to elucidate the role of mass media language in hypertension awareness and management among Hispanic elders."
0,background,18164330,1,"OBJECTIVE"
0,intervention,18164330,1,"OBJECTIVE"
0,population,18164330,1,"OBJECTIVE"
0,outcome,18164330,1,"OBJECTIVE"
1,other,18164330,1,"OBJECTIVE"
0,"study design",18164330,1,"OBJECTIVE"
1,background,18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,intervention,18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,population,18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,outcome,18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,other,18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,"study design",18164330,2,"To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patients with traumatic brain injury (TBI)."
0,background,18164330,3,"DESIGN"
0,intervention,18164330,3,"DESIGN"
0,population,18164330,3,"DESIGN"
0,outcome,18164330,3,"DESIGN"
1,other,18164330,3,"DESIGN"
0,"study design",18164330,3,"DESIGN"
0,background,18164330,4,"Prospective cohort study."
0,intervention,18164330,4,"Prospective cohort study."
0,population,18164330,4,"Prospective cohort study."
0,outcome,18164330,4,"Prospective cohort study."
0,other,18164330,4,"Prospective cohort study."
1,"study design",18164330,4,"Prospective cohort study."
0,background,18164330,5,"SETTING"
0,intervention,18164330,5,"SETTING"
0,population,18164330,5,"SETTING"
0,outcome,18164330,5,"SETTING"
1,other,18164330,5,"SETTING"
0,"study design",18164330,5,"SETTING"
0,background,18164330,6,"Acute inpatient TBI rehabilitation."
0,intervention,18164330,6,"Acute inpatient TBI rehabilitation."
0,population,18164330,6,"Acute inpatient TBI rehabilitation."
0,outcome,18164330,6,"Acute inpatient TBI rehabilitation."
1,other,18164330,6,"Acute inpatient TBI rehabilitation."
0,"study design",18164330,6,"Acute inpatient TBI rehabilitation."
0,background,18164330,7,"PARTICIPANTS"
0,intervention,18164330,7,"PARTICIPANTS"
0,population,18164330,7,"PARTICIPANTS"
0,outcome,18164330,7,"PARTICIPANTS"
1,other,18164330,7,"PARTICIPANTS"
0,"study design",18164330,7,"PARTICIPANTS"
0,background,18164330,8,"Participants were 1748 persons with TBI."
0,intervention,18164330,8,"Participants were 1748 persons with TBI."
1,population,18164330,8,"Participants were 1748 persons with TBI."
0,outcome,18164330,8,"Participants were 1748 persons with TBI."
0,other,18164330,8,"Participants were 1748 persons with TBI."
0,"study design",18164330,8,"Participants were 1748 persons with TBI."
0,background,18164330,9,"INTERVENTIONS"
0,intervention,18164330,9,"INTERVENTIONS"
0,population,18164330,9,"INTERVENTIONS"
0,outcome,18164330,9,"INTERVENTIONS"
1,other,18164330,9,"INTERVENTIONS"
0,"study design",18164330,9,"INTERVENTIONS"
0,background,18164330,10,"Not applicable."
0,intervention,18164330,10,"Not applicable."
0,population,18164330,10,"Not applicable."
0,outcome,18164330,10,"Not applicable."
1,other,18164330,10,"Not applicable."
0,"study design",18164330,10,"Not applicable."
0,background,18164330,11,"MAIN OUTCOME MEASURES"
0,intervention,18164330,11,"MAIN OUTCOME MEASURES"
0,population,18164330,11,"MAIN OUTCOME MEASURES"
0,outcome,18164330,11,"MAIN OUTCOME MEASURES"
1,other,18164330,11,"MAIN OUTCOME MEASURES"
0,"study design",18164330,11,"MAIN OUTCOME MEASURES"
0,background,18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
0,intervention,18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
0,population,18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
0,outcome,18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
1,other,18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
0,"study design",18164330,12,"Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview."
0,background,18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
0,intervention,18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
0,population,18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
0,outcome,18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
1,other,18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
0,"study design",18164330,13,"Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation."
0,background,18164330,14,"RESULTS"
0,intervention,18164330,14,"RESULTS"
0,population,18164330,14,"RESULTS"
0,outcome,18164330,14,"RESULTS"
1,other,18164330,14,"RESULTS"
0,"study design",18164330,14,"RESULTS"
0,background,18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
0,intervention,18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
0,population,18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
1,outcome,18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
0,other,18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
0,"study design",18164330,15,"Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores."
0,background,18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
0,intervention,18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
0,population,18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
1,outcome,18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
0,other,18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
0,"study design",18164330,16,"A higher BAL was associated with poorer functional status on the DRS."
0,background,18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
0,intervention,18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
0,population,18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
1,outcome,18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
0,other,18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
0,"study design",18164330,17,"Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS."
0,background,18164330,18,"CONCLUSIONS"
0,intervention,18164330,18,"CONCLUSIONS"
0,population,18164330,18,"CONCLUSIONS"
0,outcome,18164330,18,"CONCLUSIONS"
1,other,18164330,18,"CONCLUSIONS"
0,"study design",18164330,18,"CONCLUSIONS"
0,background,18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
0,intervention,18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
0,population,18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
1,outcome,18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
0,other,18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
0,"study design",18164330,19,"The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest."
0,background,18164330,20,"Injury severity had a more significant association with TBI functional status."
0,intervention,18164330,20,"Injury severity had a more significant association with TBI functional status."
0,population,18164330,20,"Injury severity had a more significant association with TBI functional status."
1,outcome,18164330,20,"Injury severity had a more significant association with TBI functional status."
0,other,18164330,20,"Injury severity had a more significant association with TBI functional status."
0,"study design",18164330,20,"Injury severity had a more significant association with TBI functional status."
0,background,18202732,1,"BACKGROUND"
0,intervention,18202732,1,"BACKGROUND"
0,population,18202732,1,"BACKGROUND"
0,outcome,18202732,1,"BACKGROUND"
1,other,18202732,1,"BACKGROUND"
0,"study design",18202732,1,"BACKGROUND"
1,background,18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
0,intervention,18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
0,population,18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
0,outcome,18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
0,other,18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
0,"study design",18202732,2,"There are 3 450 new cases of colorectal cancer in Norway annually."
1,background,18202732,3,"In half of the patients, metastatic disease will evolve with time."
0,intervention,18202732,3,"In half of the patients, metastatic disease will evolve with time."
0,population,18202732,3,"In half of the patients, metastatic disease will evolve with time."
0,outcome,18202732,3,"In half of the patients, metastatic disease will evolve with time."
0,other,18202732,3,"In half of the patients, metastatic disease will evolve with time."
0,"study design",18202732,3,"In half of the patients, metastatic disease will evolve with time."
1,background,18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,intervention,18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,population,18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,outcome,18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,other,18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,"study design",18202732,4,"Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible."
0,background,18202732,5,"MATERIAL AND METHODS"
0,intervention,18202732,5,"MATERIAL AND METHODS"
0,population,18202732,5,"MATERIAL AND METHODS"
0,outcome,18202732,5,"MATERIAL AND METHODS"
1,other,18202732,5,"MATERIAL AND METHODS"
0,"study design",18202732,5,"MATERIAL AND METHODS"
0,background,18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
0,intervention,18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
0,population,18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
0,outcome,18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
1,other,18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
0,"study design",18202732,6,"This paper is based on publications retrieved from a PubMed search, the authors' knowledge of the field and on recent conference abstracts."
0,background,18202732,7,"RESULTS AND INTERPRETATION"
0,intervention,18202732,7,"RESULTS AND INTERPRETATION"
0,population,18202732,7,"RESULTS AND INTERPRETATION"
0,outcome,18202732,7,"RESULTS AND INTERPRETATION"
1,other,18202732,7,"RESULTS AND INTERPRETATION"
0,"study design",18202732,7,"RESULTS AND INTERPRETATION"
0,background,18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
0,intervention,18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
0,population,18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
1,outcome,18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
0,other,18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
0,"study design",18202732,8,"Patients with metastatic colorectal cancer should initially be considered for surgery, and judged if secondary surgery is a possibility."
0,background,18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
0,intervention,18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
0,population,18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
1,outcome,18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
0,other,18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
0,"study design",18202732,9,"Palliative chemotherapy is used to increase survival and maintain quality of life."
0,background,18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
0,intervention,18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
0,population,18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
1,outcome,18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
0,other,18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
0,"study design",18202732,10,"5-FU/calsiumfolinat combined with oxaliplatin or irinotecan is usually given as first line treatment for patients below 75 years--and most of them respond."
0,background,18202732,11,"Median survival is close to two years."
0,intervention,18202732,11,"Median survival is close to two years."
0,population,18202732,11,"Median survival is close to two years."
1,outcome,18202732,11,"Median survival is close to two years."
0,other,18202732,11,"Median survival is close to two years."
0,"study design",18202732,11,"Median survival is close to two years."
0,background,18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
0,intervention,18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
0,population,18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
1,outcome,18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
0,other,18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
0,"study design",18202732,12,"Bevacizumab combined with an irinotecan regimen is an alternative first line treatment."
0,background,18202732,13,"Elderly patients are judged on an individual basis."
0,intervention,18202732,13,"Elderly patients are judged on an individual basis."
0,population,18202732,13,"Elderly patients are judged on an individual basis."
1,outcome,18202732,13,"Elderly patients are judged on an individual basis."
0,other,18202732,13,"Elderly patients are judged on an individual basis."
0,"study design",18202732,13,"Elderly patients are judged on an individual basis."
0,background,18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
0,intervention,18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
0,population,18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
1,outcome,18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
0,other,18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
0,"study design",18202732,14,"Half of the patients will receive second line therapy with the alternative chemotherapy schedule."
0,background,18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
0,intervention,18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
0,population,18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
1,outcome,18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
0,other,18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
0,"study design",18202732,15,"Cetuximab combined with irinotecan is a possible third line treatment."
0,background,18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
0,intervention,18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
0,population,18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
1,outcome,18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
0,other,18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
0,"study design",18202732,16,"Palliative radiotherapy is most often used for inoperable rectal cancer, local recurrences, and bone or brain metastases."
0,background,18253995,1,"BACKGROUND"
0,intervention,18253995,1,"BACKGROUND"
0,population,18253995,1,"BACKGROUND"
0,outcome,18253995,1,"BACKGROUND"
1,other,18253995,1,"BACKGROUND"
0,"study design",18253995,1,"BACKGROUND"
1,background,18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
0,intervention,18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
0,population,18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
0,outcome,18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
0,other,18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
0,"study design",18253995,2,"Obsessive compulsive disorder is a common and disabling disorder."
1,background,18253995,3,"A significant proportion of patients manifest a chronic course."
0,intervention,18253995,3,"A significant proportion of patients manifest a chronic course."
0,population,18253995,3,"A significant proportion of patients manifest a chronic course."
0,outcome,18253995,3,"A significant proportion of patients manifest a chronic course."
0,other,18253995,3,"A significant proportion of patients manifest a chronic course."
0,"study design",18253995,3,"A significant proportion of patients manifest a chronic course."
1,background,18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
0,intervention,18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
0,population,18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
0,outcome,18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
0,other,18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
0,"study design",18253995,4,"Individual randomised controlled trials (RCTs) have shown that selective serotonin re-uptake inhibitors (SSRIs) are effective in this condition."
1,background,18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,intervention,18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,population,18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,outcome,18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,other,18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,"study design",18253995,5,"Previous systematic reviews or meta-analyses summarising the evidence are methodologically problematic or limited in the scope of their analysis."
0,background,18253995,6,"OBJECTIVES"
0,intervention,18253995,6,"OBJECTIVES"
0,population,18253995,6,"OBJECTIVES"
0,outcome,18253995,6,"OBJECTIVES"
1,other,18253995,6,"OBJECTIVES"
0,"study design",18253995,6,"OBJECTIVES"
0,background,18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
0,intervention,18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
0,population,18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
0,outcome,18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
1,other,18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
0,"study design",18253995,7,"To examine the efficacy and adverse effects of serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) in adults."
0,background,18253995,8,"SEARCH STRATEGY"
0,intervention,18253995,8,"SEARCH STRATEGY"
0,population,18253995,8,"SEARCH STRATEGY"
0,outcome,18253995,8,"SEARCH STRATEGY"
1,other,18253995,8,"SEARCH STRATEGY"
0,"study design",18253995,8,"SEARCH STRATEGY"
0,background,18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
0,intervention,18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
0,population,18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
0,outcome,18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
1,other,18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
0,"study design",18253995,9,"CCDANCTR-Studies and CCDANCTR-References were searched on 12/11/2007."
0,background,18253995,10,"Reference lists were checked."
0,intervention,18253995,10,"Reference lists were checked."
0,population,18253995,10,"Reference lists were checked."
0,outcome,18253995,10,"Reference lists were checked."
1,other,18253995,10,"Reference lists were checked."
0,"study design",18253995,10,"Reference lists were checked."
0,background,18253995,11,"Experts in the field were contacted."
0,intervention,18253995,11,"Experts in the field were contacted."
0,population,18253995,11,"Experts in the field were contacted."
0,outcome,18253995,11,"Experts in the field were contacted."
1,other,18253995,11,"Experts in the field were contacted."
0,"study design",18253995,11,"Experts in the field were contacted."
0,background,18253995,12,"SELECTION CRITERIA"
0,intervention,18253995,12,"SELECTION CRITERIA"
0,population,18253995,12,"SELECTION CRITERIA"
0,outcome,18253995,12,"SELECTION CRITERIA"
1,other,18253995,12,"SELECTION CRITERIA"
0,"study design",18253995,12,"SELECTION CRITERIA"
0,background,18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
1,intervention,18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
1,population,18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
0,outcome,18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
0,other,18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
0,"study design",18253995,13,"All RCTs and quasi-RCTs examining the efficacy of SSRIs compared with placebo for OCD in adults were eligible for inclusion."
0,background,18253995,14,"DATA COLLECTION AND ANALYSIS"
0,intervention,18253995,14,"DATA COLLECTION AND ANALYSIS"
0,population,18253995,14,"DATA COLLECTION AND ANALYSIS"
0,outcome,18253995,14,"DATA COLLECTION AND ANALYSIS"
1,other,18253995,14,"DATA COLLECTION AND ANALYSIS"
0,"study design",18253995,14,"DATA COLLECTION AND ANALYSIS"
0,background,18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
0,intervention,18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
0,population,18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
0,outcome,18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
1,other,18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
0,"study design",18253995,15,"Selection of studies and data extraction were carried out by two review authors independently, and quality assessment of studies was undertaken."
0,background,18253995,16,"Data analysis was conducted using Review Manager software."
0,intervention,18253995,16,"Data analysis was conducted using Review Manager software."
0,population,18253995,16,"Data analysis was conducted using Review Manager software."
0,outcome,18253995,16,"Data analysis was conducted using Review Manager software."
1,other,18253995,16,"Data analysis was conducted using Review Manager software."
0,"study design",18253995,16,"Data analysis was conducted using Review Manager software."
0,background,18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
0,intervention,18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
0,population,18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
0,outcome,18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
1,other,18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
0,"study design",18253995,17,"Summary measures were produced using the weighted mean difference (WMD) for continuous data and relative risk (RR) for dichotomous data, with 95% confidence intervals (CI)."
0,background,18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
0,intervention,18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
0,population,18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
0,outcome,18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
1,other,18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
0,"study design",18253995,18,"SSRIs were examined as an overall group of drugs, and as individual drugs."
0,background,18253995,19,"MAIN RESULTS"
0,intervention,18253995,19,"MAIN RESULTS"
0,population,18253995,19,"MAIN RESULTS"
0,outcome,18253995,19,"MAIN RESULTS"
1,other,18253995,19,"MAIN RESULTS"
0,"study design",18253995,19,"MAIN RESULTS"
0,background,18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
0,intervention,18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
0,population,18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
1,outcome,18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
0,other,18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
0,"study design",18253995,20,"Seventeen studies were included in the review, involving 3097 participants."
0,background,18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
0,intervention,18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
0,population,18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
1,outcome,18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
0,other,18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
0,"study design",18253995,21,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57)."
0,background,18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
0,intervention,18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
0,population,18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
1,outcome,18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
0,other,18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
0,"study design",18253995,22,"The WMD for individual SSRI drugs were similar and not statistically different."
0,background,18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
0,intervention,18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
0,population,18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
1,outcome,18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
0,other,18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
0,"study design",18253995,23,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17)."
0,background,18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
0,intervention,18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
0,population,18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
1,outcome,18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
0,other,18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
0,"study design",18253995,24,"The pooled RR was shown to be similar between individual SSRI drugs."
0,background,18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
0,intervention,18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
0,population,18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
1,outcome,18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
0,other,18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
0,"study design",18253995,25,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significan"
0,background,18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
0,intervention,18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
0,population,18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
1,outcome,18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
0,other,18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
0,"study design",18253995,26,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs."
0,background,18253995,27,"AUTHORS'"
0,intervention,18253995,27,"AUTHORS'"
0,population,18253995,27,"AUTHORS'"
0,outcome,18253995,27,"AUTHORS'"
1,other,18253995,27,"AUTHORS'"
0,"study design",18253995,27,"AUTHORS'"
0,background,18253995,28,"CONCLUSIONS"
0,intervention,18253995,28,"CONCLUSIONS"
0,population,18253995,28,"CONCLUSIONS"
0,outcome,18253995,28,"CONCLUSIONS"
1,other,18253995,28,"CONCLUSIONS"
0,"study design",18253995,28,"CONCLUSIONS"
0,background,18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
0,intervention,18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
0,population,18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
1,outcome,18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
0,other,18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
0,"study design",18253995,29,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs."
0,background,18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
0,intervention,18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
0,population,18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
1,outcome,18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
0,other,18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
0,"study design",18253995,30,"The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established."
1,background,18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
0,intervention,18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
0,population,18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
0,outcome,18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
0,other,18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
0,"study design",18298983,1,"The majority of Americans die in hospitals where shortcomings in end-of-life care are endemic."
1,background,18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
0,intervention,18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
0,population,18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
0,outcome,18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
0,other,18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
0,"study design",18298983,2,"Patients often die alone, in pain, their wishes unheeded by physicians."
1,background,18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
0,intervention,18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
0,population,18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
0,outcome,18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
0,other,18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
0,"study design",18298983,3,"Hospitalists can improve end-of-life care in hospitals dramatically."
1,background,18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
0,intervention,18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
0,population,18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
0,outcome,18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
0,other,18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
0,"study design",18298983,4,"Hospitalists must relieve symptoms, such as pain, dyspnea, nausea, vomiting, delirium, and depression; communicate clearly; and provide support to patients and families."
1,background,18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
0,intervention,18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
0,population,18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
0,outcome,18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
0,other,18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
0,"study design",18298983,5,"Hospitalists can increase the number and the timeliness of hospice referrals, allowing more patients to die at home."
1,background,18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
0,intervention,18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
0,population,18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
0,outcome,18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
0,other,18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
0,"study design",18298983,6,"Finally, physicians must attend to their own sense of grief and loss to avoid burnout and to continue to reap the rewards end-of-life care provides."
1,background,18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
0,intervention,18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
0,population,18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
0,outcome,18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
0,other,18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
0,"study design",18327351,1,"Around two-thirds of people with incurable diseases in economically developed countries wish to die at home, but less than one-third succeed in doing so."
1,background,18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
0,intervention,18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
0,population,18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
0,outcome,18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
0,other,18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
0,"study design",18327351,2,"Developing primary care-based services for the dying in the community is essential to reach and serve the whole population."
1,background,18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
0,intervention,18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
0,population,18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
0,outcome,18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
0,other,18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
0,"study design",18327351,3,"Three typical &quot;trajectories&quot; or patterns of decline in the last year(s) of life have recently been described, and each of these may require different models of care to best meet the needs of patients."
1,background,18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
0,intervention,18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
0,population,18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
0,outcome,18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
0,other,18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
0,"study design",18327351,4,"The palliative care approach must be urgently extended to patients with non-malignant conditions who have comparable concerns to and in some cases even greater and more prolonged unmet needs than cancer patients."
1,background,18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
0,intervention,18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
0,population,18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
0,outcome,18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
0,other,18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
0,"study design",18327351,5,"Primary care professionals have the potential and ability to provide end-of-life care for most patients, given adequate training, resources and access to care facilities and specialist advice when needed."
1,background,18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
0,intervention,18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
0,population,18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
0,outcome,18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
0,other,18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
0,"study design",18327351,6,"They are ideally placed to identify patients at diagnosis, hospital discharge or disease progression who might benefit from an early palliative care approach."
1,background,18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
0,intervention,18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
0,population,18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
0,outcome,18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
0,other,18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
0,"study design",18327351,7,"In the UK, Australia and US, some important initiatives are gaining momentum to facilitate the delivery of primary palliative services."
1,background,18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
0,intervention,18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
0,population,18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
0,outcome,18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
0,other,18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
0,"study design",18327351,8,"In Singapore, the involvement of family physicians in end-of-life care is very low."
1,background,18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,intervention,18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,population,18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,outcome,18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,other,18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,"study design",18327351,9,"A local survey is currently being conducted to identify the challenges in getting more family physicians involved."
0,background,18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
0,intervention,18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
0,population,18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
1,outcome,18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
0,other,18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
0,"study design",18327351,10,"Given adequate time and resources, community professionals throughout the world can provide effective, equitable, and accessible primary palliative care, and form a solid bridge of communication and support between primary and secondary care."
1,background,18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
0,intervention,18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
0,population,18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
0,outcome,18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
0,other,18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
0,"study design",18367664,1,"Activation of peroxisome proliferator-activated receptor (PPAR)-alpha, a member of the nuclear receptor superfamily, modulates inflammation and tissue injury events associated with spinal cord trauma in mice."
1,background,18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,intervention,18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,population,18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,outcome,18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,other,18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,"study design",18367664,2,"Palmitoylethanolamide (PEA), the naturally occurring amide of palmitic acid and ethanolamine, reduces pain and inflammation through a mechanism dependent on PPAR-alpha activation."
0,background,18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
1,intervention,18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
1,population,18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
0,outcome,18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
0,other,18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
0,"study design",18367664,3,"The aim of the present study was to evaluate the effect of the PEA on secondary damage induced by experimental spinal cord injury (SCI) in mice."
0,background,18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
1,intervention,18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
0,population,18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
0,outcome,18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
0,other,18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
0,"study design",18367664,4,"SCI was induced by application of vascular clips to the dura mater via a four-level T(5)-T(8) laminectomy."
0,background,18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
0,intervention,18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
0,population,18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
1,outcome,18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
0,other,18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
0,"study design",18367664,5,"This resulted in severe trauma characterized by edema, neutrophil infiltration, and production of inflammatory mediators, tissue damage, and apoptosis."
0,background,18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
0,intervention,18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
0,population,18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
1,outcome,18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
0,other,18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
0,"study design",18367664,6,"Repeated PEA administration (10 mg/kg i.p.; 30 min before and 1 and 6 h after SCI) significantly reduced: 1) the degree of spinal cord inflammation and tissue injury, 2) neutrophil infiltration, 3) nitrotyrosine formation, 4) proinflammatory cytokine expr"
0,background,18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
0,intervention,18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
0,population,18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
1,outcome,18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
0,other,18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
0,"study design",18367664,7,"Moreover, PEA treatment significantly ameliorated the recovery of motor limb function."
0,background,18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
0,intervention,18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
0,population,18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
1,outcome,18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
0,other,18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
0,"study design",18367664,8,"Together, the results indicate that PEA reduces inflammation and tissue injury associated with SCI and suggest a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma."
0,background,18371488,1,"BACKGROUND"
0,intervention,18371488,1,"BACKGROUND"
0,population,18371488,1,"BACKGROUND"
0,outcome,18371488,1,"BACKGROUND"
1,other,18371488,1,"BACKGROUND"
0,"study design",18371488,1,"BACKGROUND"
1,background,18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
0,intervention,18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
0,population,18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
0,outcome,18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
0,other,18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
0,"study design",18371488,2,"Functional mitral regurgitation (MR) is a powerful predictor of poor prognosis in patients with chronic heart failure (CHF) due to left ventricular systolic dysfunction (LVSD)."
1,background,18371488,3,"However, severity of MR varies with dynamic exercise."
0,intervention,18371488,3,"However, severity of MR varies with dynamic exercise."
0,population,18371488,3,"However, severity of MR varies with dynamic exercise."
0,outcome,18371488,3,"However, severity of MR varies with dynamic exercise."
0,other,18371488,3,"However, severity of MR varies with dynamic exercise."
0,"study design",18371488,3,"However, severity of MR varies with dynamic exercise."
0,background,18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
0,intervention,18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
0,population,18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
0,outcome,18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
1,other,18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
0,"study design",18371488,4,"Accordingly, we sought to assess the prognostic value of exercise-induced changes in functional MR in patients with LVSD and functional MR at rest."
0,background,18371488,5,"METHODS"
0,intervention,18371488,5,"METHODS"
0,population,18371488,5,"METHODS"
0,outcome,18371488,5,"METHODS"
1,other,18371488,5,"METHODS"
0,"study design",18371488,5,"METHODS"
0,background,18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
1,intervention,18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
1,population,18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
0,outcome,18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
0,other,18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
0,"study design",18371488,6,"One hundred four patients with chronic heart failure due to LVSD (ejection fraction [EF] &lt; 45%) and functional MR at rest underwent conventional continuous 2-dimensional Doppler echocardiography at rest and during maximal symptom-limited exercise."
0,background,18371488,7,"The primary end point of the study was all-cause mortality."
0,intervention,18371488,7,"The primary end point of the study was all-cause mortality."
0,population,18371488,7,"The primary end point of the study was all-cause mortality."
0,outcome,18371488,7,"The primary end point of the study was all-cause mortality."
1,other,18371488,7,"The primary end point of the study was all-cause mortality."
0,"study design",18371488,7,"The primary end point of the study was all-cause mortality."
0,background,18371488,8,"The median follow-up period was 20 months."
0,intervention,18371488,8,"The median follow-up period was 20 months."
0,population,18371488,8,"The median follow-up period was 20 months."
0,outcome,18371488,8,"The median follow-up period was 20 months."
1,other,18371488,8,"The median follow-up period was 20 months."
0,"study design",18371488,8,"The median follow-up period was 20 months."
0,background,18371488,9,"RESULTS"
0,intervention,18371488,9,"RESULTS"
0,population,18371488,9,"RESULTS"
0,outcome,18371488,9,"RESULTS"
1,other,18371488,9,"RESULTS"
0,"study design",18371488,9,"RESULTS"
0,background,18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
0,intervention,18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
0,population,18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
0,outcome,18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
1,other,18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
0,"study design",18371488,10,"Fifty-six patients (54%) had ischemic cardiomyopathy."
0,background,18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
0,intervention,18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
0,population,18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
1,outcome,18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
0,other,18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
0,"study design",18371488,11,"When feasible, all 56 patients with ischemic cardiomyopathy had undergone revascularization procedures before enrollment into the study."
0,background,18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
0,intervention,18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
0,population,18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
1,outcome,18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
0,other,18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
0,"study design",18371488,12,"In the whole patient cohort, resting LV end-diastolic volume was 205 +/- 76 mL and EF was 26% +/- 9%."
0,background,18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
0,intervention,18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
0,population,18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
1,outcome,18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
0,other,18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
0,"study design",18371488,13,"Univariate predictors of death were functional class (New York Heart Association), LV EF, LV end-diastolic volume, resting mitral effective regurgitant orifice, mitral E deceleration time, tricuspid annular plane systolic excursion &lt; or = 14 mm, systol"
0,background,18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
0,intervention,18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
0,population,18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
1,outcome,18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
0,other,18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
0,"study design",18371488,14,"Exercise-induced change in mitral effective regurgitant orifice did not predict survival (HR 0.99, 95% CI 0.94-1.04, P = .63)."
0,background,18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
0,intervention,18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
0,population,18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
1,outcome,18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
0,other,18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
0,"study design",18371488,15,"By Cox multivariate analysis, resting LV end-diastolic volume and tricuspid annular plane systolic excursion &lt; or = 14 mm were the independent predictors of death."
0,background,18371488,16,"CONCLUSIONS"
0,intervention,18371488,16,"CONCLUSIONS"
0,population,18371488,16,"CONCLUSIONS"
0,outcome,18371488,16,"CONCLUSIONS"
1,other,18371488,16,"CONCLUSIONS"
0,"study design",18371488,16,"CONCLUSIONS"
0,background,18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
0,intervention,18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
0,population,18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
1,outcome,18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
0,other,18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
0,"study design",18371488,17,"Exercise Doppler echocardiography does not refine the predictive value of resting Doppler echocardiography in patients with LVSD and functional MR at rest."
0,background,18392155,1,"INTRODUCTION"
0,intervention,18392155,1,"INTRODUCTION"
0,population,18392155,1,"INTRODUCTION"
0,outcome,18392155,1,"INTRODUCTION"
1,other,18392155,1,"INTRODUCTION"
0,"study design",18392155,1,"INTRODUCTION"
1,background,18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
0,intervention,18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
0,population,18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
0,outcome,18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
0,other,18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
0,"study design",18392155,2,"We outline a transactional model of parent-child interactions which proposes that characteristics of attention-deficit/hyperactivity disorder (ADHD) appear early in a child's life and present challenges to the parent's ability to maintain consistent and r"
1,background,18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,intervention,18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,population,18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,outcome,18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,other,18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,"study design",18392155,3,"In turn, the presence of harsh or inconsistent parenting is hypothesized to contribute to the development of child oppositional behaviour and conduct problems."
0,background,18392155,4,"METHOD AND RESULTS"
0,intervention,18392155,4,"METHOD AND RESULTS"
0,population,18392155,4,"METHOD AND RESULTS"
0,outcome,18392155,4,"METHOD AND RESULTS"
1,other,18392155,4,"METHOD AND RESULTS"
0,"study design",18392155,4,"METHOD AND RESULTS"
0,background,18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
0,intervention,18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
0,population,18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
0,outcome,18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
0,other,18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
1,"study design",18392155,5,"We briefly discuss existing cross-sectional evidence in support of this model and then highlight five longitudinal studies that provide stronger support, showing that difficulties in parenting predict the development of oppositional and conduct problems i"
0,background,18392155,6,"CONCLUSION"
0,intervention,18392155,6,"CONCLUSION"
0,population,18392155,6,"CONCLUSION"
0,outcome,18392155,6,"CONCLUSION"
1,other,18392155,6,"CONCLUSION"
0,"study design",18392155,6,"CONCLUSION"
0,background,18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
0,intervention,18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
0,population,18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
1,outcome,18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
0,other,18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
0,"study design",18392155,7,"We conclude with a discussion of the clinical implications of this model and evidence, emphasizing the need for early interventions in ADHD focused on parenting."
0,background,18424647,1,"OBJECTIVE"
0,intervention,18424647,1,"OBJECTIVE"
0,population,18424647,1,"OBJECTIVE"
0,outcome,18424647,1,"OBJECTIVE"
1,other,18424647,1,"OBJECTIVE"
0,"study design",18424647,1,"OBJECTIVE"
1,background,18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,intervention,18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,population,18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,outcome,18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,other,18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,"study design",18424647,2,"The purpose of this study was to assess factors that affect the quality of performance and interpretation of sonography of adnexal masses."
0,background,18424647,3,"METHODS"
0,intervention,18424647,3,"METHODS"
0,population,18424647,3,"METHODS"
0,outcome,18424647,3,"METHODS"
1,other,18424647,3,"METHODS"
0,"study design",18424647,3,"METHODS"
0,background,18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
1,intervention,18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
1,population,18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
0,outcome,18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
0,other,18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
0,"study design",18424647,4,"Two gynecologic sonographers performed blinded reviews of up to 3 sonograms within 5 years before surgery in 325 consecutive women who underwent oophorectomy (610 sonograms)."
0,background,18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
0,intervention,18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
0,population,18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
0,outcome,18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
1,other,18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
0,"study design",18424647,5,"Three 5-point quality scores were assigned (with 5 being the best score) on the basis of the technical quality of the images, accurate description of findings, and summary impression in the report."
0,background,18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
0,intervention,18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
0,population,18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
0,outcome,18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
1,other,18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
0,"study design",18424647,6,"The location of the examination (on-site, remote, or emergency department), type of fellowship, practice experience (&lt;5, 5-10, or >10 years), and specialty (women's imaging, abdominal imaging, or other) of the radiologists were recorded."
0,background,18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
0,intervention,18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
0,population,18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
0,outcome,18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
1,other,18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
0,"study design",18424647,7,"Analysis of variance was used to assess the impact of these multiple factors on quality."
0,background,18424647,8,"RESULTS"
0,intervention,18424647,8,"RESULTS"
0,population,18424647,8,"RESULTS"
0,outcome,18424647,8,"RESULTS"
1,other,18424647,8,"RESULTS"
0,"study design",18424647,8,"RESULTS"
0,background,18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
0,intervention,18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
0,population,18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
1,outcome,18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
0,other,18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
0,"study design",18424647,9,"No significant differences were found among 31 radiologists on the basis of the type of training, years in practice, or number of examinations read."
0,background,18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
0,intervention,18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
0,population,18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
1,outcome,18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
0,other,18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
0,"study design",18424647,10,"Average scores among radiologists for technical quality, findings, and impressions were 4.96, 4.88, and 4.83, respectively."
0,background,18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
0,intervention,18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
0,population,18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
1,outcome,18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
0,other,18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
0,"study design",18424647,11,"Radiologists who specialized in women's imaging performed best in the quality of their impressions (4.86 versus 4.79; P = .029)."
0,background,18424647,12,"There were no significant differences in scores with respect to the examination location."
0,intervention,18424647,12,"There were no significant differences in scores with respect to the examination location."
0,population,18424647,12,"There were no significant differences in scores with respect to the examination location."
1,outcome,18424647,12,"There were no significant differences in scores with respect to the examination location."
0,other,18424647,12,"There were no significant differences in scores with respect to the examination location."
0,"study design",18424647,12,"There were no significant differences in scores with respect to the examination location."
0,background,18424647,13,"CONCLUSIONS"
0,intervention,18424647,13,"CONCLUSIONS"
0,population,18424647,13,"CONCLUSIONS"
0,outcome,18424647,13,"CONCLUSIONS"
1,other,18424647,13,"CONCLUSIONS"
0,"study design",18424647,13,"CONCLUSIONS"
0,background,18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
0,intervention,18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
0,population,18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
1,outcome,18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
0,other,18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
0,"study design",18424647,14,"Within this sample of radiologists, the technical quality of the examinations was not affected by the type of training or subspecialty practice."
0,background,18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
0,intervention,18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
0,population,18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
1,outcome,18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
0,other,18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
0,"study design",18424647,15,"Reports of adnexal mass findings were accurately described by all radiologists, although specialization in women's imaging improved the ability to provide an accurate impression."
0,background,18600145,1,"STUDY DESIGN AND OBJECTIVE"
0,intervention,18600145,1,"STUDY DESIGN AND OBJECTIVE"
0,population,18600145,1,"STUDY DESIGN AND OBJECTIVE"
0,outcome,18600145,1,"STUDY DESIGN AND OBJECTIVE"
1,other,18600145,1,"STUDY DESIGN AND OBJECTIVE"
0,"study design",18600145,1,"STUDY DESIGN AND OBJECTIVE"
0,background,18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
0,intervention,18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
0,population,18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
0,outcome,18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
1,other,18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
0,"study design",18600145,2,"The aim of this study was to assess the effectiveness and safety of percutaneous vertebroplasty, a new technique for the treatment of vertebral pain deriving from fracture or gross osteolytic lesion due to multiple myeloma spinal involvement."
0,background,18600145,3,"SUMMARY OF BACKGROUND DATA"
0,intervention,18600145,3,"SUMMARY OF BACKGROUND DATA"
0,population,18600145,3,"SUMMARY OF BACKGROUND DATA"
0,outcome,18600145,3,"SUMMARY OF BACKGROUND DATA"
1,other,18600145,3,"SUMMARY OF BACKGROUND DATA"
0,"study design",18600145,3,"SUMMARY OF BACKGROUND DATA"
1,background,18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,intervention,18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,population,18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,outcome,18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,other,18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,"study design",18600145,4,"Spinal osteolytic lesions are frequently associated with hematologic malignancies due to primary localization of disease (multiple myeloma and rarely lymphoma) or secondary effect of intensive corticosteroid therapy."
0,background,18600145,5,"METHODS"
0,intervention,18600145,5,"METHODS"
0,population,18600145,5,"METHODS"
0,outcome,18600145,5,"METHODS"
1,other,18600145,5,"METHODS"
0,"study design",18600145,5,"METHODS"
0,background,18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
1,intervention,18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
1,population,18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
0,outcome,18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
0,other,18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
0,"study design",18600145,6,"We treated 64 patients (34 males, 30 females; mean age 71.4+/-9.6 y) with pain refractory to conventional medical therapy (analgesics, bed-rest, bracing with orthopedic devices for more than 3 wk) localized in spine, in the absence of neurologic signs."
0,background,18600145,7,"RESULTS"
0,intervention,18600145,7,"RESULTS"
0,population,18600145,7,"RESULTS"
0,outcome,18600145,7,"RESULTS"
1,other,18600145,7,"RESULTS"
0,"study design",18600145,7,"RESULTS"
0,background,18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
0,intervention,18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
0,population,18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
1,outcome,18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
0,other,18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
0,"study design",18600145,8,"This treatment generated swift pain relief associated with an evident augmentation in vertebral resistance."
0,background,18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
0,intervention,18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
0,population,18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
1,outcome,18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
0,other,18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
0,"study design",18600145,9,"Average preprocedural pain level for all patients was reported to be 8.04+/-1.4 whereas average pain level at 1 and 6 months follow-up period was 1.82+/-1.84 and 1.92+/-1.68, respectively."
0,background,18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
0,intervention,18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
0,population,18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
1,outcome,18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
0,other,18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
0,"study design",18600145,10,"Although preprocedure and postprocedure demonstrated a statistically significant reduction in numeric pain scores (P&lt;0.01), the pain level at 1 and 6 months was not considered statistically significant."
0,background,18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
0,intervention,18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
0,population,18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
1,outcome,18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
0,other,18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
0,"study design",18600145,11,"No procedure-related complications were observed in either leakages of polymethylmethacrylate in the epidural or foraminal area or in complications of pulmonary embolism for venous plexus involvement."
0,background,18600145,12,"CONCLUSIONS"
0,intervention,18600145,12,"CONCLUSIONS"
0,population,18600145,12,"CONCLUSIONS"
0,outcome,18600145,12,"CONCLUSIONS"
1,other,18600145,12,"CONCLUSIONS"
0,"study design",18600145,12,"CONCLUSIONS"
0,background,18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
0,intervention,18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
0,population,18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
1,outcome,18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
0,other,18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
0,"study design",18600145,13,"Vertebroplasty is widely considered as an alternative, effective, simple, and safe technique in the treatment of neoplastic vertebral localizations consequent to hematologic malignancies."
0,background,18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
0,intervention,18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
0,population,18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
1,outcome,18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
0,other,18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
0,"study design",18600145,14,"The same injection of polymethylmethacrylate can be executed before radiation therapy treatment, synergizing its delayed analgesic action to pain, after failure or in the case of local recurrences."
1,background,18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,intervention,18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,population,18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,outcome,18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,other,18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,"study design",18602860,1,"Animal and epidemiological studies confirm an impact of the fatty-acid composition in the diet on cancer development."
0,background,18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
1,intervention,18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
1,population,18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
0,outcome,18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
0,other,18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
0,"study design",18602860,2,"We investigated the role of supplementation of the diet of female F344-rats with sunflower, rapeseed, olive or coconut oil on the formation of the promutagenic, exocyclic 1,N2-propanodeoxyguanosine adduct of the main lipid peroxidation product 4-hydroxy-2"
0,background,18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
0,intervention,18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
0,population,18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
0,outcome,18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
1,other,18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
0,"study design",18602860,3,"This adduct is considered as the predominant DNA adduct arising from lipid peroxidation."
0,background,18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
0,intervention,18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
0,population,18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
1,outcome,18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
0,other,18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
0,"study design",18602860,4,"The correlations between adduct levels and the different fatty acids were not uniform for all organs."
0,background,18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
0,intervention,18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
0,population,18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
1,outcome,18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
0,other,18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
0,"study design",18602860,5,"No clear relationships between fatty acids and adduct levels were found in the colon."
0,background,18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
0,intervention,18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
0,population,18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
1,outcome,18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
0,other,18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
0,"study design",18602860,6,"Significant positive correlations were observed between linoleic acid, total polyunsaturated fatty acids (PUFAs), vitamin E and DNA adduct levels in the small intestine and in the kidney."
0,background,18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
0,intervention,18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
0,population,18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
1,outcome,18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
0,other,18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
0,"study design",18602860,7,"The results indicate an increasing effect on cancer risk in these organs as a result of high intake of linoleic acid."
0,background,18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
0,intervention,18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
0,population,18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
1,outcome,18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
0,other,18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
0,"study design",18602860,8,"Inverse relationships between linoleic acid, PUFA and vitamin E intake and adduct levels were found in the glandular stomach and the lung."
0,background,18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
0,intervention,18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
0,population,18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
1,outcome,18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
0,other,18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
0,"study design",18602860,9,"We could not confirm a chemopreventive effect of linolenic acid (C-18 omega-3 PUFA) on the formation of adducts in our animal study, as was shown in white blood cells of women in a previous study."
0,background,18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
0,intervention,18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
0,population,18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
1,outcome,18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
0,other,18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
0,"study design",18602860,10,"A tendency towards a decrease in adduct levels was seen with monounsaturated fatty acids (MUFAs) in all organs except the lung."
0,background,18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
0,intervention,18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
0,population,18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
1,outcome,18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
0,other,18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
0,"study design",18602860,11,"Saturated fatty acids showed a significant positive correlation with adduct levels in the mucosa of the glandular stomach and a significant inverse correlation in the small intestine."
0,background,18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
0,intervention,18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
0,population,18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
1,outcome,18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
0,other,18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
0,"study design",18602860,12,"Saturated fatty acids are not considered to directly influence lipid peroxidation to a major extent."
0,background,18671474,1,"BACKGROUND"
0,intervention,18671474,1,"BACKGROUND"
0,population,18671474,1,"BACKGROUND"
0,outcome,18671474,1,"BACKGROUND"
1,other,18671474,1,"BACKGROUND"
0,"study design",18671474,1,"BACKGROUND"
1,background,18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
0,intervention,18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
0,population,18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
0,outcome,18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
0,other,18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
0,"study design",18671474,2,"Tizanidine hydrochloride, an alpha(2)-adrenergic receptor agonist, is a widely used medication for the treatment of muscle spasticity."
1,background,18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
0,intervention,18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
0,population,18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
0,outcome,18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
0,other,18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
0,"study design",18671474,3,"Clinical studies have supported its use in the management of spasticity caused by multiple sclerosis (MS), acquired brain injury or spinal cord injury."
1,background,18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,intervention,18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,population,18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,outcome,18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,other,18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,"study design",18671474,4,"It has also been shown to be clinically effective in the management of pain syndromes, such as: myofascial pain, lower back pain and trigeminal neuralgia."
0,background,18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
0,intervention,18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
0,population,18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
0,outcome,18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
1,other,18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
0,"study design",18671474,5,"This review summarizes the recent findings on the clinical application of tizanidine."
0,background,18671474,6,"OBJECTIVE"
0,intervention,18671474,6,"OBJECTIVE"
0,population,18671474,6,"OBJECTIVE"
0,outcome,18671474,6,"OBJECTIVE"
1,other,18671474,6,"OBJECTIVE"
0,"study design",18671474,6,"OBJECTIVE"
0,background,18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
0,intervention,18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
0,population,18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
0,outcome,18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
1,other,18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
0,"study design",18671474,7,"Our objective was to review and summarize the medical literature regarding the evidence for the usefulness of tizanidine in the management of spasticity and in pain syndromes such as myofascial pain."
0,background,18671474,8,"METHODS"
0,intervention,18671474,8,"METHODS"
0,population,18671474,8,"METHODS"
0,outcome,18671474,8,"METHODS"
1,other,18671474,8,"METHODS"
0,"study design",18671474,8,"METHODS"
0,background,18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
0,intervention,18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
0,population,18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
0,outcome,18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
1,other,18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
0,"study design",18671474,9,"We reviewed the current medical and pharmacology literature through various internet literature searches."
0,background,18671474,10,"This information was then synthesized and presented in paragraph and table form."
0,intervention,18671474,10,"This information was then synthesized and presented in paragraph and table form."
0,population,18671474,10,"This information was then synthesized and presented in paragraph and table form."
0,outcome,18671474,10,"This information was then synthesized and presented in paragraph and table form."
1,other,18671474,10,"This information was then synthesized and presented in paragraph and table form."
0,"study design",18671474,10,"This information was then synthesized and presented in paragraph and table form."
0,background,18671474,11,"RESULTS/CONCLUSION"
0,intervention,18671474,11,"RESULTS/CONCLUSION"
0,population,18671474,11,"RESULTS/CONCLUSION"
0,outcome,18671474,11,"RESULTS/CONCLUSION"
1,other,18671474,11,"RESULTS/CONCLUSION"
0,"study design",18671474,11,"RESULTS/CONCLUSION"
0,background,18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
0,intervention,18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
0,population,18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
1,outcome,18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
0,other,18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
0,"study design",18671474,12,"Tizanidine hydrochloride is a very useful medication in patients suffering from spasticity caused by MS, acquired brain injury or spinal cord injury."
0,background,18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
0,intervention,18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
0,population,18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
1,outcome,18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
0,other,18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
0,"study design",18671474,13,"It can also be helpful in patients suffering from chronic neck and/or lower back pain who have a myofascial component to their pain."
0,background,18671474,14,"Doses should be started at low dose and gradually titrated to effect."
0,intervention,18671474,14,"Doses should be started at low dose and gradually titrated to effect."
0,population,18671474,14,"Doses should be started at low dose and gradually titrated to effect."
1,outcome,18671474,14,"Doses should be started at low dose and gradually titrated to effect."
0,other,18671474,14,"Doses should be started at low dose and gradually titrated to effect."
0,"study design",18671474,14,"Doses should be started at low dose and gradually titrated to effect."
1,background,18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
0,intervention,18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
0,population,18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
0,outcome,18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
0,other,18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
0,"study design",18728841,1,"Bone metastasis from breast cancer often cause significant morbidity including pain, impaired mobility, pathological fracture, and spinal cord compression."
1,background,18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
0,intervention,18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
0,population,18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
0,outcome,18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
0,other,18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
0,"study design",18728841,2,"Bisphosphonates play an important role in preventing these skeletal related events and are the standard of care for patients with bone metastasis from breast cancer."
1,background,18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
0,intervention,18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
0,population,18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
0,outcome,18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
0,other,18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
0,"study design",18728841,3,"Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations."
1,background,18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
0,intervention,18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
0,population,18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
0,outcome,18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
0,other,18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
0,"study design",18728841,4,"It has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks."
1,background,18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
0,intervention,18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
0,population,18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
0,outcome,18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
0,other,18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
0,"study design",18728841,5,"Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, allowing safe outpatient administration, reducing the need for hospital attendance and safety monitoring."
1,background,18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,intervention,18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,population,18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,outcome,18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,other,18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,"study design",18728841,6,"Early trials have shown ibandronate may also be effective in high doses for palliation of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing a skeletal complication whilst receiving another bisphosphonate."
0,background,18806535,1,"OBJECTIVES"
0,intervention,18806535,1,"OBJECTIVES"
0,population,18806535,1,"OBJECTIVES"
0,outcome,18806535,1,"OBJECTIVES"
1,other,18806535,1,"OBJECTIVES"
0,"study design",18806535,1,"OBJECTIVES"
1,background,18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
0,intervention,18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
0,population,18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
0,outcome,18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
0,other,18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
0,"study design",18806535,2,"The communication impairments that characterize severe dementia make pain assessment challenging."
1,background,18806535,3,"As such, pain problems often go undetected."
0,intervention,18806535,3,"As such, pain problems often go undetected."
0,population,18806535,3,"As such, pain problems often go undetected."
0,outcome,18806535,3,"As such, pain problems often go undetected."
0,other,18806535,3,"As such, pain problems often go undetected."
0,"study design",18806535,3,"As such, pain problems often go undetected."
1,background,18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,intervention,18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,population,18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,outcome,18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,other,18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,"study design",18806535,4,"Our goal was to determine whether systematic pain assessment leads to improved pain management practices and decreases nursing stress in comparison with a control condition."
0,background,18806535,5,"METHODS"
0,intervention,18806535,5,"METHODS"
0,population,18806535,5,"METHODS"
0,outcome,18806535,5,"METHODS"
1,other,18806535,5,"METHODS"
0,"study design",18806535,5,"METHODS"
0,background,18806535,6,"We adopted a 3-month comparative longitudinal design."
0,intervention,18806535,6,"We adopted a 3-month comparative longitudinal design."
0,population,18806535,6,"We adopted a 3-month comparative longitudinal design."
0,outcome,18806535,6,"We adopted a 3-month comparative longitudinal design."
0,other,18806535,6,"We adopted a 3-month comparative longitudinal design."
1,"study design",18806535,6,"We adopted a 3-month comparative longitudinal design."
0,background,18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
0,intervention,18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
1,population,18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
0,outcome,18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
0,other,18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
0,"study design",18806535,7,"Nursing staff regularly assessed dementia patients' pain through the use of the Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC)."
0,background,18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
0,intervention,18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
1,population,18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
0,outcome,18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
0,other,18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
0,"study design",18806535,8,"A second group of nurses completed an attention-control measure for a control group of patients."
0,background,18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
0,intervention,18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
1,population,18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
0,outcome,18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
0,other,18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
0,"study design",18806535,9,"In addition, nursing staff regularly completed measures of work stress to investigate the effects of the workload associated with systematic pain assessment on nurse stress."
0,background,18806535,10,"RESULTS"
0,intervention,18806535,10,"RESULTS"
0,population,18806535,10,"RESULTS"
0,outcome,18806535,10,"RESULTS"
1,other,18806535,10,"RESULTS"
0,"study design",18806535,10,"RESULTS"
0,background,18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
0,intervention,18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
0,population,18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
1,outcome,18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
0,other,18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
0,"study design",18806535,11,"Regular use of the PACSLAC improved pain management practices over time as reflected in increased usage of analgesic medications (prescribed on as needed basis) in comparison with the control group."
0,background,18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
0,intervention,18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
0,population,18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
1,outcome,18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
0,other,18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
0,"study design",18806535,12,"As pain interventions increased, a corresponding decrease in observable pain behaviors (as reflected on the PACSLAC assessments that were completed by the nurses) was observed."
0,background,18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
0,intervention,18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
0,population,18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
1,outcome,18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
0,other,18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
0,"study design",18806535,13,"In addition, nurses who used the PACSLAC reported decreased distress and burnout over time."
0,background,18806535,14,"DISCUSSION"
0,intervention,18806535,14,"DISCUSSION"
0,population,18806535,14,"DISCUSSION"
0,outcome,18806535,14,"DISCUSSION"
1,other,18806535,14,"DISCUSSION"
0,"study design",18806535,14,"DISCUSSION"
0,background,18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
0,intervention,18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
0,population,18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
1,outcome,18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
0,other,18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
0,"study design",18806535,15,"This investigation provides strong support for both the importance of systematic pain assessment in long-term care and for the clinical utility of the PACSLAC in improving pain management practices and decreasing caregiver distress."
1,background,18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
0,intervention,18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
0,population,18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
0,outcome,18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
0,other,18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
0,"study design",18810121,1,"When treating the patient complaining of low back pain, the physical therapist may decide to support the lumbar spine through the temporary use of a lumbar orthosis."
1,background,18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
0,intervention,18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
0,population,18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
0,outcome,18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
0,other,18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
0,"study design",18810121,2,"In severe cases (generally involving fracture or instability) the goal of orthosis application may be immobilization or significant limitation of movement."
1,background,18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
0,intervention,18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
0,population,18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
0,outcome,18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
0,other,18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
0,"study design",18810121,3,"In less severe cases the goal is generally the reduction of spinal stress by the application of supportive pressure to the abdomen and by supporting a flexed, neutral, or extended position of the lumbar spine."
1,background,18810121,4,"A variety of orthoses is commercially available."
0,intervention,18810121,4,"A variety of orthoses is commercially available."
0,population,18810121,4,"A variety of orthoses is commercially available."
0,outcome,18810121,4,"A variety of orthoses is commercially available."
0,other,18810121,4,"A variety of orthoses is commercially available."
0,"study design",18810121,4,"A variety of orthoses is commercially available."
1,background,18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
0,intervention,18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
0,population,18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
0,outcome,18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
0,other,18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
0,"study design",18810121,5,"These include rigid orthotics and body casts, various types of corsets, elastic binders with molded plastic inserts, and all-elastic binders."
1,background,18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
0,intervention,18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
0,population,18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
0,outcome,18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
0,other,18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
0,"study design",18810121,6,"To date, however, we have not encountered a commercially available orthosis which provides abdominal support and lumbar positional support which can be varied by the patient in order to meet his changing biomechanical needs as he changes body position."
1,background,2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
0,intervention,2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
1,population,2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
0,outcome,2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
0,other,2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
0,"study design",2092556,1,"A 56-year-old patient suffered intractable radicular pain from spondylolisthesis L5/S1."
1,background,2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
1,intervention,2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
0,population,2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
0,outcome,2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
0,other,2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
0,"study design",2092556,2,"There was no help from PLIT-fusion but pain decreased substantially by spinal cord stimulation with a PISCES-system."
1,background,2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
0,intervention,2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
0,population,2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
0,outcome,2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
0,other,2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
0,"study design",2092556,3,"On Nov 8th 1987 the battery exhausted gradually whereas the patient increased the output up to maximum."
1,background,2092556,4,"When changing to a new battery he suffered an electric shock."
0,intervention,2092556,4,"When changing to a new battery he suffered an electric shock."
0,population,2092556,4,"When changing to a new battery he suffered an electric shock."
0,outcome,2092556,4,"When changing to a new battery he suffered an electric shock."
0,other,2092556,4,"When changing to a new battery he suffered an electric shock."
0,"study design",2092556,4,"When changing to a new battery he suffered an electric shock."
0,background,2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
0,intervention,2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
0,population,2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
1,outcome,2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
0,other,2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
0,"study design",2092556,5,"Acute opistonus with a jump from his wheelchair occurred with maximal innervation of the muscles of his left leg resulting in a comminuted fracture of his left acetabulum."
0,background,2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
0,intervention,2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
0,population,2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
1,outcome,2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
0,other,2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
0,"study design",2092556,6,"There seems to be a need for more information and precautions on involuntary overstimulation in the use of neurostimulators."
1,background,2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
0,intervention,2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
0,population,2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
0,outcome,2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
0,other,2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
0,"study design",2294415,1,"Adrenoleukodystrophy, a sex-linked peroxisomal disorder that results in the impaired oxidation of long-chain saturated fatty acids and causes neurologic impairment, is a rare cause of Addison's disease in children."
1,background,2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
0,intervention,2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
0,population,2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
0,outcome,2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
0,other,2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
0,"study design",2294415,2,"Adrenomyeloneuropathy is the name given to a biochemically identical but milder and more slowly progressive variant of adrenoleukodystrophy that affects young adults, in whom adrenal insufficiency may long precede nervous system dysfunction."
1,background,2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
0,intervention,2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
0,population,2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
0,outcome,2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
0,other,2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
0,"study design",2294415,3,"The transmission of adrenomyeloneuropathy, like that of most cases of adrenoleukodystrophy, is sex-linked."
1,background,2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,intervention,2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,population,2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,outcome,2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,other,2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,"study design",2294415,4,"Because of a preponderance of male patients among a group of patients with the onset of adrenal failure in childhood, we questioned whether this condition might be the initial manifestation of adrenomyeloneuropathy."
0,background,2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
0,intervention,2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
1,population,2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
1,outcome,2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
0,other,2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
0,"study design",2294415,5,"We therefore measured the plasma concentrations of very-long-chain saturated fatty acids in eight patients with adrenal insufficiency; of these, five had elevated plasma hexacosanoic acid concentrations (range, 2.42 to 6.43 mumol per liter; mean normal le"
0,background,2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
0,intervention,2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
0,population,2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
1,outcome,2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
0,other,2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
0,"study design",2294415,6,"Magnetic resonance imaging showed clear evidence of brain involvement in all five patients."
0,background,2294415,7,"Reexploration of the family histories revealed additional missed cases."
0,intervention,2294415,7,"Reexploration of the family histories revealed additional missed cases."
0,population,2294415,7,"Reexploration of the family histories revealed additional missed cases."
1,outcome,2294415,7,"Reexploration of the family histories revealed additional missed cases."
0,other,2294415,7,"Reexploration of the family histories revealed additional missed cases."
0,"study design",2294415,7,"Reexploration of the family histories revealed additional missed cases."
0,background,2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
0,intervention,2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
0,population,2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
1,outcome,2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
0,other,2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
0,"study design",2294415,8,"We conclude that the possibility of adrenomyeloneuropathy should be considered in any boy with Addison's disease."
0,background,2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
0,intervention,2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
1,population,2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
0,outcome,2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
0,other,2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
0,"study design",2323514,1,"Continuous 72-h recordings of duodenojejunal contractile activity were obtained from 20 freely ambulant subjects; pressure was detected by two strain-gauge sensors incorporated in a transnasal catheter attached to an encoder and a miniature tape recorder."
0,background,2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
0,intervention,2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
1,population,2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
0,outcome,2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
0,other,2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
0,"study design",2323514,2,"The subjects were 12 patients with irritable bowel syndrome, 6 of whom were constipation predominant and 6 of whom were diarrhea predominant, and 8 healthy controls."
0,background,2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
0,intervention,2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
0,population,2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
0,outcome,2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
1,other,2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
0,"study design",2323514,3,"The procedure was well tolerated by all subjects and did not interfere with sleep or normal activity."
0,background,2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
0,intervention,2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
0,population,2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
1,outcome,2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
0,other,2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
0,"study design",2323514,4,"In all subjects, the diurnal migrating motor complex cycle was characterized by a brief phase 1 and a prolonged phase 2; this was reversed during sleep when phase 2 was virtually absent."
0,background,2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
0,intervention,2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
0,population,2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
1,outcome,2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
0,other,2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
0,"study design",2323514,5,"All subjects showed a circadian variation in migrating motor complex propagation velocity, and there was no difference in the patterns of motor activity during sleep between any of the groups."
0,background,2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
0,intervention,2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
0,population,2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
1,outcome,2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
0,other,2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
0,"study design",2323514,6,"During the day, the duration of postprandial motor activity was shorter in irritable bowel syndrome patients than in controls, and diurnal migrating motor complex intervals were shorter in diarrhea-predominant than in constipation-predominant irritable bo"
0,background,2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
0,intervention,2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
0,population,2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
1,outcome,2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
0,other,2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
0,"study design",2323514,7,"In 11 of 12 inflammatory bowel syndrome patients, episodes of clustered contractions recurring at 0.9-min intervals were noted; these episodes had a mean duration of 46 min and were often associated with transient abdominal pain and discomfort."
0,background,2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
0,intervention,2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
0,population,2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
1,outcome,2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
0,other,2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
0,"study design",2323514,8,"In both groups of irritable bowel syndrome patients, defecation was significantly (p less than 0.01) prolonged with a greater number of voluntary abdominal contractions (p less than 0.01) than in controls."
0,background,2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
0,intervention,2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
0,population,2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
1,outcome,2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
0,other,2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
0,"study design",2323514,9,"Prolonged ambulant monitoring of proximal bowel motor activity in subjects who are free to move, eat, and sleep as they choose has, for the first time, clearly defined the striking difference in motility between the sleeping and waking state and shown tha"
0,background,2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
0,intervention,2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
1,population,2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
0,outcome,2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
0,other,2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
0,"study design",2491719,1,"After shorts general considerations about physiologic and epidemiologic features relative to sleep, snoring and apneas in elderly, authors bring analysis of 30 snorers over sixty years."
1,background,2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,intervention,2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,population,2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,outcome,2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,other,2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,"study design",2491719,2,"They all had a sleep recording, a ENT examination, and a pharyngeal C.T. scan."
0,background,2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
0,intervention,2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
0,population,2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
1,outcome,2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
0,other,2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
0,"study design",2491719,3,"The main results are following: the high frequency of Sleep Apnea Syndrome (SAS) over 60 is to be carefully considered."
0,background,2491719,4,"So, Sleep recording appears necessary in the main part of this population."
0,intervention,2491719,4,"So, Sleep recording appears necessary in the main part of this population."
0,population,2491719,4,"So, Sleep recording appears necessary in the main part of this population."
1,outcome,2491719,4,"So, Sleep recording appears necessary in the main part of this population."
0,other,2491719,4,"So, Sleep recording appears necessary in the main part of this population."
0,"study design",2491719,4,"So, Sleep recording appears necessary in the main part of this population."
0,background,2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
0,intervention,2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
0,population,2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
1,outcome,2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
0,other,2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
0,"study design",2491719,5,"Cardiovascular, pneumologic and neurologic disease are very often associated, and do constitute elements of therapeutic choice."
0,background,2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
0,intervention,2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
0,population,2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
1,outcome,2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
0,other,2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
0,"study design",2491719,6,"Velopharyngeal narrowing, without other level of superior airway closure, is the usual case."
0,background,2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
0,intervention,2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
0,population,2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
1,outcome,2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
0,other,2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
0,"study design",2491719,7,"Therapeutic management is often difficult; there is a choice, in apneic patients, between Uvulo-Palato-Pharyngoplasty (UPP), sometimes impossible because of associated pathology, and nocturnal Continuous Positive Airway Pressure (CPAP), which employment i"
1,background,2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
0,intervention,2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
0,population,2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
0,outcome,2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
0,other,2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
0,"study design",2735279,1,"The vast majority of periventricular abnormalities visualized with MR imaging in patients less than 50 years old represents multiple sclerosis (MS) lesions."
1,background,2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,intervention,2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,population,2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,outcome,2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,other,2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,"study design",2735279,2,"There are many other causes of periventricular lesions, most of which can be differentiated from MS on the basis of history and physical or MR findings."
0,background,2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
0,intervention,2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
1,population,2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
0,outcome,2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
0,other,2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
0,"study design",2735279,3,"Five cases of biopsy- or Kveim test-proved sarcoidosis with MR findings consistent with MS are reported."
0,background,2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
0,intervention,2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
0,population,2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
1,outcome,2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
0,other,2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
0,"study design",2735279,4,"Each of these patients, diagnosed as having sarcoidosis, had symptoms identical to those seen in MS."
0,background,2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
0,intervention,2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
0,population,2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
1,outcome,2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
0,other,2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
0,"study design",2735279,5,"Although these patients have not had histologic characterization of the intraparenchymal lesions seen on MR, they illustrate the difficulty of differentiating sarcoidosis with CNS involvement from MS in some patients on the basis of clinical, radiographic"
0,background,2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
0,intervention,2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
0,population,2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
1,outcome,2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
0,other,2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
0,"study design",2735279,6,"This series contributes to a growing body of evidence that neurosarcoidosis probably should be included in the differential diagnosis of isolated periventricular lesions in patients less than 50 years old."
1,background,3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,intervention,3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,population,3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,outcome,3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,other,3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,"study design",3310599,1,"Treatment of human alpha-linolenic acid deficiency (ALAD) with ethyl linolenate is reported."
0,background,3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
1,intervention,3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
1,population,3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
0,outcome,3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
0,other,3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
0,"study design",3310599,2,"The patient's scaly dermatitis nearly disappeared after 5-d supplementation with 0.1 mL ethyl linolenate."
0,background,3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
0,intervention,3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
0,population,3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
1,outcome,3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
0,other,3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
0,"study design",3310599,3,"Pretreatment content of various n-3 fatty acids in RBC was 0-15% of healthy controls."
0,background,3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
0,intervention,3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
0,population,3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
1,outcome,3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
0,other,3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
0,"study design",3310599,4,"After 14 d of supplementation, cholesterol and triglycerides were reduced by 70% of pretreatment values, 22:5n-3 and 22:6n-3 increased three- to fourfold while 18:3n-3 and 20:5n-3 remained low, indicating a rapid elongation and desaturation of 18:3n-3 in "
0,background,3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
0,intervention,3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
0,population,3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
1,outcome,3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
0,other,3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
0,"study design",3310599,5,"Urinary excretion of PGI2-M was approximately 10 times higher than in healthy control subjects, while PGI3-M excretion was low."
0,background,3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
0,intervention,3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
0,population,3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
1,outcome,3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
0,other,3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
0,"study design",3310599,6,"Linolenate supplementation increased PGI2-M excretion twofold, while PGI3-M remained near detection limit."
0,background,3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
0,intervention,3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
0,population,3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
1,outcome,3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
0,other,3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
0,"study design",3310599,7,"Platelet capacity to synthesize TXA2, and urinary excretion of TXB2+3-M were nearly unaffected by supplementation."
0,background,3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
0,intervention,3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
0,population,3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
1,outcome,3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
0,other,3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
0,"study design",3310599,8,"The results confirm that the minimal daily requirement of alpha-linolenic acid is 0.2-0.3% of total energy."
1,background,3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
0,intervention,3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
0,population,3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
0,outcome,3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
0,other,3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
0,"study design",3524412,1,"There are three superimposed centres of micturition: the sacral spinal centre, which is the oldest centre controlled by the pontine centre situated in the brain stem, which in turn is under the control of multiple subconscious structures: cerebellum, stri"
1,background,3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
0,intervention,3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
0,population,3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
0,outcome,3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
0,other,3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
0,"study design",3524412,2,"The nervous pathways consist of the classical spinal pathways as far as their point of emergence."
1,background,3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
0,intervention,3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
0,population,3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
0,outcome,3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
0,other,3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
0,"study design",3524412,3,"The innervation involves 2 systems:--a supra-levator system consisting of the essentially sympathetic superior hypogastric plexus and the essentially parasympathetic inferior hypogastric plexus which innervates the seminal tract, the bladder and the prost"
1,background,3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
0,intervention,3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
0,population,3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
0,outcome,3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
0,other,3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
0,"study design",3526756,1,"Preoperative investigations in ovarian cancer have shown that early diagnostic or screening is impossible by means of the leucocyte adherence inhibition test (LAI-test = LAI)."
1,background,3526756,2,"However, this test is important for follow-up studies."
0,intervention,3526756,2,"However, this test is important for follow-up studies."
0,population,3526756,2,"However, this test is important for follow-up studies."
0,outcome,3526756,2,"However, this test is important for follow-up studies."
0,other,3526756,2,"However, this test is important for follow-up studies."
0,"study design",3526756,2,"However, this test is important for follow-up studies."
1,background,3526756,3,"The LAI can be an additional parameter for individual decision."
0,intervention,3526756,3,"The LAI can be an additional parameter for individual decision."
0,population,3526756,3,"The LAI can be an additional parameter for individual decision."
0,outcome,3526756,3,"The LAI can be an additional parameter for individual decision."
0,other,3526756,3,"The LAI can be an additional parameter for individual decision."
0,"study design",3526756,3,"The LAI can be an additional parameter for individual decision."
1,background,3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
0,intervention,3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
0,population,3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
0,outcome,3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
0,other,3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
0,"study design",3526756,4,"It in the clinical supervision of patients has been shown that metastasizing and local recurrent tumors can be detected by this test approximately 4-8 weeks before clinical evidence."
1,background,3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
0,intervention,3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
0,population,3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
0,outcome,3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
0,other,3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
0,"study design",3534508,1,"Individuals with traumatic spinal cord injury (SCI) represent a population with extreme inactivity."
1,background,3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
0,intervention,3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
1,population,3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
0,outcome,3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
0,other,3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
0,"study design",3534508,2,"The purpose of the current research was to investigate the metabolic differences between extremely inactive disabled individuals (SCI sedentary group), active disabled individuals (SCI athletes), and able-bodied individuals."
0,background,3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
0,intervention,3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
0,population,3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
0,outcome,3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
1,other,3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
0,"study design",3534508,3,"Fasting morning blood samples were obtained for the determination of high density lipoprotein cholesterol (HDLc) subfractions, glucose, and insulin."
0,background,3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
0,intervention,3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
0,population,3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
0,outcome,3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
1,other,3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
0,"study design",3534508,4,"The sedentary SCI group was comprised of 77 consecutive male admissions to a rehabilitation center."
0,background,3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
0,intervention,3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
0,population,3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
0,outcome,3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
1,other,3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
0,"study design",3534508,5,"The 17 SCI athletes were recruited prior to competition at the annual National Wheelchair Games."
0,background,3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
0,intervention,3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
0,population,3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
1,outcome,3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
0,other,3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
0,"study design",3534508,6,"Total HDLc and both its subfractions were significantly lower (P less than 0.01) in the male SCI sedentary population than in the SCI athletes or able-bodied controls."
0,background,3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
0,intervention,3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
0,population,3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
1,outcome,3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
0,other,3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
0,"study design",3534508,7,"HDL2 was significantly elevated (P less than 0.01) in the SCI athlete compared to the SCI sedentary group (42.7 vs 34.1 mg X dl-1) and was similar to the control population (46.1 mg X dl-1)."
0,background,3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
0,intervention,3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
0,population,3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
1,outcome,3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
0,other,3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
0,"study design",3534508,8,"Glucose levels were similar in the two SCI groups but were both significantly lower (P less than 0.05) than in the able-bodied controls."
0,background,3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
0,intervention,3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
0,population,3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
1,outcome,3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
0,other,3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
0,"study design",3534508,9,"These data suggest that the extreme inactivity observed in disabled populations is associated with lower HDLc concentrations and presumably an increase in coronary heart disease risk if these values were to persist over time."
0,background,3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
0,intervention,3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
0,population,3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
1,outcome,3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
0,other,3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
0,"study design",3534508,10,"Additionally, it appears that physical activity is associated with increases in total HDLc, primarily through the HDL2 subfraction."
0,background,3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
0,intervention,3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
0,population,3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
1,outcome,3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
0,other,3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
0,"study design",3534508,11,"Glucose and insulin were similar for both SCI groups despite the marked difference in activity levels, suggesting that these parameters may not be associated with activity."
1,background,3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
0,intervention,3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
0,population,3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
0,outcome,3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
0,other,3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
0,"study design",3774661,1,"Active infection with herpes zoster may cause acute urinary retention, especially when it involves sacral dermatomes."
1,background,3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
0,intervention,3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
0,population,3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
0,outcome,3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
0,other,3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
0,"study design",3774661,2,"Although frank retention usually develops days to weeks after eruption of the typical rash, bladder incompetence infrequently develops first, raising concern over other, more ominous etiologies."
1,background,3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,intervention,3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,population,3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,outcome,3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,other,3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,"study design",3774661,3,"In the case presented, rash appearance was delayed until six weeks after the initial onset of urinary retention, a much longer interval than previously reported."
0,background,3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
0,intervention,3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
0,population,3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
1,outcome,3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
0,other,3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
0,"study design",3774661,4,"Occult herpes zoster infection should be considered in patients presenting with an acute neurogenic bladder of obscure cause."
1,background,6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
0,intervention,6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
1,population,6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
0,outcome,6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
0,other,6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
0,"study design",6152313,1,"The regional distribution of blood flow following intracranial haemorrhage at arterial pressure was measured with the 14C-iodoantipyrine autoradiographic technique in Sprague Dawley Rats."
0,background,6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
0,intervention,6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
0,population,6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
1,outcome,6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
0,other,6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
0,"study design",6152313,2,"With uncontained haemorrhage, there was a bilateral reduction in cerebral blood flow, associated with a fall in cerebral perfusion pressure."
0,background,6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
0,intervention,6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
0,population,6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
1,outcome,6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
0,other,6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
0,"study design",6152313,3,"With contained intracerebral haemorrhage there was a profound ipsilateral reduction in flow in the hemisphere adjacent to the haematoma."
0,background,6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
0,intervention,6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
0,population,6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
1,outcome,6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
0,other,6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
0,"study design",6152313,4,"This study indicates that extensive cerebral ischaemia occurs immediately after an intracerebral haemorrhage, and that this may be the result of compression of the microcirculation."
1,background,6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
0,intervention,6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
0,population,6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
0,outcome,6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
0,other,6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
0,"study design",6325730,1,"Using age-specific rates for multiple sclerosis (MS) based on a national survey, the number of &quot;naturally occurring&quot; new cases of MS among the 45 million swine flu vaccine recipients in the United States is estimated as 1,624 during the year aft"
1,background,6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,intervention,6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,population,6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,outcome,6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,other,6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,"study design",6325730,2,"Information from available reports and publications indicates no excess over the expected frequencies."
0,background,6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
0,intervention,6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
0,population,6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
1,outcome,6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
0,other,6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
0,"study design",6325730,3,"Analyses of admissions for MS before, during, and after the immunization program showed no increase to the US Army hospitals or to the Mayo Clinic."
0,background,6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
0,intervention,6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
0,population,6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
1,outcome,6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
0,other,6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
0,"study design",6325730,4,"Three independent controlled clinical investigations performed on patients with MS showed no increase in the frequency of exacerbations among those receiving swine flu vaccine as compared with those receiving placebo."
0,background,6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
0,intervention,6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
0,population,6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
1,outcome,6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
0,other,6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
0,"study design",6325730,5,"Epidemiologic features of MS do not implicate killed virus vaccine as an etiologic factor in onset or exacerbations of the disease."
0,background,6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
0,intervention,6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
0,population,6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
1,outcome,6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
0,other,6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
0,"study design",6325730,6,"There is no indication from these analyses of any association or cause-and-effect relationship between swine flu vaccine and MS."
1,background,6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
0,intervention,6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
0,population,6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
0,outcome,6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
0,other,6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
0,"study design",6450012,1,"Prior to undergoing conservative pelvic surgery for improvement of fertility, there must be meticulous preoperative evaluation."
1,background,6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,intervention,6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,population,6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,outcome,6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,other,6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,"study design",6450012,2,"This evaluation involves a history, all previous records and operative reports, psychologic evaluation, physical examination, hysterosalpingogram, laparoscopy, and tests for male factor and ovulation."
0,background,6450012,3,"In history taking, the physician is most interested in past evidence of infection."
0,intervention,6450012,3,"In history taking, the physician is most interested in past evidence of infection."
0,population,6450012,3,"In history taking, the physician is most interested in past evidence of infection."
1,outcome,6450012,3,"In history taking, the physician is most interested in past evidence of infection."
0,other,6450012,3,"In history taking, the physician is most interested in past evidence of infection."
0,"study design",6450012,3,"In history taking, the physician is most interested in past evidence of infection."
0,background,6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
0,intervention,6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
0,population,6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
1,outcome,6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
0,other,6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
0,"study design",6450012,4,"The emotional status of the patient must be considered, especially for those individuals who are seeking sterilization reversal."
0,background,6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
0,intervention,6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
0,population,6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
1,outcome,6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
0,other,6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
0,"study design",6450012,5,"Often, with a history of previous pelvic surgery the rate of success is lowered."
0,background,6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
0,intervention,6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
0,population,6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
1,outcome,6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
0,other,6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
0,"study design",6450012,6,"Physical examination is usually not useful in predicting final outcome of microsurgery; however, it does determine the patient's general preoperative status."
0,background,6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
0,intervention,6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
0,population,6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
1,outcome,6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
0,other,6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
0,"study design",6450012,7,"Hysterosalpingography and laparoscopy are complementary procedures which are the cornerstone of the preoperative evaluation."
0,background,6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
0,intervention,6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
0,population,6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
1,outcome,6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
0,other,6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
0,"study design",6450012,8,"The 1st gives evidence of the status of the uterus and the tube proximal to the block, if 1 exists."
0,background,6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
0,intervention,6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
0,population,6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
1,outcome,6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
0,other,6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
0,"study design",6450012,9,"If the block is in the isthmic portion, the hysterosalpingogram will indicate how much of the tube is patent next to the corpus."
0,background,6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
0,intervention,6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
0,population,6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
1,outcome,6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
0,other,6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
0,"study design",6450012,10,"Preoperative laparoscopy is necessary for proper and complete evaluation of pelvic status; it allows the operator to visualize the distal segment of the tube."
0,background,6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
0,intervention,6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
0,population,6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
1,outcome,6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
0,other,6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
0,"study design",6450012,11,"Laparoscopy indicates the extent of pelvic adhesion, ovary and tube involvement, mobility of the tube, extent of fimbrial involvement, and presence of disease."
0,background,6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
0,intervention,6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
0,population,6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
1,outcome,6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
0,other,6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
0,"study design",6450012,12,"When all factors are taken are into consideration, the surgeon must determine whether the benefits of surgery will outweigh the risks."
0,background,6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
0,intervention,6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
0,population,6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
1,outcome,6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
0,other,6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
0,"study design",6450012,13,"Patient age, emotional needs, other parameters of fertility, status of tubes and ovaries, etc. must all be taken into consideration.evaluationfamily planninghysterosalpingographyinfertilitylaparoscopyreproductionreversible sterilizationsterilization rever"
1,background,6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
0,intervention,6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
0,population,6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
0,outcome,6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
0,other,6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
0,"study design",6968424,1,"Traction lesions of the brachial plexus are becoming more frequent."
1,background,6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
0,intervention,6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
0,population,6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
0,outcome,6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
0,other,6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
0,"study design",6968424,2,"Many of the lesions involve avulsion of nerve roots from the spinal cord."
1,background,6968424,3,"This very often results in severe pain which is associated with deafferentation."
0,intervention,6968424,3,"This very often results in severe pain which is associated with deafferentation."
0,population,6968424,3,"This very often results in severe pain which is associated with deafferentation."
0,outcome,6968424,3,"This very often results in severe pain which is associated with deafferentation."
0,other,6968424,3,"This very often results in severe pain which is associated with deafferentation."
0,"study design",6968424,3,"This very often results in severe pain which is associated with deafferentation."
1,background,6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,intervention,6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,population,6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,outcome,6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,other,6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,"study design",6968424,4,"Although reference to this pain and the difficulty in its management has been made in several reports in the literature, there has been no long-term study of the natural history of this pain and the effects of various attempts to mitigate it."
0,background,6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
0,intervention,6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
1,population,6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
0,outcome,6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
0,other,6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
0,"study design",6968424,5,"This series reports on a long-term follow-up of 275 patients of which is 108 had evidence of avulsion lestions."
0,background,6968424,6,"Of these 108, 98 suffered significant pain."
0,intervention,6968424,6,"Of these 108, 98 suffered significant pain."
0,population,6968424,6,"Of these 108, 98 suffered significant pain."
0,outcome,6968424,6,"Of these 108, 98 suffered significant pain."
1,other,6968424,6,"Of these 108, 98 suffered significant pain."
0,"study design",6968424,6,"Of these 108, 98 suffered significant pain."
0,background,6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
0,intervention,6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
0,population,6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
1,outcome,6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
0,other,6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
0,"study design",6968424,7,"There is a remarkably constant description of the pain and the various activities that may affect it."
0,background,6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
0,intervention,6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
0,population,6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
1,outcome,6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
0,other,6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
0,"study design",6968424,8,"Drugs are of very limited use and the most valuable method of treatment found in this series was transcutaneous electrical stimulation--although, only one-third responded dramatically to this treatment."
0,background,6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
0,intervention,6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
0,population,6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
1,outcome,6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
0,other,6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
0,"study design",6968424,9,"The single most effective manoeuvre that reduces pain is absorption by the patient in work."
0,background,6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
0,intervention,6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
0,population,6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
1,outcome,6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
0,other,6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
0,"study design",6968424,10,"There remains a significant number of young men with severe pain who may expect to suffer such pain indefinitely."
0,background,6968424,11,"There is urgent need for new methods to be developed to control this pain."
0,intervention,6968424,11,"There is urgent need for new methods to be developed to control this pain."
0,population,6968424,11,"There is urgent need for new methods to be developed to control this pain."
1,outcome,6968424,11,"There is urgent need for new methods to be developed to control this pain."
0,other,6968424,11,"There is urgent need for new methods to be developed to control this pain."
0,"study design",6968424,11,"There is urgent need for new methods to be developed to control this pain."
1,background,7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
0,intervention,7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
0,population,7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
0,outcome,7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
0,other,7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
0,"study design",7166487,1,"Sjgren-Larsson syndrome (SLS) is characterized by congenital ichthyosis, mental retardation and spastic di- or tetraplegia."
1,background,7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
0,intervention,7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
0,population,7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
0,outcome,7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
0,other,7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
0,"study design",7166487,2,"All patients older than one year have glistening dots in the fundus of the eye."
1,background,7166487,3,"SLS has autosomal recessive inheritance."
0,intervention,7166487,3,"SLS has autosomal recessive inheritance."
0,population,7166487,3,"SLS has autosomal recessive inheritance."
0,outcome,7166487,3,"SLS has autosomal recessive inheritance."
0,other,7166487,3,"SLS has autosomal recessive inheritance."
0,"study design",7166487,3,"SLS has autosomal recessive inheritance."
0,background,7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
0,intervention,7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
1,population,7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
0,outcome,7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
0,other,7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
0,"study design",7166487,4,"All 35 SLS patients in Sweden, alive in 1978, were examined physically and neurologically by the authors."
0,background,7166487,5,"Prematurity was common but did not have any prognostic importance."
0,intervention,7166487,5,"Prematurity was common but did not have any prognostic importance."
0,population,7166487,5,"Prematurity was common but did not have any prognostic importance."
1,outcome,7166487,5,"Prematurity was common but did not have any prognostic importance."
0,other,7166487,5,"Prematurity was common but did not have any prognostic importance."
0,"study design",7166487,5,"Prematurity was common but did not have any prognostic importance."
0,background,7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
0,intervention,7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
0,population,7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
1,outcome,7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
0,other,7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
0,"study design",7166487,6,"Thirty-two patients had non-progressive pronounced or severe spastic diplegia, and two had severe tetraplegia."
0,background,7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
0,intervention,7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
0,population,7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
1,outcome,7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
0,other,7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
0,"study design",7166487,7,"Those who were most motor-handicapped were also most mentally retarded."
0,background,7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
0,intervention,7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
0,population,7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
1,outcome,7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
0,other,7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
0,"study design",7166487,8,"However, the degree of ichthyosis and the changes in the ocular fundus varied independently of the cerebral symptoms."
0,background,7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
0,intervention,7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
0,population,7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
1,outcome,7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
0,other,7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
0,"study design",7166487,9,"There were no morphological abnormalities of the brain found in cranial computed tomography."
0,background,7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
0,intervention,7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
0,population,7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
1,outcome,7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
0,other,7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
0,"study design",7166487,10,"Shortness of stature was due to poor development of paretic legs and contractures in joints and the spine due to spasticity."
0,background,7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
0,intervention,7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
0,population,7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
1,outcome,7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
0,other,7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
0,"study design",7166487,11,"SLS should be suspected in a child with congenital ichthyosis."
0,background,7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
0,intervention,7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
0,population,7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
1,outcome,7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
0,other,7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
0,"study design",7166487,12,"The diagnosis is confirmed when signs of spasticity and mental retardation are present before the age of three years."
0,background,7507795,1,"BACKGROUND."
0,intervention,7507795,1,"BACKGROUND."
0,population,7507795,1,"BACKGROUND."
0,outcome,7507795,1,"BACKGROUND."
1,other,7507795,1,"BACKGROUND."
0,"study design",7507795,1,"BACKGROUND."
1,background,7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
0,intervention,7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
0,population,7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
0,outcome,7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
0,other,7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
0,"study design",7507795,2,"Patients with transmurally invasive, lymph node negative colorectal carcinoma (Dukes' B) have a 5-year survival rate ranging from 53.9% to 84.9%."
1,background,7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
0,intervention,7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
0,population,7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
0,outcome,7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
0,other,7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
0,"study design",7507795,3,"The authors postulate that patients with Dukes' B colon cancer who die of their disease have occult micrometastases in their pericolic lymph nodes at the time of original diagnosis."
1,background,7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
1,intervention,7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
1,population,7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
0,outcome,7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
0,other,7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
0,"study design",7507795,4,"In an attempt to identify these occult micrometastases, pericolic lymph nodes from Dukes' B colon cancer resections were stained retrospectively with antibodies against cytokeratin (anti-keratin AE1/AE3, Boehringer Mannheim, Indianapolis, IN) and CC49 (a "
0,background,7507795,5,"The results were analyzed by univariate and multivariate analysis."
0,intervention,7507795,5,"The results were analyzed by univariate and multivariate analysis."
0,population,7507795,5,"The results were analyzed by univariate and multivariate analysis."
0,outcome,7507795,5,"The results were analyzed by univariate and multivariate analysis."
1,other,7507795,5,"The results were analyzed by univariate and multivariate analysis."
0,"study design",7507795,5,"The results were analyzed by univariate and multivariate analysis."
0,background,7507795,6,"RESULTS."
0,intervention,7507795,6,"RESULTS."
0,population,7507795,6,"RESULTS."
0,outcome,7507795,6,"RESULTS."
1,other,7507795,6,"RESULTS."
0,"study design",7507795,6,"RESULTS."
0,background,7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
0,intervention,7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
0,population,7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
1,outcome,7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
0,other,7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
0,"study design",7507795,7,"Fifty cases with 568 lymph nodes (11.3 per case) were examined with each antibody using standard immunoperoxidase techniques."
0,background,7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
0,intervention,7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
0,population,7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
1,outcome,7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
0,other,7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
0,"study design",7507795,8,"Positive staining for cytokeratin was seen in 14 patients (33 lymph nodes), 6 of whom died of colon cancer within 66 months (43%)."
0,background,7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
0,intervention,7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
0,population,7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
1,outcome,7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
0,other,7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
0,"study design",7507795,9,"Only 1 of the 36 patients with cytokeratin-negative lymph nodes died of colon cancer over the same time period (3%, P = 0.0009 univariate, P = 0.0013 multivariate)."
0,background,7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
0,intervention,7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
0,population,7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
1,outcome,7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
0,other,7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
0,"study design",7507795,10,"There was no significant difference in survival between the CC49-positive and CC49-negative groups."
0,background,7507795,11,"CONCLUSION."
0,intervention,7507795,11,"CONCLUSION."
0,population,7507795,11,"CONCLUSION."
0,outcome,7507795,11,"CONCLUSION."
1,other,7507795,11,"CONCLUSION."
0,"study design",7507795,11,"CONCLUSION."
0,background,7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
0,intervention,7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
0,population,7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
1,outcome,7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
0,other,7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
0,"study design",7507795,12,"Immunoperoxidase techniques are capable of identifying micrometastatic disease in lymph nodes missed by routine hematoxylin and eosin staining."
0,background,7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
0,intervention,7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
0,population,7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
1,outcome,7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
0,other,7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
0,"study design",7507795,13,"Further, the presence of cytokeratin-positive cells within lymph nodes correlated with a significantly poorer prognosis."
0,background,7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
0,intervention,7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
0,population,7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
1,outcome,7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
0,other,7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
0,"study design",7507795,14,"Therefore, cytokeratin staining of pericolic lymph nodes in patients with Dukes' B colorectal cancer is recommended."
0,background,7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
0,intervention,7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
0,population,7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
1,outcome,7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
0,other,7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
0,"study design",7507795,15,"Larger multicenter studies are needed, however, to confirm these results and to evaluate the appropriateness of adjuvant chemotherapy in patients whose disease is upstaged by immunohistochemical staining."
1,background,7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
0,intervention,7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
0,population,7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
0,outcome,7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
0,other,7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
0,"study design",7591589,1,"Spinal cord injury, regardless of its level, causes flaccid paralysis during the shock phase affecting the detrusor and rectal musculature."
1,background,7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
0,intervention,7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
0,population,7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
0,outcome,7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
0,other,7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
0,"study design",7591589,2,"Then, depending on the level and severity of the lesion, the bladder gains spasticity or remains flaccid."
1,background,7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,intervention,7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,population,7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,outcome,7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,other,7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,"study design",7591589,3,"Monitoring the reflex behaviour of detrusor and sphincter activities helps to select the treatment modalities."
0,background,7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
0,intervention,7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
1,population,7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
0,outcome,7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
0,other,7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
0,"study design",7591589,4,"Thirty patients with cord injuries of various levels have been urodynamically tested at 3-month intervals."
0,background,7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
0,intervention,7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
0,population,7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
1,outcome,7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
0,other,7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
0,"study design",7591589,5,"The shock phase of the acutely tested patients lasted about 8-9 weeks."
0,background,7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
0,intervention,7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
0,population,7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
1,outcome,7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
0,other,7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
0,"study design",7591589,6,"Eventually, 23 of the cases were hyperreflexic, while 7 cases remained areflexic: 2 had detrusor-sphincter dyssynergia."
0,background,7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
0,intervention,7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
0,population,7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
1,outcome,7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
0,other,7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
0,"study design",7591589,7,"The response to treatment has been investigated by cystometrographical and electromyographical methods."
1,background,7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
0,intervention,7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
0,population,7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
0,outcome,7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
0,other,7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
0,"study design",7711374,1,"Nerves leave the spinal cord as mainly motor primary rootlets and sensory rootlets."
1,background,7711374,2,"These join to nerve root before leaving the spinal canal."
0,intervention,7711374,2,"These join to nerve root before leaving the spinal canal."
0,population,7711374,2,"These join to nerve root before leaving the spinal canal."
0,outcome,7711374,2,"These join to nerve root before leaving the spinal canal."
0,other,7711374,2,"These join to nerve root before leaving the spinal canal."
0,"study design",7711374,2,"These join to nerve root before leaving the spinal canal."
1,background,7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
0,intervention,7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
0,population,7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
0,outcome,7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
0,other,7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
0,"study design",7711374,3,"After the root canal, the nerve root branches into the ventral root, which contains sensory and motor fibers innervating the extremities, and the dorsal root, that is, the dorsal ramus, which innervates the posterior structures, for example, back muscles:"
1,background,7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,intervention,7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,population,7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,outcome,7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,other,7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,"study design",7711374,4,"Especially predisposed to entrapment is the medial branch of the dorsal ramus, which innervates the multifidus muscle and also contains pain fibers."
0,background,7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
1,intervention,7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
1,population,7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
0,outcome,7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
0,other,7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
0,"study design",7711374,5,"Here we describe the influence of local anesthesia and back-muscle-training therapy on subjective and objective pain parameters in 21 low-back-pain patients who had similar clinical status and neurophysiologic findings and whose recurrent low back pain wa"
0,background,7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
0,intervention,7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
0,population,7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
1,outcome,7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
0,other,7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
0,"study design",7711374,6,"After treatment, all were pain free and back muscle activity during lumbar-pelvic rhythm was normalized."
1,background,7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,intervention,7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,population,7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,outcome,7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,other,7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,"study design",7746406,1,"We compared reactivity of EEG to external stimuli--an easily and quickly available measure--with the central conduction time (CCT) of the somatosensory evoked potentials, currently the most-used electrophysiologic method to predict outcome in severe head "
0,background,7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
0,intervention,7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
1,population,7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
0,outcome,7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
0,other,7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
0,"study design",7746406,2,"In 50 patients, comatose subsequent to SHI, we measured EEG reactivity and CCT within 48 to 72 hours and compared them with the outcome after 1.5 years."
0,background,7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
0,intervention,7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
0,population,7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
1,outcome,7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
0,other,7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
0,"study design",7746406,3,"Using discriminant analysis, EEG reactivity correctly classified 92%, CCT classified 82%, and both measures together classified 98% of the patients into globally good or bad outcome groups."
0,background,7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
0,intervention,7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
0,population,7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
1,outcome,7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
0,other,7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
0,"study design",7746406,4,"GCS allowed a correct classification in only 72% and, combined with either of the two electrophysiologic measures, did not further increase predictability."
0,background,7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
0,intervention,7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
0,population,7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
1,outcome,7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
0,other,7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
0,"study design",7746406,5,"EEG reactivity is an excellent long-term global outcome predictor in SHI, superior to CCT and GCS."
0,background,7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
0,intervention,7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
0,population,7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
1,outcome,7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
0,other,7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
0,"study design",7746406,6,"When the two electrophysiologic measures are combined, a prognostic accuracy is achieved that is better than that of any other reported method."
0,background,7775364,1,"BACKGROUND"
0,intervention,7775364,1,"BACKGROUND"
0,population,7775364,1,"BACKGROUND"
0,outcome,7775364,1,"BACKGROUND"
1,other,7775364,1,"BACKGROUND"
0,"study design",7775364,1,"BACKGROUND"
1,background,7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,intervention,7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,population,7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,outcome,7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,other,7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,"study design",7775364,2,"Sertraline and fluoxetine have pharmacokinetic and pharmacologic differences, which may be of clinical relevance."
0,background,7775364,3,"METHOD"
0,intervention,7775364,3,"METHOD"
0,population,7775364,3,"METHOD"
0,outcome,7775364,3,"METHOD"
1,other,7775364,3,"METHOD"
0,"study design",7775364,3,"METHOD"
0,background,7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
1,intervention,7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
1,population,7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
0,outcome,7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
0,other,7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
1,"study design",7775364,4,"A randomized, double-blind, parallel-group study of 6 weeks' duration comparing the efficacy and safety of sertraline (50-100 mg/day) with those of fluoxetine (20-40 mg/day) was conducted in 286 psychiatric outpatients with DSM-III-R major depression or b"
0,background,7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
0,intervention,7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
0,population,7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
0,outcome,7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
1,other,7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
0,"study design",7775364,5,"Primary efficacy measurements consisted of the 17-item Hamilton Rating Scale for Depression (HAM-D) and the Clinical Global Impressions (CGI) scale."
0,background,7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
0,intervention,7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
0,population,7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
0,outcome,7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
1,other,7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
0,"study design",7775364,6,"Secondary measurements included the Hamilton Rating Scale for Anxiety (HAM-A), the Raskin Depression Scale, the Covi Anxiety Scale, and the Leeds Sleep Questionnaire."
0,background,7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
0,intervention,7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
0,population,7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
0,outcome,7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
1,other,7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
0,"study design",7775364,7,"Additionally, scores for two items and five factors from the HAM-D were analyzed."
0,background,7775364,8,"RESULTS"
0,intervention,7775364,8,"RESULTS"
0,population,7775364,8,"RESULTS"
0,outcome,7775364,8,"RESULTS"
1,other,7775364,8,"RESULTS"
0,"study design",7775364,8,"RESULTS"
0,background,7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
0,intervention,7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
0,population,7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
0,outcome,7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
1,other,7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
0,"study design",7775364,9,"Efficacy was based on 124 evaluable patients in each treatment group."
0,background,7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
0,intervention,7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
0,population,7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
1,outcome,7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
0,other,7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
0,"study design",7775364,10,"As measured by HAM-D and CGI-Severity scores, there was a significant (p &lt; .001) improvement from baseline to each follow-up visit in both treatment groups with no statistically significant difference between groups."
0,background,7775364,11,"There was also no significant difference in the proportion of responders in each group."
0,intervention,7775364,11,"There was also no significant difference in the proportion of responders in each group."
0,population,7775364,11,"There was also no significant difference in the proportion of responders in each group."
1,outcome,7775364,11,"There was also no significant difference in the proportion of responders in each group."
0,other,7775364,11,"There was also no significant difference in the proportion of responders in each group."
0,"study design",7775364,11,"There was also no significant difference in the proportion of responders in each group."
0,background,7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
0,intervention,7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
0,population,7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
1,outcome,7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
0,other,7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
0,"study design",7775364,12,"CGI-Improvement responder rates were 69% for sertraline and 67% for fluoxetine."
0,background,7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
0,intervention,7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
0,population,7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
1,outcome,7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
0,other,7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
0,"study design",7775364,13,"Results of secondary efficacy measurements followed the same trend, although from the second week of treatment there was a numerical advantage (not statistically significant) for sertraline over fluoxetine in improving anxiety symptoms as measured by the "
0,background,7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
0,intervention,7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
0,population,7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
1,outcome,7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
0,other,7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
0,"study design",7775364,14,"Headache and nausea were the most frequently reported events for both drugs."
0,background,7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
0,intervention,7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
0,population,7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
1,outcome,7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
0,other,7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
0,"study design",7775364,15,"The incidence of early patient withdrawals due to treatment-emergent adverse events was 14% for sertraline and 13% for fluoxetine."
0,background,7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
0,intervention,7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
0,population,7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
1,outcome,7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
0,other,7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
0,"study design",7775364,16,"The starting dosage (sertraline 50 mg/day, fluoxetine 20 mg/day) was the final dosage in 76% of patients in both treatment groups."
0,background,7775364,17,"CONCLUSION"
0,intervention,7775364,17,"CONCLUSION"
0,population,7775364,17,"CONCLUSION"
0,outcome,7775364,17,"CONCLUSION"
1,other,7775364,17,"CONCLUSION"
0,"study design",7775364,17,"CONCLUSION"
0,background,7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
0,intervention,7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
0,population,7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
1,outcome,7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
0,other,7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
0,"study design",7775364,18,"Sertraline and fluoxetine were equally effective and well tolerated in patients with major depression and associated anxiety."
0,background,7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
0,intervention,7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
1,population,7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
0,outcome,7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
0,other,7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
0,"study design",7919750,1,"Duration of breast feeding was studied in 249 randomly chosen, healthy, term infants of Danish origin of which 80.7% participated."
0,background,7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
0,intervention,7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
0,population,7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
1,outcome,7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
0,other,7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
0,"study design",7919750,2,"Breast feeding was initiated by 99.5% of the mothers."
0,background,7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
0,intervention,7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
0,population,7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
1,outcome,7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
0,other,7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
0,"study design",7919750,3,"At 3, 6 and 9 months, 71%, 52% and 33%, respectively, were still breast feeding."
0,background,7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
0,intervention,7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
0,population,7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
1,outcome,7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
0,other,7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
0,"study design",7919750,4,"Only 1 infant (0.5%) was exclusively breast fed beyond 7 months of age."
0,background,7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
0,intervention,7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
0,population,7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
1,outcome,7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
0,other,7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
0,"study design",7919750,5,"In a Cox multiple regression analysis of factors influencing duration of breast feeding, we found a positive association with maternal education (p &lt; 0.001) and age (p = 0.02) and a negative association with the amount of formula given at the maternity"
0,background,7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
0,intervention,7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
0,population,7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
1,outcome,7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
0,other,7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
0,"study design",7919750,6,"Six months after delivery, 79% of the mothers with higher school education (> or = 12 years) were still breast feeding, compared to 29% with a low school education (&lt; or = 9 years)."
0,background,7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
0,intervention,7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
0,population,7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
1,outcome,7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
0,other,7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
0,"study design",7919750,7,"There is still a need for an increased effort to support mothers in breast feeding, focusing particularly on younger mothers with short school education."
0,background,7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
0,intervention,7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
0,population,7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
1,outcome,7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
0,other,7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
0,"study design",7919750,8,"Formula supplements during the first days of life, given to 73% of the infants, were associated with a shorter duration of breast feeding and should be discouraged."
1,background,8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,intervention,8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,population,8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,outcome,8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,other,8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,"study design",8009754,1,"It was hypothesised from previous observational studies in the Faroes and Denmark that dietary marine n-3 fatty acids would prolong the duration of pregnancy and thereby increase the birth weight, by influencing the production of prostaglandins involved i"
0,background,8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
1,intervention,8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
1,population,8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
0,outcome,8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
0,other,8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
0,"study design",8009754,2,"Five hundred and thirty-three healthy Danish women were randomly assigned in the 30th week of pregnancy to fish oil (2.7 g n-3 fatty acids (4 1-g capsules Pikasol oil) per day), olive oil (4 1-g capsules per day) or no oil supplementation."
0,background,8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
0,intervention,8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
0,population,8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
1,outcome,8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
0,other,8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
0,"study design",8009754,3,"The three groups differed in mean gestational age at birth (ANOVA, p = 0.006), with the fish oil group ranking highest and the olive oil group lowest."
0,background,8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
0,intervention,8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
0,population,8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
1,outcome,8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
0,other,8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
0,"study design",8009754,4,"Babies born to women allocated fish oil had on average 4.0 (95% confidence interval 1.5;6.4) days higher gestational age and 107 (95% confidence interval 1;214) g higher weight at birth than babies born to women allocated olive oil; the difference in gest"
0,background,8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
0,intervention,8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
0,population,8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
1,outcome,8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
0,other,8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
0,"study design",8009754,5,"Fish oil supplementation in the third trimester seems to prolong gestation while allowing continued growth of the foetus; this effect seems to explain the difference between the Faroes and Denmark in pregnancy duration."
1,background,8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
0,intervention,8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
0,population,8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
0,outcome,8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
0,other,8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
0,"study design",8025371,1,"Several epidemiological surveys have suggested that an alteration in the habitual intake of the type rather than the amount of dietary fat may offer a nutritional means for a reduction in mortality from severe cardiac arrhythmia which cannot be achieved a"
1,background,8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
0,intervention,8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
1,population,8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
0,outcome,8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
0,other,8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
0,"study design",8025371,2,"We have examined this possibility in a series of long-term feeding studies with the small non-human primate marmoset monkey Callithrix jacchus."
0,background,8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
0,intervention,8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
0,population,8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
1,outcome,8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
0,other,8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
0,"study design",8025371,3,"In both in vitro and in vivo studies of the mechanical performance of cardiac muscle we have found that diets rich in saturated fatty acids promote arrhythmia when the heart is subjected to pharmacological or ischemic stress."
0,background,8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
0,intervention,8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
0,population,8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
1,outcome,8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
0,other,8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
0,"study design",8025371,4,"Conversely, diets enriched in either omega-6 or omega-3 PUFA are beneficial, reducing the vulnerability to pharmacologically induced dysrhythmia in vitro or ischemic arrhythmia in vivo."
0,background,8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
0,intervention,8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
0,population,8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
1,outcome,8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
0,other,8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
0,"study design",8025371,5,"In addition, PUFA enriched diets enhance myocardial performance (left ventricular ejection fraction and end diastolic volume) and raise the electrical threshold at which ventricular fibrillation can be induced."
0,background,8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
0,intervention,8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
0,population,8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
1,outcome,8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
0,other,8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
0,"study design",8025371,6,"These diet-induced changes in cardiac performance are accompanied by significant alterations in the PUFA composition of cardiac muscle membranes, and the subsequent production of myocardial eicosanoids."
0,background,8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,intervention,8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,population,8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
1,outcome,8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,other,8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,"study design",8025371,7,"Both omega-6 and omega-3 PUFA increase the ratio of myocardial prostacyclin:thromboxane, but omega-3 PUFA is more effective as less is required to achieve a significant decrease in pro-arrhythmic thromboxane.(ABSTRACT TRUNCATED AT 250 WORDS)"
1,background,8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
0,intervention,8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
0,population,8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
0,outcome,8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
0,other,8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
0,"study design",8262801,1,"Who should be the judge of quality care--the consumer or healthcare professional?"
1,background,8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
0,intervention,8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
0,population,8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
0,outcome,8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
0,other,8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
0,"study design",8262801,2,"Traditionally, healthcare providers have decided what services consumers should receive and how consumers' needs should be met."
1,background,8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
0,intervention,8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
0,population,8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
0,outcome,8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
0,other,8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
0,"study design",8262801,3,"Current trends in healthcare delivery are changing this one-sided practice."
1,background,8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
0,intervention,8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
0,population,8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
0,outcome,8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
0,other,8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
0,"study design",8262801,4,"Throughout the United States, to determine what constitutes quality care, accrediting bodies, insurers, consumer groups, providers, and governments are collecting and analyzing data on standards for clinical practice, patient outcomes, and perceptions of "
1,background,8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,intervention,8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,population,8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,outcome,8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,other,8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,"study design",8377591,1,"In this study we investigated the output of thiobarbituric acid reactive substances (TBARS) and malondialdehyde (MDA), as thiobarbituric acid (TBA)-MDA adduct, in the urine from subjects eating a diet in which the only source of n-3 long-chain, polyunsatu"
0,background,8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
0,intervention,8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
1,population,8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
0,outcome,8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
0,other,8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
0,"study design",8377591,2,"Nine healthy men, ages 30-65, were confined in the United States Department of Agriculture Western Human Nutrition Research Center, San Francisco, CA, for 100 d; food intake and exercise levels were controlled."
0,background,8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
1,intervention,8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
0,population,8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
0,outcome,8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
0,other,8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
0,"study design",8377591,3,"All subjects were placed on a stabilization diet (StD) for 20 d, then six were fed the salmon diet for 40 d."
0,background,8377591,4,"The others remained on the StD."
0,intervention,8377591,4,"The others remained on the StD."
0,population,8377591,4,"The others remained on the StD."
0,outcome,8377591,4,"The others remained on the StD."
1,other,8377591,4,"The others remained on the StD."
0,"study design",8377591,4,"The others remained on the StD."
0,background,8377591,5,"The groups switched diets for the last 40 d."
0,intervention,8377591,5,"The groups switched diets for the last 40 d."
0,population,8377591,5,"The groups switched diets for the last 40 d."
0,outcome,8377591,5,"The groups switched diets for the last 40 d."
1,other,8377591,5,"The groups switched diets for the last 40 d."
0,"study design",8377591,5,"The groups switched diets for the last 40 d."
0,background,8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
0,intervention,8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
0,population,8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
0,outcome,8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
1,other,8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
0,"study design",8377591,6,"Both diets were isocaloric (16% protein, 54% CHO and 30% fat by energy %)."
0,background,8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
0,intervention,8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
0,population,8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
0,outcome,8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
1,other,8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
0,"study design",8377591,7,"The salmon diet contained 7.5% of calories from n-6 fatty acids (FAs) and 2% from n-3 FAs, primarily eicosapentaenoic acid and docosahexaenoic acid in a 5060 ratio, while the StD contained 7.5% from n-6 FAs and &lt; 0.3% n-3 FAs (with presumably no significant amounts of C20 or C22 n-3 FAs)."
0,background,8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
0,intervention,8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
0,population,8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
0,outcome,8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
1,other,8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
0,"study design",8377591,8,"Twenty-four hour urinary output was collected, and 2% 3-d pool samples prepared for analysis of urinary TBARS and the TBA-MDA adduct."
0,background,8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,intervention,8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,population,8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
1,outcome,8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,other,8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
0,"study design",8377591,9,"The total urinary output of each individual varied considerably, and on a daily basis the concentration of autoxidation products in an individual's urine varied also.(ABSTRACT TRUNCATED AT 250 WORDS)"
1,background,8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
0,intervention,8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
1,population,8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
0,outcome,8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
0,other,8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
0,"study design",8423917,1,"We investigated the relationship of neurologic, neuropsychological, and social interaction impairments to the work status of a large sample of penetrating head-injured patients wounded some 15 years earlier during combat in Vietnam."
0,background,8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
0,intervention,8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
0,population,8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
0,outcome,8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
1,other,8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
0,"study design",8423917,2,"Extensive standardized testing of neurologic, neuropsychological, and social functioning was done at follow-up on each head-injured patient (N = 520), as well as on a sample of uninjured controls (N = 85)."
0,background,8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
0,intervention,8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
0,population,8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
1,outcome,8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
0,other,8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
0,"study design",8423917,3,"Fifty-six percent of the head-injured patients were working at follow-up compared with 82% of the uninjured controls."
0,background,8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
0,intervention,8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
0,population,8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
1,outcome,8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
0,other,8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
0,"study design",8423917,4,"Seven systematically defined impairments proved to be most correlated with work status."
0,background,8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
0,intervention,8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
0,population,8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
1,outcome,8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
0,other,8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
0,"study design",8423917,5,"These were post-traumatic epilepsy, paresis, visual field loss, verbal memory loss, visual memory loss, psychological problems, and violent behavior."
0,background,8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
0,intervention,8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
0,population,8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
1,outcome,8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
0,other,8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
0,"study design",8423917,6,"These disabilities had a cumulative and nearly equipotent effect upon the likelihood of work."
0,background,8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
0,intervention,8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
0,population,8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
1,outcome,8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
0,other,8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
0,"study design",8423917,7,"We suggest that a simple summed score of the number of these seven disabilities can yield a residual &quot;disability score&quot; which may prove to be a practical tool for assessing the likelihood of return to work for patients in this population and per"
0,background,8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
0,intervention,8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
0,population,8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
1,outcome,8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
0,other,8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
0,"study design",8423917,8,"These findings may also help to focus rehabilitation efforts on those disabilities most likely to affect return to work."
0,background,8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
1,intervention,8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
1,population,8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
0,outcome,8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
0,other,8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
0,"study design",8604658,1,"The effect of a flaxseed oil-based diet on tumor necrosis factor alpha (TNF alpha) and interleukin 1 beta (IL-1 beta) synthesis was examined in healthy volunteers."
0,background,8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
0,intervention,8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
0,population,8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
1,outcome,8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
0,other,8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
0,"study design",8604658,2,"Use of flaxseed oil in domestic food preparation for 4 wk inhibited TNF alpha and IL-1 beta production by approximately 30%."
0,background,8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
0,intervention,8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
0,population,8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
1,outcome,8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
0,other,8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
0,"study design",8604658,3,"Fish-oil supplementation (9 g/d) continued for a further 4 wk; TNF alpha and IL-1 beta synthesis were inhibited by 74% and 80%, respectively."
0,background,8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
0,intervention,8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
0,population,8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
1,outcome,8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
0,other,8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
0,"study design",8604658,4,"There was a significant inverse exponential relation between TNF alpha or IL-1 beta synthesis and mononuclear cell content of eicosapentaenoic acid (EPA), an n--3 fatty acid derived from ingested EPA (fish oil) or metabolism of ingested alpha-linolenic ac"
0,background,8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
0,intervention,8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
0,population,8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
1,outcome,8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
0,other,8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
0,"study design",8604658,5,"Cytokine production decreased as cellular EPA increased to approximately 1% of total fatty acids."
0,background,8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
0,intervention,8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
0,population,8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
1,outcome,8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
0,other,8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
0,"study design",8604658,6,"Further increases in EPA content did not result in further decreases in cytokine production."
0,background,8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
0,intervention,8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
0,population,8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
1,outcome,8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
0,other,8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
0,"study design",8604658,7,"The results indicate that vegetable oils rich in n--3 fatty acids inhibit TNF alpha and IL-1 beta synthesis."
0,background,8620787,1,"PURPOSE"
0,intervention,8620787,1,"PURPOSE"
0,population,8620787,1,"PURPOSE"
0,outcome,8620787,1,"PURPOSE"
1,other,8620787,1,"PURPOSE"
0,"study design",8620787,1,"PURPOSE"
1,background,8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
0,intervention,8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
0,population,8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
0,outcome,8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
0,other,8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
0,"study design",8620787,2,"Our goal was to evaluate use of topical (4 percent) formalin in management of radiation-induced hemorrhagic proctitis, refractory to other methods of treatment."
1,background,8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,intervention,8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,population,8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,outcome,8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,other,8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,"study design",8620787,3,"Specifically, we wished to determine its safety, ability to stop bleeding, and complications associated with therapy."
0,background,8620787,4,"METHODS"
0,intervention,8620787,4,"METHODS"
0,population,8620787,4,"METHODS"
0,outcome,8620787,4,"METHODS"
1,other,8620787,4,"METHODS"
0,"study design",8620787,4,"METHODS"
0,background,8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
1,intervention,8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
1,population,8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
0,outcome,8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
0,other,8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
0,"study design",8620787,5,"Sixteen patients with radiation-induced hemorrhagic proctitis were treated with topical (4 percent) formalin."
1,background,8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,intervention,8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,population,8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,outcome,8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,other,8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,"study design",8620787,6,"All had been previously treated with conservative regimens such as cautery, topical steroids, or laser, but these had failed."
0,background,8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
1,intervention,8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
0,population,8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
0,outcome,8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
0,other,8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
0,"study design",8620787,7,"Five-hundred milliliters (ml) of a 4 percent formalin solution was instilled into the rectum in 50-ml aliquots."
0,background,8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
1,intervention,8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
0,population,8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
0,outcome,8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
0,other,8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
0,"study design",8620787,8,"Each aliquot was kept in contact with rectal mucosa for approximately 30 seconds."
0,background,8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
1,intervention,8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
0,population,8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
0,outcome,8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
0,other,8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
0,"study design",8620787,9,"Treatments were performed under local anesthesia in nine patients, sedation only in four, spinal in two, and general in one patient."
0,background,8620787,10,"RESULTS"
0,intervention,8620787,10,"RESULTS"
0,population,8620787,10,"RESULTS"
0,outcome,8620787,10,"RESULTS"
1,other,8620787,10,"RESULTS"
0,"study design",8620787,10,"RESULTS"
0,background,8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
0,intervention,8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
0,population,8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
1,outcome,8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
0,other,8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
0,"study design",8620787,11,"In 12 patients, bleeding stopped after a single formalin instillation; in 3, bleeding was considerably reduced but continued sporadically."
0,background,8620787,12,"One patient required three treatments before bleeding stopped."
0,intervention,8620787,12,"One patient required three treatments before bleeding stopped."
0,population,8620787,12,"One patient required three treatments before bleeding stopped."
1,outcome,8620787,12,"One patient required three treatments before bleeding stopped."
0,other,8620787,12,"One patient required three treatments before bleeding stopped."
0,"study design",8620787,12,"One patient required three treatments before bleeding stopped."
0,background,8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
0,intervention,8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
0,population,8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
1,outcome,8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
0,other,8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
0,"study design",8620787,13,"Four patients developed postoperative anal pain, of which one also had significant tenesmus and reduced capacity."
0,background,8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
0,intervention,8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
0,population,8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
1,outcome,8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
0,other,8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
0,"study design",8620787,14,"Of these four patients, only two had significant anal pain and fissures that lasted longer than one month."
0,background,8620787,15,"CONCLUSIONS"
0,intervention,8620787,15,"CONCLUSIONS"
0,population,8620787,15,"CONCLUSIONS"
0,outcome,8620787,15,"CONCLUSIONS"
1,other,8620787,15,"CONCLUSIONS"
0,"study design",8620787,15,"CONCLUSIONS"
0,background,8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
0,intervention,8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
0,population,8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
1,outcome,8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
0,other,8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
0,"study design",8620787,16,"Topical (4 percent) formalin is safe and effective in treatment of radiation-induced hemorrhagic proctitis."
0,background,8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
0,intervention,8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
0,population,8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
1,outcome,8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
0,other,8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
0,"study design",8620787,17,"A single treatment will stop bleeding in 75 percent of patients."
1,background,8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
0,intervention,8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
1,population,8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
0,outcome,8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
0,other,8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
0,"study design",8685072,1,"The in vivo pharmacokinetic interaction between two selective serotonin reuptake inhibitors (SSRI) (fluvoxamine, fluoxetine) and tricyclic antidepressants (TCAs) (amitriptyline, clomipramine) or neuroleptics (haloperidol, cyamemazine, levomepromazine, pro"
0,background,8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
1,intervention,8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
0,population,8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
0,outcome,8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
0,other,8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
0,"study design",8685072,2,"They were phenotyped twice with dextromethorphan and mephenytoin: first in steady state conditions while under treatment with TCAs or neuroleptics; and also 10 days after an associated treatment with fluvoxamine (150 mg day(-1)) or fluoxetine (20 mg day(-"
0,background,8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
0,intervention,8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
0,population,8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
1,outcome,8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
0,other,8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
0,"study design",8685072,3,"A clear and statistically significant increase in the mean urinary metabolic ratio (MR) of dextromethorphan/dextrorphan and in the mean mephenytoin S/R ratio (S/R) was seen with the fluvoxamine and fluoxetine treatment."
0,background,8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
0,intervention,8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
0,population,8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
1,outcome,8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
0,other,8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
0,"study design",8685072,4,"The mean MR increased from 0.13 to 0.27 (P&lt;0.01) with fluoxetine and from 0.34 to 0.84 with fluvoxamine (P&lt;0.05)."
0,background,8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
0,intervention,8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
0,population,8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
1,outcome,8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
0,other,8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
0,"study design",8685072,5,"The (dextromethorphan) 'extensive metabolizer' phenotype switched to the 'poor metabolizer' phenotype in six patients by the 10-day fluoxetine treatment, and in two patients by the fluvoxamine treatment."
0,background,8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
0,intervention,8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
0,population,8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
1,outcome,8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
0,other,8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
0,"study design",8685072,6,"The mean S/R increased from 0.24 to 0.34 (P&lt;0.05) with fluoxetine, and from 0.33 to 0.58 (P&lt;0.002) with fluvoxamine."
0,background,8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
0,intervention,8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
0,population,8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
1,outcome,8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
0,other,8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
0,"study design",8685072,7,"These results are in agreement with the observed modification of TCA plasma levels after the SSRI association."
0,background,8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
0,intervention,8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
0,population,8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
1,outcome,8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
0,other,8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
0,"study design",8685072,8,"During fluvoxamine treatment, amitriptyline and clomipramine plasma levels (P&lt;0.06 both) tendentially increased, and those of demethylclomiprarnine decreased (P&lt;0.06)."
0,background,8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
0,intervention,8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
0,population,8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
1,outcome,8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
0,other,8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
0,"study design",8685072,9,"Fluoxetine addition lead to a significant increase (P&lt;0.02) of the desmethylclomipramine plasma levels."
0,background,8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
0,intervention,8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
0,population,8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
1,outcome,8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
0,other,8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
0,"study design",8685072,10,"Fluvoxamine induced a moderate augmentation of the plasma levels of haloperidol and its reduced metabolite and no change in the plasma levels of cyamemazine and levomepromazine."
0,background,8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
0,intervention,8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
0,population,8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
1,outcome,8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
0,other,8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
0,"study design",8685072,11,"But patients treated with neuroleptics are to few to draw any firm conclusion."
0,background,8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
0,intervention,8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
0,population,8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
1,outcome,8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
0,other,8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
0,"study design",8685072,12,"This study suggests, that fluoxetine and fluvoxamine differ in their interaction with the metabolism of some other basic psychotropic drugs, by a mechanism which implies CYP2D6 and CYPmeph and possibly other isoformes of cytochrome P-450."
0,background,8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
0,intervention,8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
0,population,8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
1,outcome,8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
0,other,8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
0,"study design",8685072,13,"Moreover, the interactions produced varied with the TCA prescribed."
0,background,8837547,1,"OBJECTIVE"
0,intervention,8837547,1,"OBJECTIVE"
0,population,8837547,1,"OBJECTIVE"
0,outcome,8837547,1,"OBJECTIVE"
1,other,8837547,1,"OBJECTIVE"
0,"study design",8837547,1,"OBJECTIVE"
1,background,8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,intervention,8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,population,8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,outcome,8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,other,8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,"study design",8837547,2,"To describe potential therapeutic uses of calcitonin in the prevention and treatment of osteoporosis."
0,background,8837547,3,"OPTIONS"
0,intervention,8837547,3,"OPTIONS"
0,population,8837547,3,"OPTIONS"
0,outcome,8837547,3,"OPTIONS"
1,other,8837547,3,"OPTIONS"
0,"study design",8837547,3,"OPTIONS"
0,background,8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
1,intervention,8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
0,population,8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
0,outcome,8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
0,other,8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
0,"study design",8837547,4,"Parenterally and intranasally administered calcitonin (eel, salmon or human)."
0,background,8837547,5,"OUTCOMES"
0,intervention,8837547,5,"OUTCOMES"
0,population,8837547,5,"OUTCOMES"
0,outcome,8837547,5,"OUTCOMES"
1,other,8837547,5,"OUTCOMES"
0,"study design",8837547,5,"OUTCOMES"
0,background,8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
0,intervention,8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
0,population,8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
1,outcome,8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
0,other,8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
0,"study design",8837547,6,"Fracture, fracture pain and loss of bone mineral density in osteoporosis; increased bone mass, prevention of fractures, reduction of pain and improved quality of life associated with calcitonin treatment."
0,background,8837547,7,"EVIDENCE"
0,intervention,8837547,7,"EVIDENCE"
0,population,8837547,7,"EVIDENCE"
0,outcome,8837547,7,"EVIDENCE"
1,other,8837547,7,"EVIDENCE"
0,"study design",8837547,7,"EVIDENCE"
0,background,8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
0,intervention,8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
0,population,8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
0,outcome,8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
1,other,8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
0,"study design",8837547,8,"Relevant clinical studies and reports were examined, with an emphasis on recent randomized, placebo-controlled trials."
0,background,8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
0,intervention,8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
0,population,8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
0,outcome,8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
1,other,8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
0,"study design",8837547,9,"In vitro and in vivo studies of osteoclast activity were also considered."
0,background,8837547,10,"VALUES"
0,intervention,8837547,10,"VALUES"
0,population,8837547,10,"VALUES"
0,outcome,8837547,10,"VALUES"
1,other,8837547,10,"VALUES"
0,"study design",8837547,10,"VALUES"
0,background,8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
0,intervention,8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
0,population,8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
0,outcome,8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
1,other,8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
0,"study design",8837547,11,"Reducing fractures and fracture pain, increasing bone mineral density and minimizing side effects of treatment were given a high value."
0,background,8837547,12,"BENEFITS, HARMS AND COSTS"
0,intervention,8837547,12,"BENEFITS, HARMS AND COSTS"
0,population,8837547,12,"BENEFITS, HARMS AND COSTS"
0,outcome,8837547,12,"BENEFITS, HARMS AND COSTS"
1,other,8837547,12,"BENEFITS, HARMS AND COSTS"
0,"study design",8837547,12,"BENEFITS, HARMS AND COSTS"
0,background,8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
0,intervention,8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
0,population,8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
1,outcome,8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
0,other,8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
0,"study design",8837547,13,"Calcitonin reduces acute pain associated with osteoporotic fractures and has been found useful in treating chronic back pain following vertebral fractures in spinal osteoporosis."
0,background,8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
0,intervention,8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
0,population,8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
1,outcome,8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
0,other,8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
0,"study design",8837547,14,"It can prevent bone loss and may be effective in preventing fractures."
0,background,8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
0,intervention,8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
0,population,8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
1,outcome,8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
0,other,8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
0,"study design",8837547,15,"Side effects are dose related and generally mild; they include gastrointestinal, vascular and dermatologic conditions that can be treated symptomatically or by varying the dosage."
0,background,8837547,16,"Side effects are much rarer with nasal administration than with injection."
0,intervention,8837547,16,"Side effects are much rarer with nasal administration than with injection."
0,population,8837547,16,"Side effects are much rarer with nasal administration than with injection."
1,outcome,8837547,16,"Side effects are much rarer with nasal administration than with injection."
0,other,8837547,16,"Side effects are much rarer with nasal administration than with injection."
0,"study design",8837547,16,"Side effects are much rarer with nasal administration than with injection."
0,background,8837547,17,"True allergic reactions are rare."
0,intervention,8837547,17,"True allergic reactions are rare."
0,population,8837547,17,"True allergic reactions are rare."
1,outcome,8837547,17,"True allergic reactions are rare."
0,other,8837547,17,"True allergic reactions are rare."
0,"study design",8837547,17,"True allergic reactions are rare."
0,background,8837547,18,"RECOMMENDATIONS"
0,intervention,8837547,18,"RECOMMENDATIONS"
0,population,8837547,18,"RECOMMENDATIONS"
0,outcome,8837547,18,"RECOMMENDATIONS"
1,other,8837547,18,"RECOMMENDATIONS"
0,"study design",8837547,18,"RECOMMENDATIONS"
0,background,8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
0,intervention,8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
0,population,8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
1,outcome,8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
0,other,8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
0,"study design",8837547,19,"Calcitonin in both intramuscular and intranasal forms can reduce the pain of acute osteoporotic vertebral fractures and may be effective in treating that associated with chronic vertebral osteoporotic fractures."
0,background,8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
0,intervention,8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
0,population,8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
1,outcome,8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
0,other,8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
0,"study design",8837547,20,"Calcitonin may also prevent postmenopausal bone loss and increase bone density in those with established osteoporosis."
0,background,8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
0,intervention,8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
0,population,8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
1,outcome,8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
0,other,8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
0,"study design",8837547,21,"Current evidence for long-term prevention of fractures is limited and does not support the use of calcitonin as a first-line treatment for established osteoporosis."
0,background,8837547,22,"Most side effects can be avoided with nasal administration."
0,intervention,8837547,22,"Most side effects can be avoided with nasal administration."
0,population,8837547,22,"Most side effects can be avoided with nasal administration."
1,outcome,8837547,22,"Most side effects can be avoided with nasal administration."
0,other,8837547,22,"Most side effects can be avoided with nasal administration."
0,"study design",8837547,22,"Most side effects can be avoided with nasal administration."
0,background,8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
0,intervention,8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
0,population,8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
1,outcome,8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
0,other,8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
0,"study design",8837547,23,"Further trials are needed to assess fracture prevention and effective dose ranges for treating pain and increasing bone mineral density and to determine the long-term efficacy of calcitonin in secondary osteoporosis, in premenopausal women, in men and in "
0,background,8852319,1,"STUDY DESIGN"
0,intervention,8852319,1,"STUDY DESIGN"
0,population,8852319,1,"STUDY DESIGN"
0,outcome,8852319,1,"STUDY DESIGN"
1,other,8852319,1,"STUDY DESIGN"
0,"study design",8852319,1,"STUDY DESIGN"
1,background,8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,intervention,8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,population,8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,outcome,8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,other,8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,"study design",8852319,2,"This study investigated the outcome of anterior decompression and stabilization for &quot;unstable&quot; burst fractures without initial neurologic deficits in the thoracolumbar spine."
0,background,8852319,3,"OBJECTIVE"
0,intervention,8852319,3,"OBJECTIVE"
0,population,8852319,3,"OBJECTIVE"
0,outcome,8852319,3,"OBJECTIVE"
1,other,8852319,3,"OBJECTIVE"
0,"study design",8852319,3,"OBJECTIVE"
1,background,8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,intervention,8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,population,8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,outcome,8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,other,8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,"study design",8852319,4,"To determine the pain and work status of the patients, who underwent the anterior decompression and stabilization, to evaluate the relationship between residual back pain and the degree of kyphosis, and to analyze the advantages and disadvantages of surge"
0,background,8852319,5,"SUMMARY OF BACKGROUND DATA"
0,intervention,8852319,5,"SUMMARY OF BACKGROUND DATA"
0,population,8852319,5,"SUMMARY OF BACKGROUND DATA"
0,outcome,8852319,5,"SUMMARY OF BACKGROUND DATA"
1,other,8852319,5,"SUMMARY OF BACKGROUND DATA"
0,"study design",8852319,5,"SUMMARY OF BACKGROUND DATA"
0,background,8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
0,intervention,8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
1,population,8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
0,outcome,8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
0,other,8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
1,"study design",8852319,6,"A retrospective review was conducted on 45 patients with unstable burst fractures in the thoracolumbar spine treated by anterior decompression and stabilization in our institutions from 1982 to 1993."
0,background,8852319,7,"Nineteen patients were available for this study."
0,intervention,8852319,7,"Nineteen patients were available for this study."
0,population,8852319,7,"Nineteen patients were available for this study."
0,outcome,8852319,7,"Nineteen patients were available for this study."
1,other,8852319,7,"Nineteen patients were available for this study."
0,"study design",8852319,7,"Nineteen patients were available for this study."
0,background,8852319,8,"Ten patients were men and 9 were women."
0,intervention,8852319,8,"Ten patients were men and 9 were women."
0,population,8852319,8,"Ten patients were men and 9 were women."
0,outcome,8852319,8,"Ten patients were men and 9 were women."
1,other,8852319,8,"Ten patients were men and 9 were women."
0,"study design",8852319,8,"Ten patients were men and 9 were women."
0,background,8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
0,intervention,8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
0,population,8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
0,outcome,8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
1,other,8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
0,"study design",8852319,9,"Their age at surgery ranged from 15 to 76 years (average, 46 years)."
0,background,8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
0,intervention,8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
0,population,8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
0,outcome,8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
1,other,8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
0,"study design",8852319,10,"The duration of follow-up ranged from 24 to 84 months (average follow-up, 54 months)."
0,background,8852319,11,"METHODS"
0,intervention,8852319,11,"METHODS"
0,population,8852319,11,"METHODS"
0,outcome,8852319,11,"METHODS"
1,other,8852319,11,"METHODS"
0,"study design",8852319,11,"METHODS"
0,background,8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
0,intervention,8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
0,population,8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
0,outcome,8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
1,other,8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
0,"study design",8852319,12,"All clinical charts and radiologic data of these patients were reviewed by the first author."
0,background,8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
0,intervention,8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
0,population,8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
0,outcome,8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
1,other,8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
0,"study design",8852319,13,"Their pain, work, and employment statuses were assessed by the scales proposed by Denis in 1984."
0,background,8852319,14,"RESULTS"
0,intervention,8852319,14,"RESULTS"
0,population,8852319,14,"RESULTS"
0,outcome,8852319,14,"RESULTS"
1,other,8852319,14,"RESULTS"
0,"study design",8852319,14,"RESULTS"
0,background,8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
0,intervention,8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
0,population,8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
1,outcome,8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
0,other,8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
0,"study design",8852319,15,"Nine patients were rated P1, 7 were rated P2, 2 were rated P3, 1 was rated P5, 11 were rated W1, 3 were W2, 1 was W3, and 4 were rated W5."
0,background,8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
0,intervention,8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
0,population,8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
1,outcome,8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
0,other,8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
0,"study design",8852319,16,"Even the physical laborers' return to work averaged 5 months after surgery (range, 3-12 months)."
0,background,8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
0,intervention,8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
0,population,8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
1,outcome,8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
0,other,8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
0,"study design",8852319,17,"The postoperative kyphotic angle ranged from -6 degrees to 45 degrees (average, 11 degrees), and it remained -5 degrees to 45 degrees (average, 12 degrees) at final follow-up."
0,background,8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
0,intervention,8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
0,population,8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
1,outcome,8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
0,other,8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
0,"study design",8852319,18,"There was no statistical correlation between the kyphotic angle and the pain scale."
0,background,8852319,19,"CONCLUSIONS"
0,intervention,8852319,19,"CONCLUSIONS"
0,population,8852319,19,"CONCLUSIONS"
0,outcome,8852319,19,"CONCLUSIONS"
1,other,8852319,19,"CONCLUSIONS"
0,"study design",8852319,19,"CONCLUSIONS"
0,background,8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
0,intervention,8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
0,population,8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
1,outcome,8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
0,other,8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
0,"study design",8852319,20,"Anterior decompression and stabilization for unstable burst fracture without initial neurologic deficits in the thoracolumbar spine has some advantages in the view of anatomical reduction and rigid stability that allows patients an early rehabilitation, r"
1,background,8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
0,intervention,8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
0,population,8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
0,outcome,8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
0,other,8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
0,"study design",8865908,1,"The proper function of peritoneal dialysis (PD) catheters can be compromised by catheter malposition, fibrin clot, or omental wrapping."
1,background,8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,intervention,8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,population,8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,outcome,8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,other,8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,"study design",8865908,2,"The purpose of this study was to determine the efficacy of laparoscopy in the treatment of malfunctioning PD catheters."
0,background,8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
0,intervention,8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
1,population,8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
0,outcome,8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
0,other,8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
0,"study design",8865908,3,"All patients undergoing laparoscopy for catheter dysfunction at MetroHealth Medical Center in Cleveland, Ohio, from 1991 to 1995, were reviewed."
0,background,8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
0,intervention,8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
0,population,8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
1,outcome,8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
0,other,8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
0,"study design",8865908,4,"Twenty-six laparoscopies were performed in 22 patients, for malfunction occurring an average of 3.9 months following insertion (range 0.5-18 months)."
0,background,8865908,5,"Omental and/or small below wrapping as present in all but three cases."
0,intervention,8865908,5,"Omental and/or small below wrapping as present in all but three cases."
0,population,8865908,5,"Omental and/or small below wrapping as present in all but three cases."
1,outcome,8865908,5,"Omental and/or small below wrapping as present in all but three cases."
0,other,8865908,5,"Omental and/or small below wrapping as present in all but three cases."
0,"study design",8865908,5,"Omental and/or small below wrapping as present in all but three cases."
0,background,8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
0,intervention,8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
0,population,8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
1,outcome,8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
0,other,8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
0,"study design",8865908,6,"Lysis of adhesions was required in 19 of 26 cases, with repositioning only in seven."
0,background,8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
0,intervention,8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
0,population,8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
1,outcome,8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
0,other,8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
0,"study design",8865908,7,"Eight patients had failed attempts at stiff wire manipulation prior to laparoscopy."
0,background,8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
0,intervention,8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
0,population,8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
1,outcome,8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
0,other,8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
0,"study design",8865908,8,"Perioperative complications occurred in seven cases, consisting of temporary dialysate leakage (2), enterotomy (1), and early reocclusion (4)."
0,background,8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
0,intervention,8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
0,population,8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
1,outcome,8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
0,other,8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
0,"study design",8865908,9,"Repeat laparoscopy was successful in three of these four reocclusions."
0,background,8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
0,intervention,8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
0,population,8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
1,outcome,8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
0,other,8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
0,"study design",8865908,10,"The overall success rate (catheter function > 30 days after laparoscopy) was 21/22 (96%)."
0,background,8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
0,intervention,8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
0,population,8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
1,outcome,8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
0,other,8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
0,"study design",8865908,11,"Laparoscopy is highly accurate and effective in the management of peritoneal dialysis catheter dysfunction and results in prolongation of catheter life."
0,background,8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
0,intervention,8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
1,population,8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
1,outcome,8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
0,other,8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
0,"study design",8927409,1,"A review of 1300 patients with spinal cord injury (SCI), over a period of 14 years, revealed 12 patients with an 'acute abdomen'."
0,background,8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
0,intervention,8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
0,population,8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
1,outcome,8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
0,other,8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
0,"study design",8927409,2,"Seven events occurred during the initial admission, ranging from 10 days to 9 months from injury, and five during readmission of 'chronic' SCI patients."
0,background,8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
0,intervention,8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
0,population,8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
1,outcome,8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
0,other,8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
0,"study design",8927409,3,"Four were in the acute stage 10-30 days from injury, all with peptic ulcer perforations."
0,background,8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
0,intervention,8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
0,population,8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
1,outcome,8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
0,other,8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
0,"study design",8927409,4,"The remainder had either an intestinal obstruction, appendicitis or peritonitis."
0,background,8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
0,intervention,8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
0,population,8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
1,outcome,8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
0,other,8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
0,"study design",8927409,5,"All of the neurological levels were above T6 except for one patient who had a low level paraplegia."
0,background,8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
0,intervention,8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
0,population,8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
1,outcome,8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
0,other,8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
0,"study design",8927409,6,"The classical signs of an 'acute abdomen' may be missing in such patients thus delaying diagnosis by 1-4 days."
0,background,8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
0,intervention,8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
0,population,8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
1,outcome,8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
0,other,8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
0,"study design",8927409,7,"The most important signs were autonomic dysreflexia, referred shoulder tip pain, abdominal pain, abdominal distension, increased spasticity and abdominal pain with nausea and vomiting."
0,background,8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
0,intervention,8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
0,population,8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
1,outcome,8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
0,other,8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
0,"study design",8927409,8,"Less importance was given to the classical signs of abdominal tenderness, abdominal muscle rigidity, rebound, fever and of leukocytosis."
0,background,8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
0,intervention,8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
0,population,8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
1,outcome,8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
0,other,8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
0,"study design",8927409,9,"Prompt diagnosis and treatment will minimise morbidity and mortality."
1,background,8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
0,intervention,8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
0,population,8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
0,outcome,8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
0,other,8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
0,"study design",8934036,1,"Although the need for effective ovarian cancer screening is apparent, a highly sensitive and specific screening methodology has yet to be elucidated."
1,background,8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
0,intervention,8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
0,population,8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
0,outcome,8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
0,other,8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
0,"study design",8934036,2,"42-44 Given that there are more than 43 million women in the United States older than 45 years of age and that the average cost of a pelvic sonogram is $ 275 (and $ 45 for CA125 screening), the screening of this population is estimated to increase health "
1,background,8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
0,intervention,8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
0,population,8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
0,outcome,8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
0,other,8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
0,"study design",8934036,3,"45 The additional cost of BRCA1 screening varies according to the level of diagnostic effort required to establish BRCA1 gene mutations in a particular family and ranges from $ 295 to $ 1,200 per sample."
1,background,8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
0,intervention,8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
0,population,8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
0,outcome,8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
0,other,8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
0,"study design",8934036,4,"Assuming an average cost of $ 600 per sample, initial screening of these same women would likely increased costs in excess of $ 25 billion."
1,background,8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
0,intervention,8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
0,population,8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
0,outcome,8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
0,other,8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
0,"study design",8934036,5,"Current knowledge and technology in ovarian cancer screening has not yet proved beneficial for the general population or for women with fewer than two affected family members."
1,background,8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
0,intervention,8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
0,population,8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
0,outcome,8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
0,other,8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
0,"study design",8934036,6,"For women with two or more affected family members, there is a 3% chance of that patient being a proband in a hereditary cancer syndrome family."
1,background,8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
0,intervention,8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
0,population,8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
0,outcome,8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
0,other,8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
0,"study design",8934036,7,"11,46 In this group, who may be at increased risk for developing a malignancy, heightened surveillance is warranted, although there are still no data to confirm that screening even these high-risk women will reduce mortality."
1,background,8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
0,intervention,8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
0,population,8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
0,outcome,8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
0,other,8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
0,"study design",8934036,8,"Nevertheless, annual bimanual examination, serum CA125, and transvaginal sonography are recommended among this particular subgroup of women at risk, and are likely to be recommended for young, asymptomatic, at-risk women who screen positive for the 185del"
1,background,8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
0,intervention,8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
0,population,8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
0,outcome,8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
0,other,8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
0,"study design",8934036,9,"It is only through prospective, randomized trials that reliable data regarding the risk/benefit ratio of ovarian cancer screening among various populations at risk will be determined."
1,background,8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
0,intervention,8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
0,population,8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
0,outcome,8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
0,other,8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
0,"study design",8934036,10,"The results of the prospective/randomized PLCO trial and the mature data from ongoing prospective, nonrandomized screening trials for women with a family history of cancer may provide this information and are eagerly awaited."
1,background,9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
0,intervention,9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
0,population,9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
0,outcome,9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
0,other,9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
0,"study design",9031649,1,"The impact of insurance on access to physician services among elderly individuals with chronic illnesses has far-reaching policy implications."
1,background,9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,intervention,9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,population,9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,outcome,9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,other,9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,"study design",9031649,2,"Using a national probability sample of aged Medicare beneficiaries (N = 5,543), and controlling for severity of illness, comorbidities, and other covariates, we analyze this issue for the most prevalent, chronic disabling disease among the elderly: arthri"
0,background,9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
0,intervention,9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
0,population,9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
1,outcome,9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
0,other,9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
0,"study design",9031649,3,"The results from the two-part multivariate model (logistic regression followed by ordinary least squares regression) suggest that insurance status is a positive and statistically significant predictor of both initial access to care (p &lt; .01), and amoun"
0,background,9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
0,intervention,9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
0,population,9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
1,outcome,9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
0,other,9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
0,"study design",9031649,4,"Taking the results of the two-part model, we conducted a microsimulation to estimate the increase in Medicare spending that would result if various types of Medicare supplemental insurance were provided to those who had none."
0,background,9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
0,intervention,9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
0,population,9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
1,outcome,9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
0,other,9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
0,"study design",9031649,5,"Results suggest that Medicare expenditures would rise from $51 million to $59 million annually depending on the type of supplement provided."
0,background,9040921,1,"OBJECTIVE"
0,intervention,9040921,1,"OBJECTIVE"
0,population,9040921,1,"OBJECTIVE"
0,outcome,9040921,1,"OBJECTIVE"
1,other,9040921,1,"OBJECTIVE"
0,"study design",9040921,1,"OBJECTIVE"
1,background,9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,intervention,9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,population,9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,outcome,9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,other,9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,"study design",9040921,2,"To review variations in outcomes in schizophrenia across individual, historical, and cross-cultural boundaries, as well as within specific domains of functioning."
0,background,9040921,3,"METHOD"
0,intervention,9040921,3,"METHOD"
0,population,9040921,3,"METHOD"
0,outcome,9040921,3,"METHOD"
1,other,9040921,3,"METHOD"
0,"study design",9040921,3,"METHOD"
0,background,9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
0,intervention,9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
0,population,9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
0,outcome,9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
1,other,9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
0,"study design",9040921,4,"Research literature on the outcomes of schizophrenia appearing within the last 8 years was reviewed."
0,background,9040921,5,"RESULTS"
0,intervention,9040921,5,"RESULTS"
0,population,9040921,5,"RESULTS"
0,outcome,9040921,5,"RESULTS"
1,other,9040921,5,"RESULTS"
0,"study design",9040921,5,"RESULTS"
0,background,9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
0,intervention,9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
0,population,9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
1,outcome,9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
0,other,9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
0,"study design",9040921,6,"First, a review of follow-up studies published in the developed world suggests that heterogeneity in outcome across individuals with schizophrenia remains the rule, with affective symptoms, later and acute onset, and responsiveness to biological treatment"
0,background,9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
0,intervention,9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
0,population,9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
1,outcome,9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
0,other,9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
0,"study design",9040921,7,"Negative symptoms are associated with poor outcome, cognitive impairments, and incapacity in social and work domains."
0,background,9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
0,intervention,9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
0,population,9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
1,outcome,9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
0,other,9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
0,"study design",9040921,8,"Deterioration appears to occur within the first few months of onset if not already in the prodrome, with recent early-course studies finding longer duration of untreated psychosis associated with insidious onset, negative symptoms, social and work incapac"
0,background,9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
0,intervention,9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
0,population,9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
1,outcome,9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
0,other,9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
0,"study design",9040921,9,"Second, a review of recent cross-cultural and historical studies provides evidence that outcome varies across time and place, schizophrenia having a more favourable outcome in the developing world and becoming a more benign disorder over the course of thi"
0,background,9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
0,intervention,9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
0,population,9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
1,outcome,9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
0,other,9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
0,"study design",9040921,10,"Third, a review of studies of the domains of functioning within individuals identifies 4 relatively independent dimensions of depression and negative, psychotic, and disorganized symptoms."
0,background,9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
0,intervention,9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
0,population,9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
1,outcome,9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
0,other,9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
0,"study design",9040921,11,"Cognitive deficits, which are associated with negative symptoms, also constitute a relatively stable dimension over time, showing neither marked deterioration nor improvement once established early in the course of disorder."
0,background,9040921,12,"CONCLUSIONS"
0,intervention,9040921,12,"CONCLUSIONS"
0,population,9040921,12,"CONCLUSIONS"
0,outcome,9040921,12,"CONCLUSIONS"
1,other,9040921,12,"CONCLUSIONS"
0,"study design",9040921,12,"CONCLUSIONS"
0,background,9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
0,intervention,9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
0,population,9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
1,outcome,9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
0,other,9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
0,"study design",9040921,13,"The early appearance and stability over time of negative symptoms and cognitive impairments call for assertive intervention efforts early in the course of disorder to prevent chronicity and prolonged disability."
1,background,9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
0,intervention,9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
0,population,9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
0,outcome,9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
0,other,9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
0,"study design",9141327,1,"State government entities have created a range of innovative electronic information systems to support their diverse and evolving roles in the health care system."
1,background,9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
0,intervention,9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
0,population,9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
0,outcome,9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
0,other,9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
0,"study design",9141327,2,"Primary goals of these initiatives include improvement of traditional public health programs, meaningful oversight of providers, simplification of administrative procedures, and support of state purchasing decisions."
1,background,9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
0,intervention,9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
0,population,9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
0,outcome,9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
0,other,9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
0,"study design",9141327,3,"We establish a taxonomy of state efforts, describing primary capabilities to (1) provide meaningful data to state decisionmakers; (2) disseminate information to purchasers and consumers; (3) coordinate and improve government services; (4) establish mechan"
1,background,9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
0,intervention,9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
0,population,9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
0,outcome,9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
0,other,9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
0,"study design",9141327,4,"Reductions in the costs of technology and use of the Internet have dramatically increased state capabilities in recent years."
1,background,9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
0,intervention,9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
0,population,9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
0,outcome,9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
0,other,9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
0,"study design",9141327,5,"Both the successes and failures of existing programs offer important lessons for states that are initiating new electronic communication initiatives."
1,background,9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
0,intervention,9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
0,population,9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
0,outcome,9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
0,other,9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
1,"study design",9160457,1,"A prospective study was performed to determine why some persons with spinal cord injury (SCI) fail to return for scheduled evaluations in order to identify predictive factors that could be used to target those at greatest risk for noncompliance and facili"
0,background,9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
0,intervention,9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
1,population,9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
0,outcome,9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
0,other,9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
0,"study design",9160457,2,"Sixty-one noncompliant subjects and 102 persons compliant with regularly scheduled annual examinations were paid to come to the clinic for evaluation."
0,background,9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
0,intervention,9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
0,population,9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
0,outcome,9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
1,other,9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
0,"study design",9160457,3,"Each participant completed a psychological questionnaire comprised of theoretical and socioeconomic variables."
0,background,9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
0,intervention,9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
0,population,9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
1,outcome,9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
0,other,9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
0,"study design",9160457,4,"There was no difference between the two groups according to gender, race, level or completeness of injury, education, etiology of injury, responses to questions from the Health Locus of Control Scale, Health Beliefs Model, inconvenience or discomfort."
0,background,9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
0,intervention,9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
0,population,9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
1,outcome,9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
0,other,9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
0,"study design",9160457,5,"For noncompliant versus compliant persons, cost (P = 0.0002), distance (P = 0.0047), transportation (P = 0.0330), belief that follow-up was not necessary (P &lt; 0.0001), availability of good local doctor (P = 0.0001) and time (P = 0.0209) were identified"
0,background,9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
0,intervention,9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
0,population,9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
1,outcome,9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
0,other,9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
0,"study design",9160457,6,"These data indicate a need to improve the education for newly injured persons as well as those persons residing in the community on the importance of regular urological follow-up, to maintain close contact post-discharge and to assist in identifying commu"
0,background,9210739,1,"OBJECTIVE"
0,intervention,9210739,1,"OBJECTIVE"
0,population,9210739,1,"OBJECTIVE"
0,outcome,9210739,1,"OBJECTIVE"
1,other,9210739,1,"OBJECTIVE"
0,"study design",9210739,1,"OBJECTIVE"
1,background,9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
0,intervention,9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
0,population,9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
0,outcome,9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
0,other,9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
0,"study design",9210739,2,"Some prolonged and turbulent grief reactions include symptoms that differ from the DSM-IV criteria for major depressive disorder."
1,background,9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,intervention,9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,population,9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,outcome,9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,other,9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,"study design",9210739,3,"The authors investigated a new diagnosis that would include these symptoms."
0,background,9210739,4,"METHOD"
0,intervention,9210739,4,"METHOD"
0,population,9210739,4,"METHOD"
0,outcome,9210739,4,"METHOD"
1,other,9210739,4,"METHOD"
0,"study design",9210739,4,"METHOD"
0,background,9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
0,intervention,9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
0,population,9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
0,outcome,9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
1,other,9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
0,"study design",9210739,5,"They developed observer-based definitions of 30 symptoms noted clinically in previous longitudinal interviews of bereaved persons and then designed a plan to investigate whether any combination of these would serve as criteria for a possible new diagnosis of complicated grief disorder."
0,background,9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
0,intervention,9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
1,population,9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
0,outcome,9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
0,other,9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
0,"study design",9210739,6,"Using a structured diagnostic interview, they assessed 70 subjects whose spouses had died."
0,background,9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
0,intervention,9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
0,population,9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
0,outcome,9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
1,other,9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
0,"study design",9210739,7,"Latent class model analyses and signal detection procedures were used to calibrate the data against global clinical ratings and self-report measures of grief-specific distress."
0,background,9210739,8,"RESULTS"
0,intervention,9210739,8,"RESULTS"
0,population,9210739,8,"RESULTS"
0,outcome,9210739,8,"RESULTS"
1,other,9210739,8,"RESULTS"
0,"study design",9210739,8,"RESULTS"
0,background,9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
0,intervention,9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
0,population,9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
1,outcome,9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
0,other,9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
0,"study design",9210739,9,"Complicated grief disorder was found to be characterized by a smaller set of the assessed symptoms."
0,background,9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
0,intervention,9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
0,population,9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
1,outcome,9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
0,other,9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
0,"study design",9210739,10,"Subjects elected by an algorithm for these symptoms patterns did not significantly overlap with subjects who received a diagnosis of major depressive disorder."
0,background,9210739,11,"CONCLUSIONS"
0,intervention,9210739,11,"CONCLUSIONS"
0,population,9210739,11,"CONCLUSIONS"
0,outcome,9210739,11,"CONCLUSIONS"
1,other,9210739,11,"CONCLUSIONS"
0,"study design",9210739,11,"CONCLUSIONS"
0,background,9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
0,intervention,9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
0,population,9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
1,outcome,9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
0,other,9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
0,"study design",9210739,12,"A new diagnosis of complicated grief disorder may be indicated."
0,background,9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
0,intervention,9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
0,population,9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
1,outcome,9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
0,other,9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
0,"study design",9210739,13,"Its criteria would include the current experience (more than a year after a loss) of intense intrusive thoughts, pangs of severe emotion, distressing yearnings, feeling excessively alone and empty, excessively avoiding tasks reminiscent of the deceased, u"
0,background,9289524,1,"BACKGROUND"
0,intervention,9289524,1,"BACKGROUND"
0,population,9289524,1,"BACKGROUND"
0,outcome,9289524,1,"BACKGROUND"
1,other,9289524,1,"BACKGROUND"
0,"study design",9289524,1,"BACKGROUND"
1,background,9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,intervention,9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,population,9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,outcome,9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,other,9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,"study design",9289524,2,"The aim of this study was to analyse and to verify the efficacy of systematic advice for alcoholism prevention, assessing the reduction of the number in risk drinkers."
0,background,9289524,3,"PATIENTS AND METHODS"
0,intervention,9289524,3,"PATIENTS AND METHODS"
0,population,9289524,3,"PATIENTS AND METHODS"
0,outcome,9289524,3,"PATIENTS AND METHODS"
1,other,9289524,3,"PATIENTS AND METHODS"
0,"study design",9289524,3,"PATIENTS AND METHODS"
0,background,9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
1,intervention,9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
1,population,9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
0,outcome,9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
0,other,9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
1,"study design",9289524,4,"A multicenter randomized controlled clinical trial was designed, to perform in general practitioner setting, on a sample of risk drinkers (alcohol intake > 280 g weekly, without dependence) sent by random in intervention group (systematic brief advice wit"
0,background,9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
1,intervention,9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
0,population,9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
0,outcome,9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
0,other,9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
0,"study design",9289524,5,"The procedure to incorporate in both groups included physical exam, a blood test and the MALT questionnaire."
0,background,9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
0,intervention,9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
0,population,9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
0,outcome,9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
1,other,9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
0,"study design",9289524,6,"A descriptive and analytic study on included variables was realised, assessing the percentage of drinkers who reduced alcohol intake below risk limit at the end of a year follow up, as well as the reduction intake in each group."
0,background,9289524,7,"RESULTS"
0,intervention,9289524,7,"RESULTS"
0,population,9289524,7,"RESULTS"
0,outcome,9289524,7,"RESULTS"
1,other,9289524,7,"RESULTS"
0,"study design",9289524,7,"RESULTS"
0,background,9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
0,intervention,9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
0,population,9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
1,outcome,9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
0,other,9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
0,"study design",9289524,8,"Of the 139 included males, 75 were in the intervention group and 64 in the control group."
0,background,9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
0,intervention,9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
0,population,9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
1,outcome,9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
0,other,9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
0,"study design",9289524,9,"The percentage of patients not excluded by MALT > 10, and/or liver disease, that finished the 1 year follow up, was 46%, being the sample average age of 43 +/- 11.8."
0,background,9289524,10,"Patients included in both groups were initially comparable."
0,intervention,9289524,10,"Patients included in both groups were initially comparable."
0,population,9289524,10,"Patients included in both groups were initially comparable."
1,outcome,9289524,10,"Patients included in both groups were initially comparable."
0,other,9289524,10,"Patients included in both groups were initially comparable."
0,"study design",9289524,10,"Patients included in both groups were initially comparable."
0,background,9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
0,intervention,9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
0,population,9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
1,outcome,9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
0,other,9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
0,"study design",9289524,11,"At the end of a year follow up there were statistically significant differences in: percentage of risk drinkers who decreased alcohol intake below 280 g weekly (82% intervention group; 47% control group); percentage of reduction in GPT, GGT, triglycerides"
0,background,9289524,12,"CONCLUSIONS"
0,intervention,9289524,12,"CONCLUSIONS"
0,population,9289524,12,"CONCLUSIONS"
0,outcome,9289524,12,"CONCLUSIONS"
1,other,9289524,12,"CONCLUSIONS"
0,"study design",9289524,12,"CONCLUSIONS"
0,background,9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
0,intervention,9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
0,population,9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
1,outcome,9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
0,other,9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
0,"study design",9289524,13,"The efficacy of isolated advice of general practitioner was proved to achieve the alcohol intake reduction below the risk limit accepted in male risk drinkers without alcohol dependence."
0,background,9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
0,intervention,9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
0,population,9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
1,outcome,9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
0,other,9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
0,"study design",9289524,14,"The systematic follow up during a year significantly improves the results achieved with the isolated advice."
1,background,9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
0,intervention,9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
0,population,9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
0,outcome,9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
0,other,9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
0,"study design",9586400,1,"An estimated 20% of all breast cancer or ovarian and breast cancer cases have familial aggregation."
1,background,9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
0,intervention,9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
0,population,9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
0,outcome,9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
0,other,9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
0,"study design",9586400,2,"Today it is known that approximately 10% of these cases are attributable to inherited mutations of a predisposition gene that confers a high risk of developing the disease."
1,background,9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
0,intervention,9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
0,population,9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
0,outcome,9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
0,other,9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
0,"study design",9586400,3,"Several genes have been identified that differ in the risks which they determine, the proportion of cases they explain and the other cancers they may cause."
1,background,9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
0,intervention,9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
0,population,9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
0,outcome,9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
0,other,9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
0,"study design",9586400,4,"Out of all the genes reported so far, BRCA1 and BRCA2 are the most important ones."
1,background,9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
0,intervention,9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
0,population,9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
0,outcome,9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
0,other,9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
0,"study design",9586400,5,"The mutations in the remaining genes are rare or involve moderate or low risks."
1,background,9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
0,intervention,9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
0,population,9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
0,outcome,9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
0,other,9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
0,"study design",9586400,6,"The possibility to detect breast and/or ovarian cancer susceptibility genes in high risk families poses serious challenges that must be faced by health professionals related with this field."
1,background,9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
1,intervention,9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
1,population,9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
0,outcome,9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
0,other,9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
0,"study design",9629815,1,"This study aimed to assess the effect of a hospital-based smoking cessation intervention delivered by midwives during routine antenatal and postnatal care on the smoking habits of pregnant women and their partners."
0,background,9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
1,intervention,9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
0,population,9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
0,outcome,9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
0,other,9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
0,"study design",9629815,2,"At the first antenatal visit, women in the intervention group (n = 110) were given a demonstration of the immediate effects of smoking on foetal heart rate, brief smoking cessation advice and smoking cessation booklets for themselves and their partners; a"
0,background,9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
0,intervention,9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
0,population,9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
1,outcome,9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
0,other,9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
0,"study design",9629815,3,"Compared with an historical control group who received usual care (n = 110) and assuming those lost to follow-up continued to smoke, biochemically-verified maternal cessation sustained from at least 24 weeks gestation to late pregnancy was 6.4% in the int"
0,background,9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
0,intervention,9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
0,population,9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
1,outcome,9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
0,other,9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
0,"study design",9629815,4,"However, there was no difference between maternal quit rates at six months postpartum."
0,background,9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
0,intervention,9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
0,population,9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
1,outcome,9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
0,other,9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
0,"study design",9629815,5,"Partners were more likely to try to quit in the intervention group, but quit rates did not differ."
0,background,9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
0,intervention,9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
0,population,9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
1,outcome,9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
0,other,9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
0,"study design",9629815,6,"Exposure to the intervention was not associated with increased levels of psychological distress, as measured by the 12-item General Health Questionnaire."
0,background,9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
0,intervention,9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
0,population,9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
1,outcome,9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
0,other,9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
0,"study design",9629815,7,"We conclude that this type of intervention, when implemented by staff during routine care, is probably associated with a small improvement in maternal cessation in pregnancy, similar to that produced by minimal advice to quit smoking."
1,background,9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
0,intervention,9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
0,population,9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
0,outcome,9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
0,other,9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
0,"study design",9768780,1,"The transient hyperemic response (THR) in the middle cerebral artery (MCA) after the release of brief compression of the ipsilateral common carotid artery has been used to study cerebral autoregulation."
1,background,9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,intervention,9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,population,9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,outcome,9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,other,9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,"study design",9768780,2,"We conducted the present study to evaluate the reliability of THR to detect changes in cerebral autoregulation induced by graded variations in PETCO2."
0,background,9768780,3,"Seven healthy adult volunteers were recruited."
0,intervention,9768780,3,"Seven healthy adult volunteers were recruited."
1,population,9768780,3,"Seven healthy adult volunteers were recruited."
0,outcome,9768780,3,"Seven healthy adult volunteers were recruited."
0,other,9768780,3,"Seven healthy adult volunteers were recruited."
0,"study design",9768780,3,"Seven healthy adult volunteers were recruited."
0,background,9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
1,intervention,9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
0,population,9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
0,outcome,9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
0,other,9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
0,"study design",9768780,4,"Fifteen THR tests were performed on every volunteer: three at baseline PETCO2, three each at PETCO2 of 7.5 mm Hg and 15 mm Hg above the baseline, and then three each at PETCO2 of 7.5 mm Hg and 15 mm Hg below the baseline."
0,background,9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
0,intervention,9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
0,population,9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
1,outcome,9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
0,other,9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
0,"study design",9768780,5,"Transient hyperemic response ratio (THRR) and strength of autoregulation (SA) were calculated using established formulae."
0,background,9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
0,intervention,9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
0,population,9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
1,outcome,9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
0,other,9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
0,"study design",9768780,6,"Both THRR and SA were highly sensitive (96%) in detecting the changes in cerebral autoregulation induced by graded changes in PETCO2."
0,background,9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
0,intervention,9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
0,population,9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
1,outcome,9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
0,other,9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
0,"study design",9768780,7,"The within-individual variability of SA was significantly smaller than that of THRR at all levels of PETCO2."
0,background,9768780,8,"IMPLICATIONS"
0,intervention,9768780,8,"IMPLICATIONS"
0,population,9768780,8,"IMPLICATIONS"
0,outcome,9768780,8,"IMPLICATIONS"
1,other,9768780,8,"IMPLICATIONS"
0,"study design",9768780,8,"IMPLICATIONS"
0,background,9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
0,intervention,9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
0,population,9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
1,outcome,9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
0,other,9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
0,"study design",9768780,9,"This study demonstrates the reliability of the THR test, when used for repetitive measurements, in detecting changes in cerebral autoregulation induced by graded changes in PETCO2."
0,background,9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
0,intervention,9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
0,population,9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
1,outcome,9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
0,other,9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
0,"study design",9768780,10,"This test may provide a simple and noninvasive method of evaluating changes in cerebral autoregulation within an individual."
1,background,9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
0,intervention,9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
0,population,9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
0,outcome,9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
0,other,9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
0,"study design",9818026,1,"NAD(P)H:quinone oxidoreductase (DT-diaphorase; DTD) plays a major role in activating mitomycin C (MMC) in human colon and gastric carcinoma cell lines."
1,background,9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,intervention,9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,population,9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,outcome,9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,other,9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,"study design",9818026,2,"Thus, measurement of DTD in clinical tumor samples could be beneficial in designing adjuvant chemotherapy."
0,background,9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
0,intervention,9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
1,population,9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
1,outcome,9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
0,other,9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
0,"study design",9818026,3,"We explored immunological quantitation of DTD protein using a monoclonal antibody against DTD, demonstrating a close correlation between protein expression and enzyme activity of DTD in colon and gastric carcinoma cell lines and in colorectal tumor sample"
0,background,9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
0,intervention,9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
0,population,9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
1,outcome,9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
0,other,9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
0,"study design",9818026,4,"This indicates that such immunoblot analysis is a simple alternative method for quantitating DTD in clinically excised samples."
0,background,9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
0,intervention,9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
0,population,9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
1,outcome,9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
0,other,9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
0,"study design",9818026,5,"In most colorectal tumor samples, the tumors expressed larger amounts of DTD than did the peripheral normal tissues, suggesting a selective toxicity of MMC toward tumor cells."
0,background,9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
0,intervention,9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
0,population,9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
1,outcome,9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
0,other,9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
0,"study design",9818026,6,"Also tumors with nodal metastases showed significantly higher DTD levels than did tumors without metastasis."
0,background,9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
0,intervention,9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
0,population,9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
1,outcome,9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
0,other,9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
0,"study design",9818026,7,"These results raise the possibility that DTD expression is related to tumorigenesis and malignant progression of colorectal tumors."
0,background,9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
0,intervention,9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
0,population,9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
1,outcome,9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
0,other,9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
0,"study design",9818026,8,"Measurement of DTD by the immunological method described here could be beneficial in designing a rational adjuvant chemotherapy with MMC."
